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INTRODUCTION 
   
 In 2006, a fully bioresorbable everolimus-eluting polylactide scaffold, namely the Absorb 
scaffolds, was introduced. The implantation of a bioresorbable scaffold is a new approach 
that provides transient vessel support with drug delivery capability, potentially without the 
limitations of permanent metallic implants. By liberating the coronary artery from the 
metallic caging, the vessel recovers pulsatility and becomes responsive to shear stress and 
physiological cyclic strain. The vessel wall, theoretically, can remodel and exhibit plaque 
reduction in response to pharmacological treatment and physiological stimuli. BRS 
technology has been so-called “the 4th revolution in coronary interventions” that may have 
potential clinical advantages over the metallic stent technologies. This novel technology 
has been extensively investigated in the ABSORB Clinical Program, in that the first-in-man 
ABSORB Cohort B trial using the current generation Absorb scaffolds showed excellent 
results in terms of safety and efficacy. Since September 2012, this device has been widely 
used in the clinical setting. 
 
As the Absorb scaffold has a strict upper limit of expansion, quantitative coronary 
angiography (QCA)-guided implantation was a mandatory requirement in the most of 
ABSORB trials. The concerns about appropriate deployment of the Absorb scaffold with 
angiography guidance arose mainly from optical coherence tomography (OCT) substudies 
demonstrating an increased frequency of malapposition when the Absorb scaffold was 
implanted in a too large vessel. Another matter of concern is the risk of scaffold disruption, 
particularly when the device has already reached its maximal limit of expansion and is 
overexpanded in an attempt to correct persistent malapposition. Conversely, an OCT 
substudy showed an excess of proximal and/or distal edge dissections when the Absorb 
scaffold was implanted in vessels smaller than the device nominal size. However, the 
impact of quantitative angiographic guidance on clinical outcomes was so far unknown. 
Chapter1 describes vessel sizing, acute performance and patient outcome after 
implantation of bioresorbable scaffolds. The main part of this thesis relates to angiographic 
and intra coronary imaging assessment of bioresorbable scaffolds.  
 
In the early Absorb studies, several technical failure and adverse events are documented. 
Acute vessel closure, due to dislodgement of a coronary stent during deployment or an 
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early stent thrombosis, is a rare but potentially fatal complication of percutaneous coronary 
intervention. Late or very late thrombosis also remains a long-term concern with metallic 
drug-eluting stents, due to delayed healing potentially caused by the permanent presence 
of foreign bodies such as metals and coating materials. After complete bioresorption of the 
polymeric struts, the risk of very late scaffold thrombosis may theoretically be reduced due 
to the absence of foreign material. On the other hand, the thick polymeric struts (total strut 
thickness=156 Ɋm) crimped onto the delivery balloon contribute to the large profile of the 
device that may cause friction between the device and the diseased vessel wall or any 
daughter catheter, resulting in dislodgement of the scaffold. We discuss the potential 
reasons and then share such cases in the early phase of the BRS technology in Chapter2. 
 
Considering the use of the Absorb scaffolds in bifurcation lesions, we review the 
reappraisal angiographic assessment. Angiographic assessment of bifurcation lesion still 
remains to be a challenging field of research. When revisit single-vessel vs. dedicated 
bifurcation QCA in clinical bifurcation trials and phantom study, QCA results of the trial are 
affected following alignment of the methodology. This chapter emphasizes the importance 
of using the appraisal QCA methodology in Chapter3. 
 
Long term assessment of bioresorbable scaffolds beyond angiography is described in 
chapter4. Intravascular ultrasound-derived parameters have shown to be useful to assess 
the BRS resorption of metallic and polymeric scaffolds in humans. One of the most studied 
intravascular ultrasound (IVUS) techniques to evaluate the resorption process is called 
differential echogenicity. This method consists in an automated and quantitative 
three-dimensional analysis of coronary tissue components scored for echogenicity using as 
reference the mean level of the adventitia brightness where scaffold struts appear as bright 
hyperechogenic structures. In clinical studies, a continuous decrease of echogenicity over 
time has been shown in regions treated with BRS, being putatively correlated to BRS 
degradation. However, in serial human assessments, changes in the adventitia and 
plaque-media compartment of the treated regions during the follow-up period could 
possibly affect these interpretations. This chapter highlights the multimodality imaging 
assessment for the BRS, mainly focusing on the clinical application of the Absorb scaffolds. 
 
The aims of this thesis are 1) to investigate vessel sizing, acute performance and patient 
15
outcome after implantation of bioresorbable scaffolds; 2) to discuss failure mode of 
bioresorbable scaffolds;; 3) to validate bifurcation QCA and finally 4) to explore long term 
assessment of bioresorbable scaffolds beyond angiography. 
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Chapter 1 
 
Vessel Sizing, Acute Performance and Patient Outcome After 
Implantation of Bioresorbable Scaffolds 
 
 
1.1 Bioresorbable Scaffold Sizing Using QCA-Dmax 
 
Relation Between Bioresorbable Scaffold Sizing Using QCA-Dmax and 
Clinical Outcomes at 1 Year in 1,232 Patients From 3 Study Cohorts 
(ABSORB Cohort B, ABSORB EXTEND, and ABSORB II) 
 
JACC Cardiovasc Interv. 2015 Nov;8(13):1715-26.  
[Original research paper, IF 7.44] 
 
Ishibashi Y, Nakatani S, Suwannasom P, Grundeken MJ, Garcia-Garcia 
HM, Bartorelli A, Whitbourn R, Chevalier B, Abizaid A, Ormiston JA, 
Rapoza R, Veldhof S, Onuma Y, Serruys PW   
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Relation Between Bioresorbable Scaffold
Sizing Using QCA-Dmax and Clinical
Outcomes at 1 Year in 1,232 Patients From
3 Study Cohorts (ABSORB Cohort B,
ABSORB EXTEND, and ABSORB II)
Yuki Ishibashi, MD, PHD,* Shimpei Nakatani, MD,* Yohei Sotomi, MD,y Pannipa Suwannasom, MD,*yz
Maik J. Grundeken, MD,y Hector M. Garcia-Garcia, MD, PHD,* Antonio L. Bartorelli, MD,x Robert Whitbourn, MD,k
Bernard Chevalier, MD,{ Alexandre Abizaid, MD, PHD,# John A. Ormiston, MB, CHB, PHD,** Richard J. Rapoza, PHD,yy
Susan Veldhof, RN,zz Yoshinobu Onuma, MD, PHD,* Patrick W. Serruys, MD, PHDxx
ABSTRACT
OBJECTIVES This study sought to investigate the clinical outcomes based on the assessment of quantitative coronary
angiography–maximal lumen diameter (Dmax).
BACKGROUND Assessment of pre-procedural Dmax of proximal and distal sites has been used for Absorb scaffold size
selection in the ABSORB studies.
METHODS A total of 1,248 patients received Absorb scaffolds in the ABSORB Cohort B (ABSORB Clinical Investigation,
Cohort B) study (N ¼ 101), ABSORB EXTEND (ABSORB EXTEND Clinical Investigation) study (N ¼ 812), and ABSORB II
(ABSORB II Randomized Controlled Trial) trial (N ¼ 335). The incidence of major adverse cardiac events (MACE) (a
composite of cardiac death, any myocardial infarction [MI], and ischemia-driven target lesion revascularization) was
analyzed according to the Dmax subclassiﬁcation of scaffold oversize group versus scaffold nonoversize group.
RESULTS Of 1,248 patients, pre-procedural Dmax was assessed in 1,232 patients (98.7%). In 649 (52.7%) patients, both
proximal and distal Dmax values were smaller than the nominal size of the implanted scaffold (scaffold oversize group),
whereas in 583 (47.3%) of patients, the proximal and/or distal Dmax were larger than the implanted scaffold (scaffold
nonoversize group). The rates of MACE and MI at 1 year were signiﬁcantly higher in the scaffold oversize group than in the
scaffold nonoversize group (MACE 6.6% vs. 3.3%; log-rank p < 0.01, all MI: 4.6% vs. 2.4%; log-rank p ¼ 0.04), mainly
driven by a higher MI rate within 1 month post-procedure (3.5% vs. 1.9%; p¼ 0.08). The independent MACE determinants
were both Dmax smaller than the scaffold nominal size (odds ratio [OR]: 2.13, 95% conﬁdence interval [CI]: 1.22 to 3.70;
p < 0.01) and the implantation of overlapping scaffolds (OR: 2.10, 95% CI: 1.17 to 3.80; p ¼ 0.01).
CONCLUSIONS Implantation of an oversized Absorb scaffold in a relatively small vessel appears to be associated with a
higher 1-year MACE rate driven by more frequent early MI. (ABSORB Clinical Investigation, Cohort B [ABSORB Cohort B],
NCT00856856; ABSORB EXTEND Clinical Investigation [ABSORB EXTEND], NCT01023789; ABSORB II Randomized
Controlled Trial [ABSORB II], NCT01425281) (J Am Coll Cardiol Intv 2015;8:1715–26) © 2015 by the American College of
Cardiology Foundation.
From the *Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands; yAcademic Medical Center, University
of Amsterdam, Amsterdam, the Netherlands; zNorthern Region Heart Center, Maharaj Nakorn Chiang Mai Hospital, Faculty of
Medicine, Chiang Mai University, Chiang Mai, Thailand; xCentro Cardiologico Monzino, IRCCS, University of Milan, Milan, Italy;
kSt. Vincent’s Hospital, Fitzroy, Victoria, Australia; {Institut Cardiovasculaire Paris Sud, Massy, France; #Instituto de Cardiologia
Dante Pazzanese, São Paulo, Brazil; **Auckland City Hospital, Auckland, New Zealand; yyAbbott Vascular, Santa Clara, California;
zzAbbott Vascular, Diegem, Belgium; and the xxInternational Centre for Cardiovascular Health, Imperial College, London, United
Kingdom. Abbott Vascular sponsored and funded the work. Drs. Garcia-Garcia, Onuma, and Serruys are on the advisory board of
Abbott Vascular. Dr. Chevalier is a consultant for Abbott Vascular. Dr. Abizaid has received research grants for Abbott Vascular.
Dr. Ormiston has received minor honoraria and is on the advisory board of Boston Scientiﬁc. Dr. Rapoza and Ms. Veldhof are
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T he performance of the second-generation Absorb bioresorbableeverolimus-eluting scaffold was in-
vestigated in the ABSORB II (ABSORB II Ran-
domized Controlled Trial) as well as in the
Cohort B1, Cohort B2, and ABSORB EXTEND
(ABSORB EXTEND Clinical Investigation)
studies, and demonstrated excellent clinical
results (1–7). As the Absorb scaffold has a
strict upper limit of expansion, quantitative
coronary angiography (QCA)-guided implan-
tation was a mandatory requirement in
ABSORB EXTEND (7) and ABSORB II (1). The
aim was to allow the selection of a scaffold
size matching that of the reference vessel
diameter. For reasons related to the poten-
tial labeling by the regulator, the sponsoring
corporation did not want to require the use
of intravascular imaging for sizing the vessel
and for selection of the device size. The con-
cerns about appropriate deployment of the
Absorb scaffold with angiography guidance
arose mainly from optical coherence tomog-
raphy (OCT) substudies demonstrating an
increased frequency of malapposition when the
Absorb scaffold was implanted in a too large vessel
(8). Another matter of concern is the risk of scaffold
disruption (9), particularly when the device has
already reached its maximal limit of expansion and
is overexpanded in an attempt to correct persistent
malapposition. Conversely, an OCT substudy showed
an excess of proximal and/or distal edge dissections
when the Absorb scaffold was implanted in vessels
smaller than the device nominal size (8). However,
the impact of quantitative angiographic guidance on
clinical outcomes is so far unknown. Therefore, the
aim of this study was to investigate the relationship
between clinical outcomes and maximal diameter
(Dmax) by QCA, which was used as a guide for appro-
priate selection and deployment of the Absorb scaf-
fold in 2 cohorts of patients from the ABSORB
Cohort B study, ABSORB EXTEND study, and ABSORB
II trial.
METHODS
STUDY DESIGN AND POPULATION. We analyzed the
results of Absorb scaffold implantation in 1,248
patients enrolled between 2009 and 2013 in the
ABSORB Cohort B study (2,4), ABSORB EXTEND study
(7), and ABSORB II (1) randomized controlled trial.
The design of each study is described elsewhere
(4,6,7,10). In the ABSORB Cohort B, a 3.0  18-mm
Absorb scaffold only was available. In the ABSORB
EXTEND and ABSORB II studies, patients were
treated as follows (1,7): 1) a 3.5-mm Absorb scaffold
was used when both the proximal and distal Dmax
were within an upper limit of 3.8 mm and a lower
limit of 3.0 mm: 2) a 3.0-mm Absorb scaffold was used
when both the proximal and distal maximal lumen
diameters were within an upper limit of 3.3 mm and a
lower limit of 2.5 mm: 3) a 2.5-mm Absorb scaffold
was used when both the proximal and the distal
Dmax were within an upper limit of 3.0 mm and a
lower limit of 2.25 mm: and 4) scaffold overlap was
allowed. Patients demographic data and baseline
characteristics were similar among 3 studies as well as
pre-procedure minimal lumen diameter (MLD) and %
diameter stenosis. All of these trials were sponsored
and funded by Abbott Vascular. The research ethics
committee of each participating institution approved
the protocol, and all enrolled patients provided
written informed consent before inclusion.
STUDY DEVICE. The details of the study device
(Absorb, Abbott Vascular, Santa Clara, California)
have been described in detail previously (5,6). In
brief, the balloon-expandable Absorb scaffold com-
prises a poly-L-lactide backbone (6) coated with an
amorphous drug-eluting coating matrix composed of
poly-D,L-lactide polymer containing everolimus.
QCA ANALYSIS. QCA guidance of Absorb implanta-
tion relies on the angiographic diameter function
curve of the pre-treatment vessel segment that con-
tains 3 nonambiguous data points; namely, the MLD
and the Dmax with respect to the MLD of the proximal
(proximal Dmax) and distal (distal Dmax) vessel seg-
ments of interest (8,11) (Figure 1). QCA analyses were
undertaken by the sites before Absorb implantation,
and post-procedurally by an independent core labo-
ratory (Cardialysis BV, Rotterdam, the Netherlands)
using a Coronary Angiography Analysis System (Pie
Medical Imaging, Maastricht, the Netherlands).
DEFINITIONS AND ENDPOINTS. The patient popula-
tion in the present study was stratiﬁed by the differ-
ence between the angiographic maximal diameter
ABBR EV I A T I ON S
AND ACRONYMS
CI = conﬁdence interval
Dmax = maximal lumen
diameter
ID = ischemia-driven
MACE = major adverse cardiac
event(s)
MI = myocardial infarction
MLD = minimal lumen diameter
OCT = optical coherence
tomography
PMI = periprocedural
myocardial infarction
QCA = quantitative coronary
angiography
OR = odds ratio
ST = scaffold thrombosis
TLR = target lesion
revascularization
TVMI = target vessel
myocardial infarction
QCA = quantitative coronary
angiography
employees of Abbott Vascular. All other authors have reported that they have no relationships relevant to the contents of this
paper to disclose.
Manuscript received June 1, 2015; revised manuscript received July 21, 2015, accepted July 30, 2015.
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and the nominal diameter of the implanted scaffold.
The selection of device size was considered “over-
sized” (scaffold oversize group) when the patient
received 1 or more devices in vessels in which both
the proximal and the distal Dmax were smaller than
the nominal size of the device. Patients who received
Absorb scaffolds in vessels with either a proximal
or a distal Dmax or both Dmax larger than the
nominal size of the device constituted the “scaffold
nonoversize group”. When a patient received 2 or
3 overlapping Absorb scaffolds in a long lesion,
the nominal size of the proximally implanted device
was compared with the proximal Dmax, whereas
the nominal size of the distally implanted device
was compared with the distal Dmax. In the cases
of device failure (n ¼ 10), the difference between
Dmax and the implanted metallic stent was calcu-
lated. An additional analysis was performed using a
different criterion (nominal scaffold diameter within
0.4 or 0.5 mm of Dmax) and is presented in Online
Tables 1 and 2.
In the present analysis, the primary clinical
outcome assessed was ischemia-driven major
adverse cardiac events (ID-MACE), deﬁned as a
composite of cardiac death, any myocardial infarc-
tion (MI classiﬁed as Q-wave or non–Q-wave MI),
and ischemia-driven target lesion revascularization
(ID-TLR) by coronary artery bypass graft or percu-
taneous coronary intervention. Cardiac death was
deﬁned as any death due to a proximate cardiac
cause (e.g., MI, low-output failure, fatal arrhythmia).
Unwitnessed death and death of unknown cause
were classiﬁed as cardiac death. MI classiﬁcation and
criteria for diagnosis were deﬁned according to the
per-protocol deﬁnition. Q-wave MI was the devel-
opment of a new, pathological Q-wave. Non–Q-wave
MI was adjudicated if there was an elevation of CK
levels to $2 times the upper limit of normal with
FIGURE 1 The Method to Measure QCA Proximal and Distal Dmax
The method used to measure proximal and distal Dmax with QCA is shown. In the pre-procedural angiography (A), the operator has to deﬁne
the landing zone where the scaffold will be implanted (B). Within the landing zone, the peak of the diameter function curve proximal to the
minimal lumen diameter is deﬁned as proximal (P) Dmax (C), whereas the peak diameter function curve distal (D) to the minimal lumen
diameter is deﬁned as distal Dmax (D). In this case, the proximal and distal Dmax of 2.83 and 2.96 mm led to the correct sizing of the Absorb
(3.0 mm) with regard to the vessel diameter (E). DMAXD ¼ maximal lumen diameter distal; DMAXP ¼ maximal lumen diameter proximal;
MLD ¼ minimal lumen diameter; QCA ¼ quantitative coronary angiography; RVD ¼ reference vessel diameter.
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elevated creatine kinase-myocardial band levels in
the absence of new pathological Q waves (12).
Notably, this deﬁnition of per-protocol MI was
consistently applied in all trials included in the
present analysis. Target vessel myocardial infarction
(TVMI) was deﬁned as MI that occurred in the entire
major coronary vessel proximal and distal to the
target lesion, which includes upstream and down-
stream branches and the target lesion itself. ID-TLR
was deﬁned as any repeat percutaneous interven-
tion of the target lesion or bypass surgery of the
target vessel with either a positive functional
ischemia study, ischemic symptoms, or an angio-
graphic MLD stenosis $50% by core laboratory QCA,
or revascularization of a target lesion with diameter
stenosis $70% by core laboratory QCA without either
ischemic symptoms or a positive functional study.
Deﬁnite and probable scaffold thrombosis (ST) was
adjudicated according to the Academic Research
Consortium deﬁnitions (13–15). All clinical outcomes
were adjudicated by an independent clinical events
committee.
SOURCE DOCUMENT VERIFICATION AND CLINICAL
FOLLOW-UP. In the ABSORB Cohort B and ABSORB II
studies, we veriﬁed source documents in 100% of
patients through 1-year follow-up. In the ABSORB
EXTEND trial, source document veriﬁcation was
routinely performed in 100% of patients through
30-day follow-up, subsequently in a random 20% of
patients, and in 100% of all reported events for the
remaining follow-up period.
STATISTICAL ANALYSIS. All analyses were conduct-
ed using the intention-to-treat population. For the
FIGURE 2 Proximal and Distal Dmax Compared With Nominal Size of the Scaffold
The graph represents the proximal Dmax value, the distal Dmax value and the nominal size of the implanted Absorb scaffold(s) in 1,232 pa-
tients. The Dmax measurement is based on core lab assessment. According to the manufacturer, the 2.5-mm, 3.0-mm, and 3.5-mm scaffolds
cannot be dilated beyond their nominal size of 3.0 mm, 3.5 mm, and 4.0 mm, respectively. The limit of expansion of the scaffold is depicted by
a green continuous line. Theoretically, dotted red areas indicate implantation of a too “small” Absorb scaffold in a relatively large vessel, and
dotted orange areas indicate implantation of a too “large” Absorb scaffold in a relatively small vessel. Device size selection with regard to
Dmax was considered appropriate in 867 (70.4%) patients and inappropriate in 365 (29.6%) patients. Dmax ¼ maximal lumen diameter.
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present analyses, individual data were based on a
patient-level basis. Categorical variables were
compared by Fisher exact test. Continuous variables
are presented as mean  SD and were compared by
nonparametric test. Time-to-event variables are pre-
sented as Kaplan-Meier curves. To determine the in-
dependent predictors of MACE, ﬁrstly univariate
logistic regression models were constructed using the
following variables: age, male sex, current smoking,
hypertension requiring treatment, dyslipidemia
requiring treatment, any diabetes, unstable angina,
pre-procedural diameter stenosis, pre-procedural
MLD, lesion length, angulation >45, bifurcation le-
sions, calciﬁed lesions, pre-procedural visible
thrombus, Type B2/C lesions, target vessel treatment
with 2.5-mm device, treatment with overlapping
scaffolds, and scaffold implantation in a vessel with
both proximal and distal Dmax smaller than the
nominal device size. Secondly, signiﬁcant variables
(p < 0.10) in the univariate analysis were forcedly
entered into a multivariable logistic regression model
to predict for MACE. A 2-sided p value <0.05 was
considered signiﬁcant for all tests. All statistical tests
were performed with SPSS, version 22.0 for windows
(IBM, Chicago, Illinois).
RESULTS
Of a total population of 1,248 patients, pre-procedural
Dmax was assessed by the core laboratory in 1,232
(98.7 %) patients. Figure 2 displays individual values
of proximal and distal Dmax in patients who received
Absorb scaffolds of either 2.5-mm, 3.0-mm, or 3.5-mm
nominal size. The nominal size of the implanted
Absorb scaffold was larger than both proximal and
distal Dmax in 649 patients (scaffold oversize group
52.7%).
Clinical and angiographic characteristics between
the scaffold oversize group and the scaffold non-
oversize group are detailed in Table 1. The 2 groups
did not signiﬁcantly differ with regard to main base-
line clinical characteristics, whereas pre-procedural
MLD, reference vessel diameter, and both proximal
and distal Dmax were signiﬁcantly smaller in the
scaffold oversize group than in the scaffold non-
oversize group.
The scaffold oversize group was associated with a
higher risk of ID-MACE than the scaffold nonoversize
group. As illustrated in Figure 3, the graphical pre-
sentation clearly shows that a higher number of these
patients can be seen in the lower left quadrant
(scaffold oversize group) than in the other quadrants
of the graph (6.6% vs. 3.3%, p < 0.01). MACE occurred
in 46 of 760 patients when a relatively large device
size was selected, whereas it occurred in 16 of 472
patients when a relatively small device size was
selected (6.1% vs. 3.4%, p ¼ 0.04).
The MACE and MI rates at 1 year and 2 years were
signiﬁcantly higher in the scaffold oversize group
TABLE 1 Clinical and Pre- and Post-Procedural Angiographic Characteristics
Scaffold
Oversize Group
(n ¼ 649)
Scaffold
Nonoversize Group
(n ¼ 583)
p
Value
Age, yrs 61.6  10.7 60.8  10.1 0.20
Male 73.8 (479) 75.1 (438) 0.60
Current smoker 1.7 (141) 24 (140) 0.34
Hypertension requiring treatment 67.6 (439) 67.9 (396) 0.95
Dyslipidemia requiring treatment 69.8 (453) 69 (402) 0.76
Any diabetes mellitus 24 (156) 26.2 (153) 0.39
Unstable angina 24.8 (161) 22.9 (133) 0.46
Prior history of myocardial infarction 28.1 (182) 27.8 (162) 0.95
Lesion location
Right coronary artery 21.9 (142) 33.6 (196) <0.01
Left anterior descending artery 49.8 (323) 41.9 (244) 0.01
Left circumﬂex artery or ramus 9.9 (64) 9.6 (56) 0.92
Left main coronary artery 0 (0) 0.2 (1) 0.47
ACC/AHA lesion complexity
A 1.9 (12) 2.1 (12) 0.84
B1 53.9 (349) 52.8 (307) 0.73
B2 41.2 (267) 43.5 (25) 0.45
C 3.1 (20) 1.7 (10) 0.14
TIMI ﬂow grade 0 or 1 0.6 (4) 0.2 (1) 0.38
Calciﬁcation (moderate or severe) 13.4 (87) 14.4 (84) 0.62
Angulation $45 2.6 (17) 2.2 (13) 0.71
Bifurcation 4.0 (26) 4.8 (28) 0.58
Thrombus 1.5 (10) 1.9 (11) 0.67
Pre-procedural
Reference vessel diameter, mm 2.50  0.33 2.79  0.39 <0.01
Proximal Dmax, mm 2.66  0.30 3.11  0.34 <0.01
Distal Dmax, mm 2.58  0.31 2.94  0.38 <0.01
Minimal lumen diameter, mm 1.05  0.30 1.15  0.33 <0.01
Diameter stenosis, % 57.9  10.9 58.6  10.2 0.22
Obstruction lesion length, mm 12.2  5.9 13.0  5.7 0.03
Device related
2.5-mm scaffold 8.6 (56) 13.9 (81) <0.01
3.0-mm scaffold 82.4 (535) 77.4 (451) 0.03
3.5-mm scaffold 8.9 (58) 8.8 (51) 0.92
Average nominal diameter 2.97  0.24 3.00  0.21 0.03
Post-procedural
Reference vessel diameter, mm 2.58  0.30 2.82  0.34 <0.01
Minimal lumen diameter, mm 2.19  0.28 2.37  0.31 <0.01
Diameter stenosis, % 15.3  6.5 15.9  10.2 0.09
Acute decrease, % diameter stenosis 42.5  12.5 42.5  12.4 0.98
Acute gain, mm 1.13  0.34 1.21  0.38 <0.01
Acute gain/pre-procedural RVD, mm 0.46  0.14 0.44  0.14 0.02
Bailout treatment with metallic stent 1.9 (12) 0.7 (4) 0.08
Values are mean  SD, or % (n). Clinical and pre- and post-procedural angiographic characteristics are according
to the distribution of Dmax measurements minus the nominal scaffold size in the scaffold oversize group versus
the scaffold nonoversize group.
ACC/AHA ¼ American College of Cardiology/American Heart Association lesion characteristics; Dmax ¼
maximal lumen diameter; RVD ¼ reference vessel diameter; TIMI ¼ Thrombolysis In Myocardial Infarction.
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than in scaffold nonoversize group (1-year MACE:
6.6% vs. 3.3%; log-rank p < 0.01, 2-year MACE: 8.7%
vs. 5.9%; log-rank p ¼ 0.03, 1-year TVMI: 4.5% vs.
2.1%, 2-year MI: 5.5% vs. 3.0%; log-rank p ¼ 0.04),
mainly driven by a higher rate of TVMI within
1 month after the procedure (3.5% vs. 1.9%; p ¼ 0.08)
(Figure 4, Tables 2 and 3). Among the events of MI (44
of 1,232), periprocedural MI (PMI) occurred in 28 cases
(63.6%). MI occurred after 48 h in 36% of all MI
events. In the scaffold oversize group, PMI occurred
in 64% (18 cases), whereas in the scaffold nonoversize
group, the PMI rate was 35.7% (10 cases). There were
no statistically signiﬁcant differences in the incidence
of overall angiographic complications that could be
documented at the end of the procedure for patients
who had TVMI within 1 month (3.1% vs. 1.7%;
p ¼ 0.14) (Table 3). The incidence of ST tended to be
higher in the scaffold oversize group than in the
scaffold nonoversize group (Table 2) (1.54% vs. 0.51%,
OR: 3.03 [0.83 to 11.05]; p ¼ 0.10). The acute deﬁnite
ST rate was 0.15% and 0% in the scaffold oversize
group and the scaffold nonoversize group, respec-
tively (p ¼ 1.0). Subacute and late deﬁnite ST were not
signiﬁcantly different among the 2 groups (Online
Table 3). A case of a deﬁnite early ST is shown in
Figure 5.
When the appropriateness of scaffold size was
deﬁned by nominal scaffold diameter within 0.5 mm
FIGURE 3 Distribution of the Difference Between Dmax and Nominal Scaffold
Distribution of proximal and distal Dmax measurements minus nominal scaffold size in patients with or without major adverse cardiac events is shown. When the
appropriateness of scaffold size was deﬁned by nominal scaffold diameter within 0.5 mm of Dmax, the differences between the distal Dmax and nominal scaffold size are
plotted on the y-axis and x-axis, respectively. The red ﬁlled circles represent the patients who experienced ID-MACE at 1 year. The graphical presentation demonstrates
that major adverse cardiac events (MACE) were more frequently observed in patients in whom both proximal and distal Dmax were smaller than the device nominal size
(6.6% vs. 3.3%, p < 0.01) (lower left quadrant). Dmax ¼ maximal lumen diameter; ID-MACE ¼ ischemia-driven major adverse cardiac event(s).
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of Dmax, there was no statistically signiﬁcant differ-
ence inMACE between the 2 groups, (appropriate 4.5%
vs. inappropriate 6.3%; p ¼ 0.20). When the cutoff of
0.4 mm is used, there was a signiﬁcant difference in
MACE between appropriate and inappropriate scaffold
deployment (3.4% vs. 6.8%; p ¼ 0.006) (Online
Figures 1 and 2, Online Table 3).
INDEPENDENT PREDICTOR OF MACE AFTER IMPLANTA-
TION OF ABSORB SCAFFOLD(S). With multivariable
logistic regression analysis, the independent de-
terminants of 1-year MACE were: implantation of the
Absorb scaffold(s) in a vessel with both proximal and
distal Dmax smaller than the device nominal size (OR:
2.13, 95% CI: 1.22 to 3.70; p < 0.01) and overlapping
scaffolds (OR: 2.10, 95% CI: 1.17 to 3.80; p ¼ 0.01)
(Table 4).
DISCUSSION
The main ﬁndings of this study are: 1) 52.7% (n ¼ 649)
of patients had an “oversize” scaffold implantation;
2) The MACE and MI rates at 1 year were signiﬁcantly
higher in the scaffold oversize group than in the
scaffold nonoversize group (MACE: 6.6% vs. 3.3%,
log-rank p < 0.01, all MI: 4.6% vs. 2.4%; log-rank
p ¼ 0.04), mainly driven by a higher rate of MI
within 1 month after the procedure (3.5% vs. 1.9%;
p ¼ 0.08); the incidence of deﬁnite ST tended to be
higher in the scaffold oversize group than in the
scaffold nonoversize group (1.54% vs. 0.51%,OR: 3.03
[0.83 to 11.05]; p ¼ 0.10); 3) The independent de-
terminants of MACE were both Dmax smaller than the
device nominal size (OR: 2.13, 95% CI: 1.22 to 3.70;
FIGURE 4 Time-to-Event Curves of MACE and Its Components
Time-to-event curves of MACE (A) and its components (B: death, C: target vessel MI; D: ID-TLR) at 2 years, according to study group. ID-TLR ¼ ischemia-driven target
lesion revascularization; MACE ¼ major adverse cardiac event(s); MI ¼ myocardial infarction.
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p < 0.01) and overlapping scaffolds (OR: 2.10, 95% CI:
1.17 to 3.80; p ¼ 0.01).
As illustrated in the scaffold oversize group in
Figure 3, proximal and distal Dmax were signiﬁcantly
smaller than in the scaffold nonoversize group
(proximal Dmax: 2.66  0.30 mm vs. 3.11  0.34 mm;
p < 0.01, distal Dmax: 2.58  0.31 mm vs. 2.94  0.38
mm; p < 0.01, respectively) (Table 1). In the popula-
tion described in the scaffold oversize group, 2.5-mm
device size scaffolds were less frequently selected
(8.6% vs. 13.9%; p < 0.01) as compared with 3.0-mm
scaffolds (82.4% vs. 77.4%; p ¼ 0.03). In the scaffold
oversize group, acute gain normalized for pre-
procedural reference vessel diameter was higher
(0.46  0.14 vs. 0.44  0.14; p ¼ 0.02) and bailout
treatment with metallic stents was more frequently
performed (1.9% vs. 0.7%; p ¼ 0.08) compared
with the nonoversize group (Table 1). Implanting
Absorb scaffold(s) in a vessel with both proximal and
distal Dmax smaller than the device nominal size may
cause edge dissections due to the higher balloon/
device–artery ratio during scaffold deployment.
Retrospective subanalysis (8) of the ABSORB
Cohort B study demonstrated that after implantation
of a 3.0  18-mm device, patients with a Dmax
ranging between 2.5 and 3.3 mm had better acute OCT
outcomes as compared with patients with a Dmax out
of range. The implantation of a “small” Absorb scaf-
fold in a relatively large vessel can cause incomplete
strut apposition at the edge and may be associated
with scaffold disruption (9) when aggressive post-
dilation with a larger balloon is attempted to correct
such malapposition (Figure 6A). Conversely, implan-
tation of a “large” Absorb scaffold in a relatively small
vessel can cause vessel injury or underexpansion of
the scaffold (Figure 6B).
CLINICAL OUTCOMES WITH RESPECT TO Dmax.
The present study clearly demonstrates that
implanting Absorb scaffold(s) in a vessel with both
proximal and distal Dmax smaller than the device
TABLE 3 Incidence of TVMI
Scaffold
Oversize Group
(n ¼ 649)
Scaffold
Nonoversize Group
(n ¼ 583)
p
Value
TVMI at 12 months after index procedure 4.5 (29) 2.1(12) 0.025
TVMI within 1 month after index procedure 3.5 (23) 1.9 (113) 0.08
TVMI between 1 month and 12 months after
index procedure
0.9 (6) 0.2 (1) 0.13
Overall angiographic complications at the end
of procedure for TVMI within 1 month
3.1 (20) 1.7 (10) 0.14
Side-branch occlusion 2.3 (15) 1.4 (8) 0.29
Coronary dissection 1.1 (7) 0.3 (2) 0.18
Side branch occlusion þ coronary dissection 0.3 (2) 0 (0) 0.50
Not relating to device caused angiographic
complications for TVMI within 1 month
0.3 (2) 0.3 (2) 1.0
Coronary dissection due to balloon dilation
Values are % (n).
Abbreviations as in Table 2.
TABLE 2 Incidence of Clinical Events at 1 Year
Clinical Outcomes
Scaffold Oversize Group
(n ¼ 649)
Scaffold Nonoversize Group
(n ¼ 583)
OR [95% CI] p Value% (n) 95% CI % (n) 95% CI
Cardiac death 0.62 (4) 0.17–1.57 0.17 (1) 0.00–0.95 3.61 (0.40–32.39) 0.38
Myocardial infarction 4.62 (30) 3.14–5.53 2.40 (14) 1.32–4.00 1.97 (1.03–3.75) 0.049
QMI 1.23 (8) 0.53–2.41 0.34 (2) 0.04–1.23 3.63 (0.77–17.14) 0.11
NQMI 3.39 (22) 2.14–5.09 2.06 (12) 1.07–3.57 1.67 (0.82–3.40) 0.17
TVMI 4.47 (29) 3.01–6.35 2.06 (12) 1.07–3.57 2.23 (1.13–4.40) 0.025
Ischemia-driven TLR 2.62 (17) 1.53–4.16 1.54 (9) 0.71–2.91 1.72 (0.76–3.88) 0.23
Composite of cardiac death, all MI, and clinically
indicated target lesion revascularization (MACE)
6.63 (43) 4.84–8.82 3.26 (19) 1.97–5.04 2.11 (1.21–3.66) <0.01
Composite of cardiac death, target vessel MI, and
clinically indicated target lesion
revascularization (DoCE)
6.32 (41) 4.57–8.47 2.92 (17) 1.71–4.63 2.25 (1.26–3.99) <0.01
Composite of all death, all MI, and all
revascularization (PoCE)
8.01 (52) 6.04–10.37 4.46 (26) 2.93–6.47 1.87 (1.15–3.03) 0.01
Scaffold thrombosis 1.54 (10) 0.74–2.82 0.51 (3) 0.11–1.50 3.03 (0.83–11.05) 0.10
Deﬁnite ST 0.92 (6) 0.34–2.00 0.51 (3) 0.11–1.50 1.80 (0.45–7.25) 0.51
Probable ST 0.31 (2) 0.04–1.11 0 (0) 0.00–1.01 NA 1.0
Possible ST 0.31 (2) 0.04–1.11 0 (0) 0.00–1.01 NA 1.0
Incidence of clinical events at 1 year are according to the distribution of Dmax measurements minus the nominal scaffold size in the scaffold oversize group versus the scaffold nonoversize group.
CI ¼ conﬁdence interval; Dmax ¼ maximal lumen diameter; DoCE ¼ device-oriented composite endpoint; MACE ¼ major adverse cardiac event(s); MI ¼ myocardial infarction; NQMI ¼ non–Q-wave
myocardial infarction; OR ¼ odds ratio; PoCE ¼ patient-oriented composite endpoint; QMI ¼ Q-wave myocardial infarction; ST ¼ scaffold thrombosis; TLR ¼ target lesion revascularization; TVMI ¼ target
vessel myocardial infarction.
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nominal size is associated with a higher risk of ID-
MACE (6.6% vs. 3.3%; p < 0.01). The difference in
1-year MACE was observed in the scaffold oversize
group and was mainly driven by a higher MI
rate (4.5% vs. 2.1%; p < 0.01). Scaffold expansion
below nominal diameters can lead to a denser
polymer surface pattern and a higher polymer-to-
artery ratio (Online Figure 3). Furthermore, the
expanding radial force may be suboptimal in these
underdeployed conﬁgurations; presumably, these
unfavorable ﬁnal expansion diameters might cause
micro thrombus formation at the strut level and
side-branch occlusion. However, no statistically
signiﬁcant difference in the incidence of overall
angiographic complications could be documented at
the end of the procedure for the patients who sus-
tained MI within 1 month (scaffold oversize group:
3.1% vs. scaffold nonoversize group: 1.7%; p ¼ 0.14)
(Table 3).
With multivariable logistic regression analysis, the
independent determinants of 1-year MACE were: im-
plantation of an Absorb scaffold(s) in a vessel with
both proximal and distal Dmax smaller than device
nominal size (OR: 2.13, 95% CI: 1.22 to 3.70; p < 0.01)
and overlapping scaffolds (OR: 2.10, 95% CI: 1.17 to
3.80; p ¼ 0.01) (Table 4). Of note, in a juvenile porcine
model, overlapping Absorb scaffolds showed delayed
healing on histology and with OCT assessment and
slower tissue coverage than nonoverlapping scaf-
folds. Indeed, the neoendothelial coverage of the
overlapping segments was 80.1% and 99.5% at 28 and
90 days after implantation, respectively; accordingly,
coverage in humans may need up to 18 months to be
completed (16). Among the 62 patients with MACE,
FIGURE 5 A Case Example of a Deﬁnite Early Thrombosis of Absorb Scaffold Implanted in the Mid-LAD
The patient received a 3.0-mm device in a too-small vessel (proximal and distal Dmax 2.15 mm and 2.32 mm, respectively [A and B]). After Absorb scaffold implantation
(C and D, arrowheads), QCA showed an excellent result with a residual DS of 9%. Fifteen days after the procedure, the patient presented with a STEMI due to early
scaffold thrombosis (E) that was treated with a manual aspiration only (F and G). DS ¼ diameter stenosis; LAD ¼ left anterior descending coronary artery; ST ¼ scaffold
thrombosis; STEMI ¼ ST-segment elevation myocardial infarction; other abbreviations as in Figure 1.
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MI occurred in 14 (22.6%) patients who were treated
with overlapping scaffolds and were mainly PMI
(12 [19.4%]). Thus, overlapping of scaffolds might be
a contributing factor of MACE.
PRACTICAL IMPLICATIONS OF THE SELECTION OF
APPROPRIATELY SIZED ABSORB SCAFFOLDS.
Previously, we have focused mainly on the upper
limit of 0.5 mm Dmax due to the well-known issues of
device malapposition and disruption in case of over
dilation. However, scaffold underexpansion due to
the deployment of a scaffold in a vessel with a smaller
size, may be associated with a higher post-procedural
MI rate due to several different mechanisms. The
oversized scaffold could create vessel dissection or
microperforation in a small target vessel. Alterna-
tively, the underexpansion of the scaffold may lead to
a denser polymer surface pattern and a larger strut
footprint to vessel surface area causing side branch
occlusion or microthrombus formation.
In the present study, the size selection of Absorb
scaffolds with the cutoff value of 0.5-mm Dmax has
been shown to be clinically relevant. As presented in
the Results and Online Appendix, more events were
observed when the mismatch between the device and
the vessel size was beyond 0.4 mm. It could therefore
be recommended that the device–vessel mismatch
regarding Dmax should be within 0.4 mm.
The current analysis showed that the device–vessel
mismatch regarding the pre-procedural angiography
has a clinical impact. There were no differences in
MACE in the population with a post-procedure diam-
eter stenosis $10% and <10% (MACE: 5.3% vs. 4.1%;
p ¼ 0.46) or in patients with a diameter stenosis $20%
and <20% (MACE: 5.14% vs. 4.69%; p ¼ 0.77). There-
fore, the observed relationship between device–vessel
mismatch and clinical outcomes seems to speciﬁcally
relate to pre-procedural angiographic measure-
ment. It is still unclear how far the pre-procedural
device–vessel mismatch could be corrected by post-
dilation with high-pressure or low-pressure balloons.
Currently, operators with a large experience of BRS
implantation are intuitively promoting a strategy of a
high-pressure post-dilation with a noncompliant
balloon size 0.25 or 0.5 mm larger than the nominal
size of the device. A randomized trial on post-dilation
strategy (systematic vs. nonsystematic) will be able
to clarify what the optimal implantation technique
for this polymeric coronary device is.
It has been shown that QCA underestimates coro-
nary lumen diameter, whereas OCT provides correct
assessment of lumen dimension (17). Mattesini et al.
(18,19) reported that when OCT is used to guide
and optimize Absorb scaffold implantation, post-
implantation area stenosis, minimal lumen area, and
eccentricity index were similar to those observed af-
ter deployment of second-generation metallic drug-
eluting stents. The different approach for lesion
preparation and routine use of OCT guidance during
Absorb scaffold implantation might have contributed
to these results. In addition, recent studies demon-
strated with multivariable analysis that peristent
dissections shown by OCT were independent pre-
dictors of PMI (OR: 5.3, 95% CI: 1.2 to 24.3), raising
concerns about the relationship between these mi-
nor vessel injuries and a potential higher risk of
early TVMI (20). Taking into account the weakness
of QCA for accurately measuring vessel lumen
dimension and its inability to assess incomplete
scaffold apposition and/or acute scaffold disruption,
coregistration (21) of OCT imaging and x-ray angi-
ography may be useful for optimizing the percuta-
neous treatment of coronary artery disease with
bioresorbable vascular scaffolds. In future studies, a
clinical scientiﬁc question would be whether the
pre-procedural usage of intravascular imaging could
further improve clinical outcomes.
TABLE 4 Predictors of MACE After Implantation of the Absorb Scaffold(s)
Univariate Logistic
Regression
Multivariate Logistic
Regression
OR (95% CI) p Value OR (95% CI) p Value
Age, yrs 1.01 (0.98–1.03) 0.64 — —
Male 0.83 (0.47–1.46) 0.52 — —
Current smoker 0.80 (0.42–1.53) 0.51 — —
Hypertension requiring treatment 1.00 (0.90–1.10) 0.96 — —
Dyslipidemia requiring treatment 1.54 (0.84–2.83) 0.16 — —
Any diabetes mellitus 0.78 (0.42–1.46) 0.44 — —
Unstable angina 0.69 (0.35–1.34) 0.27 — —
Prior myocardial infarction 1.01 (0.99–1.04) 0.20 — —
Pre-procedural diameter stenosis, % 0.99 (0.97–1.02) 0.55 — —
Pre-procedural MLD, mm 0.76 (0.33–1.72) 0.51 — —
Obstruction length, mm 0.99 (0.94–1.04) 0.64 — —
Smallest Dmax (proximal and distal) 0.51 (0.22–1.14) 0.10 — —
Angulation $45 0.64 (0.09–4.81) 0.67 — —
Moderate/severe calciﬁcation 0.65 (0.28–1.54) 0.33 — —
Pre-procedural visible thrombus 0.94 (0.12–7.13) 0.95 — —
Bifurcation lesion CS CS — —
Type B2/C lesion 1.02 (0.61–1.71) 0.93 — —
Left anterior descending artery 0.73 (0.43–1.23) 0.24 — —
Nominal scaffold
size/post-procedural MLD
3.11 (0.73–13.16) 0.12 — —
Treatment with overlapping devices 2.08 (1.15–3.75) 0.02 2.10 (1.17–3.80) 0.01
2.5-mm device implanted 0.69 (0.27–1.75) 0.44 — —
Implanting Absorb scaffold(s) in a
vessel with both proximal and
distal Dmax smaller than
nominal size of the device
2.11 (1.21–3.66) 0.01 2.13 (1.22–3.70) <0.01
CS ¼ complete separation; ITT ¼ intention to treat; MLD ¼ minimal lumen diameter; other abbreviations as in
Table 2.
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STUDY LIMITATIONS. The current study does not
provide mechanistic data to support the occurrence of
clinical adverse events caused by sizing mismatch due
to a lack of routine intravascular imaging (e.g., intra-
vascular ultrasound, OCT, etc.). Further investigation
using intravascular imaging is needed to establish the
relationship between acutemechanistic complications
(such as underexpansion, dissection, and malap-
position, and so on) and late adverse events.
CONCLUSIONS
Selection of an appropriate scaffold size according to
the vessel Dmax showed a trend toward less frequent
ID-TLR, whereas implantation of an oversized Absorb
scaffold in a relatively small vessel may be associated
with a higher risk of MACE at 1 year. The current results
need to be conﬁrmed in the large-scale randomized
trials that are on-going, and the mechanistic etiologies
should be further elucidated in imaging studies.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
Yoshinobu Onuma, Erasmus Medical Center, ’s-
Gravendijkwal 230, Rotterdam 3015CE, the Netherlands.
E-mail: yoshinobuonuma@gmail.com.
FIGURE 6 The Potential Consequences of a Device–Vessel Mismatch Implantation
Implantation of a too “small” Absorb scaffold in a relatively large vessel can cause incomplete apposition of the device edges (A, top panel,
blue and red arrowheads). Incomplete scaffold apposition (blue and red arrow heads) and scaffold under-expansion (yellow arrowhead) are
visible in the OCT images (A, bottom panel). Implantation of a too “large” Absorb scaffold in a relatively small vessel can cause vessel injury
(B, top panel, blue and red arrowheads). Edge dissections (blue and red arrowheads) are visible in the OCT images (B, bottom panel).
ISA ¼ incomplete scaffold apposition; OCT ¼ optical coherence tomography; other abbreviations as in Figure 1.
PERSPECTIVES
WHAT IS KNOWN? QCA-Dmax–guided scaffold size selection
has been proposed to optimize the scaffold implantation proce-
dure. However, the relationship between clinical outcomes and
QCA-Dmax is unknown.
WHAT IS NEW? The device-vessel size mismatch has an impact
on clinical event after implantation of Absorb scaffold.
WHAT IS NEXT? The current results should be conﬁrmed in
large-scale randomized trials, and the mechanistic etiologies
should be further elucidated in studies using intravascular
imaging.
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ZDV
SHUIRUPHG DW WKH GLVFUHWLRQ RI WKH RSHUDWRU 3DWLHQWV ZHUH SUHVFULEHG ZLWK VWDQGDUG JXLGHOLQH
UHFRPPHQGHGPHGLFDO WKHUDS\LQFOXGLQJDQWLSODWHOHWPHGLFDWLRQVDQGDQWLDQJLQDO WKHUDS\ZKHQ
DSSURSULDWH

4XDQWLWDWLYHFRURQDU\DQJLRJUDSK\4&$HYDOXDWLRQ
$QJLRJUDSKLF YLHZVZLWKPLQLPDO IRUHVKRUWHQLQJ RI WKH OHVLRQ DQG OLPLWHG RYHUODSZLWK RWKHU
YHVVHOVZHUHXVHGZKHQHYHUSRVVLEOHIRUDOOSKDVHVRIWKHWUHDWPHQWSUHSURFHGXUDODQJLRJUDSK\
DQGDIWHUREWDLQLQJILQDOUHVXOW&RPSDULVRQEHWZHHQSUHDQGSRVWWUHDWPHQWZHUHSHUIRUPHGLQ
PDWFKHG DQJLRJUDSKLF YLHZV RI  GHJUHHV RU OHVV 7KH GLPHQVLRQDO ' DQJLRJUDPVZHUH
DQDO\]HGZLWKWKH&$66DQDO\VLVV\VWHP3LH0HGLFDO%90DDVWULFKWWKH1HWKHUODQGV,Q
HDFKSDWLHQWWKHWUHDWHGUHJLRQDQGWKHSHULWUHDWHGUHJLRQVGHILQHGE\PPSUR[LPDODQGGLVWDO
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WR WKHGHYLFHHGJHZHUHDQDO\]HG7KHFRPSXWHUGHILQHGPLQLPDO OXPLQDOGLDPHWHU UHIHUHQFH
GLDPHWHU REWDLQHG E\ DQ LQWHUSRODWHG PHWKRG DQG SHUFHQWDJH GLDPHWHU VWHQRVLV LQ WKH SRVW
SURFHGXUHDQJLRJUDP
7KH GHILQLWLRQ RI “Curvature” LV WKH LQILQLWHVLPDO UDWH RI FKDQJH LQ WKH WDQJHQW YHFWRU DW HDFK
SRLQWRIWKHFHQWHUOLQH7KLVPHDVXUHPHQWKDVDUHFLSURFDOUHODWLRQVKLSWRWKHUDGLXVRIWKHSHUIHFW
FLUFOHGHILQHGE\WKHFXUYHDWHDFKSRLQW7KHFXUYDWXUHRIWKHYHVVHOLVFDOFXODWHGDVUDGLXVRI
WKHFLUFOHLQFPZLWKDUHVHDUFKSURJUDPLQVWDOOHGLQWKH4&$$QDO\VLVVRIWZDUH&$66
3LH0HGLFDO,PDJLQJ7KHVHJPHQWRILQWHUHVWZDVGHILQHGDVWKHVWHQWHGVFDIIROGHGOHQJWK7R
HQDEOH DQDO\VLV RI FXUYDWXUH LQ WKH VDPH DQDWRPLFDO UHJLRQ WKH VFDIIROG SRVLWLRQ ZDV
VXSHULPSRVHGRQ WKH SUHSURFHGXUDO DQJLRJUDP )LJ 7KH VRIWZDUH DXWRPDWLFDOO\ GHWHFWV WKH
OXPHQ FRQWRXUV RI WKH VHOHFWHG VHJPHQW DQG FRQILJXUHV WKH FHQWHUOLQH 7KUHH SRLQWV DUH WKHQ
GHILQHGDFFRUGLQJWRWKHFHQWHUOLQHDWWKHSUR[LPDODWWKHGLVWDODQGDWWKHFHQWHURIWKH
GHILQHGVHJPHQW1H[WDSHUIHFWFLUFOH LVGUDZQWKURXJK WKHVHSRLQWVFDOFXODWLQJ WKHUDGLXVRI
WKHFLUFOHDQGWKHFXUYDWXUHYDOXH3ULRUWRDQGDIWHUWKHSURFHGXUHWKHFXUYDWXUHRIWKHVHJPHQW
RILQWHUHVWZDVUHSHDWHGO\PHDVXUHGERWKGXULQJV\VWROHDQGGLDVWROH3HUFHQWDJHUHODWLYHFKDQJH
LQFXUYDWXUH&YZDVFDOFXODWHGDVSRVW&YSUH&YSUH&YLQ WKHUHVSHFWLYHFDUGLDFSKDVHV
&\FOLFFKDQJHVLQYHVVHOFXUYDWXUHZHUHHVWLPDWHGDVGLIIHUHQFHVEHWZHHQV\VWROHDQGGLDVWROHDW
ERWKSUHWUHDWPHQWDQGSRVWWUHDWPHQW

6WDWLVWLFDODQDO\VLV
7KH.ROPRJRURY6PLUQRYWHVWZDVXVHGWRHYDOXDWHWKHQRUPDOLW\DVVXPSWLRQVRIDOOFRQWLQXRXV
YDULDEOHV'HVFULSWLYHVWDWLVWLFDODQDO\VLVZDVSHUIRUPHGZLWKFRQWLQXRXVYDULDEOHVH[SUHVVHGDV
PHGLDQLQWHUTXDUWLOHUDQJHDQGZLWKFDWHJRULFDOYDULDEOHVSUHVHQWHGDVFRXQWVSHUFHQWDJH)RU
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FRPSDULVRQEHWZHHQJURXSV0DQQ:KLWQH\U WHVWZHUHXVHGIRUWKHFRQWLQXRXVYDULDEOHV7KH
FKLVTXDUH WHVW KDV EHHQ XVHG WR DVVHVV GLIIHUHQFHV LQ FDWHJRULFDO YDULDEOHV 3UH DQG SRVW
WUHDWPHQW FRPSDULVRQVZLWKLQJURXSVZHUH DVVHVVHGZLWK:LOFR[RQ VLJQHG UDQN WHVWV%HFDXVH
WKHFXUYDWXUH F\FOLF FKDQJHVRI FXUYDWXUH DQGGLIIHUHQFHRI FXUYDWXUHEHWZHHQSUH DQGSRVW
WUHDWPHQWGLGQRWKDYHDQRUPDOGLVWULEXWLRQD ORJ WUDQVIRUPDWLRQZDVSHUIRUPHG WR DFKLHYHD
QRUPDO GLVWULEXWLRQ $ XQLYDULDWH DQDO\VLV ZDV SHUIRUPHG EHWZHHQ FXUYDWXUH DQG DQJXODWLRQ
FKDQJHVZLWKEDVHOLQHGHPRJUDSKLFDQGDQJLRJUDSKLFYDULDEOHV9DULDEOHVWKDWZHUHIRXQGWREH
VLJQLILFDQWDW WKHXQLYDULDWH OHYHOZHUH WHVWHGZLWKDPXOWLYDULDWH OLQHDUUHJUHVVLRQPRGHO 7KH
WKUHVKROGVIRUHQWU\LQWRDQGUHPRYDOIURPWKHPRGHOZHUH$OOVWDWLVWLFDOWHVWVZHUHFDUULHG
RXWDWWKHOHYHORIVLJQLILFDQFH$OODQDO\VLVZHUHSHUIRUPHGE\6366YHUVLRQ6366,QF
&KLFDJR,OOLQRLV

5HVXOWV
7KHEDVHOLQHFOLQLFDODQGDQJLRJUDSKLFFKDUDFWHULVWLFVDUHVKRZQLQ7DEOH$WRWDORISDWLHQWV
ZHUHLQYROYHGLQWKLVVWXG\RIZKLFKZHUHWUHDWHGZLWKWKH%56DQGZLWKWKH036$IORZ
FKDUWVXPPDUL]LQJSDWLHQWVHOHFWLRQLVVKRZQLQ)LJXUH7KHUHZDVQRGLIIHUHQFHLQPHGLDQDJH
>%56YV036\HDUVYV\HDUVS @RUJHQGHU7KHUHZDVDVLJQLILFDQWGLIIHUHQFH
LQFOLQLFDOSUHVHQWDWLRQRI$&667(0,%56YV036YVS 7KHUHZHUH
QRVLJQLILFDQWGLIIHUHQFHVLQWKHFDUGLRYDVFXODUULVNIDFWRUV
7KHOHIWDQWHULRUGHVFHQGLQJDUWHU\ZDVWKHPRVWFRPPRQO\WUHDWHGYHVVHOLQWKHVWXG\SRSXODWLRQ
7KHSUHWUHDWPHQWUHJLRQOHQJWKLVPPLQWKHRYHUDOOJURXS7KHUHZHUHQR
VLJQLILFDQW GLIIHUHQFHV LQ UHIHUHQFH YHVVHO GLDPHWHU PLQLPDO OXPHQ GLDPHWHU DQG SHUFHQWDJH
GLDPHWHUVWHQRVLVLQERWKJURXSV3UHWUHDWPHQWFXUYDWXUHZDVVLPLODUEHWZHHQWKH%56DQG036
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JURXSV LQERWK V\VWROH DQGGLDVWROHSKDVHV >V\VWROH   FPYV 
UHVSHFWLYHO\S DQGGLDVWROHFPYVFP
UHVSHFWLYHO\S @

*HRPHWULF FKDQJHVZLWKLQDQGEHWZHHQJURXSV7DEOH ,,,VKRZVWKHFKDQJHVLQFXUYDWXUHLQ
ERWKV\VWROHDQGGLDVWROHRIWKHWUHDWHGYHVVHOLQWKH%56DQG036JURXSV$IWHULPSODQWDWLRQRI
036 WKHUHZDVDVLJQLILFDQWGHFUHDVH LQPHGLDQGLDVWROLFFXUYDWXUHIURPFP WR
FPS DQGPHGLDQV\VWROLFFXUYDWXUHFPWRFPSUHSUHVHQWLQJ
D SHUFHQWDJH UHGXFWLRQ RI  DQG  UHVSHFWLYHO\  )ROORZLQJ DQ $EVRUE VFDIIROG
LPSODQWDWLRQWKHUHZDVDWUHQGWRZDUGVDGHFUHDVHLQWKHPHGLDQGLDVWROLFFXUYDWXUHIURP
FPWRFPS DQGPHGLDQV\VWROLFFXUYDWXUHIURPFPWRFPS 
ZKLFKWUHQGVWRZDUGVVLJQLILFDQFH$VDUHVXOW WKHGLDVWROLFFXUYDWXUHZDVVLJQLILFDQWO\
KLJKHU LQ WKH %56 FRPSDUHG ZLWK WKH036 JURXS SRVW WUHDWPHQW >%56 YV036  FP
 YV  FP  S  @ )LJXUH  3RVW WUHDWPHQW 3HUFHQWDJH
UHODWLYHUHGXFWLRQLQFXUYDWXUHZDVDOVRVPDOOHULQWKH%56JURXSFRPSDUHGZLWK036JURXSLQ
ERWKWKHGLDVWROHDQGV\VWROHSKDVHV>%56YV036YVS YV
S   UHVSHFWLYHO\@ &\FOLF FKDQJHV LQ FXUYDWXUH LH EHWZHHQ V\VWROH DQG GLDVWROH ZHUH
VLPLODUEHWZHHQWKH%56WKDQWKH036DIWHUWKHGHSOR\PHQWLQFXUYDWXUHS 

3UHGLFWLYH IDFWRUV RIPRGLI\LQJ FXUYDWXUH ,QXQLYDULDWHDQDO\VLV WKHXVHRI036SUHGLFWVD
JUHDWHUUHGXFWLRQLQFXUYDWXUHZLWKDFRHIILFLHQWRIFRQILGHQFHLQWHUYDO
S 

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'LVFXVVLRQ
,Q VXPPDU\ WKHPDMRU ILQGLQJ RI WKLV VWXG\ VKRZHG WKDW LQ WKH GHSOR\PHQW RI ORQJ FRURQDU\
GHYLFHV PP LQ OHQJWK %56 VKRZHG D QRQVLJQLILFDQW GHFUHDVH LQ FXUYDWXUH LQ WKH SRVW
WUHDWHG YHVVHO FRPSDUHG ZLWK D VLJQLILFDQW UHGXFWLRQ LQ FXUYDWXUH RI WKH WUHDWHG YHVVHO ZLWK
GHSOR\PHQWRID0368VHRI036ZDVDQLQGHSHQGHQWSUHGLFWRURIYHVVHOFXUYDWXUHFKDQJHSRVW
GHSOR\PHQW
6WHQW FRQIRUPDELOLW\ LV GHSHQGHQW RQ ERWK WKH PDWHULDO DQG GHVLJQ RI WKH VWHQW DQG GLIIHUV
EHWZHHQ WKH FRPPHUFLDO GHYLFHV WKDW DUH DYDLODEOH$Q RSHQ FHOO VWHQW GHVLJQZRXOG KDYH
KLJKHU FRQIRUPDELOLW\ FRPSDUHG WR D FORVHG FHOO GHVLJQ 7KH GLIIHUHQFH LQ FXUYDWXUH SRVW
WUHDWPHQW EHWZHHQ%56 DQG036 FRXOG EH DWWULEXWHG WR WKH GLIIHUHQFH LQ XQGHUO\LQJPDWHULDO
FRPSRVLWLRQRIWKHGHYLFHVLQWKDWDSRO\PHULFELRUHVRUEDEOHVFDIIROGKDVEHWWHUFRQIRUPDELOLW\
WRYHVVHOJHRPHWU\FRPSDUHGWRPHWDOOLFVWHQWV,QDVWXG\HYDOXDWLQJWKHEHQGLQJVWLIIQHVVRIWKH
%56FRPSDUHGWRWKH036LQYLWUR WKHPD[LPXPFRPSUHVVLYHORDGRID%56IURP$%625%
&2+257%WULDOZDVVLJQLILFDQWO\ORZHUFRPSDUHGWRWKH;,(1&(5VWHQWZKLFKVLJQLILHVEHWWHU
FRQIRUPDELOLW\ RI WKH%56 )LJXUH 7KLV LV GHVSLWH WKH IDFW WKDW WKH VWUXW WKLFNQHVV RI WKH
$%625%&RKRUW%VWHQWLVWKLFNHUWKDQWKDWRIWKH;,(1&(5VWHQWVWUXWWKLFNQHVVPYV
P$SUHYLRXVVWXG\KDGVKRZQWKDWWKHXVHRIUHODWLYHO\VKRUWHUPP%56DQG036
GHYLFHVPRGLI\EDVHOLQHYHVVHOFXUYDWXUHEXWWKHFKDQJHZDVPRUHPDUNHGLQWKH036FRPSDUHG
ZLWKWKH%56,QWKLVVWXG\WKHPHGLDQSUHWUHDWPHQWOHVLRQOHQJWKZDVPPDQGPPLQ
WKH%56DQG036JURXSVUHVSHFWLYHO\ZKLFKDUHFRPSDUDWLYHO\VKRUWHUFRPSDUHG WRRXUVWXG\
SRSXODWLRQ7RRXUNQRZOHGJHWKLVLVWKHILUVWLQYLYRVWXG\WKDWVKRZQWKDW%56GRHVQRWDIIHFW
WKHFXUYDWXUHRIWKHWUHDWHGYHVVHOVLJQLILFDQWO\LQWKHGHSOR\PHQWRIORQJVFDIIROGV7KLVPLJKW
EHRIXVHIXOVLJQLILFDQFHDVZHWUHDWORQJHUOHVLRQVZLWKRYHUODSVFDIIROGUHTXLUHG
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9DVFXODU JHRPHWU\ LV WKHPRVW LPSRUWDQW GHWHUPLQDQWRI ORFDOZDOO VKHDU VWUHVV DQG LPSURYHG
FRQIRUPDELOLW\PLJKWKDYHFOLQLFDOLPSOLFDWLRQV6WXGLHVKDYHGHPRQVWUDWHGWKDWORZZDOOVKHDU
VWUHVV SURPRWHV DWKHURVFOHURVLV DQG SODTXH SURJUHVVLRQ LQ QDWLYH DUWHULHV DQG JUHDWHU LQWLPDO
K\SHUSODVLD DIWHU VWHQW GHSOR\PHQW  0HWDOOLF VWHQWV GHSOR\HG LQ FXUYHG SRUFLQH FRURQDU\
DUWHULHVZHUHQRWHGWRFDXVHYHVVHOVWUDLJKWHQLQJLQWKHVWHQWHGVHJPHQWDQGLQFUHDVHGFXUYDWXUH
DW WKH VWHQW HGJHV $ VWXG\ E\ *\RQJ\RVL HW DO KDG IXUWKHU VKRZHG WKDW D ORQJLWXGLQDO
VWUDLJKWHQLQJ RI VWHQWV LV DQ DGGLWLRQDO SUHGLFWRU RIPDMRU DGYHUVH HYHQWV7KHUH DUH SRVVLEOH
SK\VLRORJLFDO DQG FOLQLFDO EHQHILWV DULVLQJ IURP WKH LPSURYHPHQW LQ FRQIRUPDELOLW\ LQ WKH
ELRUHVRUEDEOH VFDIIROGV $Q LQFUHDVHG FRQIRUPDELOLW\ RI WKH %56 SODWIRUP PD\ UHVXOW LQ
SK\VLRORJLFDOZDOOVKHDUVWUHVVDWWKHVWHQWHGJHVGXHWROHVVYHVVHOGLVWRUWLRQ7KLVPD\WUDQVODWH
WR FOLQLFDO EHQHILWV VXFK DV UHGXFHG ULVN RI VFDIIROG HGJH UHVWHQRVLV  +RZHYHU WKH FOLQLFDO
EHQHILWVDVVRFLDWHGZLWKEHWWHUFRQIRUPDELOLW\VWLOOQHHGVIXUWKHUHYDOXDWLRQ
6WHQW IOH[LELOLW\ DQG FRQIRUPDELOLW\ LV DOVR RQH RI WKH NH\ GHWHUPLQDQWV RI VWHQW IUDFWXUH D
FRPPRQFDXVHRIODWHVWHQWIDLOXUH+LQJHPRWLRQLHURFNLQJEDFNDQGIRUWKRQDEHQGZDVRQH
RIWKHIDFWRUVWKDWFDQLQFUHDVHWKHULVNRIVWHQWVWUXWIUDFWXUH2XUUHVXOWVVXJJHVWWKDWWKHUHLVD
VXEWOHEXWFHUWDLQF\FOLFFKDQJHRIFXUYDWXUHDIWHUGHYLFHLPSODQWDWLRQLQERWKJURXSV$OWKRXJK
WKHUH LV QR GLIIHUHQFH EHWZHHQ JURXSV RQH FDQ VSHFXODWH WKDW WKLV F\FOLFPRYHPHQW UHSHDWLQJ
JUHDWHUWKDQWLPHVDGD\EDVHGRQDYHUDJHKHDUWUDWHRIEHDWVSHUPLQXWHFDQFDXVH
PHFKDQLFDOIDLOXUHDW WKHPHWDOOLFVWUXWV ,QDVWXG\ORRNLQJDWSUHGLFWRUVRIVWHQWIUDFWXUHVWHQW
IUDFWXUH ZDV LGHQWLILHG LQ  RI  OHVLRQV WUHDWHG ZLWK WKH ;,(1&(5 VWHQW LQ RQO\ 
PRQWKVDIWHUSODFHPHQW,QWKDWVWXG\WKHWKUHHPDMRUGHWHUPLQDQWVRIVWHQWIUDFWXUHLQRUGHURI
LPSRUWDQFHZHUHKLQJHPRWLRQRVWLDO ORFDWLRQDQGWRUWXRVLW\6LQFHWKH%56LVSURJUDPPHGWR
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JHWGLVPDQWOHG LQ WKHGXHFRXUVHRI WKHELRUHVRUSWLRQ WKLVPLJKWFDXVH OHVVSUREOHPZLWK%56
WKDQZLWK036

/LPLWDWLRQV
:HDFNQRZOHGJHWKHIROORZLQJOLPLWDWLRQV7KHVWXG\LVQRQUDQGRPL]HGDQGSRSXODWLRQLQHDFK
JURXS LV UHODWLYHO\ VPDOO'DQJLRJUDSKLF DQDO\VLVPD\DOVRQRWEH WKHPRVWRSWLPDO LPDJLQJ
PRGDOLW\ WRDVVHVV WKHJHRPHWU\RIFRURQDU\YHVVHOV+RZHYHU WKHGLIIHUHQFHVEHWZHHQ WKHSUH
DQG SRVW WUHDWPHQW DQJLRJUDSKLF YLHZV ZHUH OHVV WKDQ  LQGLFDWLQJ WKDW WKH DQDO\VLV ZHUH
PDLQO\SHUIRUPHGLQWKHVDPHDQJLRJUDSKLFYLHZ

&RQFOXVLRQ
,Q WKHGHSOR\PHQWRI ORQJFRURQDU\VFDIIROGV VWHQWV PPLQ OHQJWK ELRUHVRUEDEOHYDVFXODU
VFDIIROGVSURYLGHVEHWWHUFRQIRUPDELOLW\FRPSDUHGZLWK0367KHILQGLQJVRIWKLVVWXG\DQGLWV
FOLQLFDOVLJQLILFDQFHPHULWVIXUWKHUHYDOXDWLRQ

$FNQRZOHGJHPHQWV 7KH %96 ([SDQG DQG %96 67(0, )LUVW UHJLVWULHV DUH VXSSRUWHG E\
UHVHDUFKJUDQWVIURP$EERWW9DVFXODU3URI5REHUWJan van Geuns received speaker’s fees from 
$EERWW9DVFXODU 
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5HIHUHQFHV
6HUUX\V3:2UPLVWRQ-$'XGHN'HWDO$ELRDEVRUEDEOHHYHUROLPXVHOXWLQJFRURQDU\VWHQW
V\VWHP $%625% \HDU RXWFRPHV DQG UHVXOWV IURP PXOWLSOH LPDJLQJ PHWKRGV /DQFHW
–

6DUQR * %UXLQLQJ 1 6HUUX\V 3: HW DO 0RUSKRORJLFDO DQG IXQFWLRQDO HYDOXDWLRQ RI WKH
ELRUHVRUSWLRQ RI WKH ELRUHVRUEDEOH HYHUROLPXVHOXWLQJ YDVFXODU VFDIIROG XVLQJ ,986
HFKRJHQLFLW\ DQGYDVRPRWLRQ WHVWLQJ DW WZR \HDU IROORZXS$SDWLHQW OHYHO LQVLJKW LQWR WKH
$%625%$FOLQLFDOWULDO,QW-&DUGLRYDVF,PDJLQJ–

&RORPER $ 6WDQNRYLF * 0RVHV -: 6HOHFWLRQ RI FRURQDU\ VWHQWV - $P &ROO &DUGLRO
–

2UPLVWRQ-$'L[RQ65:HEVWHU0:HWDO6WHQWORQJLWXGLQDOIOH[LELOLW\DFRPSDULVRQRI
VWHQWGHVLJQVEHIRUHDQGDIWHUEDOORRQH[SDQVLRQ&DWKHWHU&DUGLRYDVF,QWHUY–

2QXPD<6HUUX\V3:2UPLVWRQ -$ HW DO 7KUHH\HDU UHVXOWV RI FOLQLFDO IROORZXS DIWHU D
ELRUHVRUEDEOH HYHUROLPXVHOXWLQJ VFDIIROG LQ SDWLHQWVZLWK GH QRYR FRURQDU\ DUWHU\ GLVHDVH
WKH$%625%WULDO(XUR,QWHUYHQWLRQ–

 -RVHS*RPH]/DUD+HFWRU0*DUFLD*DUFLD3DWULFN:6HUUX\VHWDO$&RPSDULVRQRIWKH
&RQIRUPDELOLW\ RI (YHUROLPXV(OXWLQJ %LRUHVRUEDEOH 9DVFXODU 6FDIIROGV WR0HWDO 3ODWIRUP
&RURQDU\6WHQWV-$P&ROO&DUGLRO,QWY–

*UHJJ:6WRQH7HLUVWHLQ36'DZNLQV.'HWDO$3URVSHFWLYH5DQGRPL]HG(YDOXDWLRQRI
D1RYHO(YHUROLPXV(OXWLQJ&RURQDU\6WHQW7KH3/$7,180$3URVSHFWLYH5DQGRPL]HG
0XOWLFHQWHU 7ULDO WR $VVHVV DQ (YHUROLPXV(OXWLQJ &RURQDU\ 6WHQW 6\VWHP >352086
(OHPHQW@ IRU WKH7UHDWPHQW RI XS WR7ZR'H1RYR&RURQDU\$UWHU\/HVLRQV7ULDO IRU WKH
3/$7,18075,$/,QYHVWLJDWRUV-$P&ROO&DUGLRO–

7DQLPRWR66HUUX\V3:7KXHVHQ/HWDO&RPSDULVRQRILQYLYRDFXWHVWHQWUHFRLOEHWZHHQ
WKH ELRDEVRUEDEOH HYHUROLPXVHOXWLQJ FRURQDU\ VWHQW DQG WKH HYHUROLPXVHOXWLQJ FREDOW
FKURPLXPFRURQDU\VWHQWLQVLJKWVIURPWKH$%625%DQG63,5,7WULDOV&DWKHWHU&DUGLRYDVF
,QWHUY–

 &KRL * &KHQJ &3 :LOVRQ 10 7D\ORU &$ 0HWKRGV IRU TXDQWLI\LQJ WKUHHGLPHQVLRQDO
GHIRUPDWLRQRIDUWHULHVGXHWRSXOVDWLOHDQGQRQSXOVDWLOHIRUFHVLPSOLFDWLRQVIRUWKHGHVLJQRI
VWHQWVDQGVWHQWJUDIWV$QQ%LRPHG(QJ–

6FKPLGW : /DQ]HU 3 %HKUHQV 3 7RSROHVNL /' 6FKPLW] .3 $ FRPSDULVRQ RI WKH
PHFKDQLFDO SHUIRUPDQFH FKDUDFWHULVWLFV RI VHYHQ GUXJHOXWLQJ VWHQW V\VWHPV &DWKHWHU
&DUGLRYDVF,QWHUY–

6DQJLRUJL * 0HO]L * $JRVWRQL 3 HW DO (QJLQHHULQJ DVSHFWV RI VWHQWV GHVLJQ DQG WKHLU
WUDQVODWLRQLQWRFOLQLFDOSUDFWLFH$QQ,VW6XSHU6DQLWD–
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5LHX 5 %DUUDJDQ 3 6DLQVRXV - HW DO $VVHVVPHQW RI WKH WUDFNDELOLW\ IOH[LELOLW\ DQG
FRQIRUPDELOLW\ RI FRURQDU\ VWHQWV D FRPSDUDWLYH DQDO\VLV &DWKHWHU &DUGLRYDVFXODU
,QWHUYHQWLRQ

-DPHV32EHUKDXVHU6\HG+RVVDLQ\5LFKDUG-5DSR]D'HVLJQSULQFLSOHVDQGSHUIRUPDQFH
RI ELRUHVRUEDEOH SRO\PHULF YDVFXODU VFDIIROGV (XUR,QWHUYHQWLRQ 6XSSOHPHQW  9RO 
6XSSOHPHQW)))

6DPDG\+(VKWHKDUGL3*LGGHQV'3HW DO&RURQDU\DUWHU\ZDOO VKHDU VWUHVV LV DVVRFLDWHG
ZLWK SURJUHVVLRQ DQG WUDQVIRUPDWLRQ RI DWKHURVFOHURWLF SODTXH DQG DUWHULDO UHPRGHOLQJ LQ
SDWLHQWVZLWKFRURQDU\DUWHU\GLVHDVH&LUFXODWLRQ$XJ

:HQW]HO--.UDPV56FKXXUELHUV -&HW DO5HODWLRQVKLSEHWZHHQQHRLQWLPDO WKLFNQHVVDQG
VKHDU VWUHVV DIWHU :DOOVWHQW LPSODQWDWLRQ LQ KXPDQ FRURQDU\ DUWHULHV &LUFXODWLRQ
–

:HQW]HO--:KHODQ'0YDQGHU*LHVVHQ:-HWDO&RURQDU\VWHQWLPSODQWDWLRQFKDQJHV'
YHVVHOJHRPHWU\DQG'VKHDUVWUHVVGLVWULEXWLRQ-%LRPHFK–

*\|QJ\|VL0<DQJ3*ORJDU' HW DO$XVWULDQ:LNWRU6WHQW6WXG\*URXS DQG(XURSHDQ
3DUDJRQ 6WHQW ,QYHVWLJDWRUV /RQJLWXGLQDO VWUDLJKWHQLQJ HIIHFW RI VWHQWV LV DQ DGGLWLRQDO
SUHGLFWRUIRUPDMRUDGYHUVHFDUGLDFHYHQWV-$&&

.XUDPLWVX 6 ,ZDEXFKL0+\RGR0 HW DO ,QFLGHQFH DQG FOLQLFDO LPSDFW RI VWHQW IUDFWXUH
DIWHUHYHUROLPXVHOXWLQJVWHQWLPSODQWDWLRQ&LUF&DUGLRYDVF,QWHUY.2FW
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/HJHQGV
)LJXUH$%LRUHVRUEDEOH$EVRUEVFDIIROG7KHVHFRQGJHQHUDWLRQ$%625%%56UHYLVLRQ
KDVDVWUXWWKLFNQHVVRIXPFRQVLVWLQJRILQSKDVH]LJ]DJKRRSVOLQNHGE\EULGJHV7KH
GHYLFHLVUDGLROXFHQWEXWKDVUDGLRRSDTXHSODWLQXPPDUNHUVDWHDFKSUR[LPDODQGGLVWDOHGJH
WKDWIDFLOLWDWHHDVHRIYLVXDOL]DWLRQRQDQJLRJUDSK\

)LJXUH % &REDOW &KURPLXP (YHUROLPXV (OXWLQJ 6WHQW &R&U ((6 ;,(1&(5 7KH
;,(1&(5 DUH WKH PHWDO SODWIRUP VWHQWV DQG FRQVLVW RI D PHWDOOLF SODWIRUP PDGH RI FREDOW
FKURPLXPDOOR\7KHVWUXWVDUHVHUSHQWLQHULQJVFRQQHFWHGE\OLQNVIDEULFDWHGIURPDVLQJOHSLHFH
7KH;,(1&(5LVFRYHUHGE\DQHYHUROLPXVFRDWLQJ

)LJXUH  &XUYDWXUH $QDO\VLV RI WKH %56 DQG 036 &XUYDWXUH DQDO\VLV EHIRUH DQG DIWHU
GHSOR\PHQWRID%56)LJXUH$DQG%DQGD036)LJXUH&DQG'$IWHULPSODQWDWLRQRI
D%56WKHFXUYDWXUHFKDQJHGIURPFPWRFPZKHUDVDIWHUWKH036ZDVLPSODQWHG
WKHFXUYDWXUHFKDQJHGIURPFP WRFP%56%LRUHVRUEDEOH$EVRUEVFDIIROG036
0HWDOOLFSODWIRUPVWHQW

)LJXUH  )ORZ &KDUW RI 3DWLHQW 6HOHFWLRQ %56 %LRUHVRUEDEOH $EVRUE 6FDIIROG  &72
&KURQLF7RWDO2FFOXVLRQ0360HWDOOLF3ODWIRUPVWHQWV67(0,67HOHYDWLRQ0\RFDUGLDO,QIDUFW

)LJXUH&KDQJHLQFXUYDWXUHSRVWWUHDWPHQW LQ%56DQG0367KLVER[SORWLOOXVWUDWHVWKH
GLIIHUHQFHLQPHGLDQGLDVWROLFFXUYDWXUHSRVWWUHDWPHQWLQWKH%$6FRPSDUHGWRWKH036JURXS
)LJXUH0D[LPXPFRPSUHVVLYHIRUFHRI$%625%&RKRUW%VFDIIROGDQG;,(1&(9VWHQW
7KLV ILJXUH VKRZV WKHPD[LPXPFRPSUHVVLYH IRUFH DSSOLHG WR GHIOHFW WKH$%625%&RKRUW%
DQG ;,(1&( 9  [ PP GHYLFHV E\  PP XVLQJ  SRLQW EHQG WHVW Q  6WDWLVWLFDO
DQDO\VLV \LHOGHG S   XVLQJ 2QH ZD\ $129$ DQG 7XNH\ .UDPHU +6' 7HVWV ZHUH
SHUIRUPHGE\DQGGDWDDUHRQILOHDW$EERWW9DVFXODU5HSURGXFHGZLWKSHUPLVVLRQE\-DPHV
32EHUKDXVHUHWDO(XURLQWHUYHQWLRQ



 
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7DEOHV
7DEOH,%DVHOLQH&OLQLFDODQG$QJLRJUDSKLF&KDUDFWHULVWLFV
 %561  0361  SYDOXH
$JH\HDUV   
0HQ   
+\SHUWHQVLRQ   
+\SHUFKROHVWHUROHPLD   
'LDEHWHVPHOOLWXV   
6PRNHU$FWLYH   
)DPLO\+LVWRU\   
3UHYLRXV&9$   
3UHYLRXV$0,   
3UHYLRXV3&,   
3UHYLRXV&$%*   
&OLQLFDOSUHVHQWDWLRQ   
6WDEOHRUVLOHQWDQJLQD   
8QVWDEOHDQJLQD67(0,   
7DUJHW9HVVHO   
/$'   
/&;   
5&$   
59'PP   
0/'PP   
'LDPHWHUVWHQRVLV   
3UHWUHDWPHQWUHJLRQ
OHQJWKPP
  

9DOXHVDUHSUHVHQWHGDVQXPEHUSHUFHQWDJHVRUPHGLDQLQWHUTXDUWLOHUDQJH
$0,$FXWH0\RFDUGLDO,QIDUFW%56%LRUHVRUEDEOH$EVRUEVFDIIROG&$%*&RURQDU\$UWHU\%\SDVV
*UDIW &9$ &HUHEURYDVFXODU $FFLGHQW /$'  OHIW DQWHULRU GHVFHQGLQJ DUWHU\ /&;  /HIW FLUFXPIOH[
DUWHU\0/' 0LQLPDO OXPLQDO GLDPHWHU0360HWDOOLF 3ODWIRUP VWHQW 3&, 3HUFXWDQHRXV &RURQDU\
,QWHUYHQWLRQ 5&$ 5LJKW FRURQDU\ DUWHU\ 59'  5HIHUHQFH YHVVHO GLDPHWHU  67(0, 67 HOHYDWLRQ
0\RFDUGLDO,QIDUFW

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

7DEOH,,&KDQJHVLQFXUYDWXUHRIWKH6WXG\3RSXODWLRQ
 %561  0361  SYDOXH
3UHWUHDWPHQW&XUYDWXUHFP   
6\VWROH   
'LDVWROH   
3RVWWUHDWPHQW&XUYDWXUHFP   
6\VWROH   
'LDVWROH   
3HUFHQWDJHUHGXFWLRQLQFXUYDWXUHSRVW
SUHWUHDWPHQW
  
6\VWROH   
'LDVWROH   
SYDOXHIRUFRPSDULVRQEHWZHHQ3UHDQGSRVW
FXUYDWXUHLQV\VWROH
  
SYDOXHIRUFRPSDULVRQEHWZHHQ3UHDQGSRVW
FXUYDWXUHLQGLDVWROH
  
$EVROXWHUHGXFWLRQLQFXUYDWXUHFP   
6\VWROH   
'LDVWROH   
3HUFHQWDJH5HODWLYHFKDQJHLQFXUYDWXUHFP   
6\VWROH   
'LDVWROH   
3UHWUHDWPHQW&\FOLFFKDQJHLQFXUYDWXUHFP   
3RVWWUHDWPHQW&\FOLFFKDQJHLQFXUYDWXUHFP   

9DOXHVDUHSUHVHQWHGDVQXPEHUVRUPHGLDQLQWHUTXDUWLOHUDQJH
%56%LRUHVRUEDEOH$EVRUEVFDIIROG0360HWDOOLF3ODWIRUPVWHQW
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)LJXUHV


)LJXUH$%LRUHVRUEDEOH$EVRUEVFDIIROG




7KHVHFRQGJHQHUDWLRQ$%625%%56UHYLVLRQKDVDVWUXWWKLFNQHVVRIPFRQVLVWLQJ
RI LQSKDVH ]LJ]DJ KRRSV OLQNHG E\ EULGJHV 7KH GHYLFH LV UDGLROXFHQW EXW KDV  UDGLRRSDTXH
SODWLQXP PDUNHUV DW HDFK SUR[LPDO DQG GLVWDO HGJH WKDW IDFLOLWDWH HDVH RI YLVXDOL]DWLRQ RQ
DQJLRJUDSK\
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)LJXUH%&REDOW&KURPLXP(YHUROLPXV(OXWLQJ6WHQW&R&U((6;,(1&(5




7KH;,(1&(5DUHWKHPHWDOSODWIRUPVWHQWVDQGFRQVLVWRIDPHWDOOLFSODWIRUPPDGHRIFREDOW
FKURPLXPDOOR\7KHVWUXWVDUHVHUSHQWLQHULQJVFRQQHFWHGE\OLQNVIDEULFDWHGIURPDVLQJOHSLHFH
7KH;,(1&(5LVFRYHUHGE\DQHYHUROLPXVFRDWLQJ

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
)LJXUH&XUYDWXUH$QDO\VLVRIWKH%56DQG036



&XUYDWXUHDQDO\VLVEHIRUHDQGDIWHUGHSOR\PHQWRID%56)LJXUH$DQG%DQGD036)LJXUH
&DQG'$IWHU LPSODQWDWLRQRI D%56 WKHFXUYDWXUH FKDQJHG IURP FP WRFP
ZKHUDVDIWHUWKH036ZDVLPSODQWHG WKHFXUYDWXUHFKDQJHGIURPFP WRFP%56
%LRUHVRUEDEOH$EVRUEVFDIIROG0360HWDOOLFSODWIRUPVWHQW
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)LJXUH)ORZ&KDUWRI3DWLHQW6HOHFWLRQ




%56%LRUHVRUEDEOH$EVRUE6FDIIROG
&72&KURQLF7RWDO2FFOXVLRQ
0360HWDOOLF3ODWIRUPVWHQWV
67(0,67HOHYDWLRQ0\RFDUGLDO,QIDUFW
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)LJXUH&KDQJHLQFXUYDWXUHSRVWWUHDWPHQWLQ%56DQG036


7KLVER[SORWLOOXVWUDWHVWKHGLIIHUHQFHLQPHGLDQGLDVWROLFFXUYDWXUHSRVWWUHDWPHQWLQWKH%$6
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ABSTRACT
OBJECTIVES This study sought to evaluate the mechanism of post-procedural cardiac biomarker (CB) rise following
device implantation.
BACKGROUND A fully bioresorbable Absorb scaffold, compared with everolimus-eluting metallic stents (EES),
might be associated with a higher incidence of periprocedural myocardial injury.
METHODS In 501 patients with stable or unstable angina randomized to either Absorb (335 patients) or EES (n ¼ 166) in
the ABSORB II trial, 3 types of CB (creatine kinase, creatine kinase-myocardial band, and troponin) were obtained before
and after procedure. Per protocol, periprocedural myocardial infarction (PMI) was deﬁned as creatine kinase rise >2 the
upper limit of normal with creatine kinase-myocardial band rise.
RESULTS Incidence of side branch occlusion and any anatomic complications assessed by angiography was
similar between the 2 treatment arms (side branch occlusion: Absorb: 5.3% vs. Xience: 7.6%, p ¼ 0.07; any
anatomic complication: Absorb: 16.4% vs. EES: 19.9%, p ¼ 0.39). Fourteen patients who presented with
recent myocardial infarction at entry with normalized creatine kinase-myocardial band according to the protocol
were excluded for post-CB analysis. The overall compliance for CB was 97.8%. The CB rise subcategorized in
7 different ranges was comparable between the 2 treatment arms. PMI rate was numerically higher in the
Absorb arm according to the per-protocol deﬁnitions, and treatment with overlapping devices was the only
independent determinant of per-protocol PMI (odds ratio: 5.07, 95% conﬁdence interval: 1.78 to 14.41,
p ¼ 0.002).
CONCLUSIONS There were no differences in the incidence of CB rise and PMI between Absorb and EES. Device overlap
might be a precipitating factor of myocardial injury. (ABSORB II Randomized Clinical Trial: A Clinical Evaluation to
Compare the Safety, Efﬁcacy, and Performance of Absorb Everolimus Eluting Bioresorbable Vascular Scaffold System
Against Xience Everolimus Eluting Coronary Stent System in the Treatment of Subjects With Ischemic Heart Disease
Caused by De Novo Native Coronary Artery Lesions [ABSORB II]; NCT01425281). (J Am Coll Cardiol Intv 2015;8:1053–63)
© 2015 by the American College of Cardiology Foundation.
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T he bioresorbable everolimus-elutingscaffold (Absorb, Abbott Vascular,Santa Clara, California) was devel-
oped to provide a novel approach to treat cor-
onary artery stenosis with transient vessel
support and drug delivery (1–4). The perfor-
mance of the second-generation Absorb was
investigated in the ABSORB Cohort B trial
(ABSORB Clinical Investigation, Cohort B),
which reported excellent clinical results
(5–7). However, the clinical relevance of
this technology in comparison with metallic
drug-eluting stents still remains a matter of
debate due to the absence of randomized
comparative data between the Absorb and
conventional metallic drug-eluting stents.
The ABSORB II (ABSORB II Randomized
Clinical Trial: A Clinical Evaluation to Com-
pare the Safety, Efﬁcacy, and Performance
of Absorb Everolimus Eluting Bioresorbable
Vascular Scaffold System Against Xience
Everolimus Eluting Coronary Stent System in the
Treatment of Subjects With Ischemic Heart Disease
Caused by De Novo Native Coronary Artery Lesions)
(8) is the ﬁrst randomized clinical trial assessing the
clinical outcomes in 501 patients treated with either
the Absorb or the metallic everolimus-eluting stent
(EES) (Xience, Abbott Vascular).
In a nonrandomized comparison using historical
data, the Absorb scaffold was associated with a
higher incidence of post-procedural side branch oc-
clusion (SBO) than EES was (9). Given the increased
strut thickness of Absorb, a potential concern
exists that it might be associated with a higher in-
cidence of periprocedural myocardial injury and
periprocedural myocardial infarction (PMI) than
newer-generations of DES are (9). Therefore, the aim
of this study is to investigate the incidence and
mechanism of post-procedural cardiac biomarker
(CB) rise following Absorb scaffold versus metallic
EES implantation.
METHODS
STUDY DESIGN. The ABSORB II randomized con-
trolled trial design has been described in detail
previously (8). In brief, the ABSORB II trial was pro-
spective, multicenter, single-blinded, randomized
controlled trial that compared the safety and efﬁcacy
of the Absorb versus the EES in patients with stable
or unstable angina due to up to 2 de novo coronary
artery lesions, each located in different major
epicardial vessels, all with an angiographic maximal
luminal diameter between 2.25 and 3.8 mm as esti-
mated by online quantitative coronary angiography
and a lesion length of #48 mm. The detail of both
study devices is provided in the Online Appendix
(2,10,11). A total of 501 patients were randomized
2:1 into either the Absorb arm or the EES arm in
Europe and New Zealand.
QUALITATIVE AND QUANTITATIVE ANGIOGRAPHIC
ASSESSMENT. SBO, occurrence of no-reﬂow, abrupt
closure, dissection, and distal embolization in main
and side branches were assessed qualitatively at pre-
procedure, after balloon pre-dilation, after device
deployment, and after ﬁnal balloon inﬂation. Coro-
nary dissections were assessed using the National
Heart, Lung and Blood Institute criteria (12,13). In the
present study, according to the underlying “anatomic
complications” (assessed by angiography), CB rise
and PMI were classiﬁed into 3 types: type 1—CB rise
and PMI due to SBO; type 2—CB rise and PMI due to
other anatomic complications (e.g., slow ﬂow or no-
reﬂow, distal embolization, thrombus during proce-
dure, ﬂow-limiting dissection, coronary dissection of
National Heart, Lung and Blood Institute type D or E,
or disruption of collateral ﬂow); type 3—CB rise and
PMI without angiographically identiﬁable causes for
the CB rise (Figure 1).
The quantitative angiographic analysis by the
2-dimensional single-vessel quantitative coronary
angiography (CAAS 5.10, Pie Medical BV, Maastricht,
ABBR EV I A T I ON S
AND ACRONYMS
CB = cardiac biomarker
CI = conﬁdence interval
CK = creatine kinase
CK-MB = creatine kinase-
myocardial band
EES = everolimus-eluting
stent(s)
IVUS = intravascular
ultrasound
OR = odds ratio
PMI = periprocedural
myocardial infarction
RVD = reference vessel
diameter
SBO = side branch occlusion
TIMI = Thrombolysis In
Myocardial Infarction
ULN = upper limit of the
normal
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the Netherlands) included the reference size of the
side branch and the percentage of diameter stenosis
of any side branch lesion as well as the side branch
TIMI (Thrombolysis In Myocardial Infarction) ﬂow
grade at the following time points: pre-procedure;
after pre-dilation; after post-dilation; and post-
procedure (9). The region of interest was deﬁned as
the study device implantation site and the 5-mm
proximal and distal margins in the main branch
(Figure 2). A detailed side branch analysis was per-
formed of all side branches identiﬁed within the
region of interest pre-procedurally, during the course
of the intervention to capture any transient compli-
cations, and post-procedure. SBO was deﬁned as a
reduction in the TIMI ﬂow grade 0 to 1. Accordingly,
side branches with pre-procedural TIMI ﬂow grade
0 or 1 were excluded. Transient or ﬁnal SBO was
deﬁned as SBO that occurred during the procedure
and either disappeared or persisted at the end of
the procedure. Angiographic assessment of the side
branch was based on the consensus of 3 experienced
cardiologists (Y.I., T.M., and Y.C.) and assessed in
at least 2 different projections, with angiographic
assessment for each side branch.
IVUS IMAGE ACQUISITION. Intravascular ultrasound
(IVUS) was mandatory before and after the procedure.
The detail of an image acquisition is described in
Online Figure 1.
BLOOD SAMPLING. The protocol mandated that
blood sampling for cardiac enzymes was to be col-
lected within 6 h before the index percutaneous
FIGURE 1 Classiﬁcation According to Angiographic Mechanism After Revascularization
Type 1: cardiac biomarker rise due to side branch occlusion. Type 2: cardiac biomarker rise due to other anatomic complications. Type 3: cardiac biomarker rise without
any identiﬁable anatomic causes in the coronary artery. Pre-procedure angiography showed a focal stenosis (white arrows), side branches in the target lesion
(yellow arrows), and distal embolization was observed after device implantation (red arrow).
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coronary intervention procedure and at 6, 12, and
18 h after the procedure or at hospital discharge,
whichever came ﬁrst. These blood samples were sent
to the central core laboratory (ICON Laboratories,
Dublin, Ireland) and to local hospital laboratories
for analysis. Whenever clinically indicated, addi-
tional sampling could be taken and analyzed by the
local hospital laboratories.
This yielded a mixture of local and central lab-
oratories’ biomarker results with different upper
limits of normal (ULN). When both local and central
laboratories’ cardiac enzyme data were available
at the same time, the clinical events committee
used the central laboratories’ results for the adju-
dication of MI.
DEFINITIONS OF PERIPROCEDURAL MYOCARDIAL
INFARCTION. In this study protocol, MI was deﬁned
according to the following deﬁnitions (14–16): 1) per-
protocol (modiﬁed World Health Organization) deﬁ-
nition; and 2) extended historical deﬁnition (14). In
the protocol, MI without distinction of being sponta-
neous or PMI is deﬁned by elevation of total creatine
kinase (CK) to >2 ULN along with elevated or
“positive” creatine kinase-myocardial band (CK-MB).
A hierarchical approach was used for the adjudication
of PMI based on CB availability when an analyzable
CB was missing (extended historical deﬁnition:
CK-MB mass when CK was not available, cardiac
troponin when CK and CK-MB mass were not avail-
able). All protocol deﬁned clinical outcomes were
FIGURE 2 Detailed Analysis of SBO
The QCA analysis delineates 5-mm proximal (A) (red double arrow) and distal segment (A) (green double arrow) to the intended device implantation site (B)
(white double arrow). Any visible side branches originating from this region of interest were analyzed. The conventional QCA analysis automatically delineates an
obstruction segment in the main branch (B) (yellow double arrow). An example of side branch analysis is shown in C and D. DS ¼ diameter stenosis; QCA ¼ quantitative
coronary angiography; RVD ¼ reference vessel diameter; SBO ¼ side branch occlusion.
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adjudicated by an independent Clinical Events Com-
mittee. Fourteen patients presented with recent MI at
entry with normalized CK-MB according to the pro-
tocol, but with/without troponin elevation. These
patients were excluded for post-CB analysis. Post-hoc
adjudication was performed according to Society of
Cardiovascular Angiography and Interventions deﬁ-
nition and the universal third deﬁnition. The details
are described in the Online Appendix.
STATISTICAL ANALYSIS. All analyses were per-
formed on the intention-to-treat basis, using all pa-
tients randomized in the study, regardless of the
treatment actually received. The counts of PMI are
summarized and tabulated according to the fre-
quency. Categorical variables were compared by
Fisher exact test. Continuous variables are presented
as mean  SD and were compared by nonparametric
test. The logistic regression model was performed
for Table 5. Detail of statistical analysis is provided
in the Online Appendix. In addition to the device
type, signiﬁcant variables (p < 0.10) in the univariate
analysis were forced into a multivariate logistic
regression model to predict PMI. All statistical tests
were performed with SPSS (version 22.0 for Windows,
SPSS, Chicago, Illinois). A 2-sided p value of <0.05
was considered to indicate statistical signiﬁcance.
RESULTS
PATIENT AND PROCEDURAL CHARACTERISTICS.
Patient demographics were comparable in both arms
(Table 1). The lesion characteristics such as type B2/C
lesions, bifurcation lesions, eccentricity, moderate/
severe tortuosity, thrombus, and moderate/severe
calciﬁcation were similar between the 2-treatment
arms.
AVAILABILITY OF CARDIAC BIOMARKERS OF
MYOCARDIAL INJURY. Within 24 h before the index
procedure, 920 blood time points for the assessment
of CB were available with 458 central and 462 local
biomarker data. At least 1 of the 3 CB was available in
486 patients (97.0%) within 6 h and in 495 patients
(98.8%) within 24 h before the index procedure. At
least 1 of the 3 CB was available in 490 patients
(97.8%) within 48 h after the index procedure. In the
serial sample analysis, 1,446 blood time points for the
assessment of CB were available with 572 central and
874 local biomarker data (Figure 3). A total of 3,813
blood samples with 1,257 CK, 1,253 CK-MB, and 1,303
troponin values were available. For the post-
procedural peak-level assessment of each CB, the
central biomarker data was used in 58.4% for CK
(271 of 464), 70.9% for CK-MB (337 of 475), and 45.0%
for troponin (213 of 473). The availability of paired
biomarkers (CK and CK-MB) for per-protocol PMI
adjudication at post-procedure was available in
93.4% (313 of 335) of the Absorb arm and 96.4%
(160 of 166) of the EES arm. Troponin was available
in 98.8% (325 of 335) of the Absorb arm and 97.6%
(160 of 166) of the EES arm.
QUALITATIVE AND QUANTITATIVE ANGIOGRAPHIC
ASSESSMENT. The frequencies of “angiographic
complications” are shown in Table 2. In the present
analysis, 335 patients with 988 side branches in the
Absorb arm and 166 patients with 503 side branches in
the EES arm were assessed. Incidence of any “angio-
graphic complications” and SBO was similar between
the 2 treatment arms (any complications: Absorb:
16.4% vs. EES: 19.9%, p ¼ 0.39; SBO: 5.3% vs. 7.6%,
p ¼ 0.07). The incidence of post-procedural SBO in
the obstruction segment was signiﬁcantly lower in
the Absorb arm than in the EES arm (4.3% vs. 6.8%,
TABLE 1 Baseline Demographic Data and Angiographic Characteristics in Patients
Absorb
(335 Patients,
364 Lesions)
EES
(166 Patients,
182 Lesions) p Value
Age, yrs 61.5  10.0 60.9  10.0 0.51
Male 253 (75.5) 132 (79.5) 0.32
Body mass index, kg/m2 27.9  4.1 28.1  3.7 0.56
Current smoker 79 (23.6) 36 (21.7) 0.64
Hypertension requiring treatment 220 (65.7) 112 (67.5) 0.69
Dyslipidemia requiring treatment 238 (71.0) 123 (74.1) 0.47
Any diabetes mellitus 80 (23.9) 40 (24.1) 0.96
Unstable angina 68 (20.3) 37 (22.3) 0.61
Family history of coronary artery disease 112 (36.6) 64 (41.3) 0.33
Previous history of myocardial infarction 93 (28.0) 48 (28.9) 0.83
Number of lesions/patient 1.1  0.3 1.1  0.3 0.81
Lesion location
Right coronary artery 95 (26.1) 56 (30.8) 0.25
Left anterior descending artery 163 (44.8) 84 (46.2) 0.76
Left circumﬂex artery or ramus 106 (29.1) 42 (23.1) 0.13
ACC/AHA lesion complexity
A 5 (1.4) 1 (0.6) 0.67
B1 193 (53.2) 90 (50.0) 0.49
B2 159 (43.8) 87 (48.3) 0.32
C 6 (1.7) 2 (1.1) 1.00
TIMI ﬂow grade 0 or 1 1 (0.3) 2 (1.1) 0.26
Calciﬁcation, moderate or severe 46 (12.7) 28 (15.5) 0.37
Tortuosity, moderate or severe 34 (9.4) 13 (7.2) 0.39
Eccentric 357 (98.3) 178 (99.4) 0.43
Thrombus 5 (1.4) 4 (2.2) 0.49
Bifurcation 13 (3.6) 5 (2.8) 0.62
Reference vessel diameter, mm 2.59  0.38 2.63  0.40 0.36
Percentage of diameter stenosis 58.6  11.1 59.7  11.6 0.30
Obstruction lesion length, mm 13.8  6.5 13.8  6.6 1.00
Values are mean  SD or n (%).
ACC ¼ American College of Cardiology; AHA ¼ American Heart Association; EES ¼ everolimus-eluting stent(s).
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p ¼ 0.046), although there were no signiﬁcant dif-
ferences in the incidence of SBO according to the
reference vessel diameter (RVD) size (RVD # 0.5 mm,
0.5 mm < RVD # 1.0 mm, 1.0 mm < RVD). Each type
(type 1, type 2, and type 3) of “anatomic complica-
tions” after revascularization was similar between
the 2 treatment arms. However, 2 abrupt occlusions
were documented after EES implantation (Table 2).
INCIDENCE OF CARDIAC BIOMARKER RISE AND
PERIPROCEDURAL MI. As recently described (17),
we compared the peak value of the 3 CB values
post-procedure according to 5 rise categories (CB:
>2 ULN, >5 ULN, >10 ULN, > 35 ULN, and >70
ULN) after scaffold or stent implantation. In the
present study, the rise of 3 CB subcategorized in
7 different ranges was comparable between the 2
treatment arms (Table 3).
Per-protocol PMI (World Health Organization deﬁ-
nition) occurred in 13 of 335 patients (3.9%) in the
Absorb arm and 2 of 166 patients (1.2%) in the EES arm
(p ¼ 0.16). Incidence of PMI per protocol according to
“anatomic complications” assessed by angiography
was similar between the 2 treatment arms (Table 4).
In the post-hoc adjudication, the PMI rates according
to the third universal deﬁnition and the Society of
Cardiovascular Angiography and Interventions deﬁ-
nition were 14.2% versus 10.6% (p ¼ 0.31) and 0.6%
versus 0.6% (p ¼ 1.00), respectively.
CARDIAC BIOMARKER RISE, ANGIOGRAPHY, AND
GRAYSCALE/RADIOFREQUENCY IVUS. Figure 4
shows the magnitude of post-procedural CB rise
in patients with “anatomic complications” (type 1 and
type2)assessedbyangiography.CBrise subcategorized
in 5 different ranges was similar between the 2 treat-
ment arms in the patients with “anatomic complica-
tions.” Incidence of CB rise assessed by IVUS (data not
shown) was similar between the 2 treatment arms
as well as “angiographic complications.” There was
no statistical signiﬁcance between IVUS ﬁnding and
post-procedure CB rising (Online Appendix).
PREDICTORS OF PERIPROCEDURAL MYOCARDIAL
INFARCTION. In the multivariable analyses, treat-
ment with overlapping devices was the only inde-
pendent determinant of per-protocol PMI (odds ratio
[OR]: 5.07, 95% conﬁdence interval [CI]: 1.78 to 14.41,
p ¼ 0.002) (Table 5).
DISCUSSION
The present study is the ﬁrst randomized clinical trial
to analyze the difference in frequencies of PMI and CB
rise after implantation of Absorb scaffold or EES.
The main ﬁndings of this study follow: 1) Incidence of
any anatomic complications including SBO assessed
by angiography was similar between the 2 treatment
arms (Absorb: 16.4% vs. EES: 19.9%, p ¼ 0.39). 2) Per-
protocol PMI (World Health Organization deﬁnition)
occurred in 13 of 335 patients (3.9%) in the Absorb arm
and 2 of 166 patients (1.2%) in the EES arm (p ¼ 0.16).
Of 15 patients with per-protocol PMI, 10 PMI
(66.7%) were caused by SBO, whereas 3 (20.0%) were
due to other anatomical complications. 3) Treatment
with overlapping devices was an independent
FIGURE 3 Time Points and Availability for the Assessment of CB Pre- and
Post-Procedure
A total of 920 blood time points for the assessment of cardiac biomarkers (CB) were
available with 458 central and 462 local biomarker data within 24 h before the index
procedure. At least 1 of the 3 CB was available in 486 patients (97.0%) within 6 h and 495
patients (98.8%) within 24 h before the index procedure. At least 1 of the 3 CB was
available in 490 patients (97.8%) within 48 h after the index procedure. In the serial
sample analysis, 1,446 blood time points for the assessment of CB were available with 572
central and 874 local biomarker data.
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determinant of per-protocol PMI (OR: 5.07, 95% CI:
1.78 to 14.41, p ¼ 0.002). 4) The CB rise sub-
categorized in 7 different ranges was comparable be-
tween the 2 treatment arms.
AVAILABILITY OF CARDIAC BIOMARKER AND PERI-
PROCEDURAL CARDIAC BIOMARKER RISE. This is the
ﬁrst scaffold or metallic stent study in which 3
different CB values were available at a central core
laboratory, the compliance of enzyme collection was
high (CK: 95.3%, CK-MB: 97.5%, troponin: 97.1%). Of
note, in the RESOLUTE-All Comers (A Randomized
Comparison of a Zotarolimus-Eluting Stent With an
Everolimus-Eluting Stent for Percutaneous Coronary
Intervention) trial (14), an analyzable dataset for
cardiac troponin was available in 55.3% (1,173 of 2,121)
of patients. In addition, 44.1% (935 of 2,121) of pa-
tients had an analyzable dataset for both cardiac
troponin and CK-MB (14). In 10 patients, 3 CB simul-
taneously increased, whereas in 127 patients, discor-
dance in CB rise was documented, suggesting that
the sensitivity of CB to detect myocardial damage
varies according to the criteria and type of CB (Online
Figure 2).
The prognostic relevance of CB rise is shown by
Park et al. (18), in a large cohort of 23,604 patients,
the prognostic implication of a CK-MB rise 3 to 5
ULN. Myint et al. (19) reported that prognostic sig-
niﬁcance of troponin in acute coronary syndrome
attenuates with increased age and that older age is
associated with a worse prognosis compared with the
prognosis of younger counterparts given the same
level of troponin rise, even at very low levels of
troponin.
ANATOMICCOMPLICATIONSASSESSEDBYANGIOGRAPHY/
IVUSAND PERIPROCEDURAL CARDIAC BIOMARKER RISE
WITH ABSORB OR EES. In the previous publication
using the data of the Absorb Extend registries with a
matched cohort from SPIRIT (Clinical Evaluation of
the Xience V Everolimus Eluting Coronary Stent
System) trials (9), it was reported that the Absorb
scaffold was associated with a higher SBO rate than
Xience was. The difference was more pronounced
with small side branches with an RVD #0.5 mm.
However, there was no signiﬁcant difference in the
incidence of post-procedure CK-MB elevation. It was
hypothesized that the difference in SBO was due to
the difference in the design of the 2 devices. The
Absorb scaffold has thicker (156 mm) and wider struts
(up to 800 mm) with a higher surface coverage ratio
(26% to 32%) than Xience does (thickness: 90 mm,
widths: up to 428 mm, surface coverage: 13%).
Therefore small side branches could be more fre-
quently occluded by the implantation of Absorb
scaffold. At variance with the report by Muramatsu
et al. (9), the Absorb, compared with EES, showed a
trend toward lower incidence of post-procedural SBO.
Of note, most of the SBO occurred in small side
branches of RVD <1.0 mm in both of treatment arms
(Table 2). Although the nominal sizes of devices used
(3.01  0.31 mm vs. 3.05  0.28 mm, p ¼ 0.10) and
frequency of post-device dilation were comparable
(60.7% vs. 58.8%, p ¼ 0.67), the nominal balloon size
and the pressure used during either implantation or
post-dilation was larger and higher in the EES arm, so
that the expected balloon diameter tended to be larger
accordingly (3.29  0.35 mm vs. 3.35  0.37 mm,
p¼0.15) (17), the acute gain inminimal lumendiameter
(quantitative coronary angiography measurement
by the core laboratory) was signiﬁcantly larger in
the EES arm (1.15  0.38 mm vs. 1.46  0.38 mm,
p < 0.001) (17). Whether the aggressive (post)-
dilation may have resulted in a higher incidence
TABLE 2 Anatomic Complications Assessed by Angiography
Per-Patient Analysis
Absorb
(n ¼ 335)
EES
(n ¼ 166) p Value
Any anatomic complications assessed
by angiography
16.4 (56) 19.9 (33) 0.39
Type 1 anatomic complication assessed
by angiography
SBO 12.5 (43) 15.7 (26) 0.41
SBO after pre-dilation 0 (0) 0 (0) 1.00
SBO after device implantation 12.5 (43) 15.7 (26) 0.41
SBO improvement after NTG 0.9 (3) 0 (0) 0.55
SBO after procedure 11.6 (40) 15.7 (26) 0.26
Type 2 anatomic complication assessed by
angiography
Abrupt closure 0 (0) 1.8 (2) 0.11
Distal embolization 0.3 (1) 0 (0) 1.00
Coronary perforation 0.6 (2) 0 (0) 1.00
Flow-limiting dissection (NHLBI type F) 0.3 (1) 0 (0) 1.00
Coronary dissection after pre-dilation
(NHLBI type D or E)
1.8 (6) 1.2 (2) 1.00
Coronary dissection after device implantation 0.3 (1) 0.6 (1) 1.00
Thrombus during procedure 0.3 (1) 0 (0) 1.00
Disruption of collateral ﬂow 0.3 (1) 1.2 (2) 0.26
Per-Side Branch Analysis (n ¼ 998) (n ¼ 503)
Incidence of SBO after procedure 5.3 (52) 7.6 (39) 0.07
Location of occluded side branch
Outside scaffold segment 0 (0) 0 (0) 1.00
To-be-scaffold segment outside obstruction 0.9 (9) 1.0 (5) 1.00
Obstruction segment 4.3 (42) 6.8 (34) 0.046
RVD of occluded side branch
RVD > 1.0 mm 0.9 (9) 1.2 (6) 0.59
0.5 mm < RVD # 1.0 mm 2.9 (29) 4.2 (21) 0.22
RVD # 0.5 mm 1.3 (13) 2.4 (12) 0.14
Values are % (n).
EES ¼ everolimus-eluting stent(s); NHLBI ¼ National Heart, Lung, and Blood Institute; NTG ¼ nitroglycerin;
RVD ¼ reference vessel diameter; SBO ¼ side branch occlusion.
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of post-procedural SBO in the EES arm—due to
the presence of the bifurcation carina shift and/or
plaque shift into the oriﬁce of side branch
(16,20)—remains speculative. Among the patients
with post-dilation, the peak ratio of CK-MB post-
procedure was signiﬁcantly higher in the Absorb
arm than in the EES arm (1.43  2.41 vs. 1.00 
1.89, p ¼ 0.02). The current protocol did not
recommend post-dilation of the Absorb device with
a balloon larger than 0.25 mm with respect to the
nominal size of the device. The post-procedural CB
rise with the patients who underwent post-dilation
seems to justify retrospectively this conservative
recommendation.
As previously reported, atherosclerotic plaque
burden pre-intervention is correlated with an in-
creased rate of PMI as evidenced by subsequent
CB rise (21). Atherosclerotic plaque with larger
necrotic core are at higher risk of plaque rupture and
microembolization during percutaneous coronary
intervention with subsequent CB rise (22,23). The
present study also documented that dyslipidemia
requiring treatment was protective for troponin rise
>5 ULN, whereas the incidence of CB rise assessed
by IVUS was similar between the 2 treatment arms.
It has been hypothesized that statins may exert
anti-inﬂammatory effects, resulting in reduction
of microembolization by stabilizing the underlying
plaque (24).
ANATOMIC COMPLICATIONS ASSESSED BY ANGIO-
GRAPHY AND PERIPROCEDURAL MI WITH ABSORB
OR EES. Previous studies revealed that SBO was the
most common cause of PMI (20,25). In the present
study, 15 patients with per-protocol PMI, 10 (66.7%)
were angiographically classiﬁed as type 1 (SBO)
whereas 3 (20.0%) were type 2 (other anatomic
complication). In 2 patients (13.3%), no angiographic
complications could be identiﬁed. Thus, our results
are in concordance with previous studies (16,26,27).
PREDICTORS FOR PERIPROCEDURAL RISE OF CARDIAC
BIOMARKER FOR INJURY. The predictors of PMI can be
broadly categorized as patient-, lesion-, and
procedure-related risk factors (16,20). In the SPIRIT IV
trial, which randomized 3,687 patients in a 2:1 fashion
to receive either EES or PES, the total stent length was
a strong predictor of PMI by criteria using CK or
troponin (16). In the present study, by multivariable
analysis, treatment with overlapping devices was the
independent determinant of per-protocol PMI (OR:
5.07, 95% CI: 1.78 to 14.41, p ¼ 0.002), whereas there
was overall no signiﬁcant difference in PMI between
the 2 device types (Absorb vs. EES). In the Absorb
TABLE 4 Incidence of Per-Protocol PMI According to Anatomic Complications
Assessed by Angiography
Absorb (n ¼ 335) EES (n ¼ 166) p Value
Per-protocol PMI 3.9 (13) 1.2 (2) 0.16
Type 1: SBO 2.7 (9) 0.6 (1) 0.18
SBO after pre-dilation 0 (0) 0 (0) 1.00
SBO after device implantation 2.7 (9) 0.6 (1) 0.18
SBO improvement after NTG 0 (0) 0 (0) 1.00
SBO after procedure 2.7 (9) 0.6 (1) 0.18
Type 2: angiographic other complication 0.6 (2) 0.6 (1) 1.00
Abrupt closure 0 (0) 0.6 (1) 1.00
Distal embolization 0.3 (1) 0 (0) 1.00
Coronary perforation 0 (0) 0 (0) 1.00
Flow-limiting dissection, NHLBI type F 0 (0) 0 (0) 1.00
Coronary dissection after pre-dilation,
NHLBI type D or E
0.3 (1) 0 (0) 1.00
Coronary dissection after device
implantation
0 (0) 0 (0) 1.00
Thrombus during procedure 0 (0) 0 (0) 1.00
Disruption of collateral ﬂow 0 (0) 0 (0) 1.00
Nonindentiﬁable mechanism causes 0.6 (2) 0 (0) 1.00
Per-protocol PMI is deﬁned as the elevation of total CK to >2 ULN along with elevated or
“positive” CK-MB without clinical symptom and electrocardiogram change.
PMI ¼ periprocedural myocardial infarction; other abbreviations as in Tables 1 to 3.
TABLE 3 Comparison of the Peak Value of Cardiac Enzyme Rise Post-Procedure Using Central Lab and/or Local Lab Results
CK
n ¼ 464 of 487 (95.3%)
CK-MB*
n ¼ 475 of 487 (97.5%)
cTn
n ¼ 473 of 487 (97.1%)
Absorb
(n ¼ 306)
Xience
(n ¼ 158) p Value
Absorb
(n ¼ 315)
Xience
(n ¼ 160) p Value
Absorb
(n ¼ 316)
Xience
(n ¼ 157) p Value
Mean  SD 0.71  0.63 0.65  0.64 0.380 1.33  2.12 1.09  1.65 0.180 12.09  30.24 8.28  20.20 0.138
>2 ULN 5.2 (16) 1.9 (3) 0.135 13.7 (43) 10.0 (16) 0.304 48.1 (152) 45.9 (72) 0.696
>5 ULN 0 (0) 0.6 (1) 0.341 5.1 (16) 2.5 (4) 0.232 29.7 (94) 25.5 (40) 0.386
>10 ULN 0 (0) 0 (0) 1.000 0.6 (2) 0.6 (1) 1.000 19.0 (60) 15.3 (24) 0.372
>35 ULN 0 (0) 0 (0) 1.000 0 (0) 0 (0) 1.000 6.0 (19) 3.8 (6) 0.387
>70 ULN 0 (0) 0 (0) 1.000 0 (0) 0 (0) 1.000 3.5 (11) 1.3 (2) 0.236
Values are % (n) unless otherwise indicated. *Fourteen patients presented with recent myocardial infarction at entry with normalized CKMB according to the protocol were
excluded for post CB analysis.
CK ¼ creatine kinase; CK-MB ¼ creatine kinase-myocardial band; cTn ¼ cardiac troponin; EES ¼ everolimus-eluting stent(s); ULN ¼ upper limit of normal.
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arm, the treatment with overlapping was associated
with risk of PMI with a 3.59 OR (p ¼ 0.03), whereas in
the EES arm, OR was 5.07 (p ¼ 0.28) in the EES arm.
The p value for interaction was not signiﬁcantly
different (p ¼ 0.65), suggesting that overlapping is
associated with higher risk of MI in both the Absorb
and Xience arms. One MI (non–Q-wave) was attrib-
uted to deﬁnite scaffold thrombosis involving over-
lapping scaffolds. Of note, in a juvenile porcine model
(28), overlapping Absorb scaffolds, compared with
nonoverlapping scaffolds, showed delayed healing on
histology and optical coherence tomography and
slower tissue coverage: the coverage of the over-
lapping segment was 80.1% and 99.5% at 28 and 90
days after implantation respectively, suggesting that
complete coverage in humans may take up to
18 months. Similar ﬁndings (29,30)—delayed healing
and promotion of inﬂammation at sites of overlap—
have been reported in the atherosclerotic rabbit model
implanted with EES, suggesting the general detri-
mental effect and potential biohazard of overlapping
devices. Adjacent implantation of scaffolds instead of
true overlapping may circumvent this problem.
STUDY LIMITATIONS. The results of the current
substudy are a post-hoc analysis. The study was not
powered to detect difference in clinical events such
as PMI and per-protocol deﬁnition of PMI does not
include clinical symptoms or electrocardiographic
changes. Given the mixture and wide range of
troponin assays used across participating hospitals,
FIGURE 4 Anatomic Complication Assessed by Angiography and Periprocedural CB Rise
The ﬁgure shows magnitude of post-procedural CB rise—(A) CK, (B) CK-MB, (C) cTn—for the patients with side branch occlusion after percutaneous coronary intervention
(blue bars) and those with the other anatomical complications (red bars). *Fourteen patients presented with recent myocardial infarction at entry with normalized
CK-MB according to the protocol were excluded for post-CB analysis. CB ¼ cardiac biomarkers; CK ¼ creatine kinase; CK-MB ¼ creatine kinase-myocardial band;
cTn ¼ cardiac troponin.
66
the proportion of elevated troponin and periproce-
dural rise could be depended on the proportion of
contemporary or sensitive assays compared with
conventional troponin assays. The difference in the
health care system could inﬂuence the long-term
clinical outcomes, however, such variances are less
relevant to the current analysis focusing on the acute
procedural outcomes.
CONCLUSIONS
There were no statistically signiﬁcant differences in
the incidence of CB rise and PMI between Absorb and
EES. Overlapping of scaffolds or stents might be a
precipitating factor of myocardial injury. Larger ran-
domized trials are currently ongoing to conﬁrm these
ﬁndings. As demonstrated in the present study,
which collected all 3 CB, binary deﬁnition of PMI is
not only dependent on the selection of CB but also on
the thresholds of the CB rise which are arbitrarily
chosen.
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LQVWLWXWLRQE\$EERWW9DVFXODU$/%KDVUHFHLYHGVSHDNHUIHHVDQGWUDYHOVXSSRUWIURP$EERWW
9DVFXODU0*DQG5-G:LQVWLWXWLRQUHFHLYHVDUHVHDUFKJUDQWIURP$EERWW9DVFXODU
7KHRWKHUDXWKRUVKDYHQRFRQIOLFWVRILQWHUHVWWRGHFODUHUHJDUGLQJWKHPDQXVFULSW
)XQGLQJ7KH$%625%,,6WXG\ZDVVSRQVRUHGE\$EERWW9DVFXODU6DQWD&ODUD&$86$

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$EVWUDFWZRUGV
%DFNJURXQG 7KH VWXG\ DLPHG WR FRPSDUH E\ LQWUDYDVFXODU XOWUDVRXQG ,986 WKH DFXWH
JDLQ$*DWWKHVLWHRIWKHSUHSURFHGXUDOPLQLPDOOXPHQDUHD0/$DFKLHYHGE\HLWKHUWKH
$EVRUE VFDIIROG RU WKH ;LHQFH VWHQW DQG WR LGHQWLI\ WKH IDFWRUV FRQWULEXWLQJ WR WKH DFXWH
SHUIRUPDQFHRIWKHVHGHYLFHV
0HWKRGV2XWRID WRWDORISDWLHQWV OHVLRQV LQ WKH$%625% ,, UDQGRPL]HG WULDO
 SDWLHQWV ZLWK  OHVLRQV ZHUH LQYHVWLJDWHG E\ ,986 SUH DQG SRVWSURFHGXUH
&RPSDULVRQRI0/$SUHDQGSRVWSURFHGXUHZDVSHUIRUPHGDW WKH0/$VLWHE\PDWFKLQJ
SUHDQGSRVWSURFHGXUDO,986SXOOEDFNV 
5HVXOWV/RZHU$*RQ ,986 ORZHVW WHUWLOH RFFXUUHGPRUH IUHTXHQWO\ LQ WKH$EVRUE DUP
WKDQLQWKH;LHQFHDUPPPYVPPSULVNUDWLR&,
7KH SODTXH PRUSKRORJ\ DW WKH0/$ FURVVVHFWLRQ ZDV QRW LQGHSHQGHQWO\ DVVRFLDWHG ZLWK
,986DFXWHJDLQ7KHPDLQGLIIHUHQFHLQDFXWHJDLQLQ0/'E\DQJLRJUDSK\ZDVREVHUYHGDW
WKH WLPHRIGHYLFH LPSODQWDWLRQ ((6YV%96ǻPPYVǻPPZKLOH WKHJDLQ
IURP SRVWGLODWDWLRQ ZDV VLPLODU EHWZHHQ WKH WZR DUPV ǻPP YV ǻPP ZKHQ
SDWLHQWV XQGHUZHQW SRVWGLODWDWLRQ DOWKRXJK H[SHFWHG EDOORRQ GLDPHWHU ZDV VPDOOHU LQ WKH
$EVRUEDUPWKDQLQWKH;LHQFHDUPS GXULQJWKHSRVWGLODWDWLRQ
&RQFOXVLRQV $W WKH VLWH RI WKH SUHSURFHGXUDO 0/$ WKH LQFUHDVH RI WKH OXPHQ
SRVWSURFHGXUHZDVVPDOOHULQWKH$EVRUEDUPWKDQLQWKH;LHQFHDUP7RDFKLHYHHTXLYDOHQW
$* WR ;LHQFH WKH LPSODQWDWLRQ RI $EVRUE PD\ UHTXLUH PRUH DJJUHVVLYH VWUDWHJLHV DW
LPSODQWDWLRQDQGSRVWGLODWDWLRQWKDQWKHWHFKQLTXHXVHGLQWKH$EVRUE,,WULDO 
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,QWURGXFWLRQ
 7KH IXOO\ ELRUHVRUEDEOH VFDIIROG LV D QRYHO GHYLFH WR WUHDW FRURQDU\ DUWHU\ VWHQRVLV
SRWHQWLDOO\PLQLPL]LQJ WKH ORQJWHUP FRPSOLFDWLRQV VHHQZLWKPHWDOOLF GUXJHOXWLQJ VWHQWV
7KH HYHUROLPXVHOXWLQJ $EVRUE ELRUHVRUEDEOH YDVFXODU VFDIIROG $EVRUE $EERWW 9DVFXODU
6DQWD&ODUD&$PDGHRISRO\/ODFWLGH3//$SURYLGHVDWHPSRUDU\FRURQDU\VFDIIROGLQJ
IRUDWOHDVWPRQWKVDQGEHFRPHVIXOO\UHVRUEHGE\DSSUR[LPDWHO\\HDUV7KHILUVWLQPDQ
),0WULDOXVLQJWKH$EVRUEVKRZHGH[FHOOHQWVDIHW\UHVXOWVZLWKSRWHQWLDOODWHEHQHILWVVXFK
DVODWHOXPHQHQODUJHPHQWDQGUHVWRUDWLRQRIYDVRPRWLRQ7KH$%625%,,VWXG\LVWKHILUVW
UDQGRPL]HGWULDOEHWZHHQWKH$EVRUEVFDIIROGDQG;LHQFHPHWDOOLFVWHQWVLQSDWLHQWVZLWKXS
WRWZRGHQRYRQDWLYHFRURQDU\OHVLRQV
 ,W LV ZDUUDQWHG WKDW WKH DFXWH SHUIRUPDQFH RI $EVRUE PDWFKHV WKDW RI PHWDOOLF VWHQWV
KRZHYHUFRQFHUQH[LVWVDERXWDFXWHH[SDQVLRQDQGOXPHQJDLQZLWKWKHXVHRIDSRO\PHULF
GHYLFH,QWKH$%625%),0WULDOSRVWSURFHGXUDOLQWUDYDVFXODUXOWUDVRXQG,986LPDJLQJ
GHPRQVWUDWHGWKDWLPSODQWDWLRQRIDQ$EVRUEVFDIIROGUHVXOWHGLQDPRUHHFFHQWULFOXPHQZLWK
QRQKRPRJHQHRXV VFDIIROG H[SDQVLRQ FRPSDUHG ZLWK PHWDOOLF VWHQWV )XUWKHUPRUH
QRQUDQGRPL]HGPDWFKHGSRSXODWLRQIURPWKH$%625%DQG63,5,7WULDOVGHPRQVWUDWHGWKDW
DQJLRJUDSKLF DFXWH JDLQ LQ OXPHQ GLDPHWHU WHQGV WR EH VPDOOHU LQ WKH $EVRUE WKDQ LQ WKH
;LHQFH 7KLV WUHQG ZDV DOVR REVHUYHG LQ WKH UDQGRPL]HG $%625% -DSDQ WULDO ,Q WKH
$%625% ,, UDQGRPL]HG WULDO &OLQLFDO WULDOV JRY 1&7 SUHSURFHGXUDO DQG
SRVWSURFHGXUDO GRFXPHQWDU\ ,986 LPDJLQJ ZHUH PDQGDWRU\ DQG SURYLGHG DQ XQLTXH
RSSRUWXQLW\ WR HYDOXDWH WKH VFDIIROGVWHQW H[SDQVLRQ DW WKH SUHFLVH VLWH RI SUHSURFHGXUDO
PLQLPDO OXPHQ DUHD 0/$ DQG WR UHODWH WKH GHJUHH RI H[SDQVLRQ WR WKH PHFKDQLFDO
SHUIRUPDQFHRIERWKGHYLFHVSURFHGXUDOSDUDPHWHUVRILPSODQWDWLRQDQGWLVVXHFRPSRVLWLRQ
GHULYHGIURP,986DQDO\VHV 
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 7KHUHIRUH WKH SXUSRVH RI WKLV VWXG\ LV WR LQYHVWLJDWH WKH ,986 DFXWH JDLQ DW WKH VLWH RI
PLQLPDO OXPHQ DUHD EHWZHHQ WKH$EVRUE VFDIIROG DQG WKH;LHQFH VWHQW DQG WR LGHQWLI\ WKH
IDFWRUVFRQWULEXWLQJWRWKHDFXWHSHUIRUPDQFHRIWKHVHGHYLFHV

0HWKRGV
6WXG\GHVLJQDQGSRSXODWLRQ
 7KH$%625%,,VWXG\LVDUDQGRPL]HGFRQWUROOHGWULDOFRPSDULQJWKHVDIHW\DQGHIILFDF\RI
WKH $EVRUE HYHUROLPXVHOXWLQJ ELRUHVRUEDEOH YDVFXODU VFDIIROG DQG WKH ;LHQFH
HYHUROLPXVHOXWLQJPHWDOOLFVWHQWLQSDWLHQWVZLWKXSWRWZRde novoQDWLYHFRURQDU\OHVLRQV
7KHGHWDLOVRIWKHVWXG\DUHDYDLODEOHHOVHZKHUH$IWHUVXFFHVVIXOSUHGLODWDWLRQRIWKHWDUJHW
OHVLRQ  UDQGRPL]DWLRQZDVSHUIRUPHG2XWRI D WRWDO RISDWLHQWV  OHVLRQV 
SDWLHQWV OHVLRQVZHUH UDQGRPO\DVVLJQHG WRUHFHLYH WKH$EVRUEDQGSDWLHQWV 
OHVLRQVZHUH DVVLJQHG WR UHFHLYH WKH ;LHQFH*UD\VFDOH ,986 DQG ,986YLUWXDO KLVWRORJ\
9+ LPDJLQJ SUHSURFHGXUH DQG SRVW LPSODQWDWLRQ ZDV PDQGDWRU\ EXW GRFXPHQWDU\ 1R
WUHDWPHQWUHFRPPHQGDWLRQEDVHGRQ,986LPDJLQJZDVPDGHLQWKHSURWRFRO 

6WXG\GHYLFH
 7KH$EVRUEKDVDQDPRUSKRXVSRO\'/ODFWLGH3'//$FRDWLQJWKDWFRQWDLQVDQGFRQWUROV
WKHUHOHDVHRIWKHDQWLSUROLIHUDWLYHGUXJHYHUROLPXV7KHVFDIIROGLVPDGHRIVHPLFU\VWDOOLQH
3//$ 3//$ LV FRPSOHWHO\ ELRGHJUDGHG E\ K\GURO\VLV LQWR ZDWHU YLD WKH .UHEV F\FOH
3K\VLFDOO\WKHVFDIIROGKDVVWUXWVZLWKDQDSSUR[LPDWHWKLFNQHVVRIP7KH;LHQFHLVDQ
HYHUROLPXVHOXWLQJ FREDOW FKURPLXP DOOR\ GHYLFHZLWK D SODWIRUP FRQVLVWLQJ RI VHUSHQWLQH
ULQJVFRQQHFWHGE\OLQNVIDEULFDWHGIURPDVLQJOHSLHFH7KHRYHUDOOVWUXWWKLFNQHVVLQFOXGLQJ
74
WKHGUXJFRDWLQJLVDSSUR[LPDWHO\P

3URFHGXUHDQG,986DFTXLVLWLRQ
 3UHSURFHGXUDO ,986 ZDV PDQGDWRU\ EHIRUH GLODWDWLRQ RI WKH WDUJHW OHVLRQ ,I LW ZDV QRW
WHFKQLFDOO\IHDVLEOHIRUH[DPSOHWKH,986FDWKHWHUFRXOGQRWFURVVWKHOHVLRQSUHGLODWDWLRQ
ZLWKDVPDOOEDOORRQZDVDOORZHGWRIDFLOLWDWHWKH,986FDWKHWHULQVHUWLRQ
,986LPDJHVZHUHREWDLQHGZLWKDURWDWLRQDO0+],986FDWKHWHU5HYROXWLRQ709ROFDQR
&RUSRUDWLRQ 5DQFKR &RUGRYD &$ 86$ $IWHU LQWUDFRURQDU\ LQMHFWLRQ RI J
QLWURJO\FHULQ ,986 SXOOEDFNV ZHUH SHUIRUPHG ZLWK WKH XVH RI DQ DXWRPDWHG PRWRUL]HG
GHYLFH DW D SXOOEDFN VSHHG RI  PPV /HVLRQV ZHUH WUHDWHG ZLWK URXWLQH LQWHUYHQWLRQDO
WHFKQLTXHVWKDW LQFOXGHGPDQGDWRU\SUHGLODWLRQZLWKDEDOORRQVKRUWHUDQGPPVPDOOHU
LQ GLDPHWHU WKDQ WKH VWXG\GHYLFH7KH VL]H RI VWHQWVFDIIROGZDV GHWHUPLQHGE\ WKH WDUJHW
YHVVHO GLDPHWHU ZKLFK ZDV PHDVXUHG E\ SUHSURFHGXUDO RQOLQH TXDQWLWDWLYH FRURQDU\
DQJLRJUDSK\4&$$OOSDWLHQWVHQUROOHGLQWKH$%625%,,WULDOZHUHWUHDWHGDVIROORZV
DPPGHYLFHZDVXVHGZKHQERWKWKHSUR[LPDODQGGLVWDOPD[LPXPOXPHQGLDPHWHUV
ZHUHZLWKLQDQXSSHUOLPLWRIPPDQGDORZHUOLPLWRIPPDPPGHYLFHZDV
XVHGZKHQ ERWK WKH SUR[LPDO DQG GLVWDOPD[LPXP OXPHQ GLDPHWHUVZHUHZLWKLQ DQ XSSHU
OLPLWRIPPDQGDORZHUOLPLWRIPPDPPGHYLFHZDVXVHGZKHQERWKWKH
SUR[LPDODQGWKHGLVWDOPD[LPXPOXPHQGLDPHWHUVZHUHZLWKLQDQXSSHUOLPLWRIPPDQG
D ORZHU OLPLW RI  PP  VFDIIROGVWHQW RYHUODS ZDV DOORZHG 3RVWGLODWDWLRQ ZLWK D
EDOORRQ VKRUWHU WKDQ WKH LPSODQWHG VFDIIROGVWHQW ZDV SHUIRUPHG DW WKH GLVFUHWLRQ RI WKH
RSHUDWRUV 3RVWSURFHGXUDO ,986 LPDJHV ZHUH REWDLQHG DW WKH HQG RI WKH SURFHGXUH
SRVWGHYLFH LPSODQWDWLRQ RU SRVWGLODWDWLRQ $OO SXOOEDFNV ZHUH DQDO\]HG RIIOLQH E\ DQ
LQGHSHQGHQW FRUH ODERUDWRU\ &DUGLDO\VLV %9 5RWWHUGDP 7KH 1HWKHUODQGV XVLQJ D
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FRPPHUFLDOVRIWZDUH4,YXV0HGLV/HLGHQ7KH1HWKHUODQGV

0HDVXUHPHQWRIDFXWHJDLQRQ,986
7R DVVHVV WKH DFXWH SHUIRUPDQFH RI WKH $EVRUE DQG ;LHQFH VWHQW DW WKH VLWH RI WKH ZRUVW
VWHQRVLVSUHSURFHGXUHWKHGLIIHUHQFHRIOXPHQDUHDEHWZHHQSUHDQGSRVWSURFHGXUDO,986
LPDJHVDW WKHVLWHRI WKHSUHSURFHGXUDOPLQLPDO OXPHQDUHD0/$ZDVPHDVXUHGDVDFXWH
JDLQLQ0/$3UHSURFHGXUDO0/$ZDVGHILQHGDVWKHVPDOOHVWOXPHQDUHDZLWKLQWKHWDUJHW
OHVLRQ $IWHU LGHQWLI\LQJ WKH IUDPH RI WKH SUHSURFHGXUDO 0/$ VLWH PDWFKLQJ RI SUH DQG
SRVWSURFHGXUDO,986LPDJHVZDVSHUIRUPHGE\LGHQWLI\LQJFRPPRQODQGPDUNVVXFKDVVLGH
EUDQFKHV ELIXUFDWLRQV ODUJH FDOFLILFDWLRQV RU HFKRJHQLF PHWDOOLF PDUNHU RQ WKH GHYLFH
0DWFKLQJZDV SHUIRUPHGXVLQJ D GHGLFDWHG VRIWZDUH 4&8&06 VRIWZDUH0HGLV /HLGHQ
7KH1HWKHUODQGV7KHSUHSURFHGXUDO LPDJHRI WKH0/$ZDVPDWFKHG DQG FRPSDUHGZLWK
WKH SRVWSURFHGXUDO OXPHQ DUHD DW WKH VDPH VLWH 7KH ORZHU DFXWH JDLQ ZDV GHILQHG DV WKH
ORZHVWWHUWLOHIURPWKHZKROHSRSXODWLRQ

$QDO\VLVRI,986DQGSURFHGXUDOSDUDPHWHUV
 &RQWRXU GHWHFWLRQ ZDV SHUIRUPHG E\ H[SHULHQFHG ,986 FRUH ODE DQDO\VWV ,986PHWULFV
LQFOXGLQJ YHVVHO VWHQWVFDIIROG DQG OXPHQ DUHD ZHUH PHDVXUHG DW PP LQWHUYDOV 7R
LGHQWLI\WKHOHVLRQIDFWRUVLQWKHHYDOXDWLRQRIDFXWHJDLQDQDO\VLVZDVDOVRSHUIRUPHGXVLQJ
WKH IROORZLQJ SDUDPHWHUV SODTXH EXUGHQ OXPHQ HFFHQWULFLW\ SUHVHQFH RI FDOFLXP
UHPRGHOLQJLQGH[IURPJUD\VFDOH,986DQGWLVVXHFRPSRVLWLRQSDUDPHWHUVDEVROXWHYDOXH
DQG SHUFHQWDJH IURP ,9869+ 3ODTXH EXUGHQ ZDV REWDLQHG E\ WKH SODTXH SOXV PHGLD
FURVVVHFWLRQDO DUHD &6$ GLYLGHG E\ WKH YHVVHO &6$ (FFHQWULFLW\ LQGH[ (, ZDV
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FDOFXODWHGDVWKHUDWLRRIWKHSURMHFWHGPLQLPDODQGPD[LPDOOXPHQRUVFDIIROGVWHQWGLDPHWHU
DWWKH0/$FURVVVHFWLRQ3UHWUHDWPHQWUHIHUHQFHVHJPHQWVZHUHVHOHFWHGDVVLWHVZLWKWKH
OHDVWDPRXQWRISODTXHSUR[LPDODQGGLVWDOWRWKH0/$VLWHVSULRUWRWKHWDNHRIIRIDQ\PDMRU
VLGHEUDQFK7KHUHPRGHOLQJLQGH[5,ZDVFDOFXODWHGDVWKHYHVVHODUHDDWWKH0/$VLWH
GLYLGHGE\WKHDYHUDJHRIWKHSUR[LPDODQGGLVWDOUHIHUHQFHYHVVHODUHDV1HJDWLYHUHPRGHOLQJ
ZDVGHILQHGDVDQ5, LQWHUPHGLDWHUHPRGHOLQJDVDQ5,RIWRDQGSRVLWLYH
UHPRGHOLQJDVDQ5,! 
 /RFDWLRQ DQG FLUFXPIHUHQWLDO GLVWULEXWLRQ RI FDOFLXP ZDV TXDQWLILHG LQ JUD\VFDOH ,986
&DOFLXPZDVGHILQHGDVEULJKWHFKRHVZLWKDFRXVWLFVKDGRZLQJ7KHORFDWLRQRIWKHFDOFLXP
ZDV GHILQHG DV VXSHUILFLDO GHHS RU ERWK ,I WKH OHDGLQJ HGJH RI WKH DFRXVWLF VKDGRZLQJ
DSSHDUHGZLWKLQ WKH VKDOORZHVW  RI WKH SODTXH WKLFNQHVV LW ZDV GHILQHG DV VXSHUILFLDO
FDOFLXP ,I WKHOHDGLQJHGJHRIWKHDFRXVWLFVKDGRZLQJDSSHDUHGZLWKLQWKHGHHSHVWRI
WKHSODTXHWKLFNQHVVLWZDVGHILQHGDVGHHSFDOFLXP7KHODUJHVWFRQWLQXRXVDUFRIFDOFLXP
DQG VXPPHG DUF RI FDOFLXP DW WKH VLWH RI SUHLQWHUYHQWLRQDO OXPHQ DUHDZHUHPHDVXUHG LQ
GHJUHHVZLWKDSURWUDFWRUFHQWHUHGRQWKHOXPHQ,QDGGLWLRQWKHDUFRIFDOFLXPZDVFODVVLILHG
DVTXDGUDQWTXDGUDQWVWRTXDGUDQWVWRRUTXDGUDQWV
 WR  %\ ,9869+ DQDO\VLV WLVVXH DW WKH VLWH RI SUHSURFHGXUDO 0/$ ZDV
FDWHJRUL]HG LQWR WKH  EDVLF SODTXH WLVVXH FRPSRQHQWV ILEURXV WLVVXH ),  GDUN JUHHQ
ILEURIDWW\))OLJKWJUHHQQHFURWLFFRUH1&UHGDQGGHQVHFDOFLXP'&±ZKLWH
 ,Q WKH FRPSOLDQFH FKDUWV SUHVVXUHGLDPHWHU UHODWLRQVKLS IRU WKH $EVRUE DQG WKH ;LHQFH
3ULPH ;SHGLWLRQ HWF SURYLGHG E\ WKH PDQXIDFWXUHU WKH LQQHU GLDPHWHUV RI WKH GHYLFHV
ZHUHGHVFULEHG([SHFWHGGHYLFHGLDPHWHUZDVREWDLQHG IURP WKHGHYLFH FRPSOLDQFH FKDUW
XVLQJ WKHQRPLQDOGHYLFHGLDPHWHUDQG WKHPD[LPXPSUHVVXUHGXULQJ LPSODQWDWLRQ'XULQJ
SRVWGLODWDWLRQ WKH H[SHFWHG EDOORRQ GLDPHWHU ZDV REWDLQHG IURP WKH EDOORRQ FRPSOLDQFH
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FKDUWGDWDSURYLGHGE\WKHYDULRXVPDQXIDFWXUHUVRIEDOORRQVXVLQJWKHQRPLQDOGLDPHWHURI
WKHEDOORRQDQGWKHPD[LPXPSUHVVXUHGXULQJWKHSURFHGXUH,QFDVHWKHSUHVVXUHGXULQJWKH
SURFHGXUHH[FHHGHGWKHKLJKHVWSUHVVXUHRQWKHFKDUWWKHKLJKHVWGLDPHWHURQWKHFKDUWZDV
XVHGIRUWKHFDOFXODWLRQ 

$QJLRJUDSKLFDVVHVVPHQW
 2QOLQH4&$DQDO\VHVZHUHXQGHUWDNHQE\WKHVLWHVSULRUWR$EVRUELPSODQWDWLRQWRGHILQH
'PD[DQGSUHDQGSRVWSURFHGXUDORIIOLQH4&$ZHUHSHUIRUPHGE\DQLQGHSHQGHQWFRUH
ODERUDWRU\ &DUGLDO\VLV %9 5RWWHUGDP 7KH 1HWKHUODQGV XVLQJ &RURQDU\ $QJLRJUDSK\
$QDO\VLV 6\VWHP 3LH 0HGLFDO ,PDJLQJ 0DDVWULFKW 1HWKHUODQGV 7KH PLQLPXP OXPHQ
GLDPHWHU 0/' FKDQJHV DW GLIIHUHQW SKDVHV RI WKH SURFHGXUH ZHUH PHDVXUHG L EHIRUH
SURFHGXUH LL DIWHU GHYLFH LPSODQWDWLRQ DQG LLL LPPHGLDWHO\ DIWHU SRVWGLODWDWLRQ
$GGLWLRQDOO\ PLQLPDO GLDPHWHU RI EDOORRQ ZDV PHDVXUHG L GXULQJ VFDIIROGVWHQW
LPSODQWDWLRQ DW PD[LPXP LQIODWLRQ SUHVVXUH DQG LL GXULQJ SRVWGLODWDWLRQ DW PD[LPXP
LQIODWLRQSUHVVXUH 
 $FXWH UHFRLOZDVGHILQHGDV IROORZV:KHQD VWHQWVFDIIROGGHOLYHU\EDOORRQZDVXVHG IRU
VWHQWVFDIIROG H[SDQVLRQ DFXWH DEVROXWH VWHQWVFDIIROG UHFRLO ZDV GHILQHG DV WKH GLIIHUHQFH
EHWZHHQ WKHPHDQGLDPHWHURI WKH VWHQWVFDIIROGGHOLYHU\EDOORRQDW WKHKLJKHVW SUHVVXUH DW
LPSODQWDWLRQRIWKHVWHQWVFDIIROG;DQGWKHPHDQOXPLQDOGLDPHWHURIWKHVWHQWHGVFDIIROGHG
VHJPHQWDIWHULPSODQWDWLRQ<$FXWHDEVROXWHVWHQWVFDIIROGUHFRLOZDVFDOFXODWHGDV;±<
:KHQDSRVWGLODWLRQEDOORRQZDVXVHGLQWKHSURFHGXUHDFXWHDEVROXWHUHFRLOZDVGHILQHGDV
WKHGLIIHUHQFHEHWZHHQWKHPHDQGLDPHWHURIWKHSRVWGLODWLRQEDOORRQDWWKHKLJKHVWSUHVVXUH
LQWKHSRVWGLODWHGVHJPHQW;¶DQGWKHPHDQOXPLQDOGLDPHWHUDIWHUSRVWGLODWLRQ<¶7KH
DQJLRJUDPRI;DQG<ZDVSHUIRUPHGLQWKHVDPHDQJLRJUDSKLFYLHZVRWKDWWKHWZRLPDJHV
78
ZHUHSHUIHFWO\PDWFKHG

6WDWLVWLFDODQDO\VLV 
&DWHJRULFDO YDULDEOHV DUH SUHVHQWHG DV FRXQWV DQG SHUFHQWDJHV &RQWLQXRXV YDULDEOHV DUH
SUHVHQWHG DVPHDQV  VWDQGDUG GHYLDWLRQ$ YDOXH RI 3  ZDV FRQVLGHUHG VWDWLVWLFDOO\
VLJQLILFDQW 3DLUHG DQDO\VLV ZDV SHUIRUPHG LQ WKH SDWLHQWV ZLWK DQDO\]DEOH SUH DQG
SRVWSURFHGXUDO,986LPDJHV/RJLVWLFUHJUHVVLRQDQDO\VLVZDVSHUIRUPHGWRILQGWKHUHODWLRQ
RI WKH IROORZLQJ IDFWRUV ZLWK ,986 ORZHU DFXWH JDLQ LQ OXPHQ DUHD JHQGHU DJH REHVLW\
ERG\PDVV LQGH[  NJP WUHDWHG YHVVHO SUHSURFHGXUDO0/$ SUHSURFHGXUDO OXPHQ
HFFHQWULFLW\ SODTXH DUHD YHVVHO DUHD DOO PHDVXUHPHQWV DW WKH VLWH RI 0/$ ,Q DGGLWLRQ
SUHVHQFH RU DEVHQFH RI FDOFLXP DV ZHOO DV DUF RI FDOFLXP DW WKH VLWH RI 0/$ WLVVXH
FRPSRVLWLRQ DW WKH VLWH RI0/$ UHPRGHOLQJ LQGH[ W\SH RI VWHQWVFDIIROG DQG PD[LPDO
H[SHFWHG LQQHU GHYLFH RU EDOORRQ GLDPHWHU WKURXJKRXW SURFHGXUH LQ FDVHVZLWK RUZLWKRXW
SRVWGLODWDWLRQ ZHUH DOVR LQFOXGHG LQ WKH ORJLVWLF UHJUHVVLRQ DQDO\VLV ,Q WKH PXOWLYDULDWH
PRGHO0/$ZDV QRW LQFOXGHG GXH WR VWURQJ LQWHUDFWLRQZLWK SODTXH DUHD DQG YHVVHO DUHD
6WDWLVWLFDODQDO\VHVZHUHSHUIRUPHGZLWK6366YHUVLRQ,%01HZ<RUN

5HVXOWV
%DVHOLQHFKDUDFWHULVWLFV
 2XWRISDWLHQWVZLWKOHVLRQVZKRZHUHHQUROOHGLQWKH$%625%,,WULDOSDWLHQWV
ZLWKOHVLRQVSDWLHQWVZLWKOHVLRQVLQWKH$EVRUEDUPDQGSDWLHQWVZLWK
OHVLRQV LQ WKH;LHQFHDUPKDGERWKSUHSURFHGXUDODQGSRVWSURFHGXUDO ,986DQDO\VHV IRU
DFXWH OXPHQ DUHD JDLQ DVVHVVPHQW )LJXUH  7KHUH ZHUH QR VLJQLILFDQW GLIIHUHQFHV LQ
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EDVHOLQHSDWLHQWGHPRJUDSKLFVDQGSUHSURFHGXUDODQJLRJUDSK\GDWD7DEOH 

'LIIHUHQFHVLQSURFHGXUDOLPSODQWDWLRQVWUDWHJ\EHWZHHQ$EVRUEDQG;LHQFH 
 7DEOH  LQGLFDWHV WKH GLIIHUHQFHV LQ SURFHGXUDO VWUDWHJ\ EHWZHHQ $EVRUE DQG ;LHQFH
3UHGLODWDWLRQ VWUDWHJ\ ZDV FRPSDUDEOH EHWZHHQ ERWK DUPV $W WKH WLPH RI WKH GHYLFH
LPSODQWDWLRQQRGLIIHUHQFHVLQGHYLFHVL]HVHOHFWLRQDQGH[SHFWHGLQQHUGHYLFHGLDPHWHUZHUH
REVHUYHGZKLOHPD[LPDOSUHVVXUHGXULQJGHYLFH LPSODQWDWLRQZDVKLJKHU LQ;LHQFH WKDQ LQ
$EVRUE$W WKH WLPHRISRVWGLODWDWLRQQRPLQDOGLDPHWHURI WKHEDOORRQPD[LPDOSUHVVXUH
DQGH[SHFWHGEDOORRQGLDPHWHUZHUHVPDOOHULQWKH$EVRUEDUPWKDQLQWKH;LHQFHDUP

,986DQDO\VLV
 $ UHSUHVHQWDWLYH FDVH RI DFXWH JDLQ LQ 0/$ LV SUHVHQWHG LQ )LJXUH  2YHUDOO WKH
SUHSURFHGXUDO0/$ZDVFRPSDUDEOHEHWZHHQWKHWZRDUPV+RZHYHUSUHSURFHGXUDOYHVVHO
DUHDPPYVPPS DQGSODTXHDUHDPPYVPPS 
DWWKHVLWHRI0/$ZHUHVLJQLILFDQWO\ODUJHULQ WKH;LHQFHDUPWKDQLQWKH$EVRUEDUP7KH
SRVWSURFHGXUDOOXPHQDUHDDWWKHVLWHRISUHSURFHGXUDO0/$ZDVVLJQLILFDQWO\VPDOOHULQWKH
$EVRUEDUPPPYVPPS7KHDPRXQWRI FKDQJH LQSODTXHDUHD DQG
SODTXHEXUGHQZDVVLJQLILFDQWO\VPDOOHULQWKH$EVRUEDUPWKDQLQWKH;LHQFHDUPYV
PP S   YV  S UHVSHFWLYHO\7KH LQFUHDVH RI YHVVHO DUHD
WHQGHGWREHVPDOOHULQWKH$EVRUEDUPYVPPS $VDUHVXOWWKHUHZDVD
VLJQLILFDQW GLIIHUHQFH LQ DFXWH JDLQ IRU WKH PLQLPDO OXPHQ DUHD  PP YV PP
S7DEOH)LJXUH 

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'HYLFHH[SDQVLRQLQPLQLPDOOXPHQDUHD 
 :KHQGHYLFHH[SDQVLRQZDVGHILQHGDVWKHUDWLRRISRVWSURFHGXUDO OXPHQDUHDDW WKH
VLWHRI HSUHSURFHGXUDO0/$ WR WKHH[SHFWHG LQQHUGHYLFH DUHDFDOFXODWHG IURP WKH ODUJHVW
EDOORRQXVHGGXULQJSURFHGXUHWKH$EVRUEVFDIIROGDFKLHYHGRQDYHUDJHRQO\RIWKH
SUHGLFWHG OXPHQ DUHD ZKLOH WKH ;LHQFH VWHQW DFKLHYHG  S  )LJXUH 
/RFDWLRQRIFDOFLXPDVZHOODVWKHDUFRIFDOFLXPDQGWKHDPRXQWRI1&GLGQRWDIIHFWGHYLFH
H[SDQVLRQ)LJXUH 

4&$0/'FKDQJHVDWGLIIHUHQWSKDVHVGXULQJSURFHGXUH 
)LJXUHVKRZVWKHPLQLPXPOXPHQGLDPHWHU0/'E\4&$DQG0/$E\,986FKDQJHVDW
GLIIHUHQWSKDVHVGXULQJWKHSURFHGXUHLQWKHSDWLHQWVZKRKDGERWKSUHDQGSRVWSURFHGXUDO
,986DQDO\VHV
7KH PDLQ GLIIHUHQFH LQ DFXWH JDLQ LQ 0/' E\ 4&$ ZDV REVHUYHG DW WKH WLPH RI GHYLFH
LPSODQWDWLRQ((6YV%96ǻPPYVǻPPZKLOHWKHJDLQIURPSRVWGLODWDWLRQ
ZDV VLPLODU EHWZHHQ WKH WZR DUPV ǻPP YV ǻPP ZKHQ SDWLHQWV XQGHUZHQW
SRVWGLODWDWLRQ $FXWH UHFRLO LQ FDVHV ZLWKZLWKRXW SRVWGLODWDWLRQ ZDV FRPSDUDEOH LQ ERWK
JURXSV((6YV%(6PPYVPPS 

3UHGLFWRUVRIORZHUDFXWHJDLQ
/RZHU DFXWH JDLQ ORZHVW WHUWLOH RFFXUUHGPRUH IUHTXHQWO\ LQ WKH$EVRUE DUP WKDQ LQ WKH
;LHQFH DUP ULVN UDWLR  &,  7DEOH  5HVXOWV RI ORJLVWLF UHJUHVVLRQ
DQDO\VLVDUHVXPPDUL]HGLQ2QOLQHVXSSOHPHQW7DEOH*HQGHUDJHREHVLW\WUHDWHGYHVVHO
SUHSURFHGXUDOOXPHQHFFHQWULFLW\DWWKHVLWHRI0/$SUHVHQFHRUDEVHQFHRIFDOFLXPDVZHOO
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DV DUF RI FDOFLXP DW WKH VLWH RI 0/$ WLVVXH FRPSRVLWLRQ DW WKH VLWH RI 0/$ ZHUH QRW
LQGHSHQGHQW SUHGLFWRUV IRU ORZHU DFXWH JDLQ 7KH IROORZLQJ YDULDEOHV ZHUH VLJQLILFDQWO\
DVVRFLDWHGZLWKORZHUDFXWHJDLQLQWKHPXOWLYDULDWHPRGHO$EVRUEXVHPD[LPDOLQQHUGHYLFH
RUEDOORRQGLDPHWHU WKURXJKRXWSURFHGXUHYHVVHODUHDDQGSODTXHDUHDDW WKH0/$VLWHDQG
QHJDWLYHUHPRGHOLQJ7KHGLIIHUHQFHVLQ ,986DFXWHJDLQEHWZHHQ$EVRUEDQG;LHQFHZHUH
FRQVLVWHQWDFURVVWKHVHYDULDEOHV7DEOH

'LVFXVVLRQ
0DLQILQGLQJV
 7KHPDLQ ILQGLQJVRI WKLV VWXG\DUH/RZHUDFXWHJDLQRFFXUUHGPRUH IUHTXHQWO\ LQ WKH
$EVRUE DUP WKDQ LQ WKH ;LHQFH DUP  PP YV  PP S ULVN UDWLR 
&,   7KH SODTXH PRUSKRORJ\ DW WKH 0/$ FURVVVHFWLRQ ZDV QRW
LQGHSHQGHQWO\ DVVRFLDWHG ZLWK DFXWH JDLQ  2Q DQJLRJUDSK\ GHYLFH DFXWH UHFRLO ZDV
FRPSDUDEOH EXW H[SDQVLRQ RI WKH GHYLFHZDV GLIIHUHQW 7KH LQIOXHQFH RI SRVWGLODWDWLRQ RQ
0/'ZDVVRPHZKDWOLPLWHG

,PSDFWRIOHVLRQPRUSKRORJ\RQOXPHQHQODUJHPHQW
 7KHUHDUHFRQIOLFWLQJGDWDDERXWWKHLPSDFWRIOHVLRQPRUSKRORJ\RQOXPHQHQODUJHPHQW,Q
WKHSUHYLRXVUHSRUWVWKHH[SDQVLRQRIGUXJHOXWLQJVWHQWVZDVGUDVWLFDOO\LQIOXHQFHGE\,986
JUD\VFDOH  YLUWXDO KLVWRORJ\ SODTXH PRUSKRORJ\ LQFOXGLQJ WKH DUF DQG OHQJWK RI OHVLRQ
FDOFLXP RU TXDQWLWDWLYH OHVLRQ VLWH JHRPHWU\ OHVLRQ YHVVHO DUHD SODTXH DUHD DQG SODTXH
EXUGHQ ,Q WKH SUHVHQW VWXG\ WKH LPSDFW RI SODTXH FRPSRQHQW RQ DFXWH JDLQ LQ OXPHQ
DUHDZDVQRWUHWDLQHGLQ WKHPXOWLYDULDWHDQDO\VLVDOWKRXJKLQWKHXQLYDULDWHDQDO\VLVKLJKHU
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DPRXQWV RI ILEURWLF SODTXH QHFURWLF FRUH DQG GHQVH FDOFLXP VKRZHG ORZHU DFXWH JDLQ LQ
OXPHQDUHDLQERWKDUPV,QWKHSUHVHQWVWXG\SUHVHQFHRUDEVHQFHRIFDOFLXPDVZHOODVWKH
DUFRIFDOFLXPE\,986JUD\VFDOHGLGQRWDIIHFWWKHDFXWHJDLQDQGGHYLFHH[SDQVLRQDW0/$
)LJXUH

'LIIHUHQFHVLQSURFHGXUDOVWUDWHJ\EHWZHHQ$EVRUEDQG;LHQFH
'LIIHUHQFHV LQDFXWHSHUIRUPDQFHFDQEHGULYHQQRWRQO\E\GLIIHUHQFHV LQ WKHPHFKDQLFDO
SURSHUWLHVRI WKH$EVRUE VFDIIROG DQG WKH;LHQFHPHWDOOLF VWHQWEXW DOVRE\GLIIHUHQW LQLWLDO
LPSODQWDWLRQ VWUDWHJ\:LWKLQSUHFLVHERXQGDULHVRI H[SDQVLRQ HJ PP IRU D
GHYLFH RI  PP WKH VWUHVV VWUDLQ UHODWLRQVKLS RI WKH PHWDOOLF DQG SRO\PHULF VWUXWV DUH
FRPSDUDEOH DQG WKHPHFKDQLFDO VWUHQJWK RI WKH $EVRUE VFDIIROG LV QRW GLIIHUHQW IURP WKH
PHWDOOLF VWHQW +RZHYHU ZKHQ WKH VFDIIROG LV RYHUH[SDQGHG ! PP IRU D  PP
GHYLFH WKH VWUXW FURZQV EHJLQ DSSURDFKLQJ WKHLU JHRPHWULFDO OLPLW 7KH UDGLDO VXSSRUW LV
PD[LPL]HG ZKLOH WKHLU WHQVLOH OLPLW LV DOVR UHDFKHG 7KHUHIRUH SUHGLODWDWLRQ RSWLPDO
H[SDQVLRQ DQG DYRLGDQFH RI RYHUH[SDQVLRQ DUH HQFRXUDJHG GXULQJ WKH SURFHGXUH ZLWK
$EVRUE 
0D[LPDOH[SHFWHGGLDPHWHURIEDOORRQZLWKRUZLWKRXWSRVWGLODWDWLRQZDVVLPLODUEHWZHHQ
$EVRUE DQG ;LHQFH +RZHYHU WKH UDWLR RI SRVWSURFHGXUDO OXPHQ DUHD DW WKH VLWH RI
SUHSURFHGXUDO0/$ WR WKH H[SHFWHG LQQHU GHYLFH DUHD FDOFXODWHG IURP WKH ODUJHVW EDOORRQ
XVHGGXULQJSURFHGXUHZDVVPDOOHULQWKH$EVRUEWKDQLQWKH;LHQFH)LJXUH7KLVUHVXOW
PLJKWLPSO\WKHQHFHVVLW\RIPRUHDJJUHVVLYHVWUDWHJ\GXULQJLPSODQWDWLRQDQGSRVWGLODWDWLRQ
RI$EVRUEFRPSDUHGWR;LHQFHGXHWRWKHGHYLFHPHFKDQLFDOSURSHUWLHV
:KHQ4&$ZDVSHUIRUPHGWRDVVHVV0/'FKDQJHVDWGLIIHUHQWSKDVHVGXULQJWKHSURFHGXUH
WKH GLIIHUHQFH EHWZHHQ WKH WZR DUPVZDV DOUHDG\ VLJQLILFDQW DW WKH WLPH RI GHYLFH EDOORRQ
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H[SDQVLRQǻPPIRU;LHQFHYVǻPPIRU$EVRUES)LJXUHGHVSLWHWKH
IDFW WKDW WKH H[SHFWHG LQQHUGHYLFHGLDPHWHU DW LPSODQWDWLRQZDV VLPLODU LQERWK DUPV7KH
DFXWH GHYLFH UHFRLO ZDV FRPSDUDEOH EHWZHHQ WKH WZR DUPV 'HVSLWH OHVV DJJUHVVLYH
SRVWGLODWDWLRQ LQ WKH $EVRUE DUP WKDQ LQ WKH ;LHQFH DUP WKH DQJLRJUDSKLF JDLQ IURP
SRVWGLODWDWLRQ ZDV VLPLODU EHWZHHQ WKH WZR DUPV ǻ PP YV ǻPP S 
)LJXUH7KHVHDQJLRJUDSKLFDQDO\VHVLPSOLHGWKHGLIIHUHQFHRIWKHPHFKDQLFDOSURSHUWLHV
RIERWKGHYLFHVDQGWKHQHFHVVLW\RIGLIIHUHQWSURFHGXUDOVWUDWHJLHVIRULPSODQWDWLRQ 

&OLQLFDOLPSOLFDWLRQ
 2QWKHEDVLVRISUHYLRXVUHSRUWVRIGLVUXSWHGSRO\PHULFVFDIIROGVGXH WRRYHUH[SDQVLRQ
WKHSURWRFROGLGQRWUHFRPPHQGSRVWGLODWDWLRQRIWKHELRUHVRUEDEOHVFDIIROGGHYLFH+RZHYHU
RQDQJLRJUDSK\DVLJQLILFDQWGLIIHUHQFHLQWKHLQLWLDOH[SDQVLRQZDVQRWHG$EVRUE;LHQFH
7R DFKLHYH ZLWK WKH$EVRUE DQ DFXWH OXPHQ JDLQ HTXLYDOHQW WR WKDW RI WKH ;LHQFH GHYLFH
EDOORRQ H[SDQVLRQ ZLWK KLJKHU SUHVVXUHV DQGRU PRUH DJJUHVVLYH SRVWGLODWDWLRQ VKRXOG EH
FRQVLGHUHGZLWKLQWKHOLPLWVRIWKHUHFRPPHQGHGGLDPHWHUV6LQFHWKHGHYLFHEDOORRQRIWKH
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 3RVWLPSODQWDWLRQLQWUDYDVFXODUXOWUDVRXQGDVVHVVPHQWRI
HFFHQWULFLW\DQGDV\PPHWU\RI;LHQFHDQG$EVRUELQWKH
$%625%,,WULDOLPSDFWRQDGYHUVHFDUGLRYDVFXODUHYHQWV
3DQQLSD6XZDQQDVRP0'<XNL,VKLEDVKL0'3K'<RKHL6RWRPL0'5DIDHO&DYDOFDQWH0'
3K')HOLSH1$OEXTXHUTXH0'&DUORV0DFD\D0'-RKQ$2UPLVWRQ0'-RQDWKDQ+LOO0'
,UHQH0/DQJ0'0RKDQGHG(JUHG0'-HDQ)DMDGHW0'0DFLHM/HVLDN0'-DQ*7LMVVHQ
0'3K'-RDQQD-:\NU]\NRZVND0'3K'5REEHUW-GH:LQWHU0'3K'%HUQDUG&KHYDOLHU
0'<RVKLQREX2QXPD0'3K'3DWULFN:6HUUX\V0'3K'

$GGUHVVIRUFRUUHVSRQGHQFH
3URIHVVRU3DWULFN:6HUUX\V0'3K'
,QWHUQDWLRQDO&HQWUHIRU&LUFXODWRU\+HDOWK1+/,,PSHULDO&ROOHJH/RQGRQ/RQGRQ
7KH8QLWHG.LQJGRP 
32%R[&&5RWWHUGDP7KH1HWKHUODQGV
(PDLOSDWULFNZMFVHUUX\V#JPDLOFRP
7HOHSKRQH

%ULHIWLWOHHFFHQWULFLW\DQGDV\PPHWU\LQGLFHVDQG'R&(
.H\ZRUGV%LRUHVRUEDEOHYDVFXODUVFDIIROGV(FFHQWULFLW\$V\PPHWU\ 
7RWDOZRUGV
1XPEHURIILJXUHV
1XPEHURIWDEOHV
2QOLQHVXSSOHPHQWILOH
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 Author’s DIILOLDWLRQ
7KRUD[&HQWHU(UDVPXV8QLYHUVLW\0HGLFDO&HQWHU5RWWHUGDP7KH1HWKHUODQGV
$FDGHPLF0HGLFDO&HQWHU$PVWHUGDP7KH1HWKHUODQGV
1RUWKHUQ5HJLRQ+HDUW&HQWHU0DKDUDM1DNRUQ&KLDQJ0DL+RVSLWDO)DFXOW\RI0HGLFLQH
&KLDQJ0DL8QLYHUVLW\&KLDQJ0DL7KDLODQG
0RQWHILRUH0HGLFDO&HQWHU$OEHUW(LQVWHLQ&ROOHJHRI0HGLFLQH1HZ<RUN1<
+RVSLWDO8QLYHUVLWDULR&OtQLFR6DQ&DUORV0DGULG6SDLQ
*UHHQ/DQH&DUGLRYDVFXODU6HUYLFH$XFNODQG&LW\+RVSLWDO$XFNODQG
7 King’s ColOHJH+RVSLWDO/RQGRQ8QLWHG.LQJGRP
'LYLVLRQRI&DUGLRORJ\'HSDUWPHQWRI,QWHUQDO0HGLFLQH,,0HGLFDO8QLYHUVLW\RI9LHQQD
9LHQQD$XVWULD
)UHHPDQ+RVSLWDO1HZFDVWOHXSRQ7\QH8.
'HSDUWPHQWRI&DUGLRORJ\3DVWHXU+RVSLWDO7RXORXVH)UDQFH
,VW'HSDUWPHQWRI&DUGLRORJ\0HGLFDO8QLYHUVLW\RI3R]QDQ3RODQG
,QVWLWXW-DFTXHV&DUWLHU0DVV\)UDQFH
,QWHUQDWLRQDO&HQWUHIRU&LUFXODWRU\+HDOWK1+/,,PSHULDO&ROOHJH/RQGRQ/RQGRQ8QLWHG
.LQJGRP
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 'HFODUDWLRQRILQWHUHVWV
3:6HUUX\V%&KHYDOLHUDQG<2QXPDDUHPHPEHUVRIWKHLQWHUQDWLRQDODGYLVRU\ERDUGRI
$EERWW9DVFXODU$OORWKHUDXWKRUVGHFODUHQRFRQIOLFWRILQWHUHVW
7KH$EVRUEWULDOZDVVSRQVRUHGE\$EERWW9DVFXODU
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1.5 Post-implantation assessment of eccentricity and 
asymmetry 
 
Post-implantation intravascular ultrasound assessment of eccentricity 
and asymmetry of Xience and Absorb in the ABSORB II trial : impact on 
adverse cardiovascular events. 
 
JACC Cardiovasc Interv. 2016 in press.  
[Original research paper, IF 7.44] 
 
Suwannasom P, Sotomi Y, Ishibashi Y, Cavalcante R, Albuquerque FN, 
Macaya C, Ormiston JA, Hill J, Lang IM, Egred M, Fajadet J, Lesiak M, 
Tijssen JG, Wykrzykowska JJ, J.de Winter MR, Chevalier B, Onuma Y, 
Serruys PW. 
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 6WUXFWXUHG$EVWUDFWWRWDOZRUGV 
%DFNJURXQG0HFKDQLFDOSURSHUWLHVRIDIXOO\ELRUHVRUEDEOHSRO\ODFWLGHVFDIIROGDUHLQKHUHQWO\
GLIIHUHQWIURPWKRVHRISHUPDQHQWPHWDOOLFVWHQW
2EMHFWLYHV7KLVVWXG\LQYHVWLJDWHGWKHUHODWLRQVKLSEHWZHHQSRVWLPSODQWDWLRQHFFHQWULFLW\DQG
DV\PPHWU\RIPHWDOOLFHYHUROLPXVHOXWLQJVWHQW;LHQFHDQGIXOO\ELRUHVRUEDEOHVFDIIROG
$EVRUEDQGWKHLUUHVSHFWLYHLPSDFWRQFOLQLFDOHYHQWVDW\HDUIROORZXS
0HWKRGV7KH$%625%,,WULDOFRPSDUHGWKH$EVRUEELRUHVRUEDEOHVFDIIROGDQGWKH;LHQFH
VWHQWLQWKHWUHDWPHQWRIDGHQRYRFRURQDU\DUWHU\VWHQRVLV3URWRFROPDQGDWHG,986LPDJLQJ
ZDVSHUIRUPHGSUHDQGSRVWLPSODQWDWLRQLQSDWLHQWVZLWKOHVLRQV7KHHFFHQWULFLW\LQGH[
(,DQGDV\PPHWU\LQGH[$,ZHUHFDOFXODWHG7KHLQFLGHQFHRIGHYLFHRULHQWHGFRPSRVLWH
HQGSRLQW'R&(DFRPSRVLWHRIFDUGLDFGHDWKP\RFDUGLDOLQIDUFWLRQQRWDWWULEXWHGWRQRQWDUJHW
YHVVHOVDQGLVFKHPLFGULYHQWDUJHWOHVLRQUHYDVFXODUL]DWLRQZDVVWUDWLILHGLQJURXSV
FKDUDFWHUL]HGE\WKHIROORZLQJJHRPHWULFDOSDUDPHWHUVLFRQFHQWULFDQGV\PPHWULF&6JURXS
EI  0.7and AI  0.3); LLFRQFHQWULFDQGDV\PPHWULF&$JURXSEI  0.7 and AI > 0.3); LLL
HFFHQWULFDQGDV\PPHWULF($JURXS(,DQG$,!
5HVXOWVOHVLRQVZHUHFODVVLILHGWRWKH&6JURXSIROORZHGE\WKH&$JURXSQ 
OHVLRQVDQGWKH($JURXSQ OHVLRQV$W\HDUWKH'R&(UDWHVZHUH
DQGLQWKH($JURXS&$JURXSDQG&6JURXSUHVSHFWLYHO\ORJUDQNS 7KH
SULQFLSDOLQGHSHQGHQWGHWHUPLQDQWVRIHFFHQWULFDQGDV\PPHWULFGHYLFHPRUSKRORJ\ZHUHKLJK
SUHLPSODQWDWLRQ(,>25S @DQGWUHDWPHQWZLWKWKH$EVRUE>25
S@7KHLQGHSHQGHQWGHWHUPLQDQWVRI'R&(ZHUHOHVLRQVZLWKQHJDWLYH
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 DUWHULDOUHPRGHOLQJ>+5S @DQG$,!DIWHUGHYLFHLPSODQWDWLRQ
>SYDOXH @
&RQFOXVLRQ$V\PPHWULFGHYLFHPRUSKRORJ\LVLQGHSHQGHQWO\DVVRFLDWHGZLWKDGYHUVHHYHQWV
IROORZLQJSHUFXWDQHRXVFRURQDU\LQWHUYHQWLRQ$EVRUELPSODQWDWLRQLVPRUHIUHTXHQWO\DVVRFLDWHG
ZLWKSRVWLPSODQWDWLRQHFFHQWULFDQGDV\PPHWULFPRUSKRORJ\FRPSDUHGWRWKH;LHQFHVWHQW
>$%625%,,1&7@

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 &RQGHQVHGDEVWUDFW7RWDOZRUGV 
7KHUHODWLRQVKLSEHWZHHQWKH,986JHRPHWULFDOPRUSKRORJLHVDQGFOLQLFDOHYHQWVKDVQHYHUEHHQ
LQYHVWLJDWHGLQWKHFRQWH[WRIDUDQGRPL]HGWULDO7KLVVWXG\LQYHVWLJDWHGWKHUHODWLRQVKLSEHWZHHQ
SRVWLPSODQWDWLRQHFFHQWULFLW\DQGDV\PPHWU\RILPSODQWHGGHYLFHVDQGFOLQLFDOHYHQWVDW\HDU
IROORZXSLQWKH$%625%,,UDQGRPL]HGWULDO7KHSULQFLSDOLQGHSHQGHQWGHWHUPLQDQWVRI
HFFHQWULFDQGDV\PPHWULFPRUSKRORJ\RIVFDIIROGVWHQWSRVWLPSODQWDWLRQZHUHKLJKSUH
LPSODQWDWLRQ(,>25S @DQGWUHDWPHQWZLWK$EVRUE>25
S@/HVLRQVZLWKSUHLPSODQWDWLRQQHJDWLYHUHPRGHOLQJDQGKLJKSRVWLPSODQWDWLRQ$,
ZHUHLQGHSHQGHQWO\DVVRFLDWHGZLWK\HDU'R&(
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 $EEUHYLDWLRQ
$, DV\PPHWU\LQGH[
%96 ELRUHVRUEDEOHYDVFXODUVFDIIROG
((6 PHWDOOLFHYHUROLPXVHOXWLQJVWHQW
(, HFFHQWULFLW\LQGH[
,986 LQWUDYDVFXODUXOWUDVRXQG
'R&( GHYLFHRULHQWHGFRPSRVLWHHQGSRLQW
0, P\RFDUGLDOLQIDUFWLRQ
0/$ PLQLPDOOXPHQDUHD
0/' PLQLPDOOXPHQGLDPHWHU
4&$ TXDQWLWDWLYHFRURQDU\DQJLRJUDSK\

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 ,1752'8&7,21
%LRUHVRUEDEOHYDVFXODUVFDIIROGV$EVRUE$EERWW9DVFXODU6DQWD&ODUD&$KDYHHPHUJHGDVD
QRYHOWHFKQRORJ\ZLWKVHYHUDOSRWHQWLDODGYDQWDJHVFRPSDUHGWRSHUPDQHQWPHWDOOLFVWHQWVLQWKH
WUHDWPHQWRIFRURQDU\DUWHU\GLVHDVH%LRUHVRUEDEOHYDVFXODUVFDIIROGV%96KDYHDOHVVHU
UDGLDOVWUHQJWKWKDQPHWDOOLFGUXJHOXWLQJVWHQWV'(6$QRYHUVWUHWFKLQJRI%96PD\FDXVH
ORVVRILWVUDGLDOVWUHQJWKDQGHYHQFDXVHVPHFKDQLFDOGLVUXSWLRQRIWKHGHYLFH7KHUHIRUHWKH
LQKHUHQWGLIIHUHQFHVLQPHFKDQLFDOSURSHUW\EHWZHHQSRO\PHULFDQGPHWDOOLFGHYLFHSUHFOXGHG
DJJUHVVLYHSRVWGLODWLRQLQ%967KDWODVWIDFWFRXOGH[SODLQWKHORZDFXWHJDLQRI$EVRUEZKHQ
FRPSDUHGWRWKHPHWDOOLFHYHUROLPXVHOXWLQJVWHQW((6LQWKHUDQGRPL]HGFRQWUROOHGWULDO
$%625%,,GXHWRORZHUSUHVVXUHXVHGGXULQJLQIODWLRQDQGVPDOOHUSRVWGLODWLRQEDOORRQ
1HYHUWKHOHVVWKHUHZHUHVLPLODU\HDUFOLQLFDORXWFRPHVEHWZHHQ$EVRUEDQGPHWDOOLF((6
(FFHQWULFLW\LQGH[(,DQGDV\PPHWU\LQGH[$,DVVHVVHGE\LQWUDYDVFXODUXOWUDVRXQG,986
DUHNQRZQDVLQGLFDWRUVRIDFXWHSHUIRUPDQFHRIFRURQDU\GHYLFHV$SULRUVWXG\VXJJHVWHGD
SRVVLEOHDVVRFLDWLRQEHWZHHQWKURPEXVIRUPDWLRQDQGORZHFFHQWULFLW\LQGH[OHVLRQVDIWHU
VLUROLPXVHOXWLQJVWHQWLPSODQWDWLRQDWPRQWKIROORZXS7KH086,&WULDOVKRZHGWKDW(,!
UHIOHFWHGRSWLPDOVWHQWH[SDQVLRQFRQILUPHGE\IDYRUDEOHDQJLRJUDSKLFUHVXOWVVHHQDW
PRQWKVIROORZXS+RZHYHUWKHXQGHUVWDQGLQJRIWKHSURJQRVWLFYDOXHRIWKHHFFHQWULFLW\DQG
DV\PPHWU\LQGLFHVLQFOLQLFDOSUDFWLFHUHPDLQOLPLWHGPDLQO\GXHWRREVHUYDWLRQDOVWXGLHVXVLQJ
ROGVWHQWSODWIRUPVPDOOVDPSOHVL]HDQGVKRUWIROORZXSGXUDWLRQ
$FRPSDULVRQRIWKHDFXWHSHUIRUPDQFHEHWZHHQ$EVRUEDQGPHWDOOLF((6LQWKHDEVHQFHRI
VSHFLILFDQGPDQGDWRU\LQWUDFRURQDU\LPDJLQJJXLGDQFHLQWKH$EVRUEILUVWLQPDQDQG63,5,7
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 ),567WULDOKDVEHHQUHSRUWHGLPPHGLDWHO\DIWHULPSODQWDWLRQ$EVRUEZDVPRUHHFFHQWULFDQG
DV\PPHWULFDVFRPSDUHGWRDPHWDOOLF((6ZLWKRXWGHWHFWDEOHLPSDFWRQ0$&(DWPRQWKV.
,WLVRILQWHUHVWWRLQYHVWLJDWHWKHDFXWHSHUIRUPDQFHRIDQHZVFDIIROGVWHQWSODWIRUPDQGWKHLU
UHODWLRQVKLSVWRGHYLFHRULHQWHGFRPSRVLWHHQGSRLQW'R&(LQDODUJHUVDPSOHVL]HDQGLQWKH
FRQWH[WRIDUDQGRPL]HGWULDO7KHDLPRIWKLVVWXG\ZDVWRLQYHVWLJDWHWKHPHFKDQLVWLF
UHVSRQVHRIOHVLRQVDIWHUGHYLFHVLPSODQWDWLRQDQGWRDVVHVVWKHLPSDFWRISRVWLPSODQWDWLRQ
HFFHQWULFLW\DQGDV\PPHWU\LQGLFHVRQHDUO\DQGODWHFOLQLFDOHYHQWVWUHDWHGHLWKHUZLWKDPHWDOOLF
RUDSRO\PHULFGHYLFH

0(7+2'6
6WXG\3RSXODWLRQ
7KH$%625%,,UDQGRPL]HGFRQWUROOHGWULDOGHVLJQKDVEHHQGHVFULEHGLQGHWDLOSUHYLRXVO\,Q
VXPPDU\WKH$%625%,,WULDOLVDSURVSHFWLYHVLQJOHEOLQGHGUDQGRPL]HGDFWLYH–FRQWUROOHG
WULDO7KHVWXG\LQFOXGHGSDWLHQWVZLWKGHQRYRFRURQDU\OHVLRQVUDQGRPL]HGLQUDWLRWR
UHFHLYHHLWKHUWUHDWPHQWZLWKDQHYHUROLPXVHOXWLQJELRUHVRUEDEOHVFDIIROG$EVRUE$EERWW
9DVFXODU6DQWD&ODUD&$86$RUZLWKDQHYHUROLPXVHOXWLQJPHWDOOLFVWHQW;LHQFH$EERWW
9DVFXODU6DQWD&ODUD&$86$7KHLQFOXVLRQFULWHULDZHUHSDWLHQWVDJHG–\HDUVZLWK
HYLGHQFHRIP\RFDUGLDOLVFKHPLDZLWKRQHRUWZRGHQRYRQDWLYHOHVLRQVLQGLIIHUHQWHSLFDUGLDO
YHVVHOVZLWKDPD[LPXPOXPHQGLDPHWHUEHWZHHQPPDQGPPDVVHVVHGE\RQOLQH
TXDQWLWDWLYHFRURQDU\DQJLRJUDSK\4&$DQGDPD[LPXPOHVLRQOHQJWKRIPP

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 6WXG\GHYLFH1 
7KHGHWDLOVRIWKHVWXG\GHYLFH$EVRUEKDYHEHHQGHVFULEHGSUHYLRXVO\,QEULHIWKH2 
EDOORRQH[SDQGDEOH$EVRUEVFDIIROGLVFRPSULVHGRID3RO\/ODFWLGH3//$EDFNERQHFRDWHG3 
ZLWKDQDPRUSKRXVGUXJHOXWLQJFRDWLQJPDWUL[FRPSRVHGRI3RO\'/ODFWLGH3'//$4 
SRO\PHUFRQWDLQLQJHYHUROLPXV100 ȝg/cm7KHFRQWUROGHYLFHZDVWKHVHFRQGJHQHUDWLRQ5 
HYHUROLPXVHOXWLQJVWHQW;LHQFH$EERWW9DVFXODU6DQWD&ODUD&$ZKLFKLVDEDOORRQ6 
H[SDQGDEOHPHWDOOLFVWHQWPDQXIDFWXUHGIURPDIOH[LEOHFREDOWFKURPLXPDOOR\DQGFRDWHGZLWK7 
DWKLQQRQDGKHVLYHGXUDEOHELRFRPSDWLEOHDFU\OLFDQGIOXRULQDWHGHYHUROLPXVUHOHDVLQJ8 
FRSRO\PHU7KH;LHQFHVWHQWDQG$EVRUEVFDIIROGVKDUHWKHVDPHEDVLF08/7,/,1.GHVLJQ9 
DQGERWKGHYLFHVDUHVLPLODULQWHUPVRIGUXJGUXJGRVHGHQVLW\DQGHOXWLRQSURILOH10 
,PDJLQJDFTXLVLWLRQDQGDQDO\VLV11 
Quantitative Angiographic Assessment 12 
7ZRGLPHQVLRQDOTXDQWLWDWLYHFRURQDU\DQDO\VLV4&$ZDVSHUIRUPHGDWDQLQGHSHQGHQWFRUH13 
ODE&DUGLDO\VLV%95RWWHUGDP7KH1HWKHUODQGVZLWKWKH&$$6V\VWHP&$$63LH14 
0HGLFDO%90DDVWULFKW7KH1HWKHUODQGV,QHDFKSDWLHQWWKHVWHQWVFDIIROGVHJPHQWDQGWKH15 
SHULVWHQWVFDIIROGVHJPHQWVGHILQHGE\DOHQJWKRIPPSUR[LPDODQGGLVWDOWRWKHVFDIIROG16 
HGJHZHUHDQDO\]HGSUHDQGSRVWLPSODQWDWLRQ7KHGHWDLOVRI4&$DQGPHDVXUHPHQWRI4&$17 
PD[LPDOOXPHQGLDPHWHUV>4&$'PD[PD[LPDOOXPHQGLDPHWHULPPHGLDWHO\DGMDFHQWWRWKH18 
SUR[LPDORUGLVWDOHGJHVRIWKHVFDIIROG@KDYHEHHQGHVFULEHGHOVHZKHUH19 
IVUS acquisition 20 
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 )RUWKHSXUSRVHRIWKHVWXG\,986ZDVSHUIRUPHGEHIRUHLQWHUYHQWLRQDQGDIWHUILQDOSURFHGXUH1 
,986JUD\VFDOHZDVDFTXLUHGZLWKD)UHQFK0+]URWDWLRQDO,986FDWKHWHU2 
5HYROXWLRQ0+]9ROFDQR&RUSRUDWLRQ5DQFKR&RUGRYD&$XVLQJDXWRPDWHGSXOOEDFNV3 
DWPPSHUVHFRQGDQGIUDPHVSHUVHFRQG$OOSXOOEDFNVZHUHDQDO\]HGRIIOLQHDWPP4 
ORQJLWXGLQDOLQWHUYDOVDQGDQDO\]HGE\DQLQGHSHQGHQWFRUHODERUDWRU\&DUGLDO\VLV%95 
5RWWHUGDP7KH1HWKHUODQGVXVLQJDFRPPHUFLDOVRIWZDUH4,YXV0HGLV/HLGHQ7KH6 
1HWKHUODQGV7 
Pre- and post-implantation IVUS analysis 8 
7KHPHWKRGVRITXDQWLWDWLYH,986KDYHEHHQSUHYLRXVO\UHSRUWHG7KHSUHLPSODQWDWLRQ9 
VHJPHQWVZHUHGHILQHGE\FRUHJLVWUDWLRQZLWKSRVWLPSODQWDWLRQ,986XVLQJLGHQWLFDOODQGPDUNV10 
VXFKDVVLGHEUDQFKHVDQGFDOFLXPORFDWLRQV0DWFKLQJZDVGRQHXVLQJGHGLFDWHGVRIWZDUH11 
,YXV2FW5HJLVWUDWLRQ'LYLVLRQRI,PDJH3URFHVVLQJ>/.(%@/HLGHQ7KH1HWKHUODQGV3UH12 
WUHDWPHQWUHIHUHQFHVHJPHQWVZHUHVHOHFWHGDVVLWHVZLWKWKHOHDVWDPRXQWRISODTXHSUR[LPDO13 
DQGGLVWDOWRWKHPLQLPDOOXPHQDUHD0/$VLWHVSULRUWRWKHWDNHRIIRIDQ\PDMRUVLGHEUDQFKHV14 
7KHVFDIIROGVWHQWVHJPHQWVZHUHLGHQWLILHGE\WKHILUVWDQGWKHODVWFURVVVHFWLRQDO,986IUDPH15 
LQZKLFKVFDIIROGVWHQWVWUXWVFRXOGEHLGHQWLILHGDQGRUZKHUHWKHSUR[LPDORUGLVWDOPHWDOOLF16 
PDUNHUVFRXOGEHLGHQWLILHG7KHSRVWLPSODQWDWLRQUHJLRQRILQWHUHVWZDVWKHVHJPHQWEHJLQQLQJ17 
PPGLVWDOWRDQGH[WHQGLQJPPSUR[LPDOWRWKHVFDIIROGVWHQWVHJPHQWV18 
IVUS parameter definitions 19 
,QFRPSOHWHDSSRVLWLRQZDVGHILQHGDVRQHRUPRUHVFDIIROGVWHQWVWUXWVVHSDUDWHGIURPWKHYHVVHO20 
ZDOO3ODTXHEXUGHQZDVFDOFXODWHGDVSODTXHDUHDYHVVHODUHD5HPRGHOLQJZDVDVVHVVHGE\21 
PHDQVRIWKHUHPRGHOLQJLQGH[5,H[SUHVVHGDVWKHYHVVHODUHDDWWKH0/$VLWHGLYLGHGE\WKH22 
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 DYHUDJHRIWKHSUR[LPDODQGGLVWDOUHIHUHQFHVHJPHQW7KUHHUHPRGHOLQJFDWHJRULHVZHUHGHILQHG1 
DVIROORZVSRVLWLYHUHPRGHOLQJ5,!LQWHUPHGLDWHUHPRGHOLQJ5,EHWZHHQDQG2 
DQGQHJDWLYHUHPRGHOLQJ5,&DOFLILFDWLRQRQ,986DSSHDUVDVEULJKWHFKRHVZLWK3 
DFRXVWLFVKDGRZLQJRIWKHGHHSHUDUWHULDOVWUXFWXUHV/RFDWLRQDQGFLUFXPIHUHQWLDOGLVWULEXWLRQRI4 
FDOFLXPZHUHTXDQWLILHGRQJUD\VFDOH,9867KHODUJHVWFRQWLQXRXVDUFRIFDOFLXPDQGVXPPHG5 
DUFRIFDOFLXPDWWKHVLWHRISUHLQWHUYHQWLRQDOOXPHQDUHDZHUHPHDVXUHGLQGHJUHHVZLWKD6 
SURWUDFWRUFHQWHUHGRQWKHOXPHQ7 
(FFHQWULFLW\LQGH[(,ZDVFDOFXODWHGDVWKHUDWLRRIWKHSURMHFWHGPLQLPDODQGPD[LPDOOXPHQ8 
RUVFDIIROGVWHQWGLDPHWHU7KH,986FURVVVHFWLRQZLWKWKHORZHVWHFFHQWULFLW\LQGH[YDOXH9 
SHUSXOOEDFNZDVXVHGIRUWKHDQDO\VLV$V\PPHWU\LQGH[$,ZDVFDOFXODWHGSHUOHVLRQDV–10 
SURMHFWHGPLQLPXPOXPHQRUVFDIIROGVWHQWGLDPHWHUSURMHFWHGPD[LPDOOXPHQRUVFDIIROGVWHQW11 
GLDPHWHUWKURXJKRXWDQHQWLUHSXOOEDFN)LJXUH$12 
Geometrical morphologies definitions and clinical endpoints 13 
7KHVWXG\SRSXODWLRQZDVVWUDWLILHGDFFRUGLQJWRWKH,986FULWHULDRIHFFHQWULFLW\DQG14 
DV\PPHWU\$OHVLRQZDVFKDUDFWHUL]HGDVHFFHQWULFZKHQWKHYDOXHRI(,ZDVEHORZ15 
&RQYHUVHO\DOHVLRQZLWKSRVWLPSODQWDWLRQVFDIIROGVWHQWEI  0.7 ZDVGHILQHGDVFRQFHQWULF$16 
OHVLRQZDVFKDUDFWHUL]HGDVDV\PPHWULFZKHQWKHYDOXHRI$,ZDVRYHU7KHUHIRUHDOO17 
SRVWLPSODQWDWLRQOHVLRQVZHUHFODVVLILHGLQWRWKUHHJHRPHWULFDOPRUSKRORJLHVDVIROORZL18 
“FRQFHQWULFDQGV\PPHWULF”&6JURXS(EI  0.7 and AI  0.LL“FRQFHQWULFDQGDV\PPHWULF”19 
&$group (EI  0.7 and AI > 0.3); iii“HFFHQWULFDQGDV\PPHWULF”($JURXS(,DQG$,!20 
)LJXUH%21 
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 ,QWKHSUHVHQWDQDO\VLVWKHSULPDU\FOLQLFDORXWFRPHZDVDGHYLFHRULHQWHGFRPSRVLWHHQGSRLQW1 
'R&(DW\HDUGHILQHGDVDFRPSRVLWHRIFDUGLDFGHDWKP\RFDUGLDOLQIDUFWLRQ0,GHILQHGE\2 
4ZDYHDQGQRQ4ZDYH0,IURPQRQDWWULEXWHGWRQRQWDUJHWYHVVHOVDQGLVFKHPLDGULYHQ3 
WDUJHWOHVLRQUHYDVFXODUL]DWLRQ,'7/5E\FRURQDU\E\SDVVJUDIWRUSHUFXWDQHRXVFRURQDU\4 
LQWHUYHQWLRQ$OOFOLQLFDOHQGSRLQWVGHILQLWLRQVDUHGHVFULEHGLQWKHRQOLQHDSSHQGL['HILQLWH5 
DQGSUREDEOHVFDIIROGWKURPERVLV67ZDVDGMXGLFDWHGDFFRUGLQJWRWKH$FDGHPLF5HVHDUFK6 
&RQVRUWLXPGHILQLWLRQV$QLQGHSHQGHQWFOLQLFDOHYHQWVFRPPLWWHHDGMXGLFDWHGDOO7 
FOLQLFDORXWFRPHV8 
6WDWLVWLFDO$QDO\VLV9 
$OOVWDWLVWLFDODQDO\VHVZHUHSHUIRUPHGXVLQJ6$6UHOHDVH6$6,QVWLWXWH,QF&DU\1&RU10 
6366YHUVLRQ6366,QF&KLFDJR,/4&$DQG,986ZHUHDQDO\]HGSHUOHVLRQ$OO11 
FRQWLQXRXVYDULDEOHVZHUHSUHVHQWHGDVPHDQVWDQGDUGGHYLDWLRQ6'RUPHGLDQDQG12 
LQWHUTXDUWLOHUDQJH,45VWWRUGTXDUWLOHDVDSSURSULDWH2QHway ANOVA with Tukey’s 13 
SRVWKRFWHVWRU.UXVNDO:DOOLVWHVWZHUHXVHGIRUFRPSDULVRQVRIFRQWLQXRXVYDULDEOHVDQG&KL14 
VTXDUHWHVWZDVXVHGIRUFDWHJRULFDOYDULDEOHV7KHHQGSRLQWDQDO\VHVZHUHSHUIRUPHGDFFRUGLQJ15 
WRWKHLQWHQWLRQWRWUHDWSULQFLSOHDQGSUHVHQWHGDWDSDWLHQWOHYHO:KHQHYHUDSDWLHQWUHFHLYHG16 
PRUHWKDQRQHOHVLRQWUHDWPHQWWKHOHVLRQZLWKWKHORZHVWVFDIIROGVWHQW(,ZDVVHOHFWHGDV17 
UHSUHVHQWDWLYHRIWKDWSDWLHQW2QH\HDUFOLQLFDORXWFRPHVDPRQJWKHWKUHHJURXSVDUHFRPSDUHG18 
ZLWKWKHORJUDQNWHVW6HYHUDOSDWLHQWUHODWHGOHVLRQUHODWHGSUHDQGSRVWSURFHGXUHUHODWHG19 
YDULDEOHVZHUHDVVHVVHGLQXQLYDULDWHDQDO\VHV9DULDEOHVZLWKSLQWKHXQLYDULDWHDQDO\VLV20 
ZHUHLQFOXGHGLQWKHPXOWLYDULDEOH&R[UHJUHVVLRQPRGHO$PXOWLYDULDEOH&R[SURSRUWLRQDO21 
KD]DUGVPRGHOZDVXVHGWRGHWHUPLQHWKHLQGHSHQGHQWGHWHUPLQDQWVRI'R&($PXOWLYDULDWH22 
ORJLVWLFUHJUHVVLRQDQDO\VLVZDVXVHGWRGHWHUPLQHWKHLQGHSHQGHQWIDFWRUVDVVRFLDWHGZLWK23 
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 HFFHQWULFDQGDV\PPHWULFPRUSKRORJ\DIWHUVFDIIROGVWHQWLPSODQWDWLRQ5HFHLYHURSHUDWLQJ1 
FKDUDFWHULVWLF52&FXUYHVDQGFLQGLFHVZHUHXVHGWRDVVHVVWKHVHQVLWLYLW\DQGVSHFLILFLW\2 
YDOXHRIHFFHQWULFLW\DQGDV\PPHWU\RQFOLQLFDORXWFRPHV$OOUHSRUWHGSYDOXHVZHUHVLGHG3 
DQGYDOXHVRISZHUHFRQVLGHUHGVWDWLVWLFDOO\VLJQLILFDQW4 
5(68/765 
3DWLHQWGHPRJUDSKLFVDQGEDVHOLQHFOLQLFDOFKDUDFWHULVWLFV6 
2XWRISDWLHQWVZKRZHUHUDQGRPO\DVVLJQHGWRHLWKHUWKH$EVRUEDUPSDWLHQWV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PHWDOOLF((6DUPSDWLHQWV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,986DQDO\VLV)LJXUH&RQVHTXHQWO\WKHWRWDOVDPSOHVL]HFRQVLVWHGRISDWLHQWVZLWK9 
OHVLRQV7KH&6JURXSFRPSULVHGWKHODUJHVWSURSRUWLRQRISDWLHQWVQ OHVLRQV10 
IROORZHGE\WKH&$JURXSQ OHVLRQVDQGWKH($JURXSQ OHVLRQV11 
7KHUHZHUHVLPLODUEDVHOLQHFOLQLFDOFKDUDFWHULVWLFVDPRQJWKHWKUHHJURXSV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3UHLPSODQWDWLRQOHVLRQFKDUDFWHULVWLFVDQGGHWDLOVRIWKHSURFHGXUH13 
3UHLPSODQWDWLRQOHVLRQFKDUDFWHULVWLFV4&$DQG,986PHDVXUHPHQWVDUHVXPPDUL]HGLQ7DEOH14 
:KHQSRSXODWLRQZDVVWUDWLILHGDFFRUGLQJWRWKHSRVWLPSODQWDWLRQHFFHQWULFLW\DQGDV\PPHWU\15 
LQGLFHVWKH($JURXSKDGORZHUSUHLPSODQWDWLRQ(,DQGKLJKHUSUHLPSODQWDWLRQ$,WKDQRWKHU16 
JURXSV/RZHUYDOXHVRISUHLPSODQWDWLRQ(,ZHUHREVHUYHGPRUHIUHTXHQWO\LQWKHPHWDOOLF((617 
FRPSDUHGWRWKH$EVRUEYVS ZKLOHDV\PPHWU\LQGLFHVZHUH18 
FRPSDUDEOHLQERWKDUPV 7KHSUHVHQFHRIFDOFLXPDQGWKHSURSRUWLRQRIQHJDWLYHUHPRGHOLQJ19 
OHVLRQVZHUHFRPSDUDEOHDPRQJWKHWKUHHJURXSVEXWWKHVXPDUFRIFDOFLXPZDVVLJQLILFDQWO\20 
KLJKHULQWKH($JURXSV7KH&6JURXSKDGDFRPSDUDEOHSURSRUWLRQRI$EVRUEDQGPHWDOOLF((621 
$EVRUEYVPHWDOOLF((6S ZKLOHWKHUHZDVDKLJKHUSURSRUWLRQRI$EVRUE22 
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 LQWKH&$JURXSYVSDQGDQHYHQKLJKHUSURSRUWLRQLQWKH($JURXS1 
YVS$KLJKHUSURSRUWLRQRIRYHUODSSHGLPSODQWDWLRQZDVREVHUYHGLQWKH2 
($JURXSFRPSDUHGWRRWKHUV($&$&6SRYHUDOO7KHUDWHVRI3 
SRVWGLODWLRQZHUHHTXDODPRQJWKHJURXSV'HWDLOVRISURFHGXUDOFKDUDFWHULVWLFVDUH4 
VXPPDUL]HGLQRQOLQHWDEOH5 
3RVWLPSODQWDWLRQ4&$DQG,986PHDVXUHPHQW6 
3RVWLPSODQWDWLRQ4&$VKRZHGWKDWERWK0/'DQGDFXWHJDLQZHUHVLJQLILFDQWO\KLJKHULQWKH7 
&6JURXSFRPSDUHGWRERWKWKH($JURXSDQG&$JURXSVUHVSHFWLYHO\7KH&6JURXSKDGDOVRD8 
ODUJHUPHDQVFDIIROGVWHQWDUHDWKDQ($DQG&$JURXSUHVSHFWLYHO\7DEOH1HYHUWKHOHVVWKH9 
H[SDQVLRQLQGLFHVZHUHQRWVWDWLVWLFDOO\VLJQLILFDQWEHWZHHQ&6DQG($JURXS&6JURXS10 
YV($S 7KHFKDQJHLQ(,DQG$,IURPSUHWRSRVWLPSODQWDWLRQ11 
ZDVORZHVWLQWKH($JURXS12 
3RVWLPSODQWDWLRQOHVLRQVWUHDWHGZLWKPHWDOOLF((6ZHUHIRXQGWREHPRUHFRQFHQWULFPHWDOOLF13 
((6(,YV$EVRUE(,SDQGV\PPHWULFPHWDOOLF((6$,14 
YV$EVRUE$,SWKDQOHVLRQVWUHDWHGZLWK$EVRUERQOLQHWDEOH15 
3RVWLPSODQWDWLRQJHRPHWULFDOPRUSKRORJLHVDQGFOLQLFDORXWFRPHV16 
2QH\HDUFOLQLFDOIROORZXSZDVFRPSOHWHGLQDOOSDWLHQWV 7KH'R&(UDWHVZHUHDQG17 
LQ($JURXS&$JURXSDQG&6JURXSVUHVSHFWLYHO\ORJUDQNS )LJ$KLJKHU18 
HYHQWUDWHLQWKH($JURXSZDVGULYHQPDLQO\E\,'7/5DQGSDUWLDOO\E\QRQDWWULEXWHGWRQRQ19 
WDUJHWYHVVHOV0,ZKLOHWKHLQFLGHQFHVRIFDUGLDFGHDWKGHILQLWHRUSUREDEOHVFDIIROGVWHQW20 
WKURPERVLVZHUHQRWVLJQLILFDQWO\GLIIHUHQWDPRQJWKHJURXSV7DEOH7RIXUWKHULQYHVWLJDWH21 
WKHHYHQWVDFRPSDULVRQRIWKHV\PPHWULFOHVLRQV&6JURXSYVDV\PPHWULFOHVLRQ&$DQG($22 
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 JURXSZDVSHUIRUPHGDQGWKH0,UDWHZDVQRWHGWREHKLJKHULQWKHDV\PPHWULFJURXS1 
V\PPHWULFYVDV\PPHWULFSYDOXH 7KHW\SHRIGHYLFHVLPSODQWHGZDVQRW2 
VLJQLILFDQWO\GLIIHUHQWLQHDFKRIWKH'2&(FRPSRQHQWVRQOLQHWDEOH3 
,QGHSHQGHQWSUHGLFWRUVRISRVWLPSODQWDWLRQHFFHQWULFDQGDV\PPHWULFPRUSKRORJ\LQD4 
VFDIIROGVWHQW5 
6LQFHWKHUHZDVQRPDMRULPEDODQFHLQFOLQLFDOSDUDPHWHUVWKHORJLVWLFUHJUHVVLRQDQDO\VLVZHUH6 
SHUIRUPHGH[FOXVLYHO\DWDOHVLRQOHYHORQOLQHWDEOH7KHLQGHSHQGHQWGHWHUPLQDQWVRI7 
HFFHQWULFDQGDV\PPHWULFPRUSKRORJ\DIWHUVFDIIROGVWHQWLPSODQWDWLRQZHUHLSUHLPSODQWDWLRQ8 
KLJKOXPHQ(,>25S @LLWUHDWPHQWZLWK$EVRUE>25S9 
@LLLSUHGLODWLRQEDOORRQGLDPHWHU>25S @DQGLYSUHGLODWLRQ10 
SUHVVXUH>25S @11 
,QGHSHQGHQWSUHGLFWRUVRI'R&(DIWHUVFDIIROGVWHQWLPSODQWDWLRQ12 
7KHLQGHSHQGHQWSUHGLFWRUVIRU'R&(ZHUHLSUHLPSODQWDWLRQQHJDWLYHDUWHULDOUHPRGHOLQJ>+513 
S @DQGLLDV\PPHWU\LQGH[!DIWHULPSODQWDWLRQ>+514 
S @7DEOH2IQRWHHYHQZKHQWKHGHYLFHW\SHDQGILQDOPLQLPDOOXPHQDUHD15 
ZHUHIRUFHGWRHQWHULQWRWKHPXOWLYDULDWHPRGHOVWKHWZRYDULDEOHVZHUHQRWVLJQLILFDQW16 
PRUHRYHUHFFHQWULFLW\ZDVQRWLQGHSHQGHQWO\DVVRFLDWHGZLWK'R&(RQOLQHWDEOH7KH$,17 
FXWRIIYDOXHRIPRUHWKDQVKRZHGDVHQVLWLYLW\VSHFLILFLW\DQGDQDUHDXQGHUWKH18 
52&FXUYH$8&RIS ZKLOHWKH(,FXWRIIYDOXHRIOHVVWKDQVKRZHGD19 
VHQVLWLYLW\VSHFLILFLW\DQG$8&RIS )LJ20 
21 
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 ',6&866,211 
7KHPDMRUILQGLQJVRIWKLVVWXG\DUHWKHIROORZLQJ2 
 7KHPHWDOOLF((6KDGDPRUHV\PPHWULFDQGFRQFHQWULFPRUSKRORJ\WKDQWKH$EVRUE3 
LPPHGLDWHO\SRVWLPSODQWDWLRQ4 
  3UHLPSODQWDWLRQOXPHQ(,WUHDWPHQWZLWK$EVRUESUHGLODWLRQEDOORRQGLDPHWHUDQG5 
SUHGLODWLRQSUHVVXUHZHUHLQGHSHQGHQWGHWHUPLQDQWVRIGHYLFHHFFHQWULFLW\DQG6 
DV\PPHWU\DIWHULPSODQWDWLRQ7 
 $KLJKHU'R&(UDWHZDVREVHUYHGLQSDWLHQWVZLWKHFFHQWULFDQGDV\PPHWULFOHVLRQV8 
FRPSDUHGWRSDWLHQWVZLWKFRQFHQWULFDQGV\PPHWULFOHVLRQV9 
 7KHLQGHSHQGHQWSUHGLFWRUVRI'R&(ZHUHSUHLPSODQWDWLRQQHJDWLYHDUWHULDO10 
UHPRGHOLQJDQG$,!DIWHULPSODQWDWLRQ11 
Type of device and post-implantation geometrical morphology. 12 
:KLOHWKHSUHLPSODQWDWLRQ(,RIWKHPHWDOOLF((6DUPZDVORZHUWKDQLQWKH$EVRUEDUPOHVLRQV13 
WUHDWHGE\WKHPHWDOOLF((6EHFDPHPRUHFRQFHQWULFDQGV\PPHWULFSRVWLPSODQWDWLRQ$14 
GHFUHDVHGUDGLDOVWUHQJWKRI$EVRUEPD\EHDSODXVLEOHH[SODQDWLRQZK\WKHSRO\PHULFGHYLFH15 
FRXOGQRWRYHUFRPHWKHOXPHQHFFHQWULFLW\SULRUWRWKHLPSODQWDWLRQ5HFHQWO\)RLQHWDO16 
UHSRUWHGWKDWWKHPPDQGPPVFDIIROGVL]HVFRXOGEHH[SDQGHGXSWRPPDERYHWKHLU17 
QRPLQDOGLDPHWHUVZLWKRXWDQ\VWUXWIUDFWXUHZKHQGHSOR\HGZLWKRXWDQH[WHUQDOFRQVWUDLQLQJ18 
PRGHO%\FRQWUDVWZKHQERWKVFDIIROGVL]HVZHUHUHSHDWHGXVLQJDFRQVWUDLQLQJVLOLFRQHOHVLRQ19 
PRGHOSRVWH[SDQVLRQZLWKDQ1&EDOORRQVL]HPPODUJHUWKDQWKHVFDIIROGQRPLQDOVL]HV20 
FRXOGFDXVHVWUXWIUDFWXUHV2XUILQGLQJVDOWHUQDWLYHO\FDQEHH[SODLQHGE\WKHORZHUSUHVVXUH21 
DSSOLHGGXULQJVFDIIROGLPSODQWDWLRQDQGE\OHVVDJJUHVVLYHSRVWGLODWLRQLQWKH$EVRUEDUPWR22 
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 DYRLGVFDIIROGRYHUH[SDQVLRQ7KHUHIRUHLWLVQRWVXUSULVLQJWRVHHLQWKHPXOWLYDULDEOHORJLVWLF1 
UHJUHVVLRQWKDWWKHXVHRI$EVRUEZKHQFRPSDUHGWRPHWDOOLF((6KDVDQRGGUDWLRRIDVIDU2 
DVWKHHFFHQWULFLW\DQGDV\PPHWU\RIWKHOXPHQSRVWLPSODQWDWLRQLVFRQFHUQHG3 
Asymmetry index is impacting DoCE 4 
3UHYLRXVWULDOVIRFXVHGRQWKHRSWLPDOGHYLFHSHUIRUPDQFHDQGKDYHWULHGWRFRUUHODWH,9865 
SDUDPHWHUVDQGFOLQLFDORXWFRPHV7KHH[SDQVLRQLQGH[HFFHQWULFLW\LQGH[PLQLPDOVWHQW6 
DUHDKDYHEHHQZLGHO\XVHGDVLQGLFDWRUVRIWKHRSWLPDOVFDIIROGVWHQWH[SDQVLRQZKLOHOHVV7 
DWWHQWLRQKDVEHHQSDLGWRWKHDV\PPHWU\LQGH[$OWKRXJKWKHSUHVHQWVWXG\ZDVQRWSRZHUHGWR8 
GHWHUPLQHLQGHSHQGHQWSUHGLFWRUVRI'R&(LWVKRZVWKDWWKH$,LVDQDSSURSULDWHSDUDPHWHU9 
ZKLFKUHODWHVEHWWHUWRWKHFOLQLFDORXWFRPHVWKDQ(,7KHVXSHULRULW\RI$,RYHU(,DQG10 
H[SDQVLRQLQGH[PD\EHH[SODLQHGE\WKHPRUHJOREDODVVHVVPHQWRI$,ZKLFKUHSUHVHQWVWKH11 
ZKROHWUHDWHGOHVLRQZKLOH(,FKDUDFWHUL]HVRQO\RQHFURVVVHFWLRQRIWKHOHVLRQV7KHH[SDQVLRQ12 
LQGH[ZDVFDOFXODWHGXVLQJWKHUHIHUHQFHOXPHQDUHDVWKDWFRXOGSRWHQWLDOO\EHLQIOXHQFHGE\WKH13 
SUHVHQFHRISUR[LPDORUGLVWDOVLGHEUDQFKWKDWPDNHVXQDYDLODEOHWKHLQFOXVLRQRIHLWKHUWKH14 
SUR[LPDORUGLVWDOVHJPHQWV,QSUHYLRXVVWXGLHVDFRUUHODWLRQEHWZHHQQHJDWLYHDUWHULDO15 
UHPRGHOLQJZLWKQHRLQWLPDOK\SHUSODVLDFRXOGH[SODLQWKHLPSDFWRIQHJDWLYHDUWHULDO16 
UHPRGHOLQJDVDGHWHUPLQDQWRI'R&(17 
Theoretical  relationships between geometrical morphologies and DoCE 18 
2WDNHHWDOKDYHUHSRUWHGWKDWHFFHQWULFLW\LQGH[DVVHVVHGE\2&7DQGORQJHUVWHQWOHQJWKZHUH19 
GHWHUPLQDQWVRIWKURPEXVIRUPDWLRQIROORZLQJVLUROLPXVHOXWLQJVWHQWLPSODQWDWLRQDW20 
PRQWKV7KHSUHVHQWDQDO\VHVGHPRQVWUDWHGWKDWHFFHQWULFDQGDV\PPHWULFOHVLRQVLUUHVSHFWLYH21 
RIWKHW\SHRIGHYLFHVVKRZHGVLJQLILFDQWLQFUHDVHLQ'R&(WKDWZDVPDLQO\GULYHQE\DKLJKHU22 
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 UDWHRI7/53KDUPDFRNLQHWLFPRGHOVKDYHVKRZQWKDWVXEVWDQWLDOGUXJFRQFHQWUDWLRQ1 
LQKRPRJHQHLWLHVH[LVWIRUGLIIHUHQWVWUXWSODFHPHQWVDQGJHRPHWU\$QLQKRPRJHQRXVVWUXW2 
GLVWULEXWLRQLQHFFHQWULFDQGDV\PPHWULFOHVLRQVPD\FDXVHORZHUORFDOGUXJFRQFHQWUDWLRQ3 
VXEVHTXHQWQHRLQWLPDOK\SHUSODVLDDQGUHVWHQRVLV4 
How can we achieve optimal scaffold/stent geometrical morphology? 5 
,WUHPDLQVXQFHUWDLQZKHWKHUSRVWLPSODQWDWLRQHFFHQWULFLW\DQGDV\PPHWU\RIVFDIIROGVWHQW6 
FRXOGEHFRUUHFWHGE\DJJUHVVLYHSRVWGLODWLRQRUWKLVVKRXOGEHDYRLGHGE\PHDQVRIDJJUHVVLYH7 
OHVLRQVSUHSDUDWLRQ3UHYLRXVUHSRUWIURP0DWWHVLQLDQGFROOHDJXHVVKRZHGWKDWERWK$EVRUEDQG8 
VHFRQGJHQHUDWLRQ'(6FRXOGDFKLHYHVLPLODUHFFHQWULFLW\LQGLFHVPHDQVWHQWDQGPHDQOXPHQ9 
DUHDVZKHQWKHSURFHGXUHZDVSHUIRUPHGXQGHU2&7JXLGDQFHWRDFKLHYHRSWLPDOH[SDQVLRQE\10 
IXUWKHUSRVWGLODWLRQ%\FRQWUDVWWKHSUHVHQWVWXG\VXJJHVWHGWKDWWKHLQLWLDOOHVLRQ11 
HFFHQWULFLW\DQGDV\PPHWU\DVZHOODVWKHOHVLRQSUHSDUDWLRQLPSDFWRQWKHSRVWLPSODQWDWLRQ12 
JHRPHWULFDOPRUSKRORJ\7KHDWWHPSWWRFRUUHFWWKHHFFHQWULFLW\DQGDV\PPHWU\RIWKHLPSODQWHG13 
GHYLFHVGXULQJSRVWGLODWLRQPD\QRWEHHIIHFWLYHDVWKHSRVWGLODWLRQSURFHGXUHZDVQRWDQ14 
LQGHSHQGHQWGHWHUPLQDQWRIHFFHQWULFLW\DQGDV\PPHWU\SRVWLPSODQWDWLRQ7KHGLVFUHSDQF\15 
UHVXOWVRIWKHSUHVHQWVWXG\DQGWKHSUHYLRXVRQHPD\EHDGGUHVVHGDVIROORZL)URP0DWWHVLQL16 
SDSHUWKHRSHUDWRUVSHUIRUPHGDJJUHVVLYHOHVLRQSUHSDUDWLRQE\XVLQJFXWWLQJEDOORRQDQG17 
URWDWLRQDODWKHUHFWRP\SULRUWRGHYLFHLPSODQWDWLRQZKHQDSSURSULDWH7KHDJJUHVVLYHOHVLRQV18 
SUHSDUDWLRQPD\KDGFRUUHFWHGWKHLQLWLDOHFFHQWULFLW\DQGDV\PPHWU\RIWKHOHVLRQVSUH19 
LPSODQWDWLRQDQGWKHUHIRUHWKHSHUIRUPDQFHRIERWKGHYLFHVZHUHFRPSDUDEOHLL8WLOL]DWLRQRI20 
ODUJHUSUHGLODWLRQEDOORRQGLDPHWHUVDQGKLJKSUHGLODWLRQSUHVVXUHDUHLQGHSHQGHQWGHWHUPLQDQWV21 
RIHFFHQWULFLW\DQGDV\PPHWU\SRVWLPSODQWDWLRQLQWKHSUHVHQWVWXG\VXJJHVWLQJWKDWWKH22 
RSHUDWRUVVWUXJJOHGWRFRUUHFWWKHH[LVWLQJHFFHQWULFDQGDV\PPHWULFPRUSKRORJ\SUH23 
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 LPSODQWDWLRQ,QDGGLWLRQWKHSUHVHQFHRIFDOFLXPDQGWKHHFFHQWULFDQGDV\PPHWULFDSSHDUDQFH1 
of the lesion on IVUS may also have an influence on the operator’s decision to select WKHSUH2 
GLODWLRQEDOORRQGLDPHWHUDQGWRXVHKLJKSUHVVXUHLLLWKH$%625%,,WULDOZDVGHVLJQHGWR3 
FRPSDUHWKHHIILFDF\RIERWK$EVRUEDQGPHWDOOLF((6DFFRUGLQJWRWKHFXUUHQWSUDFWLFHZLWKRXW4 
PDQGDWRU\LPDJLQJJXLGDQFHDQGWKHUHIRUHWKHUHZHUHQRVWULFWFULWHULDWREHDFKLHYHGGXULQJWKH5 
SURFHGXUH&RQVHTXHQWO\PLQLPDOOXPHQGLDPHWHUDFXWHJDLQDQGPHDQOXPHQDUHDZHUH6 
VLJQLILFDQWORZHULQ$EVRUEWKDQLQWKHPHWDOOLF'(6)XUWKHUWULDOVRQOHVLRQSUHSDUDWLRQDQG7 
LPDJLQJJXLGDQFHWRDFKLHYHRSWLPDOJHRPHWULFDOPRUSKRORJLHVDQGVWHQWVFDIIROGH[SDQVLRQDUH8 
RILQWHUHVWWRFODULI\WKHLULPSDFWRQFOLQLFDORXWFRPHV 9 
/LPLWDWLRQ10 
2XUVWXG\ILQGLQJVPD\EHOLPLWHGE\WKHORZUDWHVRIDGYHUVHFDUGLRYDVFXODUHYHQWVWKH11 
UHODWLYHO\VLPSOHOHVLRQVFKDUDFWHULVWLFVZKLFKPD\OLPLWRXUDELOLW\WRJHQHUDOL]HRXUILQGLQJV12 
HVSHFLDOO\WRWKHSDWLHQWVZLWKFRPSOH[OHVLRQVWKDWZHFRPPRQO\VHHLQWKHGDLO\FOLQLFDO13 
SUDFWLFHVLQFHWKH\HDUIROORZXSRIWKH$%625%,,WULDOLVSXUHO\FOLQLFDOZHFRXOGQRW14 
HYDOXDWHWKHUHVWHQRVLVSURFHVVRQDQJLRJUDSK\RU,986DQGUHODWHWKHHFFHQWULFLW\DQG15 
DV\PPHWU\DVVHVVPHQWWRQHRLQWLPDOK\SHUSODVLD16 
&RQFOXVLRQ17 
7KHVFDIIROGVWHQWSHUIRUPDQFHLVGHWHUPLQHGE\SUHLQWHUYHQWLRQOHVLRQFKDUDFWHULVWLFV7KH18 
RFFXUUHQFHRI'R&(ZHUHVLJQLILFDQWO\UHODWHGWRSRVWLPSODQWDWLRQHFFHQWULFLW\DQGDV\PPHWU\19 
6FDIIROGVWHQWDV\PPHWU\LQGH[!PD\EHFRQVLGHUHGDVRQHNH\,986LQGHSHQGHQW20 
GHWHUPLQDQWRIDGYHUVHFDUGLDFHYHQWV  21 
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 5HIHUHQFH
 2QXPD<6HUUX\V3:%LRUHVRUEDEOHVFDIIROGWKHDGYHQWRIDQHZHUDLQSHUFXWDQHRXVFRURQDU\
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Figure legend

Figure 1. Method used to calculate geometrical IVUS parameters after device implantation (A) and 
example of 3 geometrical morphologies after treated with Absorb and metallic DES
Abbreviations:  SD = scaffold/stent diameter; DES = drug eluting stent

)LJXUH6WXG\IORZFKDUW
Abbreviations: EES=everolimuseluting stent; $, DV\PPHWU\LQGH[(, HFFHQWULFLW\LQGH[
IVUS=intravascular ultrasound

)LJXUH'LVWULEXWLRQRIJHRPHWULFDOPRUSKRORJ\DFFRUGLQJWRW\SHRIGHYLFHVLQ$%625%,,WULDODQG
WKHLQFLGHQFHRI'R&(RYHU\HDUIROORZXS
Abbreviations&6 FRQFHQWULFDQGV\PPHWULFJURXS&$ FRQFHQWULFDQGDV\PPHWULFJURXS
($ HFFHQWULFDQGDV\PPHWULFJURXS'R&( GHYLFHRULHQWHGFDUGLRYDVFXODUHQGSRLQW

)LJXUH&XPXODWLYHFXUYHVRIVHQVLWLYLW\DQGVSHFLILFLW\RIVFDIIROGVWHQWDV\PPHWU\LQGH[PLQLPXP
VFDIIROGVWHQWHFFHQWULFLW\LQGH[DQGUHFHLYHURSHUDWLQJFKDUDFWHULVWLFFXUYHVRIVFDIIROGVWHQWDV\PPHWU\
LQGH[DQGPLQXVPLQLPXPVFDIIROGVWHQWHFFHQWULFLW\LQGH[WRSUHGLFWGHYLFHRULHQWHGFDUGLRYDVFXODU
HQGSRLQW
3DQHO$DQG%VKRZHGFXPXODWLYHFXUYHVRIVHQVLWLYLW\PDJHQWDOLQHDQGVSHFLILFLW\UHGOLQHRI
VFDIIROGVWHQWDV\PPHWU\LQGH[!DQGPLQLPXPVFDIIROGVWHQWHFFHQWULFLW\LQGH[UHVSHFWLYHO\
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3DQHO&GHPRQVWUDWHG52&FXUYHVRIVFDIIROGVWHQWDV\PPHWU\LQGH[JUHHQOLQHDQGPLQXVPLQLPDO
VFDIIROGVWHQWHFFHQWULFLW\LQGH[EOXHOLQH
Abbreviations$, DV\PPHWU\LQGH[$8& DUHDXQGHUFXUYH&, FRQILGHQWLQWHUYDO(, HFFHQWULFLW\
LQGH[
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1.6 Clinical and procedural outcomes from a randomized 
controlled trial 
 
A bioresorbable everolimus-eluting scaffold versus a metallic 
everolimus-eluting stent for ischaemic heart disease caused by 
de-novo native coronary artery lesions (ABSORB II): an interim 1-year 
analysis of clinical and procedural secondary outcomes from a 
randomised controlled trial. 
 
Lancet. 2015 Jan 3;385(9962):43-54.  
[Original research paper, IF 39.21] 
 
Serruys PW, Chevalier B, Dudek D, Cequier A, Carrié D, Iniguez A, 
Dominici M, van der Schaaf RJ, Haude M, Wasungu L, Veldhof S, Peng L, 
Staehr P, Grundeken MJ, Ishibashi Y, Garcia-Garcia HM, Onuma Y. 
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A bioresorbable everolimus-eluting scaﬀ old versus a metallic 
everolimus-eluting stent for ischaemic heart disease caused by 
de-novo native coronary artery lesions (ABSORB II): an interim 
1-year analysis of clinical and procedural secondary outcomes 
from a randomised controlled trial
Patrick W Serruys, Bernard Chevalier, Dariusz Dudek, Angel Cequier, Didier Carrié, Andres Iniguez, Marcello Dominici, René J van der Schaaf, 
Michael Haude, Luc Wasungu, Susan Veldhof, Lei Peng, Peter Staehr, Maik J Grundeken, Yuki Ishibashi, Hector M Garcia-Garcia, Yoshinobu Onuma
Summary
Background Despite rapid dissemination of an everolimus-eluting bioresorbable scaﬀ old for treatment for coronary 
artery disease, no data from comparisons with its metallic stent counterpart are available. In a randomised controlled 
trial we aimed to compare an everolimus-eluting bioresorbable scaﬀ old with an everolimus-eluting metallic stent. 
Here we report secondary clinical and procedural outcomes after 1 year of follow-up.
Methods In a single-blind, multicentre, randomised trial, we enrolled eligible patients aged 18–85 years with evidence 
of myocardial ischaemia and one or two de-novo native lesions in diﬀ erent epicardial vessels. We randomly assigned 
patients in a 2:1 ratio to receive treatment with an everolimus-eluting bioresorbable scaﬀ old (Absorb, Abbott Vascular, 
Santa Clara, CA, USA) or treatment with an everolimus-eluting metallic stent (Xience, Abbott Vascular, Santa Clara, 
CA, USA). Randomisation was stratiﬁ ed by diabetes status and number of planned target lesions. The co-primary 
endpoints of this study are vasomotion (change in mean lumen diameter before and after nitrate administration at 
3 years) and diﬀ erence between minimum lumen diameter (after nitrate administration) after the index procedure 
and at 3 years. Secondary endpoints were procedural performance assessed by quantitative angiography and 
intravascular ultrasound; composite clinical endpoints based on death, myocardial infarction, and coronary 
revascularisation; device and procedural success; and angina status assessed by the Seattle Angina Questionnaire and 
exercise testing at 6 and 12 months. Cumulative angina rate based on adverse event reporting was analysed post hoc. 
This trial is registered at ClinicalTrials.gov, number NCT01425281.
Findings Between Nov 28, 2011, and June 4, 2013, we enrolled 501 patients and randomly assigned them to the 
bioresorbable scaﬀ old group (335 patients, 364 lesions) or the metallic stent group (166 patients, 182 lesions). Dilatation 
pressure and balloon diameter at the highest pressure during implantation or postdilatation were higher and larger in the 
metallic stent group, whereas the acute recoil post implantation was similar (0·19 mm for both, p=0·85). Acute lumen 
gain was lower for the bioresorbable scaﬀ old by quantitative coronary angiography (1·15 mm vs 1·46 mm, p<0·0001) and 
quantitative intravascular ultrasound (2·85 mm² vs 3·60 mm², p<0·0001), resulting in a smaller lumen diameter or area 
post procedure. At 1 year, however, cumulative rates of ﬁ rst new or worsening angina from adverse event reporting were 
lower (72 patients [22%] in the bioresorbable scaﬀ old group vs 50 [30%] in the metallic stent group, p=0·04), whereas 
performance during maximum exercise and angina status by SAQ were similar. The 1-year composite device orientated 
endpoint was similar between the bioresorbable scaﬀ old and metallic stent groups (16 patients [5%] vs ﬁ ve patients [3%], 
p=0·35). Three patients in the bioresorbable scaﬀ old group had deﬁ nite or probable scaﬀ old throm boses (one deﬁ nite 
acute, one deﬁ nite sub-acute, and one probable late), compared with no patients in the metallic stent group. There were 
17 (5%) major cardiac adverse events in the bioresorbable scaﬀ old group compared with ﬁ ve (3%) events in the metallic 
stent group, with the most common adverse events being myocardial infarction (15 cases [4%] vs two cases [1%], respectively) 
and clinically indicated target-lesion revascularisation (four cases [1%] vs three cases [2%], respectively).
Interpretation The everolimus-eluting bioresorbable scaﬀ old showed similar 1-year composite secondary clinical 
outcomes to the everolimus-eluting metallic stent.
Funding Abbott Vascular.
Introduction
The implantation of a bioresorbable scaﬀ old is a new 
approach that provides transient vessel support with drug 
delivery capability, potentially without the limitations of 
permanent metallic implants.1,2 By liberating the coronary 
artery from the metallic caging, the vessel recovers 
pulsatility and becomes responsive to shear stress and 
physiological cyclic strain.3–5 The vessel wall, theoretically, 
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can remodel and exhibit plaque reduction in response to 
pharmacological treatment and physiological stimuli. 
The potential of this technology has been shown in some 
studies with up to 3-year follow-up with several imaging 
modalities.6–11
The use of bioresorbable scaﬀ olds has several 
challenges that justify careful assessment of this 
technology. First, the mechanical property of the 
polymeric scaﬀ old should match that of metallic stents; 
the acute recoil of the scaﬀ old has previously been 
reported to be similar to that noted with an equivalent 
device in metal.12 The mechanical integrity and the 
absence of recoil has to be maintained for 6 months, 
during which time the biological process of restenosis 
(consisting of neointimal formation and constrictive 
remodelling) fully subsides, therefore not justifying a 
permanent prosthesis beyond this time.13 The second 
challenge to be taken into consideration is that the 
bioresorption of the polymeric scaﬀ old should not 
trigger an inﬂ ammatory reaction that could result in 
late renarrowing of the vessel. Over time, the polymer 
is replaced by a provisional matrix made of proteoglycan 
that evolves into de-novo connective tissue.14 Eventual 
late enlargement of the scaﬀ old and lumen has been 
documented at 2–3 years, compensating for the 
intraluminal growth of the neointima.15
In a randomised, single-blind, active-controlled trial 
(the ABSORB II study), we aimed to compare a 
bioresorbable everolimus-eluting scaﬀ old with a metallic 
everolimus-eluting stent to treat ischaemic heart disease. 
Because the bioresorbable scaﬀ old has been commercially 
available since August, 2012, and has been widely and 
rapidly disseminated in the absence of comparative data 
from randomised trials, the steering committee and trial 
funder decided to report secondary clinical and 
procedural endpoints at 1 year. Hence, we report 
secondary endpoints for clinical, procedural, anginal, 
and disease-related quality-of-life outcomes.
Methods
Study design and participants
The ABSORB II trial is a prospective, randomised, 
active-controlled, single-blind, parallel two-group, 
multicentre clinical trial. Eligible participants were aged 
18–85 years with evidence of myocardial ischaemia, 
were suitable for coronary artery bypass graft surgery, 
and had one or two de-novo native lesions in diﬀ erent 
epicardial vessels. Patients with acute myocardial 
infarction before the procedure without normalised 
cardiac enzymes, evidence of ongoing acute myocardial 
infarction before the procedure, unstable arrhythmia, or 
left ventricular ejection fraction less than 30% were 
excluded. Full inclusion and exclusion criteria are 
provided in the appendix.
A data safety monitoring board reviewed the cumulative 
safety data from the trial at given intervals for the purpose 
of safeguarding the interests of the participants. All 
patients provided informed consent before being 
included in the trial and all participating sites received 
medical ethics committee approval for the study.
Randomisation and masking
We randomly assigned patients in a 2:1 ratio to receive 
either treatment with an everolimus-eluting bioresorbable 
scaﬀ old (Absorb, Abbott Vascular, Santa Clara, CA, USA) 
or treatment with an everolimus-eluting metallic stent 
(Xience, Abbott Vascular, Santa Clara, CA, USA). 
Randomisation was by a centralised interactive 
voice–web-based service and was stratiﬁ ed by diabetes 
status (diabetes vs no diabetes) and number of target 
lesions (single vs dual). Patients were masked to treatment 
allocation (not informed of type of device implanted) for 
the duration of trial and study staﬀ  were instructed not to 
reveal treatment allocation to patients or referring 
physicians. Study investigators and physicians doing the 
procedure were not masked to treatment allocation.
Procedures
The trial protocol allowed the treatment of up to 
two de-novo native coronary artery lesions, each located 
in diﬀ erent major epicardial vessels, with a maximum 
lumen diameter between 2·25 mm and 3·8 mm as 
assessed by online quantitative coronary angiography 
and a maximum lesion length of 48 mm. The methods 
of quantitative coronary angiography, angiographic 
acute recoil analysis, and quantitative intravascular 
ultrasound have been previously reported.12,16 All 
patients underwent coronary angiography, intravascular 
ultrasound, and intravascular ultrasound–virtual 
histology imaging before and after device implantation.
Patients had clinical follow-up at 30 days, 180 days, 
and 1 year. All patients and treating physicians were 
asked to adhere to the European Society of Cardiology 
Guidelines in terms of tobacco usage, exercise, healthy 
food intake, maintenance of an adequate weight 
(body-mass index) and waist circumference, achieve-
ment of target blood lipid concentrations, and blood 
pressure control.17,18 A patient diary was provided to 
facilitate collection of these data. We collected Seattle 
Angina Questionnaires at preimplantation, 180 days, 
and 1-year follow-ups. Exercise testing, including ECG 
recording, was done at 180 days and 1 year.19,20 ST-T 
depression of 0·1 mV at maximum exercise or chest 
pain during exercise classiﬁ ed as indicative of 
ischaemia.17,21 Recurrent or worsening angina as 
diagnosed by the site was captured on adverse event 
forms including or excluding the angina episodes that 
occurred during index admission to hospital or in the 
7 days after index procedure (whichever came ﬁ rst).
Three types of biomarkers (creatine kinase, creatine 
kinase-MB, and troponin I) were simultaneously 
sampled between 6 h after the procedure and discharge, 
and were analysed in a central core laboratory (ICON, 
Dublin, Ireland). When additional local laboratory 
See Online for appendix
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values were available, the highest value per reference 
was taken into consideration for adjudication of 
myocardial infarction.
Outcomes
The two co-primary endpoints were vasomotion (assessed 
by change in mean lumen diameter before and after nitrate 
administration at 3 years by quantitative angiography) and 
minimum lumen diameter at 3 years after nitrate admin-
istration minus minimum lumen diameter postprocedure 
after nitrate administration (assessed by quantitative 
angiography). These outcomes will be analysed after 3 years 
of follow-up.
Intravascular ultrasound secondary endpoints were 
quantitative analysis of lumen area, plaque area, scaﬀ old 
area, and neointima area.
Outcomes measured for composite clinical secondary 
endpoints were death (cardiac vs vascular vs 
non-cardiovascular), myocardial infarction (Q-wave vs 
non-Q-wave; attributable vs non-attributable to target 
vessel), target-lesion revascularisation, target-vessel revasc-
ul arisation, non-target-vessel revas culari sation, and all 
coronary revascularisations (all re vascularisations clinically 
indicated vs non-clinically indicated). Composite clinical 
secondary endpoints were death plus all myocardial 
infarction; cardiac death plus myocardial infarction 
attributable to target vessel plus clinically indicated 
target-lesion revascularisation (ie, target-lesion failure; 
device-oriented composite endpoint); cardiac death plus all 
myocardial infarction plus clinically indicated target-lesion 
revascularisation (ie, major adverse cardiac events); cardiac 
death plus all myocardial infarction plus clinically indicated 
target-vessel revascularisation (ie, target-vessel failure); 
and death plus all myocardial infarction plus all 
revascularisation (patient-oriented composite endpoint). 
Myocardial infarction per protocol was deﬁ ned as the 
development of new pathological Q-wave or creatine 
kinase rise of two or more times of upper limit of normal 
accompanied by creatine kinase-MB rise.6,8,16
We also assessed scaﬀ old or stent thrombosis timing 
(acute vs sub-acute vs late vs very late) and evidence 
(deﬁ nite vs probable vs possible) and acute success (device 
success and procedural success). We deﬁ ned device 
success as successful delivery and deployment of the ﬁ rst 
study scaﬀ old or stent at the intended target lesion and 
successful withdrawal of the delivery system with 
attainment of ﬁ nal in-scaﬀ old or in-stent residual stenosis 
of less than 50% by quantitative coronary angiography.16 
We deﬁ ned procedural success as device success without 
the occurrence of cardiac death, target-vessel myocardial 
infarction, or repeat target-lesion revascularisation during 
the hospital stay (maximum of 7 days).
Statistical analyses
The sample size for the trial was calculated on the basis 
of the ﬁ rst co-primary endpoint (superiority for 
vasomotion). Assuming a two-tailed superiority t test, a 
2:1 randomisation ratio, an α of 0·05, and true changes 
in mean lumen diameter of 0·07 mm for the 
bioresorbable scaﬀ old and 0 mm for the metallic stent 
(SD 0·20 for both), we estimated that 260 lesions in 
the bioresorbable scaﬀ old group and 130 lesions in the 
metallic stent group would be needed for 90% power. 
Allowing for a 29% attrition rate and 10% of patients with 
dual lesions, we estimated that 334 patients in the in 
the bioresorbable scaﬀ old group and 167 patients in the 
metallic stent group would be needed.
The endpoint analyses presented in this report were 
by intention to treat. Binary variables are summarised 
with counts and percentages. For exact 95% CIs, we 
used the Clopper-Pearson method. Continuous 
variables are summarised with means and SDs. For 
95% CIs for the mean, we used the Gaussian approxi-
mation. χ² or Fisher’s exact test was used to compare 
binary variables, and Student’s t-test or non-parametric 
test was used to compare continuous variables. All 
p values in this 1-year report are for descriptive 
purposes and no formal hypothesis testing was done. 
The power calculations were done with PASS version 11 
and statistical analyses were done with SAS software 
version 9.2.
Figure 1: Trial proﬁ le
335 patients assigned to the bioresorbable
scaﬀold group
364 lesions treated
364 preimplantation and postimplantation 
QCA measurements
329 preimplantation IVUS measurements
330 postimplantation IVUS measurements
318 paired IVUS measurements
311 preimplantation and postimplantation 
IVUS-HV measurements
298 paired IVUS-VH measurements
166 patients assigned to metallic stent group
182 lesions treated
182 preimplantation and postimplantation 
QCA measurements
169 preimplantation IVUS measurements
176 post-implantation IVUS measurements
167 paired IVUS measurements
160 pre-implantation IVUS-VH measurements
167 post-implantation IVUS-VH measurements
158 paired IVUS-VH measurements
501 patients enrolled
166 patients had 30-day clinical follow-up
165 patients had 180-day clinical follow-up
1 patient withdrew consent
164 patients had 1-year clinical follow-up
166 included in intention-to-treat analysis
329 patients had 1-year clinical follow-up
335 included in intention-to-treat analysis
1 patient withdrew consent
1 patient withdrawn by physician
331 patients had 180-day clinical follow-up
1 patient died3 patients withdrew consent
1 patient withdrew consent
334 patients had 30-day clinical follow-up
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This trial is registered at ClinicalTrials.gov, number 
NCT01425281.
Role of the funding source
The study funder was involved in study design, data 
collection, data analysis, data interpretation, and writing 
of this report. The corresponding author had full access 
to all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
Between Nov 28, 2011, and June 4, 2013, we enrolled 
501 patients from 46 sites in Europe and New Zealand, 
and randomly assigned them to the bioresorbable 
scaﬀ old group (335 patients) or the metallic stent group 
(166 patients; ﬁ gure 1).
Table 1 shows patient demographics, risk factors, and 
use of antianginal drugs and antiplatelet therapy at 
baseline. The prevalence of diabetes was 24%, with more 
than a quarter of these patients being insulin dependent. 
Roughly 20% of patients presented with unstable angina. 
More than 80% of patients had single-vessel disease. The 
complexity of the treated lesions is described according 
to the AHA/ACC classiﬁ cation.22
At 1 year, 329 (98%) patients in the bioresorbable 
scaﬀ old group and 164 (99%) patients in the metallic 
stent group were in clinical follow-up. In the 
bioresorbable scaﬀ old group, six patients withdrew 
consent by 1 year. In the metallic stent group, one patient 
died and one patient withdrew consent. 
All lesions were predilated with the exception of 
two lesions in the metallic stent group (table 2). For 
quantitative coronary angiography, pre-procedural 
measurements did not diﬀ er between the two groups, 
whereas for quantitative intravascular ultrasound, both 
pre-procedural vessel area and plaque area were larger in 
the metallic stent group than in the bioresorbable scaﬀ old 
group. Rates of clinical device success and clinical 
procedural success were similar in the two treatment 
groups (table 2). The nominal size of devices used and the 
acute recoil after device implantation were also similar 
between treatment groups. Balloon dilatation after device 
implantation was done in a similar proportion of patients. 
However, dilatation pressure was signiﬁ cantly higher and 
balloon diameter at the highest pressure during implan-
tation or postdilatation of the device was signiﬁ cantly 
larger in the metallic stent group. Therefore, the acute 
gain in minimum lumen diameter (by quantitative 
coronary angiography) and minimum lumen area (by 
quantitative intravascular ultrasound), and the ﬁ nal 
minimum lumen diameter and minimum lumen area, 
were signiﬁ cantly larger in the metallic stent group than 
in the bioresorbable scaﬀ old group.
The compliance of enzyme collection was high (476 [95%] 
patients for creatine kinase, 487 [97%] patients for creatine 
kinase-MB, and 485 [97%] patients for troponin). Overall, 
we noted no signiﬁ cant diﬀ erences in the pooled 
normalised values for each enzyme. When the 
three enzymes were subcategorised according to 
the relationship to their upper limit of normal for each 
respective assay, there were no diﬀ erences in the rise of 
creatine kinase-MB and troponin between the bioresorbable 
scaﬀ old and metallic stent groups. However, for the 
non-speciﬁ c creatine kinase enzyme, frequency of the cate-
gories of more than one and more than two times higher 
than upper limit of normal were higher in the bioresorbable 
scaﬀ old group than in the metallic stent group (table 3).
Bioresorbable scaﬀ old 
group
Metallic stent group
Patients
Number of patients 335 166
Age in years 61·5 (10·0) 60·9 (10·0)
Sex
Men 253/335 (76%) 132/166 (80%)
Women 82/335 (24%) 34/166 (20%)
Body-mass index (kg/m²) 27·9 (4·1) 28·1 (3·7)
Current tobacco use 79/335 (24%) 36/166 (22%)
Hypertension (history or needing medication) 231/335 (69%) 119/166 (72%)
Dyslipidaemia (history or needing medication) 252/335 (75%) 133/166 (80%)
LDL cholesterol <2 mmol/L (80 mg/dL) 113/324 (35%) 51/160 (32%)
All diabetes 80/332 (24%) 40/166 (24%)
Diabetes mellitus treated with insulin 22/80 (28%) 14/40 (35%)
Family history of premature coronary artery disease 112/306 (37%) 64/155 (41%)
Previous cardiac intervention in target vessel 14/120 (12%) 5/56 (9%)
Previous myocardial infarction 93/335 (28%) 48/166 (29%)
Recent myocardial infarction with normalised enzyme 11/335 (3%) 3/166 (2%)
Stable angina 214/335 (64%) 107/166(64%)
Stable angina CCS III or IV 47/214 (22%) 24/107 (22%)
Unstable angina 68/335 (20%) 37/166 (22%)
Unstable angina Braunwald Class III 16/68 (24%) 10/37 (27%)
Silent ischaemia 42/335 (13%) 19/166 (11%)
Single-vessel disease 278/335 (83%) 141/166 (85%)
Use of antianginal drugs at baseline
β blockers 245/335 (73%) 117/166 (70%)
Calcium channel blocker 86/335 (26%) 41/166 (25%)
Nitrate 82/335 (24%) 54/166 (33%)
Dual antiplatelet therapy at 30 days 329/332 (99%) 166/166 (100%)
Target vessel
Number of lesions 364 182
Left anterior descending artery 163/364 (45%) 84/182 (46%)
Left circumﬂ ex artery 106/364 (29%) 42/182 (23%)
Right coronary artery 95/364 (26%) 56/182 (31%)
Two or more lesions treated 29/335 (9%) 16/166 (10%)
Calciﬁ cation (moderate or severe) 46/363(13%) 28/184 (15%)
ACC/AHA lesion class
A 5/363 (1%) 1/180 (1%)
B1 193/363 (53%) 90/180 (50%)
B2 159/363 (44%) 87/180 (48%)
C 6/363 (2%) 2/180 (1%)
Data are n/N (%), in which N refers to number of patients with data available, or mean (SD) unless otherwise stated.
Table 1: Patient and lesion baseline characteristics
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Figure 2 shows the ﬁ ve domains of Seattle Angina 
Questionnaire related to angina stability, frequency, physical 
limitation, disease perception, and treatment satisfaction. 
We noted substantial improvement in every domain at 
6 and 12 months with respect to the pre-procedural 
assessment, and no signiﬁ cant diﬀ erence between the 
two treatment groups. Before the procedure, 94 (29%) 
patients subsequently assigned to the bioresorbable scaﬀ old 
group and 48 (29%) patients subsequently assigned to the 
metallic stent group were free from angina within 1 month 
before the questionnaire, whereas at 1 year 227 (74%) 
patients in the bioresorbable group and 113 (74%) patients 
in the metallic stent group were angina-free within 1 month 
before to the questionnaire (ﬁ gure 2).
In a post-hoc analysis, we assessed time and duration of 
angina through adverse event reporting. Cumulative 
angina rates at 1 year were lower in the bioresorbable 
scaﬀ old group than in the metallic stent group (72 [22%] 
vs 50 [30%], p=0·04; ﬁ gure 3). Likewise, after exclusion of 
angina episodes that occurred during index admission to 
hospital or in the 7 days after the index procedure, angina 
rates were also lower (54 [16%] vs 42 [26%], p=0·01). 
Although the investigators and research staﬀ  were 
instructed to keep blinding intact, 37 patients (32 in the 
bioresorbable scaﬀ old group and 5 in the metallic stent 
group) were potentially unblinded mainly through 
discharge letters to the referring physicians. A sensitivity 
analysis showed that excluding these 37 patients from the 
analysis did not aﬀ ect the outcomes from adverse event 
reporting (data not shown).
We did a prespeciﬁ ed analysis of exercise testing. 
465 (93%) patients received an exercise test at 6 months 
and 430 (86%) patients received one at 12 months (table 4). 
At 6 months, we noted ST depression of 0·1 mV or more 
or chest pain in 56 (18%) patients in the bioresorbable 
scaﬀ old group and 32 (20%) patients in the metallic stent 
group (p=0·57), by comparison with 43 patients (15%) 
and 22 (15%) patients at 1 year (p=0·90), respectively.
Bioresorbable scaﬀ old group Metallic stent group Diﬀ erence (95% CI) p value
Procedural details
Number of lesions 364 182 ·· ··
Balloon dilatation prior to device implantation 364 (100%) 180 (99%) 1·10% (–0·21, 3·92) 0·11
Planned overlap with the same type of device 56 (15%) 20 (11%) 4·40% (–1·93, 9·94) 0·16
Unforeseen additional implantation with the same device 14 (4%) 11 (6·0) –2·20% (–6·91, 1·44) 0·25
More than one study device implanted 70 (19%) 27 (15%) 4·40% (–2·57, 10·62) 0·21
Nominal size of study device (mm) 3·01 (0·31) 3·05 (0·28) –0·04 (–0·10, 0·01) 0·10
Balloon dilatation after device implantation 221 (61%) 107 (59%) 1·92% (–6·66, 10·67) 0·67
Nominal diameter of balloon used (implantation or post–dilatation; mm) 3·08 (0·34) 3·16 (0·36) –0·08 (–0·14, 0·01) 0·02
Maximum balloon pressure used (implantation or post-dilatation; atm) 14·23 (3·43) 15·03 (3·33) –0·80 (–1·4, –0·2) 0·01
Expected diameter of balloon used (implantation or post-dilatation; mm) 3·29 (0·35) 3·35 (0·37) –0·06 (–0·14, 0·02 ) 0·15
Angiographic acute recoil of device following implantation per device (mm) 0·19 (0·19) 0·19 (0·18) –0·00 (–0·04, 0·03) 0·85
Device success
Clinical device success 361 (99%) 182 (100%) –0·82% (–2·39, 1·31) 0·55
Clinical procedural success 322 (96%)* 164 (99%)* –2·68% (–5·46, 0·80) 0·16
Angiographic analysis
Lesion length obstruction (mm) 13·8 (6·5) 13·8 (6·6) 0·00 (–1·18, 1·18) 1·00
Total scaﬀ olded or stented length (mm) 21·1 (8·8) 20·9 (7·4) 0·24 (–1·17, 1·65) 0·74
Reference vessel
Pre-procedure diameter (mm) 2·59 (0·38) 2·63 (0·40) –0·03 (–0·10, 0·04) 0·36
Postprocedure diameter (mm) 2·64 (0·36) 2·80 (0·34) –0·16 (–0·22, –0·09) <0·001
p between pre-procedure and postprocedure 0·0699 <0·0001 ·· ··
Minimum lumen diameter
Pre-procedure diameter (mm) 1·07 (0·32) 1·05 (0·32) 0·02 (–0·03, 0·08) 0·44
Post-procedure in-stent or in-scaﬀ old diameter (mm) 2·22 (0·33) 2·50 (0·33) –0·28 (–0·34, –0·22) <0·001
p between pre-procedure and post-procedure <0·0001 <0·0001
In-stent/in-scaﬀ old acute gain (mm) 1·15 ± 0·38 1·46 ± 0·38 –0·30 (–0·37, –0·24) <0·001
Diameter stenosis
Pre-procedure percent diameter stenosis (%) 59% (11) 60% (12) –1·07 (–3·11, 0·97) 0·30
Post-procedure in-stent/in-scaﬀ old percent diameter stenosis (%) 16% (7) 10% (5) 5·37 (4·38, 6·36) <0·001
p between pre-procedure and post-procedure <0·001 <0·001
Post-procedural curvature, cm–¹ 0·29 (0·23) 0·24 (0·19) 0·04 (0·01, 0·08) 0·02
(Table 2 continues on next page)
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1-year target-lesion failure, a device oriented clinical 
endpoint (composite of cardiac death, target-vessel 
myocardial infarction, or clinically indicated target-lesion 
revascularisation) was 5% (16 patients) in the 
bioresorbable group and 3% (ﬁ ve patients) in the metallic 
stent group (p=0·35; table 5). The 1-year patient-oriented 
clinical endpoint (composite of all death, any myocardial 
infarction, and all revasc ularisation) was 7% (24 patients) 
in the bioresorbable scaﬀ old group compared with 9% 
(15 patients) in the metallic stent group (p=0·47). We 
noted only one non-cardiac death, which was due to 
cancer in the metallic stent group.
Myocardial infarctions (as deﬁ ned by the protocol) 
occurred in 15 (4%) patients in the bioresorbable scaﬀ old 
group and two (1%) patients in the metallic stent group 
(p=0·06), which were mainly driven by periprocedural 
non-Q-wave myocardial infarctions occurring in 13 (4%) 
patients in the bioresorbable scaﬀ old group and two (1%) 
patients in the metallic stent group (p=0·16). Rates of all 
revascularisations were 4% (12 patients) and 7% 
(12 patients) in the bioresorbable scaﬀ old and the metallic 
stent groups, respectively (p=0·08). We documented 
two deﬁ nite scaﬀ old thromboses, one acutely within 
24 hours of implantation and the second sub-acutely on 
Bioresorbable scaﬀ old group Metallic stent group Diﬀ erence (95% CI) p value
(Continued from previous page)
Greyscale and radiofrequency intravascular ultrasonographic analysis
Pre-procedural dense calcium (%)† 4·90% (4·73) 4·68% (4·10) 0·22 (–0·61, 1·05) 0·60
Pre-procedural necrotic core (%)† 16·20% (6·86) 16·15% (6·90) 0·05 (–1·27, 1·37) 0·94
Pre-procedural ﬁ brotic tissue (%)† 31·47% (11·39) 30·62% (11·42) 0·85 (–1·33, 3·04) 0·44
Pre-procedural ﬁ brofatty tissue (%)† 47·43% (16·91) 48·55% (16·86) –1·12 (–4·35, 2·11) 0·50
Vessel area
Pre-procedure area, mm²) 11·51% (3·40) 12·34% (3·42) –0·83 (–1·47, –0·19) 0·02
Post-procedure area (mm²) 13·17% (3·55) 14·28% (3·59) –1·11 (–1·78, –0·44) 0·001
p between pre-procedure and post-procedure <0·001 <0·001
Plaque area
Pre-procedure plaque area / media (mm²) 6·67 (2·52) 7·30 (2·68) –0·63 (–1·12, –0·13) 0·01
Post-procedure plaque area / media (mm²) 7·11 (2·46) 7·43 (2·44) –0·32 (–0·78, 0·14) 0·18
p between pre-procedure and post-procedure <0·001 0·03
Mean lumen area
Pre-procedure mean lumen area (mm²) 4·84 (1·39) 5·02 (1·47) –0·19 (–0·47, 0·08) 0·16
Post-procedure mean lumen area (mm²) 6·06 (1·44) 6·85 (1·60) –0·80 (–1·09, –0·50) <0·001
p between pre-procedure and post-procedure <0·001 <0·001
Minimal lumen area
Pre-procedure minimal lumen area (mm²) 2·04 (0·72) 2·13 (0·83) –0·10 (–0·25, 0·05) 0·20
Post-procedure minimal lumen area (mm²) 4·89 (1·38) 5·73 (1·51) –0·84 (–1·12, –0·57) <0·001
p between pre-procedure and post-procedure <0·001 <0·001
Acute gain in minimal lumen area (mm²) 2·85 (1·25) 3·60 (1·34) –0·75 (–0·99, –0·50) <0·001
Data are n (%) or mean (SD) unless otherwise stated. *Percentage based on number of patients (335 in the bioresorbable scaﬀ old group, 166 in the metallic stent group). †Postprocedural variables not presented.
Table 2: 1-year angiographic and intravascular ultrasound outcomes
Creatine kinase Creatine kinase-MB Troponin
Biosorbable 
scaﬀ old group 
(n=315)
Metallic 
stent group 
(n=161)
p value Biosorbable 
scaﬀ old group 
(n=324)
Metallic 
stent group 
(n=163)
p value Biosorbable 
scaﬀ old group 
(n=325)
Metallic 
stent group 
(n=160)
p value
Mean* (SD) 0·69 (0·61) 0·63 (0·63) 0·363 1·27 (1·99) 1·06 (1·64) 0·218 13·38 (30·64) 9·08 (21·01) 0·121
>1 × ULN 51 (16%) 14 (9%) 0·024 104 (32%) 42 (26%) 0·150 204 (63%) 99 (62%) 0·848
>2 × ULN 16 (5%) 3 (2%) 0·090 43 (13%) 16 (10%) 0·270 158 (49%) 73 (46%) 0·535
>3 × ULN 4 (1%) 3 (2%) 0·693 23 (7%) 10 (6%) 0·690 124 (38%) 59 (37%) 0·785
>5 × ULN 0 1 (1%) 0·338 16 (5%) 4 (2%) 0·192 97 (30%) 41 (26%) 0·333
>10 × ULN 0 0 1·000 2 (1%) 1 (1%) 1·000 62 (19%) 24 (15%) 0·269
Data are n (%) unless otherwise stated. ULN=upper limit of normal. *Mean of the ratio relative to the upper limit of normal for the respective biomarker, as reported by 
central or local laboratory.
Table 3: Cardiac biomarkers less than 48 h after the index procedure
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day 2, both in the bioresorbable scaﬀ old group. 
One probable scaﬀ old thrombosis occurred on day 335. 
The rate of deﬁ nite scaﬀ old thrombosis was 0·6% in 
bioresorbable scaﬀ old and 0% in metallic stent, p=1·0) 
and the overall rate of deﬁ nite or probable scaﬀ old 
thrombosis was 0·9% in bioresorbable scaﬀ old and 0% in 
metallic stent (p=0·55; table 5).
The incidence of any anatomical complications as 
assessed by angiography was similar between the 
two treatment groups (56 patients [16%] in the 
bioresorbable scaﬀ old group vs 33 patients [20%] in the 
metallic stent group, p=0·39), with sidebranch occlusion 
occurring more often in the metallic stent group (39/503 
[8%] sidebranches) than in the bioresorbable scaﬀ old 
group (52/998 [5%] sidebranches, p=0·07). Of 15 patients 
with periprocedural myocardial infarction, 10 (67%) were 
angiographically classiﬁ ed as type 1 (sidebranch occlusion), 
whereas three (20%) were type 2 (other angiographic 
complications).30,31 In multivariate analysis, treatment with 
overlapping devices was the only independent determinant 
of per-protocol periprocedural myocardial infarction 
(OR 4·36, 95% CI 1·48–12·61, p=0·012).
When we subcategorised cardiac biomarker rise 
according to contemporary criteria for periprocedural 
myocardial infarction (the third universal deﬁ nition33 
and the SCAI deﬁ nition32), periprocedural myocardial 
infarction rates were 5% in the bioresorbable scaﬀ old 
group versus 2% in the metallic stent group 
(creatine kinase-MB >5 × upper limit of normal), 
30% versus 26% (troponin >5 × upper limit of normal), 1% 
versus 1% (creatine kinase-MB >10 × ULN), and 3% versus 
1% (troponin >70 × upper limit of normal).
Discussion
The main ﬁ ndings of this interim report of secondary 
outcomes and post-hoc analysis of 1-year follow-up data 
are that the device success rate of the bioresorbable 
scaﬀ old matched that of the metallic stent; acute recoil of 
both devices were similar; the procedural lumen gain 
was slightly less with the bioresorbable scaﬀ old than 
with the metallic stent because of the use of smaller 
balloons at lower pressure for deployment and dilatation 
of the bioresorbable scaﬀ old; and that functional 
assessment, anginal status as assessed by the Seattle 
Angina Questionnaire, and secondary clinical endpoints 
did not diﬀ er between treatment groups, whereas the 
cumulative rate of recurrent or worsening angina 
reported through adverse event forms was lower in the 
bioresorbable scaﬀ old group than in the metallic stent 
group (panel).
Despite diﬀ erences in the crossing proﬁ le of the 
two devices (1·4 mm for Absorb scaﬀ old vs 1·1 mm for 
the Xience stent), the polymeric device achieved success 
rates in implantation similar to the metallic stent in the 
context of the simple lesions included in the current trial. 
However, this ﬁ nding might not be generalisable to a 
routine population of patients receiving percutaneous 
coronary intervention. The current generation of the 
Absorb scaﬀ old has a strut thickness of 150 μm, compared 
with 80 μm for the Xience stent. However, intrinsically 
the polymeric device is more ﬂ exible than the metallic 
device. In this study, we noted the conformability of the 
coronary anatomy for the bioresorbable scaﬀ old to be 
better than that of the metallic stent, as previously shown 
by the increased curvature of scaﬀ olded coronary arteries 
on quantitative angiography.23,24
In this study, the acute recoil of the polymeric device 
was similar to that described in a previous report.12,25 
However, because of the inherent limitation in elongation-
at-break of polylactide, operators tended to restrain 
themselves from dilating the polymeric device using the 
aggressive technique typically used for implantation of 
metallic stents. Accordingly, the diﬀ erences in acute gain 
noted on angiography and intravascular ultrasound seem 
to be related to the signiﬁ cant diﬀ erences in balloon size 
and pressure used for deployment and postdilatation. On 
the basis of previous reports of disrupted polymeric 
scaﬀ olds due to overexpansion, the protocol did not 
recommend postdilatation of the bioresorbable scaﬀ old 
device.26,27 If this procedure was to be done, balloons had 
to be at least 0·25 mm larger than the nominal diameter 
of the bioresorbable scaﬀ old. Mattesini and colleagues28 
reported that the Absorb scaﬀ old showed similar 
postprocedure area stenosis, minimum lumen area, and 
eccentricity index to second-generation drug-eluting 
stent. As concluded by the authors, the diﬀ erent approach 
for lesion preparation and routine use of optical coherence 
Figure 2: Seattle Angina Questionnaire responses
Figure shows ﬁ ve domains of the Seattle Angina Questionnaire related to angina stability, frequency, physical 
limitation, disease perception, and treatment satisfaction in addition to number of patients with no angina. 
The bars show 95% CIs. SAQ=Seattle Angina Questionnaire. *p value from post-hoc test. †p value from χ² test.
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tomography guidance during bioresorbable scaﬀ old 
expansion might have contributed to these results.
Few data about the eﬀ ect of lesion morphology on acute 
lumen gain are available. Brown and colleagues29 showed 
that in 25 patients with Absorb scaﬀ olds, there was no 
correlation between the arc of ﬁ brocalciﬁ cation and 
scaﬀ old expansion as assessed on optical coherence 
tomography. In this study, presence of calcium and its 
circular extension on intra vascular ultrasound greyscale 
did not aﬀ ect the acute gain in lumen area for both the 
polymeric and metallic devices. Although we noted 
diﬀ erences in postprocedural minimum lumen diameter 
and minimum lumen area, reassuringly exercise testing 
showed similar functional results in both groups, 
suggesting that the subtle diﬀ erences in postprocedural 
lumen dimension is clinically negligible.
The rate of per protocol myocardial infarction was 4% 
in the bioresorbable scaﬀ old group and 1% in the metallic 
stent group. This diﬀ erence was mostly due to the 
non-Q-wave myocardial infarction (4% vs 1%) driven by 
cardiac biomarker rise within 48 h after the index 
procedure.
Figure 3: Time to ﬁ rst occurrence and duration of angina
Figure shows time to ﬁ rst occurrence and duration of angina through adverse event reporting (post-hoc analysis). Rectangular frames show the two cross-sectional 
time windows of 4 weeks during which patients completed Seattle Angina Questionnaires. ETT=exercise tolerance testing. ECG=electrocardiogram. 
PCI=percutaneous coronary intervention.
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When we subcategorised periprocedural myocardial 
infarctions according to biomarker criteria,32,33 we noted 
a wide range of values (from <1% to 27–32%) with 
similar proportions of patients in the two treatment 
groups, emphasising the arbitrary character of any 
deﬁ nition of periprocedural myocardial infarction
The rise of these three cardiac enzymes subcategorised in 
ﬁ ve diﬀ erent ranges was similar between the two treatment 
groups (table 3). In particular, only a small proportion of 
patients with a creatine kinase-MB rise in the range of 
more than ten times the upper limit of normal was reported 
and the same (<1%) in both treatment groups. As opposed 
to lower concentration ranges, this range of more than 
ten times the upper limit of normal of creatine kinase-MB 
has been reported as a threshold for worse late outcomes.34
Two myocardial infarctions in the bioresorbable 
scaﬀ old (one Q-wave and one non-Q-wave) were 
attributed to deﬁ nite scaﬀ old thrombosis, in one case 
involving overlapping scaﬀ olds and in the other case 
involving bifurcation scaﬀ olding (a protocol deviation).
In-vivo assessment of endothelial shear stress with a 
fusion of frequency domain optical coherence tomography 
and three-dimensional angiography has demonstrated 
alternance of high shear stress on top of the protruding 
struts and low shear stress at the base of the struts.35,36 
Nevertheless, a summary of published and presented data 
at international meetings suggested that the overall rate of 
scaﬀ old thrombosis in stable or unstable patients was 
0·93% (25 of 2699 patients), a ﬁ gure comparable with our 
results. Of note, most thromboses were acute and sub-acute. 
6 months after index procedure 12 months after index procedure
Bioresorbable 
scaﬀ old group 
(n=335)
Metallic stent 
group (n=166)
Diﬀ erence (95% CI) p 
value
Bioresorbable 
scaﬀ old group 
(n=335)
Metallic stent 
group (n=166)
Diﬀ erence (95% CI) p 
value
Participated in 
exercise test
308 (92%) 157 (95%) –2·64% (–6·89, 2·54) 0·28 288 (86%) 142 (85%) 0·43% (–5·71, 7·42) 0·9
Treadmill 176 (57%) 84 (53%) 3·64% (–5·81, 13·12) 0·45 152 (53%) 74 (52%) 0·67% (–9·24, 10·62) 0·9
Cycling 132 (43%) 73 (46%) –3·64% (–13·12, 5·81) 0·45 136 (47%) 68 (48%) –0·67% (–10·62, 9·24) 0·9
Maximum heart 
rate (beats per 
min)
131·8 (23·0) 131·5 (23·3) 0·2 (–4·3, 4·7) 0·93 132·6 (21·1) 134·5 (20·7) –1·9 (–6·1, 2·3) 0·38
Maximum 
workload (watts)
133·7 (44·1) 138·3 (47·4) –4·6 (–17·7, 8·4) 0·48 130·8 (42·9) 144·1 (45·8) –13·3 (–26·4, –0·1) 0·05
Maximum 
workload (METS)
9·02 (2·81) 9·05 (3·41) –0·03 (–0·89, 0·83) 0·95 9·32 (2·70) 9·41 (3·05) –0·09 (–0·92, 0·74) 0·83
Terminated by 
physician due to 
>0·2 mV ST 
depression*
3/70 (4%) 5/29 (17%) –12·96% (–30·49, –0·69) 0·05 4/82 (5%) 2/34 (6%) –1·00% (–14·54, 7·19) 1
Test terminated by 
patient (angina or 
dyspnea†
43/218 (20%) 20/114 (18%) 2·18% (–7·12, 10·44) 0·63 36/198 (18%) 24/104 (23%) –4·90% (–15·04, 4·34) 0·31
Exercise duration 
(min)
8·10 (3·28) 8·53 (3·76) –0·43 (–1·13, 0·26) 0·22 8·55 (3·73) 8·99 (3·86) –0·44 (–1·21, 0·33) 0·26
≥0·1 mV ST 
depression
47 (15%) 28 (18%) –2·52% (–10·16, 4·32) 0·48 32 (11%) 15 (11%) 0·63% (–6·27, 6·45) 0·85
Chest pain during 
exercise
15 (5%) 8 (5%) –0·23% (–5·23, 3·68) 0·92 16 (6%) 12 (8·5%) –2·90% (–9·01, 1·94) 0·25
≥0·1 mV ST 
depression or 
chest pain
56 (18%) 32 (20%) –2·20% (–10·19, 5·07) 0·57 43 (15%) 22 (15%) –0·46% (–8·23, 6·36) 0·9
Antianginal 
medication
β blocker‡ 235/331 (71%) 112/165 (68%) 3·12% (–5·27, 11·90) 0·48 232/329 (71%) 108/164 (66%) 4·66% (–3·88, 13·54) 0·29
Calcium channel 
blocker
69 (21%) 35 (21%) –0·37% (–8·32, 6·90) 0·92 78 (24%) 38 (23%) 0·54% (–7·69, 8·12) 0·89
Nitrate 59 (18%) 44 (27%) –8·84% (–16·98, –1·22) 0·02 64 (19·5%) 43 (26%) –6·77% (–14·98, 0·91) 0·09
Use of dual 
antiplatelet 
therapy
323 (97%) 161 (97%) 0·30% (–2·62, 4·35) 1·00 275 (83%) 138 (83%) –0·30% (–6·93, 7·11) 0·93
Data are n (%) or mean (SD) unless otherwise stated. *Data are n/N (%), in which N is the number of exercise tests terminated by physician. †Data are n/N (%), in which N is 
the number of exercise tests terminated by patient. ‡Data are n/N (%), in which N is the number of patients who had available information on medication.
Table 4: Results of exercise testing
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Although the angina status as assessed by 
cross-sectional Seattle Angina Questionnaires 
assessment was similar between the bioresorbable 
scaﬀ old and metallic stent groups, the cumulative rate of 
recurrent or worsening angina assessed through adverse 
event reporting was signiﬁ cantly lower with the 
bioresorbable scaﬀ old. The Seattle Angina 
Questionnaires represents assessment of a 4-week 
window (recall period) and does not take fully into 
account earlier episodes of angina, whereas the angina 
assessed through adverse event reporting represents the 
cumulative rate of angina at 1 year. The decrease in the 
cumulative rate of angina for bioresorbable scaﬀ old was 
directionally consistent with the lower reported rates of 
nitrate use and all revascularisations. This observation is 
so far unexplained and merits additional research 
although return of vasomotion, reduction of compliance 
mismatch, and improved conformability of the 
bioresorbable scaﬀ old have been reported in previous 
studies.3,6,7,9,23,24
Although the protocol allowed inclusion of long 
lesions, the population still represents relatively simple 
lesions compared to the complex lesions frequently 
encountered in daily practice. The generalisability of the 
study might therefore be limited.
This report does not present the primary endpoints 
and endpoints reported were not powered. However, we 
Bioresorbable 
scaﬀ old 
group 
(n=335)
Metallic 
stent 
group 
(n=166)
Diﬀ erence (95% CI)† p value
Outcomes
All deaths 0 1 (1%) –0·61% (–3·35 to 0·65) 0·33
Cardiac deaths 0 0 0·00% (NA) 1·00
Myocardial infarction per protocol 15 (4%) 2 (1%) 3·32% (–0·25 to 6·26) 0·06
Q-wave 2 (1%) 0 0·60% (–1·71 to 2·18) 1·00
Non-Q-wave 13 (4%) 2 (1%) 2·72% (–0·78 to 5·53) 0·16
All target-lesion revascularisation 4 (1%) 3 (2%) –0·61% (–4·08 to 1·60) 0·69
Clinically indicated target-lesion 
revascularisation
4 (1%) 3 (2%) –0·61% (–4·08 to 1·60) 0·69
All target-vessel revascularisation 8 (2%) 8 (5%) –2·43% (–7·01 to 0·86) 0·15
Clinically indicated target-vessel 
revascularisation
6 (2%) 6 (4%) –1·82% (–6·01 to 1·04) 0·23
Non-clinically indicated target-vessel 
revascularisation
3 (1%) 3 (2%) –0·91% (–4·35 to 1·19) 0·40
Non-target-vessel revascularisation 6 (2%) 6 (4%) –1·82% (–6·01 to 1·04) 0·23
Clinically indicated non-target-vessel 
revascularisation
5 (1%) 4 (2%) –0·91% (–4·66 to 1·55) 0·49
Non-clinically indicated non-target-vessel 
revascularisation
3 (1%) 2 (1%) –0·31% (–3·46 to 1·63) 1·00
All revascularisation 12 (4%) 12 (7%) –3·65% (–8·89 to 0·37) 0·08
Clinically indicated revascularisation 9 (3%) 9 (5%) –2·74% (–7·50 to 0·75) 0·12
Non-clinically indicated revascularisation 6 (2%) 5 (3%) –1·22% (–5·21 to 1·49) 0·52
Composite secondary endpoints
Cardiac death, all myocardial infarction, 
clinically indicated target-vessel 
revascularisation (target-vessel failure)
18 (5%) 8 (5%) 0·59% (–4·26 to 4·41) 0·78
Cardiac death, target-vessel myocardial 
infarction, and clinically indicated 
target-lesion revascularisation (target-lesion 
failure; device-oriented composite 
endpoint)
16 (5%) 5 (3%) 1·80% (–2·48 to 5·16) 0·35
Cardiac death, all myocardial infarction, and 
clinically indicated target-lesion 
revascularisation (major adverse cardiac 
events)
17 (5%) 5 (3%) 2·11% (–2·20 to 5·51) 0·28
All death, all myocardial infarction, and all 
revascularisation (patient-oriented 
composite endpoint)
24 (7%) 15 (9%) –1·84% (–7·69 to 2·98) 0·47
Thrombosis endpoints
Deﬁ nite scaﬀ old or stent thrombosis 2 (0·6%) 0 0·61% (–1·72 to 2·19) 1·00
Acute (0–1 day) 1 (0·3%) 0 0·30% (–1·98 to 1·67) 1·00
Sub-acute (2–30 days) 1 (0·3%) 0 0·30% (–1·98 to 1·68) 1·00
Late (31–365 days) 0 0 0·00% (NA) 1·00
Deﬁ nite or probable scaﬀ old or stent 
thrombosis
3 (0·9%) 0 0·91% (–1·45 to 2·65) 0·55
Data are n (%).
Table 5: Secondary clinical outcomes at 1-year follow-up
Panel: Research in context
Systematic review
Bioresorbable scaﬀ olds are a novel approach to treat coronary 
artery stenosis by providing transient scaﬀ olding and local 
drug delivery, potentially without the long-term limitation of 
metallic drug-eluting stents such as very late stent 
thrombosis.1,2
The potential of this technology, such as re turn of 
vasomotion, cyclic strain and shear stress, has been shown in 
some observations up to 3-year follow-up using multiple 
imaging modalities obtained in the ABSORB ﬁ rst-in-man 
trials.3–5,6–11 Widespread dissemination of revascularisation 
with a bioresorbable scaﬀ old has, however, occurred without 
randomised comparison with its metallic counterpart.
We searched PubMed with the terms “bioresorbable” AND 
“scaﬀ old” AND “randomized controlled trial” to ﬁ nd papers 
published between Jan 1, 1999, and Aug 19, 2014, that 
reported randomised controlled trials which investigated the 
safety or eﬃ  cacy of a bioresorbable scaﬀ old compared with a 
metallic stent. We identiﬁ ed two articles (one related to our 
own trial design and the second related to a physician-initiated 
study), both describing the rationale and design of these 
ongoing trials but found no articles reporting the results of 
randomised controlled trials.
Interpretation
To our knowledge, this trial is the ﬁ rst randomised controlled 
comparison of a bioresorbable scaﬀ old with a metallic stent. 
These data suggest that despite a signiﬁ cant but modest 
reduction in acute performance, 1-year angina and clinical 
outcomes of the Absorb bioresorbable scaﬀ old are similar to 
the Xience metallic stent. The post-hoc observation of 
reduction in angina through adverse event reporting 
warrants further investigation.
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thought it important to report these secondary 
prespeciﬁ ed randomised endpoints in the absence of any 
current comparative data. Additionally, the angina rate 
diagnosed by the site was not prespeciﬁ ed and it is thus 
hypothesis generating. This measure is being 
investigated in the ABSORB III and IV trials. Both 
studies have adequately powered prespeciﬁ ed angina 
endpoints to detect diﬀ erence between two treatments.
In this randomised comparison, the Absorb everolimus-
eluting bioresorbable scaﬀ old showed similar one-year 
clinical outcomes to the everolimus-eluting Xience 
metallic stent. Exercise performance and angina status by 
Seattle Angina Questionnaires were also similar. The 
reported reduction of angina through adverse event 
reporting warrants further clinical and physiological 
investigation.
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Aims Weevaluated the feasibility and the acute performance of the everolimus-eluting bioresorbable vascular scaffolds (BVS)
for the treatment of patients presenting with ST-segment elevation myocardial infarction (STEMI).
Methods
and results
The present investigation is a prospective, single-arm, single-centre study, reporting data after the BVS implantation in
STEMI patients.Quantitative coronaryangiographyandoptical coherence tomography (OCT)datawere evaluated.Clin-
ical outcomes are reported at the 30-day follow-up. The intent-to-treat population comprises a total of 49 patients. The
procedural successwas97.9%. Pre-procedureTIMI-ﬂowwas0 in50.0%of thepatients; after theBVS implantation, aTIMI-
ﬂow III was achieved in 91.7% of patients and the post-procedure percentage diameter stenosis was 14.7+ 8.2%. No
patients had angiographically visible residual thrombus at the end of the procedure. Optical coherence tomography ana-
lysis performed in 31 patients showed that the post-proceduremean lumen areawas 8.02+1.92 mm2, minimum lumen
area 5.95+1.61 mm2, mean incomplete scaffold apposition area 0.118+0.162 mm2, mean intraluminal defect area
0.013+0.017 mm2, andmeanpercentagemalapposed struts per patient 2.80+3.90%. Scaffoldswith.5%malapposed
struts were 7. At the 30-day follow-up, target-lesion failure rate was 0%. Non-target-vessel revascularization and target-
vesselmyocardial infarction (MI)werereported.Anon-target-vessel non-Q-waveMIoccurred.Nocasesof cardiacdeath
or scaffold thrombosis were observed.
Conclusion In the present series, the BVS implantation in patients presenting with acute MI appeared feasible, with high rate of ﬁnal
TIMI-ﬂow III and good scaffold apposition. Larger studies are currently needed to conﬁrm these preliminary data.
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Introduction
Primary percutaneous coronary intervention has been demon-
strated to be superior to thrombolytic strategy and is currently the
treatmentof ﬁrst choice for patients presentingwith ST-segment ele-
vation myocardial infarction (STEMI) in experienced centres with
limited time delay.1 First-generation drug-eluting stents (DES) have
been shown to reduce the need for repeat revascularization com-
pared with bare-metal stents (BMS),2–4 and the newer-generation
DES with improved biocompatibility of polymers may lower the
rate of clinical events also in acute patients.5,6 However, the implant-
ation of metal devices is not devoid of important limitations, such as
permanent cagingof the vesselwithpermanent impairmentof coron-
ary vasomotion, side branch jailing, impossibility of late lumen
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enlargement, non-invasive imaging and future surgical revasculariza-
tion of stented segments.7 Moreover, in spite of the beneﬁcial effect
of neointimal inhibition, the antiproliferative drug elution has been
shown to interfere with the vascular healing processes providing
the background for delayed strut coverage andpersistent or acquired
malapposition.8,9 The above-mentioned limitations can be proposed
for both stable and acutepatients; however, primary stenting has add-
itional speciﬁc characteristics that should be highlighted. Stent place-
ment in acute thrombotic lesions has been reported to be an
independent predictor of late stent malapposition after the BMS10
or DES11 implantation. Possible explanations for this phenomenon
could be the thrombus sequestration behind the struts—which sub-
sequently resolves—and the vasoconstriction during the acute
phase. Both these factors may predispose to stent under-
deployment, malapposition and ﬁnally to stent thrombosis. The
everolimus-eluting bioresorbable vascular scaffold (BVS) has been
designed to overcome the general limitations of the metallic stents
and recently has been shown to provide excellent results for the
treatment of stable patients.12,13 However, so far very limited data
are available on the use of this novel device in patients with acute
coronary syndromes (ACS).14,15 Given this background, a pilot
study investigating the feasibility and acute performance of the BVS
for the treatment of patients presenting with STEMI was initiated.
Methods
Rationale
As of 1 September 2012, the BVS (ABSORB; Abbott Vascular, Santa
Clara, CA,USA) has been commercially available in theNetherlands.
Based on previous experience and available evidence, reported in
ABSORB Cohort A and B Trial13,16 our institution initiated the use
of BVS for the treatment of patients presenting for PCI in everyday
clinical practice, with a preference for patients with a good life ex-
pectancy as demonstrated by the presence of limited co-morbidities.
As these patients might have more complex lesions compared with
the ABSORB study patients16,17 the BVS-EXPAND registry was
initiated. The BVS-EXPAND also included patients with ACS (un-
stable angina or non-STEMI). After the ﬁrst experience with ACS
patients and an interim analysis, a decision was made to extend
BVS utilization to the treatment of STEMI.
As an additionalmeasure for assessing the safety of a treatment ap-
proach with BVS in STEMI, optical coherence tomography (OCT)
imaging was performed, according to clinical judgement, for a more
comprehensive evaluation of the acute procedural outcome.
Study design
The present report is an investigator initiated, prospective, single-
arm, single-centre study to assess feasibility and performance of
the second-generation everolimus-eluting BVS for the treatment of
patients presenting with STEMI.
Subjects enrolled were patients of ≥18-year-old admitted with
STEMI, deﬁned as at least 1 mm ST-segment elevation in two or
more standard leads or at least 2 mm in twoormore contiguous pre-
cordial leads or new left bundle branch block within 12 h after the
onset of symptoms. Culprit lesions were located in vessels within
the upper limit of 3.8 mm and the lower limit of 2.0 mm by online
quantitative coronary angiography (QCA). The absorb BVS was
implanted according to the manufacturer’s indication on target-
vessel diameter ranges and absorb BVS diameters to be used. The
absorb BVS with a nominal diameter of 2.5 mm was implanted in
vessels ≥2.0 and ≤3.0 mm by online QCA; the 3.0 mm BVS was
implanted in vessels ≥2.5 and ≤3.3 mm by online QCA; the
3.5 mm BVS was implanted in vessels ≥3.0 and ≤3.8 mm. Given
the manufacturer’s indication on maximum scaffold expansion, for
each nominal diameter a further expansion of 0.5 mm was allowed.
Enrolled subjects were willing to comply with speciﬁed follow-up
evaluation and to be contacted by telephone. Exclusion criteria com-
prise pregnancy, known intolerance to contrast medium, uncertain
neurological outcome after cardiopulmonary resuscitation, previous
percutaneous coronary intervention with the implantation of a metal
stent, left main (LM) disease previous coronary artery bypass grafting
(CABG), age superior to 75 years, and participation to another inves-
tigational drug or device study before reaching the primary endpoints.
The enrolment period started on 1November 2012 and ended on 30
March 2013. Dual antiplatelet therapy after the BVS implantation was
planned to have a duration of 12 months. Baseline and post-BVS im-
plantation QCA analysis, OCT analyses at post-BVS implantation,
and clinical outcomes at the 30-day follow-up were evaluated.
Deﬁnitions
Success rates were deﬁned as follows: device success was the attain-
ment of ,30% ﬁnal residual stenosis of the segment of the culprit
lesion coveredby the BVS, by angiographic visual estimation. Proced-
ure success was deﬁned as device success and no major peri-
procedural complications (Emergent CABG, coronary perforation
requiring pericardial drainage, residual dissection impairing vessel
ﬂow—TIMI-ﬂow II or less). Clinical success was deﬁned as proced-
ural success and no in-hospital major adverse cardiac events
(MACE). All deaths were considered cardiac unless an undisputed
non-cardiac causewas identiﬁed.Myocardial infarction (MI) and scaf-
fold thrombosis were deﬁned according to the Academic Research
Consortium deﬁnition.18 Target-lesion revascularization (TLR) was
deﬁned as clinically driven if at repeat angiography the diameter sten-
osis was.70%, or if a diameter stenosis.50%was present in asso-
ciation with (i) presence of recurrent angina pectoris, related to the
target vessel; (ii) objective signs of ischaemia at rest (ECGchanges)or
during exercise test, related to the target vessel; and (iii) abnormal
results of any functional diagnostic test.
Thedevice-orientedendpoint target-lesion failurewasdeﬁnedasthe
composite of cardiac death, target-vessel MI, or ischaemia-driven TLR.
Majoradverse cardiaceventsdeﬁnedasthecompositeofcardiacdeath,
any re-infarction (Q- or non-Q-wave), emergent bypass surgery
(CABG), or clinically driven TLR. Target-vessel failure (TVF) was
deﬁned as cardiac death, target-vessel MI, or clinically driven TVR.
Ethics
This is an observational study, performed according to the privacy
policy of the Erasmus MC and to the Erasmus MC regulations for
the appropriate use of data in patient-oriented research, which are
based on international regulations, including the declaration of
Helsinki. The BVS received the CE mark for clinical use, indicated
for improving coronary lumen diameter in patients with ischaemic
heart disease due to de novo native coronary artery lesions with no
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restriction in terms of clinical presentation. Therefore, the BVS can
be currently used routinely in Europe in different settings comprising
the acute MI without a speciﬁc written informed consent in addition
to the standard informed consent to the procedure. Given this back-
ground, a waiver from the hospital Ethical Committee was obtained
for written informed consent, as according to Dutch law written
consent is not required, if patients are not subject to acts other
than as part of their regular treatment.
Study device
The second-generation everolimus-eluting BVS is a balloon expand-
able device consisting of a polymer backbone of poly-L-lactide acid
(PLLA) coated with a thin layer of amorphous matrix of poly-D and
-L-lactide acid (PDLLA) polymer (strut thickness 157 mm). The
PDLLA controls the release of the antiproliferative drug everolimus
(100 mg/cm2), 80% of which is eluted within the ﬁrst 30 days. Both
PLLAandPDLLAare fully bioresorbable. Thepolymers aredegraded
via hydrolysis of the ester bonds and the resulting lactate and its oli-
gomers aremetabolized by the Krebs cycles. Small particles (,2 mm
in diameter) may be also phagocytized and degraded by macro-
phages.19 According to preclinical studies, the time for complete
bioresorption of the polymer backbone is 2–3 years.20 The BVS
edges contain two platinum markers for accurate visualization
during angiography or other imaging modalities.
Quantitative coronary angiography
analysis
Quantitative coronary angiography (QCA) analyseswere performed
using the Coronary Angiography Analysis System (Pie Medical
Imaging, Maastricht, Netherlands).
Analyses were performed at pre-procedure, after thombectomy,
after balloon dilatation, and after the BVS implantation with a meth-
odology already reported.21
In caseof thrombotic total occlusion, pre-procedureQCAanalysis
was performed as proximally as possible from the occlusion (in case
of a side branch distally to the most proximal take off of the side
branch). Intracoronary thrombus was angiographically identiﬁed
and scored in ﬁve grades as previously described.22 Thrombus
grade was assessed before procedure and after thombectomy.
The QCA measurements included reference vessel diameter
(RVD)—calculated with interpolate method—percentage diameter
stenosis, minimal lumen diameter (MLD), and maximal lumen diam-
eter (Dmax). Acute gain was deﬁned as post-procedural MLD minus
pre-procedural MLD (MLD value equal to zero was applied when
culprit vessel was occluded pre-procedurally). Complications occur-
ring any time during the procedure, such as dissection, spasm, distal
embolization, and no-reﬂow were reported. As additional informa-
tion, MI SYNTAX I and MI SYNTAX II scores providing long-term
risk stratiﬁcation for mortality and MACE in patients presenting
with STEMI were assessed.23
Optical coherence tomography image
acquisition and analysis
Optical coherence tomography imaging after the BVS implantation
was encouraged in all patients but was not mandatory, subordinated
to device availability and left at the operator’s discretion.
Therefore, OCT imaging of the culprit lesion after treatment was
performed in a subset of the population. The image acquisition was
performedwithC7XR imaging console and theDragonﬂy intravascu-
lar imaging catheter (both St. JudeMedical, St. Paul, MN,USA). Image
acquisition has been previously described.24 Brieﬂy, after positioning
theOCTcatheter distally to themostdistal scaffoldmarker, the cath-
eter is pulled back automatically at 20 mm/s with simultaneous con-
trast infusion by a power injector (ﬂush rate 3–4 mL/s). In cases
where the entire scaffold region was not imaged in one pullback, a
second more proximal pullback was performed for complete visual-
ization. Images were stored and analysed ofﬂine.
Analysis of theOCT imageswasperformedwith theSt Jude/Lightlab
ofﬂine analysis software (St. Jude Medical), using previously described
methodology for BVS analysis.17 Analysis was performed in 1-mm lon-
gitudinal intervals within the treated culprit segment, after exclusion of
frames with ,75% lumen contour visibility. Lumen, scaffold, and
incomplete scaffold apposition (ISA) area were calculated in accord-
ance with standard methodology for analysis of bioresorbable scaf-
folds17 (Figure 1A and B), while in sites with overlapping scaffolds,
analysis was performed using previously suggested modiﬁcations25
(Figure 1D). Speciﬁcally, the lumen contour is traced at the lumen
border and in the abluminal (outer) side of apposed struts, while in
the case of malapposed struts the contour is traced behind the
malapposed struts. In cases where the scaffold struts are completely
covered by tissue or thrombus, the lumen contour is traced above
the prolapsing tissue (Figure 1C). The scaffold area is traced following
interpolation of points located in the mid-point of the abluminal
border of the black core in apposed struts and the mid-point of the
abluminal strut frame border in malapposed or side branch-related
struts, so that the scaffold area is identical to the lumen area in the
absence of ISA and tissue prolapse. Incomplete scaffold apposition
area is traced in the case of malapposed struts as the area delineated
between the lumen and scaffold contours (Figure 1B).
A special consideration should bementioned concerning BVS ana-
lysis inMIwith the presence of increased tissue prolapse and residual
thrombus post-implantation21,26 (Figures 1C and 2). Tissue prolapse
area can be quantiﬁed as the difference between the scaffold and
the lumen area. For the calculation of prolapse area, in the case
thatoneormore scaffold struts are completely coveredby thrombus
or tissue, the total black core area of these struts is also measured.
Prolapse area is then calculated as [scaffold area + ISA area2
lumen area2 embedded black core area]. The area of non-attached
intraluminal defects (e.g. thrombus) is also measured. Atherothrom-
botic area is then calculated as the sumof prolapse area and intralum-
inal defect area and normalized as a percent ratio of the scaffold area
(atherothrombotic burden, ATB).21,26 It should be noted that in the
case of bioresorbable scaffolds where measurements of the scaffold
area are performed using the abluminal side of the scaffold struts,
ATB is overestimated compared with metal platform stents where
measurements of the stent area are performed from the adluminal
(inner) side of the struts. Additionally, ﬂow area was assessed as
[scaffold area + ISA area2 atherothrombotic area2 total strut
area] and the minimal ﬂow area was recorded.
A scaffold strut is deﬁned as incompletely apposed when there is
no contact between the abluminal border of the strut and the
vessel wall. This does not include struts located in front of side
branches or their ostium (polygon of conﬂuence region), which are
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deﬁned as side branch-related struts. Intraluminal struts that are part
of adjacent clusters of apposed struts in overlapping scaffolds are also
not considered malapposed.25 For illustrative proposes, OCT
bi-dimensional images are reported by three-dimensional rendering
by dedicated software (Intage Realia, KGT, Kyoto, Japan)17 (Figures 2
and 3).
Statistical analysis
Continuous variables are presented as mean and standard deviation,
and categorical variables are reported as count and percentages. De-
scriptive statistics was provided for all variables. The present study is
intended to be a ‘ﬁrst experience investigation’ evaluating feasibility
and acute performance of the everolimus-eluting BVS for the treat-
ment of patients presenting with STEMI. A patient population of at
least 30 patients was planned to be included in the present study.
Comparisons among multiple means were performed with analysis
of variance (one-wayANOVA). Score (Wilson) conﬁdence intervals
were reported formeasures of success.TypeA intraclass correlation
coefﬁcients (ICCs) for absolute agreement were used for assessing
intra- and interobserver agreement, while measurement error and
95% limits of agreement were assessed by Bland–Altman analysis.
The ICCs were computed with a two-way random effects model
(single measures). All statistical tests were performed with SPSS,
version 15.0 for windows (IL, USA).
Results
From1November 2012 to 30 April 2013, a total of 267 patients pre-
sented with acute MI. Twenty-one of those patients were treated
percutaneously without any stent implantation (thrombectomy or
balloon dilatation alone). Seventy-four had a culprit lesion located
in a coronary vesselwith a vessel diameterout of the range availability
of the BVS (i.e. RVD .4.0 mm). Out of the remaining 172 patients,
125 were meeting the inclusion and none of the exclusion criteria
of the present study (47 patients excluded for age, previous PCI or
CABG, left main disease). Seventy-six of those patients were
treated with metal stents and 49 cases (48 implanted with BVS)
were enrolled in the present study (Figure 4, Table 1). Therefore,
the patients implanted with BVS constitute the ~38% of the patients
eligible for the present investigation.
Figure1 Methodology of optical coherence tomography analysis. (A) Good scaffold apposition and absence of incomplete scaffold apposition or
tissue prolapse, (B) incomplete scaffold apposition, (C) sites with high tissue prolapse and struts completely covered by thrombus, and (D) overlap-
ping scaffolds.Upperpanel showsbaseline images,middle panel showsquantitativemeasurements, and lowerpanel showsmethodology for analysis.
ISA, incomplete scaffold apposition; ATA, atherothrombotic area.
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Baseline clinical characteristics of the 172 patients (49 patients
included in the intent-to-treat population and 123 patients implanted
withmetal stents) with vessels size in the range of the BVS availability
are reported in Table 1. In the intent-to-treat population thirty-eight
patientsweremale (77.6%),mean agewas 58.9+10.5 years. Lesions
were distributed as follows: left anterior descending 21 (42.9%), right
coronary artery 22 (44.9%), and circumﬂex 6 (12.2%). Baseline clin-
ical data of the enrolled patients were compared with the general
population presenting with acute MI and implanted with a metal
stent in vessels theoretically suitable for BVS implantation. Minimal
differences were observed between the two groups. Namely, age
58.9+10.5 vs. 66.4+ 12.2, P, 0.001 and previous PCI 0% vs.
12.2%, P ¼ 0.007. All the other clinical characteristics of the two
populations did not show any signiﬁcant difference.
Mean door-to-balloon timewas 31.3+19.5 min. All patients were
treated with unfractionated heparin at the dose of 70–100 UI/kg and
dual antiplatelet therapy (aspirin plus, prasugrel in 45 patients or clopi-
dogrel in 4 patients). Manual thrombectomy was performed in 38
patients. In 16 cases, direct stenting was performed; a total of 65 scaf-
folds were implanted (12 patients received overlapping scaffolds—
overlap was systematically intended to be minimal). The scaffolds
lengths used were 12, 18, and 28 mm, with scaffolds diameters 2.5,
3.0, and 3.5 mm. Mean scaffold length per-lesion was 26.40+
13.86 mm, mean scaffold diameter per-lesion was 3.2+34 mm. A
highly supportive wire was used in ﬁve cases and radial approach was
performed in 26 patients (53.0%) (Table 2). The procedural success
was 97.9% (48/49 patients); in one patient, the delivery of the BVS
was unsuccessful (due to the remarkable vessel tortuosity was not
Figure 2 Bioresorbable vascular scaffolds implantation in a culprit and a non-culprit lesion in myocardial infarction. (A) Coronary angiography
demonstrating a stenotic lesion in proximal LAD (proximal non-culprit lesion) and a total occlusionof themid-LAD (culprit lesion). (B)Angiography
following thrombusaspiration. (C)Angiography following implantationof a3.5 × 12 mmbioresorbablevascular scaffolds at theproximalLAD lesion
and a 3.0 × 28 mmbioresorbable vascular scaffolds at themid-LAD lesion. (D)Optical coherence tomography image from theproximal non-culprit
lesion showing absence of tissue prolapse and thrombus in the 3.5 × 12 mm scaffold. (E and F) Optical coherence tomography images from the
culprit lesion showing complete coverage of the bioresorbable vascular scaffolds by tissue prolapse and presence of small amount of intraluminal
defect. (G) Three-dimensional optical coherence tomography rendering in the proximal non-culprit lesion with complete scaffold visualization in-
dicating the absence of prolapsing material. (H) Conversely, in the three-dimensional rendering of the culprit lesion, the morphology of the bior-
esorbable vascular scaffolds cannot be fully visualized due to high levels of tissue prolapse (*).
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possible to advance theBVS at the siteof the lesion) and ametallicDES
was implanted. Clinical success was 97.9% (48/49 patients).
Quantitative coronary angiography
analysis
TheQCA is reportedonly in patients implantedwith BVS. In 50.0%of
those patients, pre-procedure TIMI-ﬂow was 0 and the RVD was
2.94+0.77 mm. In the non-totally occluded vessels, the RVD was
2.62+0.63 mm, with an MLD of 0.75+ 0.44 mm and a mean diam-
eter stenosis of 70.8+12.5%. After thrombectomy and balloon dila-
tation, TIMI-ﬂow grade 0 was present in 2.5 and 0.0% of patients,
respectively, and TIMI-ﬂow III in 52.5 and 59.3%of the cases, respect-
ively. After the scaffold implantation, there were no cases of TIMI-
ﬂow 0, and a TIMI-ﬂow III was achieved in 91.7% of patients, the
mean post-procedure in-scaffold % diameter stenosis was 14.7+
8.2%, in-scaffold MLD was 2.44+0.49 mm (Table 3). No angiogra-
phically visible residual thrombus was observed at post-procedure.
Optical coherence tomography ﬁndings
Optical coherence tomography analysis was performed in a sub-
group of 31 patients implanted with BVS. Mean lumen area was
8.02+1.92 mm2, minimum lumen area 5.95+1.61 mm2, and
minimum ﬂow area 5.62+1.66 mm2. Incomplete scaffold appos-
ition (ISA) was observed in 20 patients with a mean ISA area of
0.118+0.162 mm2 and a mean percentage of malapposed struts
per patients equal to 2.80+ 3.90%. The mean prolapse area was
0.60+0.26 mm2, and the mean intraluminal defect area was
0.013+ 0.017 mm2. Scaffolds with .5% malapposed struts were 7
(Table 4). The OCT analysis stratiﬁed by scaffold size (5 BVS
2.5 mm, 13 BVS 3.0 mm, 24 BVS 3.5 mm) showed different lumen,
scaffold, and ﬂow areas, but similar amounts of incomplete stent ap-
position, plaque prolapse, and intraluminal mass areas (Table 5). In
three cases, the observation of scaffold malapposition by OCT,
guided an additional post-dilatation and in one patient the visualiza-
tion of considerable intraluminal thrombus as assessed by OCT led
to a repeated thrombus aspiration.
Intra-observer variability was excellent. Intraclass correlation
coefﬁcients were 0.999 for lumen area and 0.999 for scaffold area,
and the corresponding measurement errors and limits of agreement
were0.01 mm2 (20.12 to0.15 mm2) for lumenarea and20.01 mm2
(20.20 to0.17 mm2) for scaffold area. Similarly, inter-observer intra-
class correlation coefﬁcientswere0.997 for lumen area and 0.987 for
scaffold area, and the corresponding measurement errors and limits
of agreementwere20.01 mm2 (20.30 to 0.28 mm2) for lumen area
and 20.22 mm2 (20.68 to 0.24 mm2) for scaffold area.
Clinical outcomes
At the 30-day follow-up, the rate of the device-oriented endpoint,
target-lesion failure, was 0%. None of the patients experienced
target-vessel re-infarction, emergent bypass surgery, or clinically
driven TLR. No cases of cardiac death or scaffold thrombosis were
reported. The MACE rate was 2.6% as one patient, after discharge
developed a non-Q-wave MI related to a non-target-vessel lesion
and underwent a non-target-vessel revascularization within the
Figure 3 Bioresorbable vascular scaffold implantation in a thrombotic bifurcation lesion treated with provisional approach. (A) Coronary angi-
ography pre-intervention. (B) Angiography following bioresorbable vascular scaffold implantation in the LAD, showing pinching of the ostium of
the diagonal (D). (C) Final angiographic result following side branch dilation with 2.0 × 15 mm balloon. (D–F and J) Optical coherence tomography
cross-sectional images and l-mode after bioresorbable vascular scaffolds implantation showing the compromiseof the sidebranch after implantation
andpresenceof thrombusat the sidebranchostium. (G– I andK)Optical coherence tomographycross-sectional images and l-modeafter sidebranch
dilation, showing the opening of the carina of the side branch. (L andM) Three-dimensional reconstructions conﬁrm the opening of the side branch
ostium.
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30 days post-procedure. This was the only event reported in the
studied population (Table 6).
Discussion
The everolimus-eluting BVS has been tested so far only in elective
patients with stable, unstable angina, or silent ischaemia;16,17,27–29
showing promising results up to 4-year follow-up30 for the ﬁrst-
generation and up to 2 years for the second-generation BVS.12,13,31
The present study represents an early investigation reporting clinical
and angiographic data on the use of the second-generation BVS for
the treatment of patients presenting with STEMI and evaluating
acute results with high-resolution intracoronary imaging (OCT).
Ahigh device, procedural, and clinical success rateswereobserved
with all the scaffolds achieving a residual stenosis ,30% and no
in-hospital MACE. Such data are supportive of feasibility and good
acute performance of the BVS for the treatment of patients with
acute MI.
Angiographic data
The everolimus-eluting BVS was implanted in patients presenting
with ST-segment elevation and a thrombus burden 4 or 5 in 63.0%
of the cases. A theoretical concern related to the implantation of
the BVS in such thrombotic lesions is the fact that scaffold positioning
and placement may need a more aggressive lesion preparation (pre-
dilatation) compared with standard metal devices, due to its slightly
higher proﬁle. We hypothesized that this strategy might be prone
to an increase in distal embolization following balloon inﬂations,
favouring no-reﬂow and reducing the rate of ﬁnal TIMI-ﬂow III.
However, the analysis of the post-procedural angiographies
revealed a TIMI-ﬂow III in 91.7% of the cases; such results are in
line with recently reported large trials evaluating the performance
of metallic stents in patients presenting with acute MI.5,6 Less throm-
bus embolizationmay result fromadifferent pattern of thrombusdis-
lodgment and compression to the arterial wall after deployment of a
device with a larger strut width (157 mm) compared with currently
available metallic stents. The percentage of vessel wall area
Figure 4 Flow-chart of the study. From 1 November 2012 to 30 April 2013, a total of 267 patients presented with acute myocardial infarction.
Twenty-oneof thosepatientswere treatedpercutaneously butwithout anystent implantation (thrombectomyorballoondilatation alone). Seventy-
four had a culprit lesion located in a coronary vessel with a vessel diameter out of the range availability of the bioresorbable vascular scaffolds (i.e.
reference vessel diameter .4.0 mm). Out of the remaining 172 patients, 125 were meeting the inclusion and none of the exclusion criteria of the
present study (47 patients excluded for age, previous PCI or CABG, left main disease). Seventy-six of those patients were treated with metal stents
and 49 cases (48 implanted with BVS) were included in the present study.
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covered by the BVS polymer (scaffold/vessel ratio) has been previ-
ously evaluated to be 26%,32 a value considerably higher compared
with what observed for conventional metallic DES (i.e. EES provides
a percentage stent/vessel ratio equal to 12%).32 This characteristic of
the BVS might be associated to an increased capacity of capturing
debris and thrombotic material behind the struts before emboliza-
tion to distal microcirculation. This so-called snow racket concept
(entrapment of thrombotic material between the stent and the
vessel) is currently thebasis for thedesignof noveldevices andclinical
studies.33
Optical coherence tomography ﬁndings
Given its high resolution, OCT allows the assessment of in vivo strut
apposition and presence of thrombus.24,34–36
The present analysis was performed at 1 mm intervals in theOCT
pullback. Although, the possibility for a more strict assessment of
OCTanalysis in thrombotic lesionmaybeconsidered,21 thismethod-
ology is the current standard applied in our institution for clinical
studies, and the most commonly used in the literature.
Previous reports deﬁned a stentmalapposed if at least 5%of struts
were observed to be malapposed;37,38 in the present investigation,
only seven scaffolds (22.6%) investigated with OCT showed a strut
malapposition of .5%, with an overall mean struts malapposition
equal to 2.8+ 3.90%.A recently reported study using a similarmeth-
odology to investigate malapposition after metallic balloon expand-
able stent implantation in STEMI patients showed a total of 37.1%
malapposed stents (stents with .5% malapposition) with a mean
percentage of strut malapposition equal to 5.99+7.28%.38 In add-
ition, the mean ISA area was 0.118+ 0.162 mm2, a value in line
with data reported formetallic stent implantation in patients present-
ing with STEMI.21,38 Similarly, the amount of intraluminal defect after
scaffold implantation was minimal and comparable with what is
observed in metallic stents.21 Notably, these results were consistent
among different scaffold sizes.
Clinical outcomes
In thepresent series, noneof patients treatedwithBVSexperienced a
clinical event related to the treated vessel at the 30-day follow-up.
These observations support the feasibility of BVS implantation in
patients presenting with acute STEMI.
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Table 2 Procedural data intent-to-treat population
Procedural data N 5 49
Medications
Aspirin, n (%) 49 (100)
Prasugrel, n (%) 45 (91.8)
Clopidogrel, n (%) 4 (8.2)
Glycoprotein IIb/IIIa antagonists, n (%) 17 (34.7)
Unfractionated heparin, n (%) 49 (100)
Mean door-to-balloon time (min) 31.3+19.5
Manual thrombectomy, n (%) 38 (77.5)
Direct stenting, n (%) 16 (32.7)
Pre-dilatation, n (%) 33 (67.3)
Mean pre-dilatation balloon diameter
per-lesion (mm)
2.6+0.67
Post-dilatation, n (%) 10 (20.4)
Mean post-dilatation balloon diameter
per-lesion (mm)
3.5+0.47
Overlapping, n (%) 12 (24.5)
Overlap scaffolds diameters 3.5 mm–3.5 mm, n (%) 5 (10.2)
Overlap scaffolds diameters 3.5 mm – 3 mm n (%) 5 (10.2)
Overlap scaffolds diameters 3.5 mm–2.5 mm, n (%) 1 (2.0)
Overlap scaffolds diameters, 3 mm–2.5 mm, n (%) 1 (2.0)
Total number of scaffolds, n. 65
Mean scaffolds per-lesion, n. 1.35+0.60
Mean scaffold length per-lesion (mm) 26.40+13.86
Mean scaffold diameter per-lesion (mm) 3.2+34
Supportive wire, n. (%) 5 (10.2)
Radial approach, n. (%) 26 (53.0)
Data are expressed as mean+ SD or number and proportion, n (%).
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Table1 Baselineclinical characteristics intent-to-treat
population andpatients treatedwithmetallic stent in the
enrolment period
Clinical characteristics BVS
(N 5 49)
Metal stents
(N 5 123)
P-value
Age (year) 58.9+10.5 66.4+12.2 ,0.001
Male, n (%) 38 (77.6) 93 (75.6) 0.845
Hypertension, n (%) 19 (38.8) 53/105 (50.5) 0.225
Hypercholesterolemia, n (%) 11 (22.4) 30/100 (30.0) 0.435
Diabetes, n (%) 4 (8.2) 14/116 (12.1) 0.590
Smoke, n (%) 27 (69.2) 46/116 (39.7) 0.120
Family history of CAD, n (%) 12 (24.5) 31/95 (32.6) 0.343
Peripheral vascular
disease, n (%)
1 (2.0) 8 (6.5) 0.449
Kidney disease, n (%) 1 (2.0) 7 (5.7) 0.442
Prior MI, n (%) 1 (2.0) 14 (11.4) 0.070
Prior PCI, n (%) 0 (0.0) 15 (12.2) 0.007
Prior CABG, n (%) 0 (0.0) 3 (2.4) 0.559
COPD, n (%) 2 (4.1) 5 (4.1) 1.000
Culprit vessel 0.624
LM, n (%) 0 (0) 2 (1.6)
LAD, n (%) 21 (42.9) 52 (42.3)
RCA, n (%) 22 (44.9) 46 (37.4)
LCX, n (%) 6 (12.2) 21 (17.1)
SVG, n (%) 0 (0) 2 (1.6)
Patients with vessels diameters not feasible for BVS implantation (i.e. reference
vessel diameter ≥4.0 mm) were excluded.
Data are expressed as mean+ SD or number and proportion, n (%).
CAD, coronary artery disease; MI, myocardial infarction; PCI, percutaneous
coronary intervention; CABG, coronary artery bypass graft; COPD, chronic
obstructive pulmonary disease; LM, left main; LAD, left anterior descending; RCA,
right coronary artery; LCX, circumﬂex; SVG, saphenous vein graft.
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Table 3 Angiographic analysis in patients implanted
with bioresorbable vascular scaffolds
Angiographic data N 5 48
Pre-procedure
TIMI-ﬂow, % (n)
0 50.0% (23/46)
1 15.2% (7/46)
2 21.7% (10/46)
3 13.0% (6/46)
Thrombus burden, % (n)
0 0.0% (0/46)
1 6.5% (3/46)
2 17.4% (8/46)
3 13.0% (6/46)
4 13.0% (6/46)
5 50.0% (23/46)
Total occlusion (N ¼ 23)
RVD (mm) 2.94+0.77
Non-total occlusion (N ¼ 23)
RVD (mm) 2.62+0.63
MLD (mm) 0.75+0.44
Diameter stenosis (%) 70.8+12.5
After thrombectomy
TIMI-ﬂow, % (n)
0 2.5% (1/40)
1 7.5% (3/40)
2 37.5% (15/40)
3 52.5% (21/40)
Thrombus burden, % (n)
0 0.0% (0/40)
1 30.0% (12/40)
2 35.0% (14/40)
3 22.5% (9/40)
4 10.0% (4/40)
5 2.5% (1/40)
After pre-dilatation
TIMI-ﬂow, % (n)
0 0.0% (0/27)
1 7.4% (2/27)
2 33.3% (9/27)
3 59.3% (16/27)
Before BVS implantation
RVD (mm) 2.63+0.53
MLD (mm) 1.21+0.46
Diameter stenosis (%) 53.2+16.1
Dmax (mm) 3.01+0.52
Post-procedure
TIMI-ﬂow, % (n)
0 0.0% (0/48)
1 0.0% (0/48)
Continued
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Table 3 Continued
Angiographic data N 5 48
2 8.3% (4/48)
3 91.7% (44/48)
In-scaffold
RVD (mm) 2.86+0.52
MLD (mm) 2.44+0.49
Diameter stenosis (%) 14.7+8.2
In-segment
RVD (mm) 2.74+0.59
MLD (mm) 2.20+0.53
Diameter stenosis (%) 21.8+12.0
MI syntax score Ia 10.0 (7.0–15.0)
MI syntax score IIa 7.0 (4.25–10.0)
Dominant right coronary artery, % (n) 93.8% (45/48)
Scaffold-to-artery ratio 1.19+0.24
Complications occurring any time during the procedure, % (n)
Dissection 6.3% (3/48)
Spasm 4.2% (2/48)
Distal embolism 14.6% (7/48)
No-reﬂow 2.1% (1/48)
Data are expressed as mean+ SD or proportion (%).
aMI syntax scores I and II are expressed as median (interquartile range).
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Table 4 Optical coherence tomography ﬁndings
post-implantation in patients implanted with
bioresorbable vascular scaffolds
OCT variables N 5 31
Analysed length (mm) 28.16+ 13.29
Analysed struts, n 245+ 135
Minimum lumen area (mm2) 5.95+ 1.61
Mean lumen area (mm2) 8.02+ 1.92
Lumen volume (mm3) 225.78+ 113.63
Minimum scaffold area (mm2) 6.69+ 1.94
Mean scaffold area (mm2) 8.54+ 1.97
Scaffold volume (mm3) 240.07+ 118.48
Minimum ﬂow area (mm2) 5.62+ 1.66
ISA area (mm2) (N ¼ 20) 0.118+ 0.162
Mean prolapse area (mm2) 0.60+ 0.26
Mean intraluminal defect area (mm2) 0.013+ 0.017
Maximum intraluminal defect area (mm2) 0.094+ 0.077
Mean atherothrombotic area (mm2) 0.61+ 0.27
Mean atherothrombotic burden (%) 7.29+ 3.12
Malapposed struts per patient (%) 2.80+ 3.90
Scaffolds with at least 1 malapposed strut, n (%) 20 (64.5)
Scaffolds with .5% malapposed struts, n (%) 7 (22.6)
ISA, incomplete scaffold apposition.
Data are expressed as mean+ SD or number and proportion, n (%).
172
Data showed in the present report with optimal acute perform-
ance in terms of ﬁnal TIMI-ﬂow and scaffold apposition may suggest
that everolimus-eluting BVS could be considered for the treatment
of patients presenting with STEMI, however, due to the limited
number of patients and events, caution should be made in reaching
ﬁrm conclusions. Further larger studies are needed to fully evaluate
the performance of the present device in STEMI patients.
Limitations
Thepresent study represents a feasibility studywith a limited number
ofpatients.The small sample sizedoesnot allowreaching conclusions
in terms of clinical outcomes. The lackof a head-to-head comparison
with the current standard of care is a major limitation of the present
study.A longer follow-up is needed to fully evaluate the performance
of this novel device in patients presenting with acute MI. During the
enrolment period, the implantation of either metallic stent or BVS
in STEMI patients was left to the operator’s discretion; this method-
ology may be prone to selection bias. Therefore, these data should
not stimulate at the current state of knowledge the use of BVS in
patients presenting with acute MI. Larger randomized studies are
needed to conﬁrm these preliminary observations.
Conclusion
In the present investigation, the implantation of the everolimus-eluting
BVSwasobserved tobe feasible inpatientspresentingwithSTEMIwith
optimal acute performance. These data are preliminary and need
further conﬁrmation in randomized controlled trials to deﬁne the
true role of BVS for the treatment of patients presenting with acute
myocardial infarction.
Funding
Conﬂict of interest: Dr R.J. van Geuns received speakers fee from
Abbott Vascular. Abbott Vascular is providing institution research
grant for the Erasmus MC. Antonios Karanasos received funding
support from the Hellenic Heart Foundation and St Jude Medical.
References
1. Task Force onMyocardial Revascularization of the European Society of C, the Euro-
pean Association for Cardio-Thoracic S, European Association for Percutaneous
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 5 Optical coherence tomography ﬁndings post-implantation stratiﬁed by scaffold size in patients implanted with
bioresorbable vascular scaffolds
OCT variables
Scaffold size 2.5 mm (N5 5) 3.0 mm (N5 13) 3.5 mm (N 5 24) P
Analysed length (mm) 18.80+1.30 22.23+6.46 21.33+7.38 0.628
Minimum lumen area (mm2) 4.08+0.24 5.60+0.93 7.18+1.58 0.001
Mean lumen area (mm2) 5.42+0.75 7.18+1.03 9.25+1.72 0.001
Minimum scaffold area (mm2) 4.53+0.51 6.13+1.02 8.06+1.82 0.001
Mean scaffold area (mm2) 5.62+0.28 7.66+0.88 9.82+1.70 0.001
Minimum ﬂow area (mm2) 3.84+0.28 5.17+0.86 6.77+1.60 0.001
ISA area (mm2) (N ¼ 25) 0.190+0.318 (N ¼ 3) 0.063+0.072 (N ¼ 10) 0.133+0.177 (N ¼ 12) 0.429
Mean prolapse area (mm2) 0.40+0.19 0.54+0.27 0.62+0.29 0.246
Mean intraluminal defect area (mm2) 0.007+0.008 0.016+0.021 0.012+0.018 0.628
Maximum intraluminal defect area (mm2) 0.072+0.081 0.102+0.086 0.068+0.065 0.096
Mean atherothrombotic area (mm2) 0.40+0.19 0.56+0.27 0.64+0.30 0.237
Mean atherothrombotic burden (%) 6.00+4.66 7.42+3.79 6.20+3.39 0.594
ISA, incomplete scaffold apposition.
Data are expressed as mean+ SD or number and proportion, n (%).
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Table 6 Clinical outcomes at the 30-day follow-up
intent-to-treat population
Clinical events N 5 49 95% CI
Target-lesion failure (0/49) 0% (0–7.41)
TVF (0/49) 0% (0–7.41)
Cardiac death (0/49) 0% (0–7.41)
Target-vessel MI (0/49) 0% (0–7.41)
Q-wave MI (0/49) 0% (0–7.41)
Non Q-wave MI (0/49) 0% (0–7.41)
Clinically driven target-vessel
revascularization
(0/49) 0% (0–7.41)
Any MI (1/49) 2.6% (0–10.69)
Q-wave MI (0/49) 0% (0–7.41)
Non Q-wave MI (1/49) 2.6% (0–10.69)
Major adverse cardiac events (1/49) 2.6% (0–10.69)
Non-target-vessel revascularization (1/49) 2.6% (0–10.69)
Deﬁnite or probable scaffold thrombosis (0/49) 0% (0–7.41)
Data are expressed number and proportion, n (%). 95%CI, 95% conﬁdence interval.
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&RQFOXVLRQV7KHLPSODQWDWLRQRIWKHHYHUROLPXVHOXWLQJELRUHVRUEDEOHYDVFXODUVFDIIROGLQDQ
H[SDQGHGUDQJHRIFRURQDU\OHVLRQW\SHVDQGFOLQLFDOSUHVHQWDWLRQVZDVREVHUYHGWREHVDIHDQG
IHDVLEOHZLWKSURPLVLQJDQJLRJUDSKLFUHVXOWVDQGPLGWHUPFOLQLFDORXWFRPHV
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,QWURGXFWLRQ

7KHHYHUROLPXVHOXWLQJELRUHVRUEDEOHYDVFXODUVFDIIROGV%96UHSUHVHQWDQRYHODSSURDFKIRU
WUHDWPHQWRIFRURQDU\DUWHU\GLVHDVH6LPLODUO\WRFRQYHQWLRQDOPHWDOVWHQWVWKHDEVRUE%96SURYLGH
DFXWHOXPHQJDLQYHVVHOVFDIIROGLQJDQGGUXJHOXWLRQWRWKHYHVVHOZDOOLPPHGLDWHO\DIWHU
LPSODQWDWLRQ+RZHYHUDWYDULDQFHRIVWDQGDUGVWHQWVWKHSRO\PHULFVWUXFWXUHRIWKLVGHYLFH
DOORZVDJUDGXDOELRUHVRUSWLRQRIWKHLPSODQWRYHUWLPH&RPSOHWHVFDIIROGELRUHVRUSWLRQLV
K\SRWKHVL]HGWRRIIHUVHYHUDODGYDQWDJHVRYHUSHUPDQHQWPHWDOGHYLFHVFRPSULVLQJUHDFTXLUHPHQW
RISK\VLRORJLFDOYDVRPRWLRQODWHOXPHQHQODUJHPHQWQRQLQYDVLYHLPDJLQJDQGIXWXUHWUHDWPHQW
ZLWKE\SDVVJUDIWLQJ,QDGGLWLRQWKHDEVHQFHRIDIRUHLJQERG\FRXOGDYRLGSKHQRPHQDVXFK
DVSHUPDQHQWVLGHEUDQFKMDLOLQJODWHDFTXLUHGPDODSSRVLWLRQDQGWKHRFFXUUHQFHRIODWHDQGYHU\
ODWHVWHQWWKURPERVLV
7KHDEVRUE%96KDVEHHQLQLWLDOO\WHVWHGLQKXPDQVLQWZRFRKRUWVWXGLHVERWKVKRZLQJSURPLVLQJ
UHVXOWVLQWHUPVRIVXUURJDWHDQGFOLQLFDOHQGSRLQWV+RZHYHUEHLQJWKRVHVWXGLHVDQHDUO\
HYDOXDWLRQRIWKLVWHFKQRORJ\WKH\ZHUHFKDUDFWHUL]HGE\DSDWLHQWSRSXODWLRQVKRZLQJVWDEOH
FRURQDU\DUWHU\GLVHDVHDQGUHODWLYHO\VLPSOHOHVLRQV
$WWKHFXUUHQWVWDWHRIWKHDUWYHU\OLPLWHGGDWDDUHDYDLODEOHRQ%96SHUIRUPDQFHLQUHDOZRUOG
SDWLHQWVLQFOXGLQJWKRVHSUHVHQWLQJZLWKDFXWHFRURQDU\V\QGURPHVDQGFRPSOH[FRURQDU\OHVLRQV
$ODFNRILQIRUPDWLRQLVHVSHFLDOO\HYLGHQWZKHQFRQVLGHULQJLPSRUWDQWOHVLRQVXEVHWVVXFKDV
FDOFLILHGSODTXHVORQJOHVLRQVELIXUFDWLRQVDQGWRWDORFFOXVLRQV
*LYHQWKLVEDFNJURXQGWKHSUHVHQWVWXG\DLPVWRUHSRUWVDQJLRJUDSKLFDQGFOLQLFDOGDWDDIWHUDQ
H[SDQGHGFOLQLFDOXVHRIWKHVHFRQGJHQHUDWLRQ%96LPSODQWHGLQSDWLHQWVDGPLWWHGZLWKGLIIHUHQW
FOLQLFDOSUHVHQWDWLRQVLQFOXGLQJDFXWHFRURQDU\V\QGURPHVDQGKDYLQJDEURDGUDQJHRIFRURQDU\
OHVLRQW\SHV
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0HWKRGV

7KLVLVDQLQYHVWLJDWRULQLWLDWHGSURVSHFWLYHVLQJOHFHQWUHVLQJOHDUPSRVWPDUNHWVWXG\DLPLQJWR
HYDOXDWHWKHIHDVLELOLW\VDIHW\DQGSHUIRUPDQFHRIWKHDEVRUE%96IRUWUHDWPHQWRISDWLHQWVZLWK
FRURQDU\DUWHU\GLVHDVHLQURXWLQHFOLQLFDOSUDFWLFH(QUROOHGSDWLHQWVZHUHVXEMHFWVSUHVHQWLQJZLWK
VWDEOHXQVWDEOHDQJLQDRUQRQ67VHJPHQWHOHYDWLRQP\RFDUGLDOLQIDUFWLRQFDXVHGE\de novo
VWHQRWLFOHVLRQVLQQDWLYHFRURQDU\DUWHULHV1RUHVWULFWLRQVZHUHDSSOLHGWROHVLRQFRPSOH[LW\'XH
WRWKHDEVRUE%96VL]HDYDLODELOLW\D'PD[SUR[LPDODQGGLVWDOPHDQOXPHQGLDPHWHUZLWKLQWKH
XSSHUOLPLWRIPPDQGWKHORZHUOLPLWRIPPE\RQOLQH4&$ZDVUHTXLUHG([FOXVLRQ
FULWHULDZHUHPLQLPDODQGFRPSULVHGDOOHUJLHVRUFRQWUDLQGLFDWLRQVWRDQWLSODWHOHWPHGLFDWLRQ
IHPDOHSDWLHQWZLWKFKLOGEHDULQJSRWHQWLDORUFXUUHQWO\EUHDVWIHHGLQJDFXWH67VHJPHQWHOHYDWLRQ
P\RFDUGLDOLQIDUFWLRQDQGSRVW&$%*SDWLHQWV
(WKLFV
7KLVLVDQREVHUYDWLRQDOVWXG\SHUIRUPHGDFFRUGLQJWRWKHSULYDF\SROLF\RIWKH(UDVPXV0&DQG
WRWKH(UDVPXV0&UHJXODWLRQVIRUWKHDSSURSULDWHXVHRIGDWDLQSDWLHQWRULHQWHGUHVHDUFKZKLFK
DUHEDVHGRQLQWHUQDWLRQDOUHJXODWLRQVLQFOXGLQJWKHGHFODUDWLRQRI+HOVLQNL7KH%96UHFHLYHGWKH
&(PDUNIRUFOLQLFDOXVHLQGLFDWHGIRULPSURYLQJFRURQDU\OXPHQGLDPHWHULQSDWLHQWVZLWK
LVFKHPLFKHDUWGLVHDVHGXHWRGHQRYRQDWLYHFRURQDU\DUWHU\OHVLRQVZLWKQRUHVWULFWLRQLQWHUPVRI
FOLQLFDOSUHVHQWDWLRQ7KHUHIRUHWKH%96FDQEHFXUUHQWO\XVHGURXWLQHO\LQ(XURSHLQGLIIHUHQW
VHWWLQJVZLWKRXWDVSHFLILFZULWWHQLQIRUPHGFRQVHQWLQDGGLWLRQWRWKHVWDQGDUGLQIRUPHGFRQVHQWWR
WKHSURFHGXUH7KHUHIRUHDZDLYHUIURPWKHKRVSLWDO(WKLFDO&RPPLWWHHZDVREWDLQHGIRUZULWWHQ
LQIRUPHGFRQVHQWDVDFFRUGLQJWR'XWFKODZZULWWHQFRQVHQWLVQRWUHTXLUHGLISDWLHQWVDUHQRW
VXEMHFWWRDFWVRWKHUWKDQDVSDUWRIWKHLUUHJXODUWUHDWPHQW

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6WXG\GHYLFH
7KHGHYLFHXVHGLQWKHSUHVHQWVWXG\LVWKHVHFRQGJHQHUDWLRQ$EVRUE%96$EERWW9DVFXODU6DQWD
&ODUD&$86$DEDOORRQH[SDQGDEOHVFDIIROGZLWKDSRO\PHUEDFNERQHRI3RO\/ODFWLGH$FLG
3//$FRDWHGZLWKDWKLQOD\HURIDPL[WXUHRIDQDPRUSKRXVPDWUL[RI3RO\'DQG/ODFWLGH
DFLG3'//$SRO\PHUFRQWUROOLQJWKHUHDOLVHRIPLFURJUDPVFPRIWKHDQWLSUROLIHUDWLYHGUXJ
HYHUROLPXV7ZRSODWLQXPPDUNHUVORFDWHGDWHDFK$EVRUE%96HGJHDOORZLQJIRUDFFXUDWH
YLVXDOL]DWLRQRIWKHUDGLROXFHQW$EVRUE%96GXULQJDQJLRJUDSK\RURWKHULPDJLQJPRGDOLWLHV
$SSUR[LPDWHO\RIWKHGUXJLVHOXWHGZLWKLQWKHILUVWGD\V%RWK3//$DQG3'//$DUHIXOO\
ELRUHVRUEDEOH7KHSRO\PHUVDUHGHJUDGHGPDLQO\YLDK\GURO\VLVUHVXOWLQJROLJRPHUVRIODFWDWH
PHWDEROL]HGE\.UHEVF\FOH. Small particles, less than 2 ȝm in diameter, have alVREHHQVKRZQWR
EHSKDJRF\WLVHGDQGGHJUDGHGE\PDFURSKDJHV
5HLQVHUWLRQRIWKHGHYLFHDIWHULQLWLDOIDLOXUHWRFURVVWKHOHVLRQLVQRWFXUUHQWO\DGYLVHGE\WKH
PDQXIDFWXUHU+RZHYHUEDVHGRQLQWHUQDO$EERWW9DVFXODUHDUO\EHQFKWHVWLQJUHLQVHUWLRQZDV
DFFHSWHGDVIHDVLEOHE\RXUVWDIIXSWRPLQDIWHUILUVWFRQWDFWZLWKEORRG
'HILQLWLRQV
'HYLFH6XFFHVVZDVGHILQHGDVWKHDWWDLQPHQWRIILQDOLQVHJPHQWUHVLGXDOVWHQRVLVDIWHU
DEVRUE%96LPSODQWDWLRQE\DQJLRJUDSKLFYLVXDOHVWLPDWLRQ3URFHGXUH6XFFHVVZDVGHILQHGDV
GHYLFHVXFFHVVDQGQRPDMRUSHULSURFHGXUDOFRPSOLFDWLRQV(PHUJHQW&$%*FRURQDU\SHUIRUDWLRQ
UHTXLULQJSHULFDUGLDOGUDLQDJHUHVLGXDOGLVVHFWLRQLPSDLULQJYHVVHOIORZ–7,0,IORZ,,RUOHVV
&OLQLFDOVXFFHVVZDVGHILQHGDVSURFHGXUDOVXFFHVVDQGQRLQKRVSLWDOPDMRUDGYHUVHFDUGLDFHYHQWV
0$&($OOGHDWKVZHUHFRQVLGHUHGFDUGLDFXQOHVVDQXQGLVSXWHGQRQFDUGLDFFDXVHZDVLGHQWLILHG
0\RFDUGLDOLQIDUFWLRQ0,DQGVFDIIROGWKURPERVLVZHUHGHILQHGDFFRUGLQJWRWKH$FDGHPLF
5HVHDUFK&RQVRUWLXP$5&GHILQLWLRQ$Q\7DUJHWOHVLRQUHYDVFXODUL]DWLRQ7/5ZDVGHILQHGDV
FOLQLFDOO\GULYHQLIDWUHSHDWDQJLRJUDSK\DGLDPHWHUVWHQRVLV!ZDVREVHUYHGRULIDGLDPHWHU
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VWHQRVLV!ZDVSUHVHQWLQDVVRFLDWLRQZLWKUHFXUUHQWDQJLQDSHFWRULVREMHFWLYHVLJQVRI
LVFKDHPLD(&*FKDQJHVDWUHVWRUGXULQJH[HUFLVHWHVWOLNHO\WREHUHODWHGWRWKHWDUJHWYHVVHO
DEQRUPDOUHVXOWVRIDQ\LQYDVLYHIXQFWLRQDOGLDJQRVWLFWHVW
7KHGHYLFHRULHQWHGHQGSRLQWWDUJHWOHVLRQIDLOXUHZDVGHILQHGDVWKHFRPSRVLWHRIFDUGLDFGHDWK
WDUJHWYHVVHOP\RFDUGLDOLQIDUFWLRQRULVFKHPLDGULYHQWDUJHWOHVLRQUHYDVFXODUL]DWLRQ0DMRU
DGYHUVHFDUGLDFHYHQWV0$&(GHILQHGDVWKHFRPSRVLWHRIFDUGLDFGHDWKDQ\UHLQIDUFWLRQ4RU
1RQ4:DYHHPHUJHQWE\SDVVVXUJHU\&$%*RUFOLQLFDOO\GULYHQWDUJHWOHVLRQ
UHYDVFXODUL]DWLRQ7/57DUJHWYHVVHOIDLOXUH79)ZDVGHILQHGDVFDUGLDFGHDWKWDUJHWYHVVHO
P\RFDUGLDOLQIDUFWLRQ0,RUFOLQLFDOO\GULYHQWDUJHWYHVVHOUHYDVFXODUL]DWLRQ795'HOLYHU\
IDLOXUHZDVGHILQHGDVRSHQLQJRIVFDIIROGIURPLWVFRYHUDQGLQVHUWLRQLQWRWKHJXLGLQJFDWKHWHU
ZLWKRXWILQDOLPSODQWDWLRQ,QDQDWWHPSWWRVWXG\UHLQVHUWLRQWLPHEHWZHHQUHJLVWUDWLRQRISURGXFW
LQPDWHULDOOLVWRIRXUGDWDEDVHDQGDQJLRJUDSKLFUHFRUGLQJRILPSODQWDWLRQZDVUHJLVWHUHG,IWKLV
ZDVDERYHPLQLQLWLDOOHVLRQSDVVDJHZDVSUHVXPHGIDLOHGDQGUHLQVHUWLRQDVVXPHG
$OOSRWHQWLDOHYHQWVZHUHDGMXGLFDWHGE\DORFDOLQGHSHQGHQW&OLQLFDO(YHQWV&RPPLWWHH&(&
4XDQWLWDWLYHFRURQDU\DQJLRJUDSK\
4XDQWLWDWLYHFRURQDU\DQJLRJUDSK\4&$DQDO\VHVZHUHSHUIRUPHGXVLQJWKH&RURQDU\
$QJLRJUDSK\$QDO\VLV6\VWHP3LH0HGLFDO,PDJLQJ0DDVWULFKW1HWKHUODQGV
7KH4&$PHDVXUHPHQWVZHSHUIRUPHGSUHDQGSRVW%96LPSODQWDWLRQThe 37 ȝm platinum rDGLR
PDUNHUVORFDWHGDWHDFKHQGRIWKH$EVRUE%96DLGHGLQWKHORFDOLVDWLRQRIWKHQRQUDGLRRSDTXH
VFDIIROGIRU4&$$QDO\VHGSDUDPHWHUVLQFOXGHGUHIHUHQFHYHVVHOGLDPHWHU59'FDOFXODWHGZLWK
LQWHUSRODWHPHWKRGSHUFHQWDJHGLDPHWHUVWHQRVLV'6DQGPLQLPDOOXPHQGLDPHWHU0/'
$FXWHJDLQZDVGHILQHGDVSRVWSURFHGXUDO0/'PLQXVSUHSURFHGXUDO0/'7KHDQJLRJUDSKLF
DQDO\VLVZHUHSHUIRUPHGE\WKUHHLQYHVWLJDWRUV<,<2DQG5'ZKRZKHUHH[WHQVLYHO\WUDLQHGLQ
DQH[SHULHQFHGFRUHODE&DUGLDO\VLV%95RWWHUGDP7KH1HWKHUODQGV
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$FDOFLILHGFRURQDU\FXOSULWOHVLRQZDVGHILQHGDVDOUHDG\UHSRUWHG‘UHDGLO\DSSDUHQWGHQVLWLHV
QRWHGZLWKLQWKHDSSDUHQWYDVFXODUZDOODWWKHVLWHRIWKHVWHQRVLV’ By qualitative assessment of the 
DQJLRJUDPVWDUJHWOHVLRns were classified as severe (‘UDGLRRSDFLWLHVQRWHGZLWKRXWFDUGLDFPRWLRQ
SULRUWRFRQWUDVWLQMHFWLRQJHQHUDOO\LQYROYLQJboth sides of the arterial wall’), moderate (‘GHQVLWLHV
QRWHGRQO\GXULQJWKHFDUGLDFF\FOHSULRUWRFRQWUDVWLQMHFWLRQ’), or none/mild (lesions other than 
VHYHUHDQGPRGHUDWHFDOFLILHGOHVLRQV7KH,QWHUDQGLQWUDREVHUYHUYDULDELOLW\LQWKHTXDOLWDWLYH
DQDO\VLVRIFRURQDU\FDOFLXPRQFRURQDU\DQJLRJUDPVKDYHEHHQDOUHDG\UHSRUWHG
7RSURYLGHLQVLJKWVRQWKHFRURQDU\ELIXUFDWLRQWUHDWPHQWZLWK%96ZHSHUIRUPHGDIXOODQDO\VLVRI
WHFKQLTXHVDQGPDWHULDOXVHGDQGZHUHSRUWHGWKHRFFXUUHQFHRIVLGHEUDQFKLPSDLUPHQWDQHQG
SRLQWDOUHDG\UHSRUWHGLQWKHOLWHUDWXUHas “sideEUDQFKWURXEOe”DQGGHILQHGDVIROORZDWOHDVW
RIWKHIROORZLQJSURFHGXUDOSDUDPHWHUV6LGHEUDQFK7,0,IORZJUDGHDIWHUPDLQYHVVHO
VWHQWLQJQHHGRIJXLGHZLUHVGLIIHUHQWIURPWKHZRUNKRUVHZLUHWRUHZLUHVLGHEUDQFKDIWHU
PDLQYHVVHOVFDIIROGLQJIDLOXUHWRUHZLUHWKHVLGHEUDQFKDIWHUPDLQYHVVHOVFDIIROGLQJRU
IDLOXUHWRGLODWHWKHVLGHEUDQFKDIWHUPDLQYHVVHOVFDIIROGLQJDQGVLGHEUDQFKUHZLULQJ

6WDWLVWLFDODQDO\VLV
&DWHJRULFDOYDULDEOHVDUHUHSRUWHGDVFRXQWVDQGSHUFHQWDJHVFRQWLQXRXVYDULDEOHVDVPHDQ
VWDQGDUGGHYLDWLRQSYDOXHVZHUHFDOFXODWHGZLWKFisher’s Exact test for binary variables, 
Wilcoxon’s Rank SumWHVWIRUFRQWLQXRXVYDULDEOHV&RPSDULVRQVDPRQJPXOWLSOHPHDQVZHUH
SHUIRUPHGZLWKDQDO\VLVRIYDULDQFHZD\$129$. $SYDOXHZDVFRQVLGHUHGVWDWLVWLFDOO\
VLJQLILFDQW6WDWLVWLFDODQDO\VHVZHUHSHUIRUPHGXVLQJ6366YHUVLRQIRUZLQGRZV,/86
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5HVXOWV
)URP6HSWHPEHUWR-XO\DWRWDORISHUFXWDQHRXVFRURQDU\LQWHUYHQWLRQVZHUH
SHUIRUPHGLQRXUFHQWHU$WRWDORISDWLHQWVKDYHEHHQHQUROOHGLQWKHSUHVHQWVWXG\ZLWK
WUHDWHGFRURQDU\OHVLRQV%DVHOLQHFOLQLFDOFKDUDFWHULVWLFVDUHUHSRUWHGLQWDEOH6HYHQW\WKUHH
SDWLHQWVVKRZHGPXOWLYHVVHOGLVHDVH$WRWDORIOHVLRQVZHUHFODVVLILHGDVW\SH
%RU&PHDQOHVLRQOHQJWKZDVPPELIXUFDWLRQOHVLRQVZLWKVLGHbranch  2 mm were D
WRWDORIOHVLRQZHUHGHILQHGZLWKVHYHUHRUPRGHUDWHFDOFLILFDWLRQDQGLQFDVHZDVSUHVHQWD
WRWDORFFOXVLRQ7DEOH
/HVLRQSUHSDUDWLRQZDVSHUIRUPHGLQDODUJHSDUWRIWKHFDVHVPDLQO\WKURXJKEDOORRQSUHGLODWDWLRQ
URWDWLRQDODWKHUHFWRP\ZDVQHFHVVDU\LQRIFDVHV0XOWLSOHVFDIIROGLPSODQWDWLRQSHU
OHVLRQZDVDOORZHGDQGRIWHQSHUIRUPHGXSWRWKHLPSODQWDWLRQRIVFDIIROGV
5HLQVHUWLRQRIWKHVFDIIROGDVVXPHGLIWLPHEHWZHHQUHJLVWUDWLRQRISURGXFWLQPDWHULDOOLVWDQG
DQJLRJUDSKLFUHFRUGLQJRILPSODQWDWLRQZDV!PLQXWHVZDVUHSRUWHGLQFDVHV1RVFDIIROG
GLVORGJPHQWZDVUHSRUWHG
%DLORXWZLWKPHWDOVWHQWVZDVSHUIRUPHGLQRQO\FDVHV%DOORRQSRVWGLODWDWLRQZDVSHUIRUPHGLQD
UHPDUNDEOHSHUFHQWDJHRIFDVHVZLWKRIWHQDEDOORRQVFDIIROGUDWLR!7DEOH
7KHRYHUDOOGHYLFHSURFHGXUHDQGFOLQLFDOVXFFHVVUDWHVSHUOHVLRQZHUHUHVSHFWLYHO\
DQG
4&$DQDO\VLV7KHPHDQSUHSURFHGXUHUHIHUHQFHYHVVHOGLDPHWHU59'ZDVPPZLWK
DPHDQSHUFHQWDJHGLDPHWHUVWHQRVLV'6RIDQGDPHDQPLQLPDOOXPHQGLDPHWHU
0/'HTXDOWRPP3RVWSURFHGXUHZDVREVHUYHGD'6RIDQGD
PHDQ0/'HTXDOWRPPZLWKDPHDQDFXWHJDLQRIPP7,0,IORZZDV
REVHUYHGLQRIWKHILQDODQJLRJUDPV7DEOH
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%LIXUFDWLRQ/HVLRQV$WRWDORIOHVLRQVZHUHORFDWHGDWWKHVLWHRIDELIXUFDWLRQZLWKDVLGH
branch  2.0PP,QFDVHVDSURYLVLRQDO7VWHQWLQJWHFKQLTXHZDVXVHGLQDGGLWLRQ7VWHQWLQJ
FXORWWH7VWHQWLQJDQGVPDOOSURWUXVLRQWHFKQLTXHVZHUHSHUIRUPHG,QFDVHVEUDQFKZLUH
SURWHFWLRQZDVXVHGSUHGLODWDWLRQDQGSRVWGLODWDWLRQRIWKHPDLQYHVVHOZDVRIWHQSHUIRUPHG6LGH
EUDQFKGLODWDWLRQSRVW09VWHQWLQJZDVQHFHVVDU\LQOHVLRQV$ILQDO7,0,IORZLQWKHPDLQ
YHVVHOV09ZDVREVHUYHGLQRQO\RQHFDVHDWWKHVLGHEUDQFKWKLVZDVUHSRUWHGLQOHVLRQV
)DLOXUHWRUHZLUHWKHVLGHEUDQFKZDVQHYHUUHSRUWHGEXWLQRQHFDVHWKHRSHUDWRUZDVXQDEOHWRUH
FURVVWKHVFDIIROGZLWKDVPDOOEDOORRQRIPPLQGLDPHWHU7DEOH7KHRYHUDOORIUDWHRIVLGH
EUDQFKLPSDLUPHQWZDV
&DOFLILHGOHVLRQV$WRWDORIFDOFLILHGOHVLRQVZHUHWUHDWHGZLWK%96ZLWKVHYHUH
FDOFLILFDWLRQZLWKPRGHUDWHFDOFLILFDWLRQDQGFRPSDUHGZLWKQRQFDOFLILHGOHVLRQV*LYHQDQRQ
VLJQLILFDQWGLIIHUHQFHLQSUHSURFHGXUH59'0/'DQG'6QRGLIIHUHQFHVZHUHREVHUYHGDIWHU
WUHDWPHQWEHWZHHQFDOFLILHGDQGQRQFDOFLILHGOHVLRQVLQWHUPVRI0/'6HYHUHFDOFLILHG2.38 ± 0.38 
mm, moderate calcified 2.41 ± 0.39 mm, noncalcified 2.42 ± 0.43 mm; p=0.889), %DS (6HYHUH
FDOFLILHG20.3 ± 10.5 %, moderate calcified 17.8 ± 7.7%, noncalcified 16.8 ± 8.6%; p=0.112) and 
acute gain (6HYHUHFDOFLILHG1.36 ± 0.41mm, moderate calcified 1.48 ± 0.44mm, noncalcified 1.56 
± 0.54 mm; p=0.109). These results were achieved with an overall higher use of buddy wires in 
calcified lesions (sHYHUHFDOFLILHG18.2%, moderate calcified 9.3%, noncalcified 3.0%; p=0.016)
Lesion preparation was more aggressive in calcified lesions with a higher use of rotational 
atherectomy (6HYHUHFDOFLILHG18.2%, moderate calcified 4.7%, noncalcified 1.5%; p<0.001) and 
scoring balloons (6HYHUHFDOFLILHG15 .2%, moderate calcified 3.5%, noncalcified 0.8%; p=0.001). 
Success rates were high in calcified vessels showing no significant differences when compare do 
noncalcified ones. Device success in VHYHUHFDOFLILHGOHVLRQVZDV97.0%, in moderate calcified 
100%and in noncalcified  99.2%; p=0.251. (Table 6)
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Total Occlusions Vessels showing a total occlusion were 29. After vessel disobstruction total 
occluded vessel were treated with BVS achieving a final MLD and %DS not different from other 
lesion types (MLD: 2.51 ± 0.53 mm vs 2.40 ± 0.39; p=0.163; %DS: 17.2 ± 9.4% vs 17.7 ± 8.6%; 
p=0.780), with a high rate of final device success (96.6% vs 98.2%; p=0.465) and procedure 
success96.6% vs 98.6%; p=0.393). To reach those results supportive wires were used much more 
frequently in occluded vessels (54.2% vs 2.1%; p<0.001). (Table 7)
Long Lesions In a total of 79 lesions (31.7%) more than one device was implanted. 7KHPHDQ
OHVLRQOHQJWKWUHDWHGZLWK%96ZDVPP7KHPD[LPXPOHVLRQOHQJWKFRYHUHGE\
%96ZDVPP2YHUODSSLQJRI%96ZLWK%96ZDVRIWHQSHUIRUPHGZLWKDWRWDORI
RYHUODSSLQJ7KHJUHDWPDMRULW\ZHUHSHUIRUPHGXVLQJVFDIIROGRIWKHVDPHGLDPHWHU
RUZLWKDPD[LPXPRIPPGLIIHUHQFHLQQRPLQDOGLDPHWHU,QFDVHVDPPVFDIIROGZDV
SODFHGLQRYHUODSZLWKDPPGHYLFH
Clinical outcomesSurvival data at 6 months after the procedure were available for 98.9 % of 
patients. A questionnaire was sent to all living patients with specific queries on rehospitalization 
and cardiovascular events. For patients who suffered an adverse event at another center, medical 
records or discharge letters from the other institutions were systematically reviewed. General 
practitioners and referring physicians were contacted for additional information if necessary.
At 6month followup all causedeath was reported in 3 cases. In 2 cases nontarget vessel 
revascularisations were performed. A total of 4 definite or probable scaffold thrombosis (ST) 
occurred within sixmonth after index procedure; none of them was acute or subacute. Of note one 
of those 4 cases was meeting the ARC criteria for ST but no clear thrombus was observed by optical 
coherence tomography (OCT). In the remaining 3 cases, severe calcification, bifurcation lesion and 
long overlap were observed but BVS underexpansion was the factor that was present in all of them.

Description of the Scaffold thrombosis cases  
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
&DVH$\HDUROGPDOHSDWLHQWVPRNHUZLWKKLVWRU\RIFHUHEURYDVFXODUDFFLGHQWDQGVWDEOH
DQJLQDSHFWRULVZDVWUHDWHGDIWHUSUHGLODWDWLRQRQORQJOHVLRQLQYROYLQJWKHRVWLDOOHIWDQWHULRU
GHVFHQGLQJ/$'DQGWKHELIXUFDWLRQZLWKWKHILUVWGLDJRQDO'XVLQJD%96[PP
'HVSLWHDSRVWGLODWDWLRQZDVSHUIRUPHGZLWKDQRQFRPSODLQW1&EDOORRQDWKLJKSUHVVXUHWKH
%96UHPDLQHGXQGHUH[SDQGHGZLWKDQLPSDLUHGIORZLQWKHILUVWGLDJRQDO$WWKHGD\SRVW3&,
WKHSDWLHQWZDVUHDGPLWWHGZLWK167(0,DQGDQJLRJUDSKLFDOO\ZDVREVHUYHGDWRWDOUHRFFOXVLRQ
RIWKH/$'EHJLQQLQJIURPWKHRVWLXP$IWHUSUHGLODWDWLRQD'(6[PPZDVLPSODQWHG2I
QRWHDWGD\DIWHUWKHVHFRQG3&,WKHSDWLHQWVZDVDJDLQUHDGPLWWHGIRULQVWDEOHDQJLQDSHFWRULV
FDXVHGE\DUHRFFOXVLRQDOVRRIWKHPHWDOVWHQWLQWKHSUR[LPDO/$'7KHSDWLHQWVZDVWUHDWHGZLWK
&$%*
/HVLRQNH\FKDUDFWHULVWLFV Ostial lesion, long lesion, bifurcation, impaired side-branch TIMI 
flow and BVS underexpansion
&DVH$\HDUROGPDOHZLWKKLVWRU\RIG\VOLSLGDHPLDDQGK\SHUWHQVLRQZDVDGPLWWHGZLWK
167(0,$QJLRJUDSKLFDOO\ZDVREVHUYHGDORQJVHYHUHO\FDOFLILHGFKURQLFWRWDORFFOXVLRQ&72
RIWKHSUR[LPDODQGPLG/$'ZLWKVHYHUHFDOFLILFDWLRQDQGLQYROYHPHQWRI'$IWHU3UHGLODWDWLRQ
[[PP%96ZHUHLPSODQWHG7KHSURFHGXUHZDVFRPSOLFDWHGE\SLQFKLQJRI'DQG
WKURPEXVIRUPDWLRQ$GGLWLRQDOEDOORRQLQJRIWKHRVWLXPRIWKHVLGHEUDQFKZDVSHUIRUPHGEXWDW
WKHHQGRIWKHSURFHGXUHUHPDLQHG%96XQGHUH[SDQVLRQDQGKD]LQHVVLQWKHPLG/$'$WGD\
WKHSDWLHQWGHYHORSHGDQRQ4ZDYH0,GXHWRGHILQLWHVFDIIROGWKURPERVLVLQWKHSUR[LPDO/$'
ZKLFKZDVWUHDWHGZLWKWKURPEHFWRP\DQG'(6LPSODQWDWLRQ
/HVLRQNH\FKDUDFWHULVWLFV CTO, long lesion, bifurcation, severe calcification, thrombus 
formation and BVS underexpansion  

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&DVH$\HDUROGPDOHSDWLHQWVPRNHUZLWKKLVWRU\RIK\SHUWHQVLRQZDVDGPLWWHGZLWK
167(0,GXHWRDVXERFFOXVLYHOHVLRQLQWKH/$'ORFDWHGDWWKHVLWHRIDWRUWXRXVWULIXUFDWLRQZLWK
WKHILUVWDQGVHFRQGGLDJRQDO7KHLQLWLDO7,0,IORZZDV$IWHUSUHGLODWDWLRQD[PP%96
ZDVLPSODQWHGDQGDIWHUSRVWGLODWDWLRQD7,0,,,,IORZZDVDFKLHYHG$WGD\WKHSDWLHQWZDVUH
DGPLWWHGZLWK167(0,$QJLRJUDSKLFDOO\DSUR[LPDO%96HGJHVXEWRWDOUHVWHQRVLVZDVREVHUYHG
ZLWKDGLVWDO7,0,IORZ$'(6VWHQW[PPZDVGHSOR\HGFRYHULQJWKH%96DQGDODUJH
SUR[LPDOVHJPHQW2IQRWHWKLVFDVHZDVPHHWLQJWKH$5&FULWHULDIRUVWHQWWKURPERVLVDQGZDV
DGMXGLFDWHGDVVXFKE\WKH&(&EXWVKRXOGEHPHQWLRQHGWKDWDQ2&7SHUIRUPHGEHIRUH
SUHGLODWDWLRQGLGQRWVKRZHGDQ\FOHDULQWUDOXPLQDOWKURPEXV
/HVLRQNH\FKDUDFWHULVWLFVtortuous trifurcation (no thrombus by OCT)
&DVH$\HDUROGPDOHZLWKVHYHUHSHULSKHUDOYDVFXODUGLVHDVHGLDEHWHVPHOOLWXV
G\VOLSLGDHPLDK\SHUWHQVLRQDQGUHGXFHGOHIWYHQWULFXODUIXQFWLRQZDVDGPLWWHGZLWKVWDEOHDQJLQD
SHFWRULV$QJLRJUDSK\UHYHDOHGDORQJDQGVHYHUHO\FDOFLILHGOHVLRQPLG/$'LQYROYLQJWZR
ELIXUFDWLRQV'DQG'$JJUHVVLYHSUHSDUDWLRQZDVSHUIRUPHGZLWKURWDWLRQDODWKHUHFWRP\DQG
KLJKSUHVVXUHGLODWDWLRQVZLWK1&DQGFXWWLQJEDOORRQV7ZRRYHUODSSLQJ%96ZHUHSODFHGZLWKD
TXLWHORQJVHJPHQWRIRYHUODSPP'HVSLWHH[WHQVLYHSRVWGLODWDWLRQXQGHUH[SDQVLRQUHPDLQHG
DWWKHHQGRIWKHSURFHGXUH)LYHPRQWKVDIWHULQGH[3&,WKHSDWLHQWXQGHUZHQWQRQFDUGLDFVXUJHU\
7KHDQWLSODWHOHWWKHUDS\ZDVLQWHUUXSWHGERWKDVSLULQDQGFORSLGRJUHODQGWKHSDWLHQWGHYHORSHGD
167(0,GXHWRDVFDIIROGWKURPERVLVWKDWZDVWUHDWHGZLWKEDOORRQGLODWDWLRQDQGHSWLILEDWLGH
8QIRUWXQDWHO\WKHSDWLHQWGLHGIHZGD\VODWHUEHFDXVHRIKHDUWIDLOXUH
/HVLRQNH\FKDUDFWHULVWLFVSevere calcification, bifurcation, long overlap, no antiplatelet 
therapy and BVS underexpansion  

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'LVFXVVLRQ

7KHSUHVHQWLQYHVWLJDWLRQUHSUHVHQWVHQHYDOXDWLRQRIWKHIHDVLELOLW\RI%96LPSODQWDWLRQLQ
HYHU\GD\FOLQLFDOSUDFWLVHUHIOHFWHGE\LQDZLGHUDQJHRIFRURQDU\OHVLRQVVXEVHWVLQFOXGLQJ
ELIXUFDWLRQVFDOFLILHGYHVVHOVFKURQLFWRWDORFFOXVLRQVDQGORQJOHVLRQLQSDWLHQWVZLWKVWDEOH
FRURQDU\DUWHU\GLVHDVHDQGDFXWHFRURQDU\V\QGURPHV$WYDULDQFHRISUHYLRXVUHSRUWVZHDOVR
DLPHGWRSURYLGHDGHWDLOHGGHVFULSWLRQRISURFHGXUDOGDWDHQWHFKQLTXHVWKDWZHUHXVHGWRDOORZWKH
XVHRIWKLVQRYHOGHYLFHLQFKDOOHQJLQJVXEVHWV
%LIXUFDWLRQOHVLRQV$FRPPRQFRQFHUQUHJDUGLQJWKLVWHFKQRORJ\LVWKHIDFWWKDWLPSODQWDWLRQRI
WKH%96LQELIXUFDWLRQOHVLRQVPLJKWUHVXOWLQWRVLGHEUDQFKFRPSURPLVHGXHWRWKHWKLFNVWUXW
QDWXUHRIWKLVGHYLFH,QNHHSLQJZLWKWKLVFRQFHSWDUHFHQWVWXG\SHUIRUPHGE\RXUJURXSVKRZHG
WKDW%96GHSOR\PHQWFRXOGEHDVVRFLDWHGZLWKDQLQFUHDVHGVPall (0.5PPVLGHEUDQFKRFFOXVLRQ
DQGDFRQVHTXHQWLQFUHDVHRIHQ]\PHVUHOHDVHDIWHUSURFHGXUH
+RZHYHULQWKHSUHVHQWUHSRUWWKHHIIHFWRI%96LPSODQWDWLRQLQZKDWLVFRPPRQO\FRQVLGHUHGD
bifurcation lesion (with a side branch  2 mm) ZDVVSHFLILFDOO\LQYHVWLJDWHG
5HZLULQJRIWKHVLGHEUDQFKLQWKRVHFDVHVDQGFRQVHTXHQWEDOORRQLQJPDLQO\ZLWKVPDOOEDOORRQ
PPLQGLDPHWHURIWKH6%RVWLXPLVIHDVLEOHDVZHDOUHDG\UHSRUWHGDQGVDIHDOVRLQWHUPV
RIVFDIIROGJHRPHWU\DQGIUDFWXUH,QWKHSUHVHQWVWXG\VLGHEUDQFKEDOORRQLQJZDV
SHUIRUPHGLQRQHWKLUGRIWKHSDWLHQWVZLWKSURPLVLQJUHVXOWV,QPDMRULW\RIWKHFDVHV
WKLVZDVGRQHZLWKVHTXHQWLDOEDOORRQLQJDQGSUR[LPDORSWLPL]DWLRQWHFKQLTXH327NLVVLQJ
EDOORRQRQO\LQFDVHV
7DNLQJLQWRFRQVLGHUDWLRQWKHUDWHVRI7,0,IORZLQWKHPDLQYHVVHORULQWKHVLGHEUDQFKWKH
UDWHRIIDLOXUHWRUHZLUHWKHVLGHEUDQFKDQGIDLOXUHWRGLODWHWKHVLGHEUDQFKWKH%96SHUIRUPHGDW
OHDVWDVJRRGDVPHWDOOLFVWHQWVDFFRUGLQJWRKLVWRULFDOGDWD
190
,QDGGLWLRQWKHUDWHRIWKHFRPSRVLWHHQGSRLQWRIVLGHEUDQFKLPSDLUPHQWZDVREVHUYHGWREH
HQFRXUDJLQJHVSHFLDOO\ZKHQFRPSDUHGZLWKGDWDUHFHQWO\UHSRUWHGE\%XU]RWWDHWDOZLWKUDWHVRI
VLGHEUDQFKLPSDLUPHQWLQVLUROLPXVDQGHYHUROLPXVHOXWLQJVWHQWVUHVSHFWLYHO\DQG
7KHVHGDWDDUHVXSSRUWLYHRIWKHFRQFHSWWKDW%96FRXOGEHXVHGVDIHO\LQELIXUFDWLRQOHVLRQVZLWK
VLGHEUDQFKPPZLWKDVLQJOHVFDIIROGDSSURDFKDQGFRXOGSURYLGHUHVXOWVVLPLODUWRPHWDOOLF
VWHQWV
&DOFLILHGOHVLRQV$WRWDORIFDOFLILHGOHVLRQVZLWKDFRQVLGHUDEOHSHUFHQWDJHRIKHDYLO\FDOFLILHG
SODTXHVZHUHWUHDWHGZLWK%96$ODUJHQXPEHURIWKRVHOHVLRQVZHUHORFDWHGLQGLIIXVHO\GLVHDVHG
YHVVHOVZLWKDQRYHUDOOPHDQWUHDWHGOHVLRQOHQJWKRIPRUHWKDQPPVHYHUHFDOFLILHGJURXS
4&$DQDO\VLVVKRZHGILQDO0/''6DFXWHJDLQDQGGHYLFHSURFHGXUDODQGFOLQLFDOVXFFHVVQRW
GLIIHUHQWIURPQRQFDOFLILHGOHVLRQV7KHVHUHVXOWVZHUHREWDLQHGDWWKHFRVWRIDPRUHDJJUHVVLYH
OHVLRQSUHSDUDWLRQZLWKDFRQVLGHUDEOHXVHRIURWDWLRQDODWKHUHFWRP\DQGVFRULQJEDOORRQV
6XFKDSSURDFKLVQHHGHGWRIDFLOLWDWHWKHGHOLYHU\RIWKHVFDIIROGJLYHQLWVVOLJKWO\KLJKHUSURILOH
FRPSDUHGZLWKVHFRQGJHQHUDWLRQ'(6,QDGGLWLRQDSSURSULDWHOHVLRQSUHSDUDWLRQFRXOGDYRLG
VFDIIROGXQGHUH[SDQVLRQRUQHHGIRUDJJUHVVLYHSRVWGLODWDWLRQ7KLVVWUDWHJ\FRXOGEHUHOHYDQWDOVR
ZKHQXVLQJPHWDOOLFVWHQWV2XUGDWDPLJKWVXJJHVWIHDVLELOLW\RI%96LPSODQWDWLRQLQFDOFLILHG
YHVVHOVZLWKRSWLPDOUHVXOWVJLYHQDQDGHTXDWHOHVLRQSUHSDUDWLRQ
2QWKHRWKHUKDQGVKRXOGEHPHQWLRQHGWKDWPDQ\RIWKHDGYDQWDJHVSURSRVHGIRU%96QDPHO\WKH
UHVWRUDWLRQRIWKHYDVRPRWLRQDQGYHVVHOSK\VLRORJ\FRXOGEHPLQLPL]HGLQDUWHU\DWDYHU\
DGYDQFHGVWDJHRIWKHDWKHURVFOHURVLVSURFHVVHYHQFRQVLGHULQJWKHIDFWWKDWSDWLHQWVZLWKGLIIXVHG
FDOFLILHGYHVVHOVKDYHDOVRDPXOWLYHVVHOGLVHDVHWKDWPLJKWEHQHILWIURPDWHPSRUDU\LPSODQW
DOORZLQJIXWXUHVXUJLFDOWUHDWPHQWV
7RWDORFFOXVLRQV6XFFHVVIXOUHFDQDOL]DWLRQRIWRWDORFFOXVLRQVKDVEHHQSUHYLRXVO\DVVRFLDWHGZLWK
DVLJQLILFDQWLPSURYHPHQWLQDQJLQDV\PSWRPVDQGFRPSOHWHFRURQDU\UHYDVFXODUL]DWLRQ
ZDVGHPRQVWUDWHGWRKDYHDQLPSRUWDQWLPSDFWRQORQJWHUPFOLQLFDORXWFRPHV
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9HVVHOVZLWKWRWDORFFOXVLRQVKDYHSHFXOLDUFKDUDFWHULVWLFVLQWHUPVRIYDVFXODUUHPRGHOLQJWKLVLVD
G\QDPLFSURFHVVLQYROYLQJUHJXODWLRQRIYDVFXODUFHOOPLJUDWLRQDQGPLWRVLVDQGDSRSWRVLVUDWHVLQ
UHVSRQVHWRVHYHUDOIDFWRUVFRPSULVLQJEORRGIORZDQGSUHVVXUHVKHDUVWUHVVFLUFXPIHUHQWLDOVWUHWFK
DQGZDOOWHQVLRQ5HGXFWLRQRUHYHQPRUHDEVHQFHRIEORRGIORZLQWRWDOO\RFFOXGHGYHVVHOV
PLJKWSURPRWHQHJDWLYHUHPRGHOLQJDQGSODTXHJURZWKRQWKHRWKHUKDQGUHVWRUDWLRQRIIORZFRXOG
KDYHDQRSSRVLWHHIIHFW
5HFHQWO\3DUN--DQGFROOHDJXHVUHSRUWHGDWPRQWKIROORZXSDIWHUVXFFHVVIXOWRWDORFFOXVLRQ
UHYDVFXODUL]DWLRQDIORZGHSHQGHQWYDVFXODUUHPRGHOLQJSURFHVVLQKXPDQFRURQDU\DUWHULHV
DVVRFLDWHGZLWKLQFUHDVHVLQOXPHQGLDPHWHUOXPHQDUHDDQGH[WHUQDOHODVWLFPHPEUDQHDUHD
7KLVSURFHVVZDVREVHUYHGLQDODUJHSDUWRIWUHDWHGYHVVHOVZLWKDPHDQOXPHQGLDPHWHU
LQFUHDVHRIPP,986DQDO\VLVRIWKRVHYHVVHOVUHYHDOHGWKDWWKHDPRXQWRILQFRPSOHWH
VWHQWDSSRVLWLRQLQFUHDVHGVLJQLILFDQWO\GXULQJPRQWKVLQSDWLHQWVZLWKSRVLWLYHUHPRGHOLQJDQG
OXPHQDUHDLQFUHDVHEXWQRWLQWKRVHZLWKRXWOXPHQDUHDLQFUHDVH
,QWKLVVFHQDULRFKRRVLQJDPHWDOVWHQWEDVHGRQWKHYHVVHOGLDPHWHUDWWKHLQGH[SURFHGXUHPLJKW
OHDGWRVWHQWXQGHUVL]LQJ
*LYHQWKLVEDFNJURXQGDWKHRUHWLFDODGYDQWDJHRI%96LPSODQWDWLRQLQSDWLHQWVZLWKWRWDORFFOXVLRQ
LVWKHIDFWWKDWLWPLJKWDOORZDWPLGWHUPIROORZXSDIWHUWKHORVVRIVFDIIROGPHFKDQLFDOLQWHJULW\
ODWHOXPHQHQODUJHPHQWZLWKRXWODWHDFTXLUHGPDODSSRVLWLRQDVDWWKDWWLPHWKHUHPQDQWVRIWKH
ELRUHVRUEDEOHLPSODQWFDQIROORZWKHYHVVHOUHPRGHOLQJ
/RQJOHVLRQVDQGRYHUODS,QWKHSUHVHQWVHULHVVHYHUDOOHVLRQVZHUHWUHDWHGZLWKPRUHWKDQRQH
VFDIIROGXSWRDPD[LPXPRIVFDIIROGVIRUDPD[LPXPOHVLRQOHQJWKRIPP2SHUDWRUVZHUH
DGYLVHGWRPLQLPL]HWKHH[WHQVLRQRIRYHUODSSLQJVHJPHQWXVLQJDPDUNHUWRPDUNHUWHFKQLTXH
,QWKHPHWDOVWHQWHUDORQJVHJPHQWVWUHDWPHQWKDVEHHQDVVRFLDWHGWRDQLQFUHDVHGULVNRIVWHQW
WKURPERVLVDQGFRXOGUHVXOWVLQSUHYHQWLRQRIIXWXUHVXUJLFDOUHYDVFXODULVDWLRQV,QD
MXYHQLOHSRUFLQHPRGHOSDSHUIURP)DURRTRYHUODSSLQJ$EVRUEVFDIIROGVVKRZHGGHOD\HGKHDOLQJ
RQKLVWRORJ\DQG2&7DQGVORZHUWLVVXHFRYHUDJHWKDQLQQRQRYHUODSSLQJVFDIIROGVWKHFRYHUDJH
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RIWKHRYHUODSSLQJVHJPHQWZDVDQGDWDQGGD\VDIWHULPSODQWDWLRQUHVSHFWLYHO\
VXJJHVWLQJWKDWFRPSOHWHFRYHUDJHLQKXPDQVPD\WDNHXSWRPRQWKV
%RWKWKHVHLVVXHVFRXOGEHRYHUFRPHZLWKWKHXVHRIELRUHVRUEDEOHWHFKQRORJLHVDQGWKH
LQWURGXFWLRQLQWKHQHDUIXWXUHRIELRUHVRUEDEOHVFDIIROGZLWKWKLQQHUVWUXWVFRXOGPLWLJDWHWKHHIIHFW
RIRYHUODSRQGHOD\HGYDVFXODUKHDOLQJ
&OLQLFDORXWFRPHV0LGWHUPFOLQLFDORXWFRPHVUHYHDOHGDUHODWLYHO\UHDVVXULQJVDIHW\SURILOHRIWKH
%96ZKHQXVHGLQDODUJHUDQJHRIOHVLRQW\SHDQGLQSDWLHQWVZLWKHLWKHUVWDEOHV\PSWRPVRUDFXWH
FRURQDU\V\QGURPHV5HJDUGLQJWKHRFFXUUHQFHRIVFDIIROGWKURPERVLV67DWYDULDQFHRISUHYLRXV
UHSRUWVQRDFXWHRUVXEDFXWH67VZHUHREVHUYHGLQWKHSUHVHQWLQYHVWLJDWLRQ7KLVGDWXPFRXOGEH
UHODWHGWRSURFHGXUDOFKDUDFWHULVWLFVLQFOXGLQJDPHWLFXORXVOHVLRQSUHSDUDWLRQSUH%96LPSODQWDWLRQ
DQGDQDGYDQFHGVWDJHLQOHDUQLQJFXUYHRIWKHRSHUDWRUVLQWHUPVRI%96LPSODQWDWLRQ
7KHUHYLVLRQRIWKHFDVHVZLWK67UHYHDOHGWKDWVHYHUDOIDFWRUVPLJKWEHDVVRFLDWHGZLWKVXFKHYHQW
FRPSULVLQJVHYHUHOHVLRQFDOFLILFDWLRQWKHSUHVHQFHRIELIXUFDWLRQVORQJRYHUODSDQGDQWLSODWHOHW
WKHUDS\GLVFRQWLQXDWLRQ+RZHYHUWKHIDFWRUWKDWZDVSDUWLFXODUO\FRQVLVWHQWZDVVFDIIROGXQGHU
H[SDQVLRQ3UHYLRXVLQYHVWLJDWLRQVGHVFULEHGVWHQWXQGHUH[SDQVLRQDVDQLPSRUWDQWSUHGLFWRURI67
ZLWKERWKEDUHPHWDOVWHQWVDQG'(6ZLWKDQLPSDFWRQWKHRFFXUUHQFHRI67WKDWZDV
K\SRVWDVL]HGWREHVXSHULRUWRVWHQWPDODSSRVLWLRQ7KHPHFKDQLVPVEHKLQGWKHVHILQGLQJV
FRXOGEHWKHIDFWWKDWVWHQWXQGHUH[SDQVLRQWUDQVODWHVLQWRDQDEQRUPDOVKHDUVWUHVV,QSDUWLFXODU
LQFUHDVHGUDGLDOWUDQVSRUWRIEORRGFRPSRQHQWVDQGORZZDOOVKHDUVWUHVVZHUHGHVFULEHGWR
SURPRWHSODWHOHWGHSHQGHQWWKURPERVLV,QDGGLWLRQWKHLPSDFWRIXQGHUH[SDQVLRQRQVKHDU
VWUHVVFRXOGEHSRWHQWLDWHGE\WKHSUHVHQFHRIWKH%96WKLFNVWUXWV
$OWKRXJKJLYHQWKHVPDOOQXPEHURISDWLHQWVDQGHYHQWUHSRUWHGLQWKHSUHVHQWVWXG\LWLVQRW
SRVVLEOHWRUHDFKILUPFRQFOXVLRQVRXUILQGLQJVVXJJHVWWKDWRSWLPDO%96H[SDQVLRQZLWKOHVLRQ
SUHSDUDWLRQDQGDSSURSULDWHVFDIIROGSRVWGLODWDWLRQVKRXOGEHSXUVXHGJLYHQWKHSRVVLEOHUHOHYDQW
FOLQLFDOLPSOLFDWLRQV

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/LPLWDWLRQV

7KHSUHVHQWUHSRUWLVDQLQYHVWLJDWRULQLWLDWHGVLQJOHFHQWHUVLQJOHDUPVWXG\7KHFKRLFHIRU%96
LPSODQWDWLRQZDVOHIWWRRSHUDWRUGLVFUHWLRQWKLVFRXOGEHVRXUFHRIVHOHFWLRQELDV7KHDEVHQFHRID
FRPSDUDWRUDUPLVOLPLWLQJWKHLQWHUSUHWDWLRQRIRXUGDWD7KHOLPLWHGQXPEHURISDWLHQWVGRHVQRW
DOORZUHDFKLQJILUPFRQFOXVLRQVRQFOLQLFDORXWFRPHV7KHVKRUWIROORZXSLVSUHYHQWLQJWKH
DYDLODELOLW\RILQIRUPDWLRQRQORQJWHUPVDIHW\DQGHIILFDF\



&RQFOXVLRQ

7KHLPSODQWDWLRQRIWKHHYHUROLPXVHOXWLQJELRUHVRUEDEOHYDVFXODUVFDIIROGLQDQH[SDQGHGUDQJHRI
FRURQDU\OHVLRQW\SHVDQGFOLQLFDOSUHVHQWDWLRQVZDVREVHUYHGWREHVDIHDQGIHDVLEOH/DUJHUVWXGLHV
ZLWKORQJHUIROORZXSDQGDGLUHFWFRPSDULVRQZLWKFXUUHQWO\DYDLODEOHPHWDOOLFGUXJHOXWLQJVWHQWV
DUHQHHGHGWRIXOO\HYDOXDWHWKHSRVVLEOHDGGLWLRQDOYDOXHRIWKHELRUHVRUEDEOHWHFKQRORJLHVDQDOO
FRPHUVVHWWLQJ

$FNQRZOHGJPHQWV
7KLVVWXG\ZDVVXSSRUWHGE\DQXQUHVWULFWHGJUDQWIURP$EERWW9DVFXODU
7KHDXWKRUVZDQWWRWKDQN,VDEHOOD.DUGLMV-RKDQQHV6FKDDUDQG0DUWLMQ$NNHUKXLVIRUWKHLU
FRQWULEXWLRQLQWKHHYHQWDGMXGLFDWLRQ


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7DEOH
%DVHOLQHFOLQLFDOFKDUDFWHULVWLFV

&OLQLFDOFKDUDFWHULVWLFV 1 
$JH 
0DOHQ 
+\SHUWHQVLRQQ 
+\SHUFKROHVWHUROHPLDQ 
'LDEHWHVQ 
,QVXOLQGHSHQGHQWQ 
6PRNHQ 
3HULSKHUDOYDVFXODUGLVHDVHQ 
&9$Q 
.LGQH\GLVHDVHQ 
3ULRU0,Q 
3ULRU3&,Q 
3ULRU*$%*Q 
&23'Q 
+LVWRU\RIKHDUWIDLOXUHQ 
&9$ FHUHEURYDVFXODUDFFLGHQW3&, SHUFXWDQHRXVFRURQDU\LQWHUYHQWLRQ&$%* FRURQDU\DUWHU\E\SDVVJUDIW
&23' FKURQLFREVWUXFWLYHSXOPRQDU\GLVHDVH'DWDDUHH[SUHVVHGDVPHDQVWDQGDUGGHYLDWLRQRUQXPEHUDQG
SURSRUWLRQ
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7DEOH
/HVLRQFKDUDFWHULVWLFV

/HVLRQFKDUDFWHULVWLFV 1 / 
1XPEHURI'LVHDVHG9HVVHO 
2QHYHVVHOGLVHDVH 
7ZRYHVVHOGLVHDVH 
7KUHHYHVVHOGLVHDVH 
1XPEHURI7UHDWHG/HVLRQVSHUYHVVHO 
OHVLRQ 
OHVLRQ 
OHVLRQV 
OHVLRQV 
OHVLRQV 
/HVLRQ/RFDWLRQ 
/$' 
/&; 
5&$ 
',$*21$/ 
/0&$5DPXV 
$+$$&&/HVLRQ&ODVVLILFDWLRQ 
$ 
% 
% 
& 
/HVLRQ/HQJWKPP 
5DQJHPLQPD[PP 
%LIXUFDWLRQ/HVLRQQ 
7RWDO2FFOXVLRQ 
&DOFLILFDWLRQ/HVLRQ 
'DWDDUHH[SUHVVHGDVPHDQVWDQGDUGGHYLDWLRQRUQXPEHUDQGSURSRUWLRQ
 
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7DEOH
3URFHGXUDOGDWDSHUOHVLRQDQDO\VLV

/HVLRQFKDUDFWHULVWLFV / 
1XPEHURI6FDIIROGRUVWHQW–SHUOHVLRQ 
$YHUDJH 
VFDIIROGRUVWHQW 
VFDIIROGRUVWHQW 
VFDIIROGVRUVWHQWV 
VFDIIROGVRUVWHQWV 
VFDIIROGVRUVWHQWV 
VFDIIROGVRUVWHQWV 
2YHUODSSLQJ 
2YHUODSSLQJ%96%96 
2YHUODSVFDIIROGVGLDPHWHUVPPPPQ 
2YHUODSVFDIIROGVGLDPHWHUVPPPPQ 
2YHUODSVFDIIROGVGLDPHWHUVPPPPQ 
2YHUODSVFDIIROGVGLDPHWHUVPPPPQ 
2YHUODSVFDIIROGVGLDPHWHUVPPPPQ 
2YHUODSVFDIIROGVGLDPHWHUVPPPPQ 
2YHUODSSLQJ%960HWDO 
%DLORXWVFDIIROGVWHQW–SHUOHVLRQ 
ZLWK%96 
ZLWK0HWDOOLFVWHQW 
3UHGLODWDWLRQ 
7\SHRISUHGLODWDWLRQEDOORRQ 
1RQFRPSOLDQW 
6HPLFRPSOLDQW 
7KHXVDJHRIVFRULQJVFRUHIOH[RUFXWWLQJ 
$YHUDJHVL]HRIEDOORRQ 
%DOORRQDUWHU\SUH59'5DWLRH[FOXGLQJ
WRWDORFFOXVLRQEHIRUHSURFHGXUH

Balloon / scaffold ratio 1 
Balloon 0.5mm smaller  scaffold size 
0D[SUHVVXUH 
8VHRIRWKHUGHYLFHVIRUOHVLRQSUHSDUDWLRQ 
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5RWDWLRQDO$WKHUHFWRP\ 
0DQXDO7KURPEHFWRP\ 
'DXJKWHU&DWKHWHU 
%XGG\ZLUH 
3RVWGLODWDWLRQ 
7\SHRISRVWGLODWDWLRQEDOORRQ 
&RPSOLDQW 
1RQFRPSOLDQW 
$YHUDJHVL]HRIEDOORRQ PP
0D[SUHVVXUH 
%DOORRQ$UWHU\ 
%DOORRQ!6FDIIROGVL]H 
%DOORRQ!6FDIIROGVL]HPP 
'HYLFH6XFFHVVSHUOHVLRQ 
3URFHGXUH6XFFHVVSHUOHVLRQ 
&OLQLFDO6XFFHVVSHUOHVLRQ 
7\SHRISUHGLODWDWLRQEDOORRQLVUHSRUWHGLQDVXEJURXSRISDWLHQWV7\SHRISRVGLODWDWLRQEDOORRQLVUHSRUWHGLQ
DVXEJURXSRISDWLHQWV'DWDDUHH[SUHVVHGDVPHDQVWDQGDUGGHYLDWLRQRUQXPEHUDQGSURSRUWLRQ

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 Occluded(L =29)
Nonoccluded
(L  = 220)
P value
QCA postprocedure    
RVD (mm) 3.01 ± 0.47 2.88 ± 0.41 0.103
MLD (mm) 2.51 ± 0.53 2.40 ± 0.39 0.163
% DS (%) 17.2 ± 9.4 17.7 ± 8.6 0.780
Acute gain (mm)  1.51 ± 0.49 
Procedural characteristics   
Daughter catheter, % (n) 3.4%(1/29) 1.8% (4/220) 0.465
Buddy wire, % (n)  10.3%(3/29) 6.8% (15/220) 0.449
Type of first wire (after recanalization)   
Supportive 54.2% (13/24) 2.1%(4/195) <0.001
Nonsupportive 45.8% (11/24) 97.9% (191/195) <0.001
Device Success after disobstruction per 
lesion, % (n) 100%(29/29) 99.1%(218/220) 1.0
Procedure Success after disobstruction 
per lesion, % (n) 100% (29/29) 98.6% (217/220) 1.0
Clinical Success after disobstruction per 
lesion, % (n) 100% (29/29) 98.6% (217/220) 1.0
'DWDDUHH[SUHVVHGDVPHDQVWDQGDUGGHYLDWLRQRUQXPEHUDQGSURSRUWLRQ
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Abstract
Aims: Bioresorbable scaffolds are increasingly used in patients with coronary artery disease undergoing per-
cutaneous coronary interventions. ABSORB EXTEND is an ongoing study that will recruit 800 patients. This 
report evaluates acute and late scaffold failure in the first 450 patients enrolled in ABSORB EXTEND who 
have completed 12 months follow-up.
Methods and results: Clinical event data from the first 450 patients enrolled in ABSORB EXTEND have 
demonstrated low rates of ischaemia-driven MACE (4.2%) and target vessel failure (4.7%) at 12 months. 
There have been seven cases of device failure in this study: three cases of scaffold dislodgement (0.67%) and 
four cases of subacute or late scaffold thrombosis (0.89%). All scaffold dislodgements occurred in the left 
circumflex (LCX), and in two cases dislodgement was observed after reinsertion of the same device. Two 
cases of subacute scaffold thrombosis and two late scaffold thromboses were observed. Two out of four cases 
of scaffold thrombosis seemed to be related to either premature discontinuation of dual antiplatelet therapy 
(DAPT) or resistance to clopidogrel.
Conclusions: This is the first report specifically describing the incidence and the potential mechanisms of 
scaffold dislodgement and scaffold thrombosis as seen in the ABSORB EXTEND trial.
KEYWORDS
• bioresorbable 
scaffold
• scaffold 
dislodgement
• scaffold thrombosis
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Introduction
Acute vessel closure, due to dislodgement of a coronary stent dur-
ing deployment or an early stent thrombosis, is a rare but poten-
tially fatal complication of percutaneous coronary intervention 
(PCI)1. Late or very late thrombosis also remains a long-term con-
cern with metallic drug-eluting stents, due to delayed healing 
potentially caused by the permanent presence of foreign bodies 
such as metals and coating materials1-4.
The Absorb everolimus-eluting poly-L-lactic acid (PLLA) biore-
sorbable vascular scaffold system (BVS; Abbott Vascular, Santa Clara, 
CA, USA) is a novel approach to treat coronary lesions5-8. After com-
plete bioresorption of the polymeric struts8, the risk of very late scaf-
fold thrombosis may theoretically be reduced due to the absence of 
foreign material9,10. On the other hand, the thick polymeric struts (total 
strut thickness 156 ȝm) crimped onto the delivery balloon contribute 
to the large profile of the device that may cause friction between the 
device and the diseased vessel wall or any daughter catheter, resulting 
in dislodgement of the scaffold10. Until now, however, there have been 
no specific reports of these acute and late complications with the 
Absorb BVS beyond anecdotal presentations of isolated cases.
ABSORB EXTEND (unique identifier NCT01023789) is an 
international prospective, single-arm study that will recruit 800 
patients with long lesions (length up to 28 mm) or lesions in small 
vessels (2.0-3.8 mm diameter). Treatment of two de novo native 
coronary artery lesions is also permitted when each lesion is located 
in a different epicardial vessel. The details of the trial are described 
in the previous report11.
The first 450 patients enrolled in ABSORB EXTEND have com-
pleted 12 months follow-up and this interim report presents seven 
cases of device failure detected in this population. Three cases of 
scaffold dislodgement (0.67%) and four cases of subacute or late 
scaffold thrombosis (0.89%) are described in detail to evaluate the 
underlying mechanisms and to make some practical recommenda-
tions to avoid these serious complications.
Case descriptions
CASE 1. SCAFFOLD DISLODGEMENT SUBSEQUENTLY 
CRUSHED BY METALLIC STENTS
In a 74-year-old man coronary angiography showed a severe 
lesion with a percentage diameter stenosis (DS) of 83% (Table 1) 
in the mid segment of a calcified left circumflex (LCX) coronary 
artery (Figure 1A). After the first predilatation with a 2.5×15 mm 
balloon, a 3.0×18 mm Absorb BVS failed to cross the tortuous 
proximal LCX. After the second dilatation, the same Absorb scaf-
fold was reinserted (time between the first and second insertion 
of the scaffold is unknown). However, the same Absorb scaf-
fold still failed to cross and unexpectedly dislodged from the bal-
loon at a site of fluoroscopic calcification proximal to the lesion 
when the device was pushed forward (Figure 1B, Figure 1C). Two 
3.0×18 mm metallic everolimus-eluting metallic stents (EES) 
were deployed in an overlapping fashion to crush the dislodged 
scaffold against the vessel wall, and an additional 3.0×18 mm 
EES was deployed at the target lesion (Figure 1D). The follow-up 
was uneventful during 12 months.
Figure 1. Case 1. A) Coronary angiography showing a severe lesion in the mid segment of a calcified left circumflex (LCX) coronary artery. B) & 
C) The same Absorb scaffold still failed to cross and unexpectedly dislodged. D) Two metallic everolimus-eluting metallic stents (EES) were 
deployed in an overlapping fashion to crush the dislodged scaffold against the vessel wall, and an additional EES was deployed at the target lesion.
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CASE 2. A DISLODGED SCAFFOLD LEFT INSIDE 
A PREVIOUSLY IMPLANTED METALLIC STENT
In a 60-year-old man diagnostic coronary angiography showed 
a moderate stenosis (Table 1) in the mid segment of a highly tor-
tuous LCX. Two metallic stents had previously been implanted in 
the left anterior descending coronary artery (LAD) and it seemed 
that the proximal stent had partially jailed the ostium of the 
LCX (Figure 2A). After predilation using a 2.5×15 mm balloon, 
a 3.0×18 mm Absorb BVS was advanced beyond the ostium of the 
LCX, but it failed to progress into the proximal LCX despite the use 
of an extra support guidewire (Figure 2B). While the Absorb BVS 
delivery system and extra support guidewire were being withdrawn, 
the Absorb scaffold unexpectedly dislodged from the balloon and 
became positioned with its distal edge in the proximal LCX and its 
proximal edge in the LMS (Figure 2C). An attempt to retrieve the 
dislodged scaffold was made with a GooseNeck® snare (ev3 Inc., 
Plymouth, MN, USA). However, it failed as the dislodged scaffold 
was inadvertently pushed into the metallic stent located in the prox-
imal LAD. Following this, another guidewire was inserted into the 
LAD and a second attempt was made to retrieve the dislodged scaf-
fold using the GooseNeck snare, but it failed again. A balloon was 
Table 1. QCA analysis before and after the procedure in all cases.
Case No.
MLD, 
mm
RVD, 
mm
DS, 
%
Obstruction 
length, mm
Curvature,  
cm–1
Angulation, 
degree
before procedure
1 0.37 2.24 83 13.97 0.439 32.6
2 0.98 2.57 62 7.78 0.436 47.4
3 0.91 2.41 62 9.30 0.421 54.9
4 0.91 2.59 65 9.10 0.116 20.5
5 0.74 2.88 74 12.37 0.353 23.8
6 1.00 2.54 61 18.13 0.233 21.4
7 0.88 2.28 61 8.65 0.147 19.7
after procedure
1 2.16 2.39 11 – 0.413 25.6
2 2.60 2.74   5 – 0.305 40.5
3 2.30 2.46   7 – 0.418 44.8
4 2.03 2.79 27 – 0.118 19.2
5 3.07 3.13   2 – 0.293 21.5
6 2.12 2.44 13 – 0.225 18.7
7 2.02 2.38 15 – 0.144 19.5
DS: diameter stenosis; MLD: minimal lumen diameter; QCA: quantitative coronary 
angiography; RVD: reference vessel diameter
Figure 2. Case 2. A) Coronary angiography showing a moderate stenosis in the mid segment of a highly tortuous LCX. Two metallic stents 
had previously been implanted in the left anterior descending coronary artery (LAD) and it seemed that the proximal stent had partially jailed 
the ostium of the LCX. B) An Absorb BVS was advanced beyond the ostium of the LCX, but it failed to progress. C) The Absorb scaffold 
unexpectedly dislodged and became positioned with its distal edge in the proximal LCX and its proximal edge in the left main stem (LMS). 
D1) A balloon was then inflated to crush the dislodged scaffold in the proximal LAD. D2) An EES was successfully deployed at the target 
lesion. E) Final result. F1) & F2) Five months later, coronary angiography revealed a severe stenosis in the proximal LAD and LCX.
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then inflated to crush the dislodged scaffold in the proximal LAD 
and finally an EES was successfully deployed at the target lesion 
(Figure 2D, Figure 2E). Five months later, coronary angiography 
revealed a severe stenosis in the proximal LAD and proximal LCX 
(Figure 2F), and the patient was referred for surgical treatment.
CASE 3. SCAFFOLD DISLODGEMENT DUE TO A TORTUOUS 
VESSEL
A 61-year-old male underwent coronary angiography which 
showed a moderate stenosis (Table 1) in the mid segment of a calci-
fied LCX (Figure 3A). After the first predilatation with a 2.5×15 mm 
balloon, a 3.0×18 mm Absorb BVS failed to cross the lesion. After 
two additional predilatations with a 3.0×15 mm balloon, the same 
Absorb BVS system was reinserted, but it was unable to pass 
a moderate bend in the LCX proximal to the predilated lesion. 
Another attempt was made to deliver the scaffold using 
a GuideLiner™ catheter (Vascular Solutions Inc., Minneapolis, 
MN, USA) and the scaffold delivery system was apparently posi-
tioned at the target lesion (Figure 3B1). However, after balloon 
inflation, the radiopaque markers at the edges of the scaffold were 
not visible on fluoroscopy (Figure 3B1, Figure 3B2). When the 
GuideLiner™, guidewire and the Absorb BVS delivery system 
were removed together as a single unit, the dislodged scaffold was 
found to be inside the GuideLiner™. Following this, a 2.75×18 mm 
EES was successfully deployed at the target lesion without any fur-
ther procedural complications (Figure 3C). The patient had an une-
ventful clinical course and was discharged two days after the 
procedure. Approximately three months after the procedure, the 
patient passed away at home (unwitnessed sudden death). This 
event was adjudicated as a possible stent thrombosis by the clinical 
events committee of the ABSORB EXTEND trial.
CASE 4. SUBACUTE SCAFFOLD THROMBOSIS AT THE SITE 
OF OVERLAPPING SCAFFOLDS
In a 56-year-old man coronary angiography showed a moderate ste-
nosis (Table 1) in the proximal segment of the LCX (Figure 4A1, 
Figure 4A2). After predilatation, a 3.0×28 mm Absorb scaffold 
failed to be delivered. Two additional predilatations were per-
formed and the same Absorb BVS system was reinserted over an 
extra support guidewire (ASAHI GRAND SLAM™; Abbott 
Vascular, Santa Clara, CA, USA), but was unable to cross. A proxi-
mal scaffold deformation was observed (post-withdrawal observa-
tion) after having retracted the Absorb BVS system and the 
guidewire. Following this, two 3.0×18 mm Absorb BVS were suc-
cessfully deployed (Figure 4B, Figure 4C). The distance between 
the scaffold radiopaque markers in the overlapping segment was 
2.56 mm as measured by QCA.
Six days after the procedure the patient presented with a non-
STEMI and was treated with thrombolytic therapy. Angiography on 
day seven revealed a thrombotic lesion at the site of the overlapping 
scaffolds in the mid segment of the LCX (Figure 4D1, Figure 4D2). 
The patient claimed to be fully compliant with dual antiplatelet ther-
apy (DAPT). An EES was successfully implanted to cover the lesion 
and the overlapping segment of the scaffolds (Figure 4E, Figure 4F).
Figure 3. Case 3. A) Coronary angiography showing a moderate stenosis in the mid segment of a calcified LCX. B1) The scaffold delivery 
system was apparently positioned at the target lesion. B2) When the GuideLiner™ system was removed together as a single unit, the dislodged 
scaffold was found to be inside the GuideLiner™. C) An EES was successfully deployed at the target lesion.
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CASE 5. SUBACUTE SCAFFOLD THROMBOSIS OCCURRING 
TWO DAYS AFTER DISCONTINUATION OF DAPT
A 58-year-old woman underwent PCI with a 3.0×18 mm Absorb 
BVS in the mid segment of the LAD (Figure 5A, Figure 5B). On 
day 27, the patient stopped taking both aspirin and clopidogrel. Two 
days after DAPT discontinuation, she presented with a non-STEMI 
and was treated by thrombolysis. On day 32, coronary angiography 
showed a patent LAD with haziness (Figure 5C, Figure 5D). DAPT 
was restarted and follow-up was uneventful.
CASE 6. LATE SCAFFOLD THROMBOSIS IN A PATIENT WITH 
RESISTANCE TO CLOPIDOGREL
An 80-year-old woman underwent PCI with a 3.0×18 mm Absorb 
BVS for a moderate stenosis (Table 1) in the mid segment of the 
LAD (Figure 6A-Figure 6C).
Seventy-five days after the index procedure, she presented with 
an acute anterior STEMI. Coronary angiography showed complete 
thrombotic occlusion of the LAD proximal to the scaffold up to the 
take-off of a diagonal branch (Figure 6D). Primary PCI with a man-
ual thrombectomy and a balloon dilatation was successfully per-
formed (Figure 6E-Figure 6G). At the time of the emergency 
procedure, the patient reported that she was scrupulously taking her 
Figure 4. Case 4. A1) & A2) Coronary angiography showing a moderate stenosis in the proximal segment of the LCX. B1) & B2) Two Absorb 
BVS were successfully deployed. C1) & C2) Final results. D1) & D2) Angiography on day seven revealed a thrombotic lesion at the site of the 
overlapping scaffolds in the mid segment of the LCX. E1), E2) & F) An EES was successfully implanted to cover the lesion and the 
overlapping segment.
Figure 5. Case 5. A) Coronary angiography showing a moderate 
stenosis in the proximal segment of the LAD. B) An Absorb BVS was 
successfully deployed at the target lesion. C) & D) On day 32, 
coronary angiography showed a patent LAD with haziness.
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DAPT. However, the platelet aggregation test indicated that she 
was either not on DAPT or resistant to clopidogrel, since her ADP-
induced aggregation of platelets was normal. The patient claimed to 
be fully compliant with DAPT and hence a higher dose of clopi-
dogrel (150 mg daily) was prescribed to prevent further scaffold 
thrombosis. The follow-up was uneventful.
CASE 7. LATE SCAFFOLD THROMBOSIS OF UNKNOWN CAUSE
A 56-year-old man with dyslipidaemia, a family history of coronary 
artery disease (CAD) and angina class II underwent PCI with 
a 3.0×18 mm Absorb BVS in the mid segment of the LAD (Figure 
7A, Figure 7B). After Absorb BVS implantation, post-dilation was 
performed with a 3.0×9.0 mm balloon (non-compliant balloon) at 
maximal pressure of 16 atm (rated balloon pressure: 18 atm).
At day 239, following a bee sting, he presented with an acute ante-
rior STEMI. The patient was still on DAPT at that time. Urgent coro-
nary angiography revealed total occlusion of the LAD, proximal to the 
previously implanted Absorb scaffold (Figure 7C). Following manual 
thrombectomy, an EES was successfully deployed (Figure 7D).
Discussion
The main findings of the current report are the following: 1) in the 
first 450 patients enrolled in the ABSORB EXTEND trial, scaffold 
dislodgement occurred in three cases; 2) all dislodgements occurred 
Figure 6 Case 6. A) Coronary angiography showing a moderate stenosis in the mid segment of the LAD. B) & C) An Absorb BVS was 
successfully deployed at the target lesion. D) Coronary angiography showed complete thrombotic occlusion of the LAD. E) Primary PCI with 
a manual thrombectomy was performed. F1) & F2) Coronary angiography showed a patent LAD with haziness after thrombectomy. G) 
Coronary angiography showed a patent LAD without haziness after balloon dilatation.
Figure 7. Case 7. A) Coronary angiography showing a moderate 
stenosis in the mid segment of the LAD. B) An Absorb BVS was 
successfully deployed at the target lesion. C) At day 239, coronary 
angiography revealed a total occlusion of the LAD, proximal to the 
preciously implanted Absorb scaffold. D) Following manual 
thrombectomy, an EES was successfully deployed.
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in the LCX, and in two cases dislodgement was observed after rein-
sertion of the same device; 3) two subacute scaffold thromboses 
and two late scaffold thromboses were observed; 4) two scaffold 
thromboses seemed to be related to either premature discontinua-
tion of DAPT or resistance to clopidogrel.
SCAFFOLD DISLODGEMENT
Dislodgement of a metallic stent from the delivery balloon during 
deployment is a rare complication, reported in 0.32-1.2% of proce-
dures in the early 2000s12. Metallic stent dislodgement from the 
delivery system occurs most often when the stent balloon device is 
pulled back into the guiding catheter, because the target lesion can-
not be either reached or crossed despite a forceful pushing manoeu-
vre13-15. Risk factors for stent dislodgement include severe coronary 
angulations, coronary tortuosity, diffuse long lesions and calcified 
lesions. In addition, stent dislodgement has been reported to be the 
highest in the LMS or LAD16.
In the current series which included relatively simple lesions 
(mean lesion length: 11.6 mm, type B2/C lesions according to the 
American College of Cardiology/American Heart Association: 
38.6%, calcification: 13.2%), scaffold dislodgement was observed 
in 0.67% (3/450). All cases of dislodgement occurred in the LCX 
(mean baseline vessel angulation: 45.0 degrees; mean baseline ves-
sel curvature: 0.432 cm–1). One scaffold was dislodged when the 
crimped scaffold was retracted after the delivery failure of the 
device, one was dislodged from the balloon when the device was 
advanced through a 6 Fr daughter catheter, and one was observed 
after crossing the ostium of the LCX jailed by a metallic stent previ-
ously implanted in the LAD. Of these three cases, two scaffold dis-
lodgements occurred when the same scaffolds were reinserted after 
failed delivery attempts.
The Absorb BVS has a crossing profile of 1.4 mm with a strut 
thickness of 156 ȝm, and consists of in-phase zigzag hoops linked 
by straight bridges17. Alternative processing techniques have been 
developed to enhance polymeric scaffold retention, and bench-top 
testing indicates retention forces equivalent to those observed 
with metallic stents. However, these thick polymeric struts with 
a large crossing profile may contribute to friction between the 
device and a tortuous/calcified vessel or a daughter catheter, 
resulting in device dislodgement when forcefully pushing the 
scaffold10. In case 3, a 6 Fr GuideLiner™ with a 6 Fr guiding cath-
eter was used, which was not compatible with the current version 
of the Absorb scaffold. Usage of the 6 Fr GuideLiner™ system 
should be avoided.
The risk of scaffold dislodgement may increase with the combi-
nation of several factors, including tortuous and calcified vessels 
proximal to the target lesion, prolonged exposure to moisture dur-
ing repeated removal and reinsertion of a scaffold, and friction 
against a tightly fitting delivery catheter (such as the GuideLiner™) 
where enough dimensional clearance for the scaffold is not assured. 
To prevent scaffold dislodgement, it is recommended to avoid pro-
longed contact with moisture in the setting of repeated removal and 
reinsertion of the same device after a failed delivery. It would be 
advisable to use a new scaffold in such a situation. In the case of 
heavily calcified lesions, optimal lesion preparation using cutting/
scoring balloons or rotational atherectomy should be considered 
before implantation of the Absorb BVS.
If dislodgement of a device occurs, prompt recognition and an 
attempt at percutaneous retrieval using a snare system or a multi-
wire technique is advisable. If the retrieval manoeuvres are not 
technically feasible or fail, the dislodged scaffold could be crushed 
against the arterial wall by implantation of a metallic stent. In this 
case, however, the operator should be aware that the crushed poly-
meric scaffold will result in a circular and non-laminated structure 
as seen with crushed metallic stents.
SCAFFOLD THROMBOSIS
Metallic stent thrombosis is multifactorial, including procedure-
related factors such as underexpansion, multiple stent use, dissec-
tions, and late acquired stent malapposition due to resolution of 
thrombus on the vessel wall or abnormal vessel healing1-4,18.
In the current series, two subacute and two late scaffold thrombo-
ses were observed (0.89%). Acutely after implantation, PLLA poly-
mer is, at least in vitro, somewhat less thrombogenic than a metal 
without a coating19. In the blood flow, however, the presence of 
thick struts creates alteration of shear stress, resulting in high shear 
stress on top of the strut and low shear stress behind the strut which 
may trigger platelet aggregation20. Preclinical reports have demon-
strated that metallic stents with the thinner struts are less throm-
bogenic21,22. During the acute/subacute phase after implantation of 
an Absorb scaffold, efficient platelet inhibition is mandatory22. The 
optimal duration of DAPT after implantation of Absorb scaffolds 
has not been investigated. In a porcine coronary angioplasty model, 
the polymeric struts were associated with lesser granuloma for-
mation than the first-generation sirolimus-eluting stents, suggest-
ing that the bioresorption process does not provoke any significant 
inflammation. In the ABSORB Cohort B trial, tissue coverage as 
assessed by optical coherence tomography (OCT) was almost com-
plete (97%) at six months5. The optimal duration of DAPT after 
implantation of Absorb scaffolds has not been investigated. The 
protocols of previous ABSORB trials mandated at least six months 
of DAPT. It is noteworthy that the mean duration of DAPT was 
403 days in the ABSORB Cohort B trial5. Given the paucity of data, 
the optimal duration of DAPT should be prospectively assessed in 
future studies.
In the present series, late scaffold thrombosis occurred in one case 
with overlapping Absorb scaffolds. In a juvenile porcine model, the 
overlapping Absorb scaffolds showed delayed healing and slower tis-
sue coverage than in non-overlapping scaffolds23: the coverage of the 
overlapping segment was 80.1% and 99.5% at 28 and 90 days after 
implantation, respectively, suggesting that complete coverage in 
humans may take up to 18 months4. In case of overlapping scaffolds, 
a relatively longer duration of DAPT with more potent agents (e.g., 
ticagrelor or prasugrel) could be considered.
One late scaffold thrombosis occurred following a bee sting. The 
mechanism responsible for STEMI in this patient could have been 
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coronary artery spasm (partly mediated by psychological stress 
related to the intensity of the anaphylactic reaction) with thrombo-
sis secondary to cardiovascular collapse24. However, the precise 
mechanism of scaffold thrombosis in this case remains uncertain.
Conclusion
This is the first report specifically describing the incidence and the 
potential mechanisms of scaffold dislodgement and scaffold throm-
bosis seen in the ABSORB EXTEND trial. To avoid scaffold dis-
lodgement, appropriate lesion preparation is mandatory. In case of 
unsuccessful initial delivery, a second insertion of the same scaf-
fold should be avoided. Adherence to antiplatelet therapy is of para-
mount importance to avoid acute or subacute scaffold thrombosis.
Impact on daily practice
Bioresorbable scaffolds are increasingly used in patients with 
coronary artery disease undergoing percutaneous coronary inter-
ventions; however, the early clinical experiences in the ABSORB 
EXTEND trial (n=450) demonstrated scaffold dislodgement in 
0.67% and scaffold thrombosis in 0.89% of cases. To avoid scaf-
fold dislodgement, appropriate lesion preparation is mandatory 
and a second insertion of the same scaffold should be avoided. 
Adherence to the antiplatelet therapy is of paramount impor-
tance to avoid acute or subacute scaffold thrombosis.
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Table 1. The rate of ST in individual populations*.
Study (journal/
international congress)
Popula-
tion
Follow-
up
Total, 
N
Acute ST 
in total, 
N (%)
Subacute 
ST in 
total, 
N (%)
Early ST
in total, 
N (%)
ST in
total, 
N (%)
SAP, 
N
ST in
SAP,
N (%)
ACS, 
N
ST in ACS, 
N (%)
STEMI, 
N
ST in 
STEMI, 
N (%)
Kraak et al, AMC single-centre (EIJ 2014) All-comers 6 mo 135 0 (0%) 3 (2.2%) 3 (2.2%) 4 (3.0%) 82 1 (1.2%) 53 3 (5.7%) 17 0 (0%)
ABSORB FIRST, (EuroPCR 2014) All-comers 1 mo 800 0 (0%) 2 (0.3%) 2 (0.3%) 2 (0.3%) 295 N/A 505 N/A N/A N/A
Azzalini et al, (EuroPCR 2014) All-comers N/A 339 0 (0%) 4 (1.2%) 4 (1.2%) 4 (1.2%) N/A 3 (N/A) N/A 0 (N/A) N/A 1 (N/A)
Abizaid et al, ABSORB EXTEND (EIJ 2014) SAP 12 mo 512 0 (0%) 2 (0.4%) 2 (0.4%) 4 (0.8%) 512 4 (0.8%) – – – –
Serruys et al, ABSORB B (EIJ 2014) SAP 36 mo 101 0 (0%) 0 (0%) 0 (0%) 0 (0%) 101 0 (0%) – – – –
Onuma et al, ABSORB A (JACC CI 2013) SAP 60 mo 30 0 (0%) 0 (0%) 0 (0%) 0 (0%) 30 0 (0%) – – – –
CORONARY CTO (EuroPCR 2014) SAP 6 mo 35 0 (0%) 0 (0%) 0 (0%) 0 (0%) 35 0 (0%) – – – –
Serruys et al, ABSORB II (Lancet 2014) SAP/UAP 12 mo 335 1 (0.3%) 1 (0.3%) 2 (0.6%) 3 (0.9%) 267 3 (1.1%) 68 0 (0%) – –
ASSURE registry (EuroPCR 2014) SAP/UAP 12 mo 183 0 (0%) 0 (0%) 0 (0%) 0 (0%) 144 0 (0%) 39 0 (0%) – –
BVS EXPAND (EuroPCR 2014) SAP/UAP 6 mo 200 0 (0%) 0 (0%) 0 (0%) 4 (2.2%) N/A N/A N/A N/A – –
Gori et al (EIJ 2014) ACS 1 mo 150 1 (0.7%) 1 (0.7%) 2 (1.4%) 4 (2.7%) – – 150 4 (2.7%) 66 N/A
POLAR ACS (EuroPCR 2014) ACS 12 mo 100 0 (0%) 0 (0%) 0 (0%) 0 (0%) – – 100 0 (0%) 16 0 (0%)
Kajiya et al (EIJ 2013) STEMI 3 mo 11 0 (0%) 0 (0%) 0 (0%) 0 (0%) – – – – 11 0 (0%)
Diletti et al, BVS STEMI (EHJ 2014) STEMI 1 mo 49 0 (0%) 0 (0%) 0 (0%) 0 (0%) – – – – 49 0 (0%)
Kocka et al, PRAGUE-19 (EHJ 2014) STEMI 4 mo 41 0 (0%) 1 (2.4%) 1 (2.4%) 1 (2.4%) – – – – 41 1 (2.4%)
Wiebe et al (CRC 2014) STEMI 6 mo 25 0 (0%) 0 (0%) 0 (0%) 0 (0%) – – – – 25 0 (0%)
Ielasi et al, RAI registry (EIJ in press) STEMI 6 mo 74 0 (0%) 1 (1.4%) 1 (1.4%) 1 (1.4%) – – – – 74 1 (1.4%)
Weighted average excluding the 
GHOST-EU registry
Average F/U: 
10.6 months
3,120 0.06% 0.48% 0.54% 0.89% 1,171 0.68% 410 1.71% 299 0.67%
Capodanno et al, GHOST (EIJ 2014) All-comers 6 mo 1,189 5 (0.4%) 11 (0.9%) 16 (1.3%) 23 (2.1%) 626 9 (1.4%) 563 14 (2.5%) 192 4 (2.1%)
Weighted average including the 
GHOST-EU registry
Average F/U: 
10.3 months
4,309 0.16% 0.60% 0.76% 1.22% 1,797 0.94% 973 2.16% 491 1.22%
*ACS: acute coronary syndrome; SAP: stable/silent angina pectoris; ST: scaffold thrombosis; STEMI: ST-segment elevation myocardial infarction. CRC: Clinical Research in Cardiology; 
EHJ: European Heart Journal; EIJ: EuroIntervention; JACC CI: JACC Cardiovascular Interventions
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2.3  Early and late scaffold restenosis 
 
Early (before 6 months), late (6-12 months) and very late (after 12 
months) angiographic scaffold restenosis in the ABSORB Cohort B 
trial. 
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Abstract
Aims: The long-term follow-up of the first-in-man ABSORB Cohort B trial showed that angiographic binary 
restenosis can occur early, late or very late after implantation of the Absorb everolimus-eluting bioresorbable 
vascular scaffold (Absorb BVS). Since the mechanical support of the scaffold decreases during bioresorption, 
the mechanism of in-segment restenosis (ISR) of the Absorb BVS might be different from that of metallic 
stents. The objective of the current analysis was to review the multimodality imaging of cases with binary 
restenosis to elucidate the mechanism of ISR after Absorb BVS implantation.
Methods and results: The ABSORB Cohort B trial enrolled 101 patients with a maximum of two de novo 
coronary lesions. At the three-year imaging and clinical follow-up, there were six cases of in-segment binary 
restenosis: two early ISR (<6 months), one late ISR (6-12 months) and three very late ISR (>12 months). 
Three of these ISR cases seemed to be induced by anatomical or procedural factors. In the other three cases, 
intravascular imaging (IVUS/OCT) demonstrated that the main mechanism of restenosis was significant 
intra-scaffold tissue growth, while the structural circularity and diameter of the scaffold were not affected.
Conclusions: Early and late restenosis after implantation of the Absorb bioresorbable scaffold could be 
related to anatomical or procedural factors. In this small cohort of patients late or very late restenosis seems 
to be attributed to pure intra-scaffold tissue growth without extrinsic encroachment of the scaffold.
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• bioresorbable 
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• restenosis
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Introduction
The Absorb everolimus-eluting bioresorbable vascular scaffold 
(Absorb BVS; Abbott Vascular, Santa Clara, CA, USA) shows 
unique potential in vascular repair, such as late lumen enlargement, 
restoration of vasomotion and plaque media reduction1-4. However, 
in-scaffold restenosis may occur as frequently as with metallic 
drug-eluting stents (DES). Since the Absorb BVS loses its mechan-
ical strength during bioresorption, unlike metallic stents, the mech-
anism of in-scaffold restenosis might be unique and different from 
DES and bare metal stents (BMS).
The process of lumen loss (LL) is a “time limited phenomenon” 
due to negative remodelling of the vessel and neointimal hyperpla-
sia inside the stent, which occurs three to six months after implan-
tation5,6. Beyond this critical period, the mechanical support of the 
scaffold and the active pharmacological inhibition of the neointima 
are no longer necessary. According to this concept, mechanical sup-
port of the scaffold could decrease approximately six months after 
implantation. Actually, it has been established in humans that the 
mechanical integrity is maintained over a period of six months but 
subsides afterwards7. However, one could speculate that the plaque 
behind the struts of the scaffold might progress and narrow the 
lumen once the scaffold has lost its mechanical strength.
Timing of restenosis and its potential mechanism after implanta-
tion of the Absorb BVS have not been investigated. We report six 
cases of ISR (quantitative coronary angiography [QCA] diameter 
VWHQRVLVZLWKLQWKHVFDIIROGHGVHJPHQWDQGPPSUR[LPDO
and distal to the scaffolded segment) observed in the ABSORB 
Cohort B trial (101 patients, 102 lesions) according to the timing, 
and describe in detail the intravascular findings in an attempt to 
elucidate the mechanism of this complication. Two cases were early 
ISR (<6 months), one case was late ISR (6-12 months), and three 
cases were very late ISR (>12 months) (Table 1, Figure 1).
Case histories
CASE 1. EARLY ISR DUE TO MYOCARDIAL BRIDGE
A 57-year-old man with a history of hypertension, dyslipidae-
mia, smoking and COPD presented with stable angina. The coro-
nary angiography showed a type B2 lesion in the mid left anterior 
descending (LAD) artery with severe stenosis in systole (percent-
DJHGLDPHWHUVWHQRVLV>'6@EXWZLWKRXWVLJQLILFDQWVWHQRVLV
LQGLDVWROH'6WKXVZLWKW\SLFDOHYLGHQFHRIDP\RFDUGLDO
bridge (Figure 2A-Figure 2C). After predilatation with a 2.75 mm 
VHPLFRPSOLDQWEDOORRQDîPP$EVRUE%96ZDVGHSOR\HG
and post-dilated with a 3.5 mm non-compliant balloon at 16 atm 
(Figure 2D)2QGD\WKHSDWLHQWH[SHULHQFHGUHFXUUHQWDQJLQDDQG
underwent re-catheterisation. The angiography revealed a focal ISR 
at the site of the myocardial bridge (QCA minimum lumen diameter 
>0/'@PP'6//PP(Figure 2E). This 
ISR was treated by implantation of a 3.5×15 mm XIENCE V stent 
(Abbott Vascular) inside the Absorb BVS (Figure 2F). At three years, 
angiography revealed a significant re-ISR of this XIENCE V stent 
4&$0/'PP'6//PP(Figure 2G). 
Table 1. Case summary.
Case 1 Case 2 Case 3 Case 4 Case 5 Case 6
Timing Early Early Late Very late Very late Very late
Day 89 168 354 383 567 833
Age 57 69 57 76 62 42
Sex Male Male Male Male Male Female
History of DM no no no no no no
Pre procedure
RVD (mm) 2.51 2.05 2.64 2.82 2.97 2.24
Lesion length 10.3 5.9 12.0 8.1 15.4 10.2
%DS (%) 71.5 72.5 70.0 71.0 64.5 52.5
MLD (mm) 0.72 0.58 0.79 0.82 1.05 1.06
Post procedure
%DS (%) 16.7 27.0 16.0 24.5 23.5 9.0
MLD (mm) 1.91 1.94 2.08 2.10 1.95 1.93
At TLR
Clinical presentation Stable angina No angina Stable angina Unstable angina Unstable angina Stable angina
Examination for ischaemia – FFR: 0.72 Asynergy on echo. – – Myocardial 
scintigram positive
%DS (%) 59.0 63.5 64.0 67.0 71.0 63.7
MLD (mm) 1.20 0.89 0.79 0.90 0.81 0.72
LL (mm) 0.90 0.50 1.58 1.20 1.47 1.38
DM: diabetes mellitus; RVD: reference vessel diameter; %DS: % diameter stenosis; MLD: minimum lumen diameter; LL: lumen loss; FFR: fractional 
flow reserve; TLR: target lesion revascularisation
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Figure 1. Cumulative frequency distribution curves of angiographic % diameter stenosis (%DS). A) %DS at 6 (circle) and 24 months (dot) of 
Cohort B1. B) %DS at 12 (circle) and 36 months (dot) of Cohort B2. If the patient had TLR before the planned angiography, %DS at the time 
of TLR (before repeat revascularisation) was used for the %DS at the later time point. Blue dots (Ɣ) and blue circles (ż) represent %DS in 
TLR patients who experienced early ISR (<6 months). Green dots (Ɣ) and green circles (ż) represent %DS in TLR patients who experienced 
late ISR (6-12 months). Red dots (Ɣ) and red circles (ż) represent %DS in TLR patients who experienced very late ISR.
Figure 2. Early ISR due to myocardial bridge. The white arrows indicate the metallic markers of the implanted scaffold, while the white dotted 
line illustrates the implanted EES. The red arrows show the scaffold struts of the previously implanted Absorb BVS located inside the metal 
stent on IVUS (H) and OCT (I).
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Optical coherence tomography (OCT) revealed intra-scaffold tis-
sue growth with homogeneous light reflectivity. Of interest, OCT 
and intravascular ultrasound (IVUS) showed that some struts of the 
previously implanted Absorb BVS were located inside the metal 
stent (Figure 2H, Figure 2I). Finally, this re-ISR lesion was treated 
by a coronary artery bypass graft (CABG).
CASE 2. EARLY ISR AT PROXIMAL EDGE
$\HDUROGPDOHZLWKDKLVWRU\RIG\VOLSLGDHPLDDQGSUHYLRXV
coronary intervention of the left circumflex (LCX) artery presented 
with stable angina. Coronary angiography showed a type B1 severe 
stenosis in the mid right coronary artery (RCA) (Figure 3A). After 
SUHGLODWDWLRQZLWKDPPVHPLFRPSOLDQWEDOORRQDîPP
Absorb BVS was deployed and post-dilated with a 3.0 mm bal-
loon at 15 atm (expected diameter according to the manufacturer 
was 3.3 mm) (Figure 3B). As the IVUS catheter failed to pass 
through the implanted scaffold, the guiding catheter was changed 
from JR4 to AL1. After repeated attempts to cross the IVUS cath-
eter through the scaffold by seating the guiding catheter deeply up 
to the proximal edge of the scaffold in order to perform the proto-
col-related imaging, the operator was unable to cross the scaffold 
and the procedure was ended (Figure 3C)2QGD\WKHSDWLHQW
underwent a planned repeat angiography, which showed a type 1B 
,65DW WKHSUR[LPDO HGJHRI WKH VFDIIROG 4&$0/'PP
'6//PPZLWKRXWVLJQLILFDQW UHVWHQRVLV LQ WKH
scaffold itself (Figure 3D). Greyscale IVUS (IVUS-GS) showed 
a high-echoic intra-scaffold tissue growth in the segment proximal 
to the scaffold, with maintained circularity of the scaffold (Figure 
3E, Figure 3F7KLV,65ZDVWUHDWHGE\LPSODQWDWLRQRIDîPP
XIENCE V stent with full coverage of the previously implanted 
Absorb BVS.
CASE 3. LATE ISR WITH HOMOGENEOUS INTRA-SCAFFOLD 
TISSUE ON OCT
In a 57-year-old man with a history of dyslipidaemia and smok-
ing, and presenting with unstable angina, coronary angiogra-
phy showed a severe type B1 stenosis in the proximal LAD with 
TIMI grade 2 flow (Figure 4A). After predilatation with a 2.5 mm 
Figure 3. Early ISR at proximal edge. The white and black arrows indicate the metallic markers of the implanted scaffold. In panels E and F, 
the red arrows show the polymeric strut on IVUS.
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VHPLFRPSOLDQWEDOORRQDîPP$EVRUE%96ZDVGHSOR\HG
and post-dilated with a 3.0 mm non-compliant balloon at 20 atm 
(Figure 4B)2QGD\WKHSDWLHQWKDGUHFXUUHQFHRIDQJLQDSHF-
toris. On day 354, the patient underwent a planned repeat angi-
ography, which showed a significant type 1C ISR (QCA MLD: 
PP'6//PPLQWKHERG\RIWKHVFDIIROG
(Figure 4C). OCT showed that the circularity of the scaffold was 
maintained throughout the pullback (the mean scaffold area was 
5.67 mm2 and the minimum scaffold area was 4.73 mm2) and all the 
struts were completely apposed and covered. At the site of the mini-
mal lumen area (MLA), OCT revealed homogeneous signal-rich 
intra-scaffold tissue (Figure 4D-Figure 4G). On virtual histology 
IVUS (IVUS-VH), intra-scaffold tissue was documented as fibrous 
(Figure 4E). A XIENCE V stent was implanted to cover the previ-
ously implanted Absorb BVS.
CASE 4. VERY LATE ISR AT THE PROXIMAL EDGE
A 76-year-old gentleman with a history of dyslipidaemia, chronic 
kidney failure and coronary intervention to the mid LAD (non-tar-
get lesion) presented with stable angina. The coronary angiogra-
phy showed a type B1 moderate stenosis in the mid LAD (Figure 
5A). After predilatation with a 2.5 mm semi-compliant balloon, 
D îPP$EVRUE %96ZDV GHSOR\HG +RZHYHU WKH$EVRUE
BVS did not cover the proximal part of the predilated segment, 
resulting in geographical miss (Figure 5B). After implantation of 
the scaffold, the jailed diagonal branch became occluded. Since 
this closure resulted in chest pain, bradycardia and hypotension, the 
side branch was dilated with a 1.5 mm balloon (Figure 5C). OCT 
post procedure revealed a small dissection in the proximal edge of 
the scaffold, presumably due to the geographical miss during the 
procedure (Figure 5D, Figure 5E). The patient refused the scheduled 
follow-up angiography at six months. One year later, the patient 
presented with recurrence of angina pectoris, and repeat angiogra-
phy showed a type 1B ISR in the segment proximal to the scaffold 
4&$0/'PP'6//PP(Figure 5F), 
while the scaffolded segment was free from significant restenosis. 
A 3.0×15 mm XIENCE V stent was implanted to overlap the proxi-
mal part of the previously implanted Absorb BVS.
CASE 5. VERY LATE ISR WITH HOMOGENEOUS INTRA-
SCAFFOLD TISSUE ON OCT
A 62-year-old man with a history of hypertension, smoking and 
COPD presented with stable angina. Coronary angiography 
showed a type B1 severe stenosis in the proximal LAD (Figure 6A). 
Although the proximal maximum luminal diameter (Dmax) on 
4&$ZDVPPDPP$EVRUE%96ZDVSODQQHG(Figure 6B, 
Figure 6C). After predilatation with a 2.5 mm semi-compliant bal-
ORRQWKLVîPP$EVRUE%96ZDVLPSODQWHGDQGSRVWGLODWHG
with a 3.5 mm non-compliant balloon at 12 atm (Figure 6F). Post-
procedural OCT showed large incomplete stent apposition (ISA)
PD[,6$DUHDPP2, max ISA distance 1.63 mm, the number 
of cross-sections with ISA: 25 frames) at the proximal edge of the 
scaffold, but additional dilatation was not performed (Figure 6D, 
Figure 6E). At one year, the planned follow-up coronary angi-
RJUDSK\ VKRZHG SDWHQF\ RI WKH VFDIIROG 4&$0/' PP
'6//PP(Figure 6G). OCT showed persistent 
numerous malapposed struts with intraluminal mass attached to or 
free from the vessel wall at the proximal edge of the previously 
Figure 4. Late ISR with homogeneous intra-scaffold tissue on OCT. The white arrows show the metallic marker of the implanted scaffold. 
In panels F and G, the red triangles show the scaffold struts on OCT (case 3).
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Figure 5. Very late ISR at the proximal edge. The white arrows show the metallic marker of the implanted scaffold. In panel B, the yellow 
arrows show the proximal edge of the predilatation balloon. The angiograms are matched anatomically between predilatation and scaffold 
implantation, and the white dotted lines show the proximal edge of the implanted scaffold. The red arrows show the small dissection observed 
post procedure on OCT in panels D and E.
Figure 6. Very late ISR with homogeneous intra-scaffold tissue on OCT. The white arrows show the metallic marker of the implanted scaffold. 
The red line shows the point of Dmax on QCA, which is superimposed on the angiogram at scaffold implantation in panel B. The red line is 
superimposed on the angiogram at OCT study in panel D (case 5).
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implanted scaffold (Figure 7a). On the three-dimensional OCT 
image, the intraluminal masses were interlinked to the malapposed 
struts and connected proximally to the vessel wall (Figure 7a’). 
On day 564 the patient was hospitalised with unstable angina and 
underwent a repeat angiography on day 567, which showed a type 
&,65LQWKHERG\RIWKHVFDIIROG4&$0/'PP'6
DQG//PP. OCT showed homogeneous signal-rich 
intra-scaffold tissue in the middle of the scaffold segment with per-
sistent malapposed struts at the proximal edge (Figure 7B-E)10. After 
predilatation, repeat OCT revealed an extensive tissue protrusion 
with maintained circularity of the scaffold (Figure 7B’-E’). On OCT 
DQDO\VLVWKHPHDQVFDIIROGDUHDZDVPP2, and the minimum 
scaffold area was 6.23 mm2 (Figure 7A). This ISR was treated by 
LPSODQWDWLRQRIDîPP;,(1&(9VWHQWZKLFKRYHUODSSHG
the proximal part of the previously implanted Absorb BVS.
CASE 6. VERY LATE ISR WITH ISO-ECHOIC INTRA-SCAFFOLD 
TISSUE ON IVUS-GS
In a 42-year-old female with a history of smoking presenting with 
stable angina, coronary angiography demonstrated a type B1 mod-
erate stenosis in the mid LAD (Figure 8A). After predilatation with 
DPPVHPLFRPSOLDQWEDOORRQDîPP$EVRUE%96ZDV
implanted. After post-dilatation with a 3.0 mm non-compliant bal-
loon at 20 atm, post-procedural angiography showed a residual 
VWHQRVLVRI(Figure 8B). At one year, a planned repeat angi-
ography showed patency of the previously implanted scaffold 
4&$0/'ZDVPP'6ZDVDQG//ZDVPP
(Figure 8C)2QGD\WKHSDWLHQWXQGHUZHQWDUHSHDWDQJLRJUD-
phy because of stable angina with ischaemia on a myocardial scin-
tigraphy: the angiogram showed a type 1B ISR at the distal margin of 
WKHVFDIIROGVHJPHQW4&$0/'PP'6DQG//
Figure 7. Very late ISR with homogeneous intra-scaffold tissue on OCT. The white arrows show the metallic marker of the implanted scaffold. 
OCT images pre TLR before ballooning are shown in panels B to E, and those after ballooning are shown in panels B’ to E’. In panels b to e, 
the corresponding cross-sections to ISR site are shown at 12-month follow-up.
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PP(Figure 8D). IVUS-GS showed that the scaffold circular-
ity was maintained and that the eccentric intra-scaffold tissue was 
iso-echoic (Figure 8E-G). On IVUS-VH, small necrotic core and 
dense calcium were detected in the intra-scaffold tissue (Figure 8E’-
G’). In this case, the ISR lesion was treated by the implantation of 
a 3.0×23 mm XIENCE V which overlapped the distal part of the 
previously implanted Absorb BVS.
Discussion
The main findings of the current report are the following: 1) out of 
101 patients enrolled in the ABSORB trial, at three years early reste-
QRVLVRFFXUUHGLQWZRFDVHVODWH,65LQRQHFDVHDQG
YHU\ODWH,65LQWKUHHFDVHVWKHHDUO\,65ZDVDVVRFLDWHG
with a myocardial bridge (case 1); 3) two of the three late ISR cases 
may have been caused by procedural edge injury at the index pro-
cedure (one case was due to the injury caused by deep insertion of 
the guiding catheter [case 2], while the other case could be attrib-
uted to proximal geographical miss [case 4]); 4) in three cases (one 
late ISR and two very late ISR), the mechanism of ISR could not be 
identified (case 3, case 5, and case 6) , but in all cases the circularity 
of the scaffold was maintained.
It is noteworthy that ISR occurred in patients without diabetes, 
with relatively large vessels (reference vessel diameter 3 or more 
mm) and short lesion length (less than 10 mm).
ISR ASSOCIATED WITH MYOCARDIAL BRIDGE
Myocardial bridging (MB) is a potential cause of myocardial 
ischaemia and in such cases medical therapy, with beta-block-
ers or calcium channel blockers, is recommended as a first-line 
strategy. Although intracoronary stent implantation is another 
therapeutic approach to prevent external systolic compression and 
ischaemia caused by the MB, this therapy is still controversial 
because of concerns regarding high restenosis rates, plaque pro-
lapse and stent fracture12,13. In the current series, one early TLR 
occurred in a myocardial bridge at three months after implantation 
of an Absorb BVS, followed by a second failure occurring after 
implantation of a metallic drug-eluting stent. This case suggests 
that scaffold implantation for a myocardial bridge treatment should 
be discouraged. Myocardial bridges generate compressive pressure 
(up to 300 mmHg) capable of fully closing the vessel in systole. 
Although the initial radial strength of an Absorb BVS is approxi-
PDWHO\PP+JDQGVXSHULRUWRWKLVFRPSUHVVLYHSUHVVXUHWKLV
systolic external compression occurs at least 100,000 times/day, 
and in the course of bioresorption a bioresorbable transient scaffold 
might yield to such a mechanical stress3,14.
In this case, at three years, OCT and IVUS detected one scaf-
fold strut inside the area of the metal stent, while post procedure no 
disrupted strut had been detected on IVUS. The location of a poly-
meric strut inside the metallic stent may suggest that the discontin-
ued strut could protrude between the metallic mesh of the stent after 
TLR at three months.
ISR PRESUMABLY TRIGGERED BY PROCEDURAL INJURY
It has been shown that procedural vessel injury might lead to late 
intra-scaffold tissue growth15. In one case in the current series, 
the deeply inserted AL1 guide catheter might have injured the 
edge of the scaffold at baseline and led to proximal edge ISR at 
six months.
Figure 8. Very late ISR with iso-echoic intra-scaffold tissue on IVUS-GS. The white arrows show the metallic marker of the implanted scaffold.
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Geographical miss is also a known cause of restenosis16,17. In one 
case, the predilatation might have caused “barotrauma” to the prox-
imal plaque and the Absorb BVS did not cover the injured edge 
segment. Actually, a proximal edge dissection not scaffolded by the 
Absorb BVS was observed on OCT. The edge ISR could therefore 
be related to the proximal plaque injury associated with geographi-
cal miss.
MAINTAINED CIRCULARITY OF SCAFFOLD AREA IN LATE/
VERY LATE ISR
As previously described, the radial strength of the fully bioresorb-
able scaffold declines following polymer hydrolysis at six months, 
and this device becomes malleable without any supportive prop-
erties at 12 months. One could therefore speculate that the scaf-
fold might become encroached by plaque growth behind the struts. 
In the balloon angioplasty era, Serruys et al demonstrated that the 
incidence of restenosis reaches a plateau at four months6. Ormiston 
et al demonstrated that the late loss in response to balloon injury 
reached a maximum before six months and then regressed, while 
some cases with an intermediate stenosis at six months showed 
very late lumen narrowing at five years.
In this study, we observed three ISR cases without any possi-
ble causal relationship with procedural or anatomical factors: one 
case presented a late ISR and two cases a very late ISR. As shown 
in Figure 9, the circularity of the Absorb BVS, especially at MLA 
cross-section, was preserved post procedure in all cases. In addi-
tion, there were no changes in mean/minimum scaffold area.
This report suggests that the perceived relative weakness of the 
scaffold related to its polymeric nature does not seem to have any 
direct impact on the restenosis phenomenon, and late lumen loss 
seems to be the result of intra-scaffold tissue growth rather than late 
scaffold recoil.
Late and very late restenosis have also been reported with 
metallic drug-eluting stents. In the SPIRIT II trial, the rate of 
LVFKDHPLDGULYHQ7/5VWHDGLO\LQFUHDVHGIURPDWRQH\HDU
WRDWWZR\HDUVDQGDWWKUHH\HDUV20-22. In the ABSORB 
Cohort B trial, the rate of ischaemia-driven TLR beyond one year 
LQFUHDVHG VLPLODUO\  DW RQH \HDU  DW WZR \HDUV DQG
DWWKUHH\HDUV7KHVHGDWDVXJJHVWWKDW,65ZLWKWKH$EVRUE
BVS occurs as frequently as with metallic DES, and a reduced 
mechanical strength of the scaffold cannot be implicated in the 
occurrence of ISR.
Figure 9. Intravascular imaging of the late and very late restenosis.
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MORPHOLOGICAL CHARACTERISTICS OF INTRA-SCAFFOLD 
TISSUE IN LATE/VERY LATE ISR
On IVUS-VH, a typical neointimal restenosis within one year after 
BMS implantation appears as fibrous or fibro-fatty tissue (green or 
green-yellow)23. Neointima after DES implantation or beyond one 
year after BMS implantation is sometimes detected as necrotic core 
tissue (red and red-white) on IVUS-VH23. It should be noted that 
intramural thrombus also has the appearance of fibrous or fibro-
fatty tissue24. In the current series, two IVUS-VH images were 
available: one was a late ISR and the other was a very late ISR. In 
the late ISR case, the intra-scaffold tissue appeared as fibrous tis-
sue, while, in the very late ISR case, the small necrotic core and 
dense calcium were interspersed in fibrous tissue (Figure 9).
OCT has been used to evaluate the efficacy of stenting by ana-
lysing tissue characteristics of in-stent intima25. Goto et al dem-
onstrated that homogeneous high-signal band is a typical in-stent 
intima within one year after BMS implantation, while heterogene-
ous mixed-signal band is observed at all timing points after DES 
implantation24. In the current series, two OCT images were avail-
able: both of them were late ISR. In these cases, the intra-scaffold 
tissue appeared as a homogeneous tissue (Figure 9).
Limitations
The sample size was small and the first-in-man trial had no control 
arm. The current findings therefore need to be confirmed in a large 
randomised trial.
Conclusion
The current analysis suggests that early and late restenosis after 
implantation of the Absorb bioresorbable scaffold could be related 
to anatomical or procedural factors. Late or very late restenosis 
could be attributed to intra-scaffold tissue growth but not to the 
encroachment of the scaffold.
Impact on daily practice
Since the Absorb everolimus-eluting bioresorbable vascular scaf-
fold (BVS) loses its mechanical strength during bioresorption, 
the mechanism of in-scaffold restenosis (ISR) could be differ-
ent from metallic stents. In the ABSORB Cohort B trial, at three 
years, ISR with the BVS occurs as frequently as with drug-elut-
ing metallic stents. By investigating the ISR according to the 
time line of the mechanical change of the BVS, the perceived rel-
ative weakness of the scaffold does not seem to have any direct 
impact on the restenosis phenomenon, and seems to be the result 
of intra-scaffold tissue growth rather than late scaffold recoil and 
extrinsic encroachment of the scaffold. The disappearance of the 
device was not found to be a disadvantage in relation to ISR in 
the current study.
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Chapter 3 
 
Validation and application of bifurcation algorithm 
 
 
3.1 Dedicated bifurcation Quantitative Coronary Angiography 
(QCA) software 
 
The need for dedicated bifurcation Quantitative Coronary 
Angiography (QCA) software algorithms to evaluate bifurcation 
lesions. 
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Abstract
Single-vessel quantitative coronary angiography (QCA) software is inaccurate when used in bifurcation 
lesions due to the specific anatomical characteristics of bifurcations, including the natural step-down in diam-
eters after every bifurcation. Dedicated bifurcation QCA software has been developed to overcome the limi-
tations of single-vessel QCA in bifurcations. A phantom validation study has shown the superior accuracy of 
these bifurcation QCA algorithms compared to the single-vessel QCA software. These QCA software algo-
rithms are currently highly recommended to assess bifurcation lesions.
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Introduction
Visual estimation of stenosis on coronary angiography has been 
regarded as unreliable due to a marked intraobserver and interob-
server variability1,2. Therefore, quantitative coronary angiography 
(QCA) software was developed to provide an objective, accurate and 
reproducible quantification of coronary lesions3,4. Parameters derived 
from QCA have subsequently been used as surrogate endpoints in 
randomised clinical trials evaluating the efficacy of new stent tech-
nologies and the effect of new pharmaceutical agents on coronary 
artery disease progression/regression5-7. As described in detail else-
where in this Bifurcation Supplement8, the human coronary vascula-
ture tree is subject to fractal geometry. As a result, there is a natural 
step-down in vessel diameter after every bifurcation. In this review 
we will outline why this natural step-down phenomenon results in 
inaccurate QCA measurements when conventional single-vessel 
QCA software is used and why dedicated bifurcation QCA software 
algorithms are essential to provide accurate measurements.
Challenges in QCA of bifurcation lesions: why 
conventional single-vessel algorithms are 
inaccurate in bifurcations
When conventional single-vessel software is used in bifurcation 
lesions, two analyses should be performed: one from the proximal 
main branch to the distal main branch (Figure 1A), and the other 
from the proximal main branch to the side branch (Figure 1B) (or 
alternatively by starting from the side branch ostium, Figure 1C). 
In 2009, it was already acknowledged that the use of conventional 
single-vessel software was inaccurate to assess bifurcation lesions 
for several reasons which we will address here9.
Why is the use of single-vessel software so problematic? First 
and foremost, because it completely ignores the natural anatomy of 
the bifurcation. In the bifurcation core or the so-called polygon of 
confluence (POC), single-vessel algorithms detect non-existing ves-
sel contours crossing the bifurcation, something which frequently 
requires manual corrections, which by definition are arbitrary and 
introduce bias (Online Figure 1). Even more problematic is that it 
sometimes even creates what we call “pseudo-stenoses”, in which 
the minimal lumen diameter (MLD) is incorrectly located at the site 
of the side branch ostium in the middle of the POC, instead of locat-
ing the MLD at the true MLD site (Figure 2).
Another challenge in QCA of bifurcations is to assess an accurate 
reference diameter (RefD) to calculate the percent diameter stenosis 
(%DS). If the single-vessel algorithm is applied to a bifurcation lesion, 
this will lead to an inaccurate RefD due to the natural differences in 
diameters proximal and distal to the bifurcation, which is most pro-
nounced at the side branch ostium10. The so-called interpolated RefD 
will be estimated as too large in the ostia of the distal branches because 
of the larger proximal diameters (compare interpolated RefD lines in 
Figure 2B and Figure 2C). Vice versa, the reference diameter of the 
distal part of the proximal main branch will be underestimated, due 
to the influence of the smaller distal branch on the interpolated RefD 
(again, compare interpolated RefD lines in Figures 2B and Figure 2C). 
Alternatively, a single reference point could be chosen for each seg-
ment (i.e., one proximal for the proximal main branch segment, one 
distal in the side branch for the side branch segment, and one distal in 
the main branch for the distal main branch segment). However, choos-
ing such reference points is arbitrary and therefore not reproducible. 
Furthermore, it is conceivable that a RefD based on a single point is 
less accurate than when the RefD is based on the complete segment.
Another problem with the use of a single-vessel algorithm 
in bifurcation lesions is the need for manual segment selection. 
Because the conventional software does not recognise where the 
proximal branch stops and the distal main branch or side branch 
begins, this needs to be indicated by the analyst, which introduces 
another bias and it will therefore be very challenging to indicate 
exactly the same segments pre-procedure, post-procedure and at 
follow-up. This is particularly true because the stenoses are located 
in close proximity to the ostium of the distal branch in most cases.
Dedicated bifurcation QCA software packages
To overcome the above-mentioned shortcomings of single-vessel 
software, dedicated bifurcation QCA algorithms were developed. 
Two different QCA software packages are currently available and 
will be described in detail below.
CAAS (PIE MEDICAL IMAGING)
The Cardiovascular Angiography Analysis System (CAAS; Pie 
Medical Imaging BV, Maastricht, The Netherlands) bifurcation 
QCA software has been validated against a precision-manufactured 
bifurcation phantom model10-13. In the CAAS bifurcation QCA 
Figure 1. The use of single-vessel quantitative coronary angiography (QCA) software in a bifurcation. When using single-vessel QCA software, one 
analysis is performed of the main branch (A), and one of the side branch, starting in the proximal main branch (B) or side branch ostium (C).
237
software, the analysis is initialised by three user-defined points: 
one indicating the proximal boundary of the main branch and 
two indicating the distal boundaries of the two daughter branches 
(Figure 3A). Next, the algorithm automatically detects the contours 
using the “minimal cost algorithm”, a mathematical modelling 
process based on the differences in the local greyscale and video 
densitometry (Figure 3B)12,14. If this modelling system erroneously 
detects a contour outside the vessel, the contour can be corrected 
either by drawing the contour manually or by using the “restriction 
function”, excluding an area from the automatic contour detection. 
The two-dimensional dedicated bifurcation algorithm assumes the 
bifurcation as a single object with a left, middle and right contour, 
without making any further assumptions. The “point of bifurcation” 
(POB) is then defined as the mid-point of the largest possible circle 
touching all three (i.e., left, middle and right) contours, and is the 
point where all three centrelines (i.e., the lines through the middle 
of the vessel) from the proximal main branch, distal main branch 
and side branch meet (Figure 3C). The intersections of the circle 
with the centrelines indicate the boundaries of the POC (Figure 3D, 
Figure 3E). The diameter values are obtained differently inside the 
POC from those in straight segments outside the POC. Outside the 
POC, diameters are determined by the shortest distance between the 
vessel’s outer borders, as in the conventional straight-vessel QCA 
algorithm. Within the POC, however, another mathematical algo-
rithm, the so-called “minimum freedom” approach, is used. This 
approach uses the shortest distances from a centreline point to the 
vessel contours. The distance between these two points on the vessel 
contours is defined as the diameter of the centreline point and hence 
the true diameter at the bifurcation (Figure 3F, Moving image 1). 
The RefD outside the POC is determined from the “healthy” (non-
stenotic) part of the branch. Within the POC, the RefD is based on 
a curvature-based interpolation technique, assuming smooth blood 
flow from the proximal main branch to the distal branches, the cur-
vature being constant at the POC (Online Figure 2).
QANGIO XA (MEDIS MEDICAL IMAGING SYSTEMS)
Some of the first basic steps are essentially the same for the 
QAngio® XA bifurcation software (Medis medical imaging systems 
bv, Leiden, The Netherlands) as for the CAAS bifurcation software 
described above15,16. First, the analyst defines the segment of analy-
sis by indicating one proximal start point and an endpoint in each of 
the distal branches. Then, two wavepath centrelines from proximal 
to distal are detected. These can be semi-automatically (by provid-
ing an additional support point) or manually corrected if necessary 
(Online Figure 3B). Subsequently, the vessel contour is automati-
cally detected using the minimal cost algorithm (Online Figure 3C). 
If the vessel contour erroneously detects a contour outside the ves-
sel, the contour can be either semi-automatically corrected (by indi-
cating a support point manually on the vessel edge) or manually 
corrected by re-drawing the contour by hand. Although the steps 
above are more or less similar between CAAS and QAngio XA, 
there is a difference between the two software packages with regard 
to the anatomic points which are used to define the bifurcation and 
its measurements. Unlike CAAS using the POB as the cornerstone 
for its subsequent analyses, QAngio XA uses the carina point on the 
middle contour as well. This carina point can be manually edited 
Figure 2. Quantitative coronary angiography of a bifurcation lesion using single-vessel or bifurcation software. Panel A shows a bifurcation lesion. 
Panel B shows quantitative coronary angiography (QCA) analysis of this bifurcation lesion using single-vessel software creating a “pseudo-
stenosis” (red arrow). Panel C shows QCA analysis of the same bifurcation lesion using the bifurcation software. In all panels, the white arrow 
indicates the true location of the MLD of the proximal main branch, the red arrow the pseudo-stenosis found with single-vessel QCA at the actual 
location of the point of bifurcation (white dot in C).
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by dragging this point to the correct position, if found to be more 
appropriate by the analyst. Hereafter, the middle contour detection 
procedure is executed again, based on the available image informa-
tion and new carina point, which serves as a support point. Besides 
that, the position of the “proximal delimiter” of the bifurcation core 
is automatically determined. This proximal delimiter and the cari-
nal point are important landmarks for the software algorithm to 
define the four “building blocks” of the bifurcation analysis model 
(proximal main branch, bifurcation core, distal main branch and 
side branch). QAngio XA has two different bifurcation models. As 
recommended by the company, the T-shape model should be used 
in the vast majority (probably ~>90%) of bifurcation lesions and is 
selected as default setting in the current version of the QAngio XA 
software. Alternatively, the Y-shape model can be used. Use of the 
Y-shape model is recommended by the company only in specific 
anatomical subsets (e.g., in cases with equally sized distal branches 
and/or a narrow distal bifurcation angle), or when evaluating spe-
cific treatment approaches (skirt stenting for example).
In the T-shape model, the bifurcation core is defined as the area 
in-between the proximal delimiter, the first diameter of the distal 
main branch and by a virtual contour between the proximal and 
distal main branch segments (Figure 4A). The virtual contour sepa-
rates the main branch from the side branch, creating two sections: 
1) the main branch section consisting of the proximal main branch, 
bifurcation core and distal main branch (Figure 4B, Figure 4C); and 
2) the side branch section starting at the virtual contour, continuing 
into the side branch (Figure 4B, Figure 4D). The diameter function 
is calculated using Medis straight vessel algorithms for the entire 
main branch section, whereas an adjusted Medis ostial algorithm is 
used for the side branch section, reconstructing a proximal flare to 
correspond to the “mouth” of the ostium17,18. The bifurcation core is 
excluded when calculating the RefD function, which is calculated 
for the proximal main branch segment, distal main branch segment, 
and side branch section separately. Within the bifurcation core, the 
Figure 3. CAAS bifurcation software (Pie Medical). In the CAAS bifurcation QCA software, the segment of analysis is indicated by one 
proximal and two distal delimiter points (white arrows, A). After automatic detection of the contours (B), the “point of bifurcation” (POB) is 
defined as the mid-point of the largest possible circle touching all three contours (C). The intersections of the circle with the centrelines (D) 
indicate the boundaries of the POC (E). The diameter values within the POC are determined by the “minimum freedom” approach (F).
Figure 4. T-shape model of the QAngio XA bifurcation QCA 
software. A) The anatomic landmarks used to define the four 
“building blocks” of the bifurcation analysis model: the proximal 
delimiter, the first diameter of the distal main branch, the virtual 
contour between the proximal and distal main branch segments, and 
the carinal point. B) The interpolated reference diameter (virtual 
contour) of the bifurcation core, which is determined linearly by 
means of a straight reference diameter function. C) The QCA 
(including the diameter function) of the combined main branch, with 
a separate diameter function for each building block. D) QCA of the 
side branch, including the diameter function using the adjusted 
Medis ostial algorithm.
interpolated reference diameters are determined linearly by means 
of a straight RefD function (corresponding to the virtual contour of 
the bifurcation core) (Figure 4A, Figure 4C).
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In the Y-shape model, the bifurcation core is defined as the area 
between the proximal delimiter and the carinal point (Figure 5A). 
Three different segments are analysed in the Y-shape model: 1) the 
proximal section from the proximal boundary to the carina point; 
2) the “distal 1” section from the first distal 1 diameter to the dis-
tal 1 boundary; and 3) the “distal 2” section from the first distal 2 
diameter to the distal 2 boundary. The interpolated RefD functions 
of the three segments (proximal, distal 1 and distal 2) outside the 
bifurcation core are derived by an iterative regression technique17. 
The RefD function of the bifurcation core itself is based on two 
interpolated reference contours (spline-based)18. The graph of the 
RefD function of the proximal main branch displays the combined 
function of the proximal main branch and the bifurcation core, up 
to the carinal point. This combined function is straight for the prox-
imal segment and curved in the bifurcation core (Figure 5B). The 
RefD functions of the distal sections are straight and displayed as 
one function (Figure 5C, Figure 5D).
Comparison of single-vessel software with 
dedicated bifurcation QCA software algorithms 
in a bifurcation phantom
To assess the inaccuracy of the single-vessel software in bifurcation 
lesions objectively, and to validate both QAngio XA and CAAS 
bifurcation software algorithms, a phantom validation study was 
performed by our group. For this analysis, six precision phantoms 
with a total of 18 bifurcations made from Plexiglas with a tolerance 
ȝPZHUHXVHG13. The 18 bifurcations were analysed three times: 
1) with the conventional single-vessel algorithm of CAAS (version 
5.10); 2) with the bifurcation algorithm of CAAS (version 5.10); 
and 3) with the bifurcation algorithm of QAngio XA (version 7.3) 
(Online Figure 4)10. The single-vessel analysis was performed from 
the proximal main branch to the distal main branch and from the 
proximal main branch to the side branch10.
We found that conventional single-vessel analysis underesti-
mated the RefD and %DS in the proximal main branch, whilst 
these parameters were overestimated in the distal main branch and 
side branch (case example in Online Figure 4). Overall, combining 
all three segments of the 18 bifurcations (54 segments), the accu-
racy and precision with single-vessel software was very poor with 
regard to the RefD (-0.108±0.352 mm) and %DS (5.69±11.28%)10. 
The bifurcation algorithms on the other hand proved to be highly 
accurate and precise, with comparable accuracy and precision 
between the CAAS and QAngio XA (with systematic use of the 
T-shape model) bifurcation software models with regard to MLD 
(0.012±0.103 vs. 0.012±0.093 mm, p=0.104), RefD (0.050±0.043 vs. 
–0.045±0.064 mm, p=0.106), and %DS (0.94±4.07 vs. 0.74±3.81%, 
p=0.121) (Figure 6).
Why is this important?
The most important conclusion from the study above is that the 
conventional single-vessel QCA method is inaccurate in bifurcation 
lesions and that both CAAS and QAngio XA (when systematically 
using the T-shape model) bifurcation algorithms are highly accurate 
Figure 5. Y-shape model of the QAngio XA software. A) The 
anatomic landmarks used to define the four building blocks of the 
bifurcation analysis. B) The QCA of the proximal section, consisting 
of the proximal segment (up to the proximal delimiter) and the 
bifurcation core. C) & D) The QCA and reference vessel diameter 
functions of the distal 1 and distal 2 branches. Note that the 
reference diameter functions of the distal sections are straight and 
displayed as one function.
and precise in bifurcation lesions. But why is this so important? 
Overestimation of the %DS of the distal main and side branch by 
single-vessel analysis may potentially have clinical implications. 
We are already aware that ostial side branch stenosis severity is 
overestimated with visual estimation19. However, the side branch 
stenosis will also be overestimated when single-vessel QCA analy-
sis is used pre-procedure, which may lead to the overtreatment of 
insignificant stenosis (e.g., treatment of side branch without sig-
nificant stenosis).
Besides clinical implications, use of single-vessel QCA may 
also have implications in clinical trials. The major randomised tri-
als comparing single stenting with systematic double stenting have 
used the single-vessel analysis (Online Table 1)20-22. Inclusion of 
lesions based on the single-vessel analysis may result in biased 
selection of target lesions, with an overestimation of “true” bifur-
cation rates (i.e., Medina 0,1,1; 1,0,1; or 1,1,1)9. Furthermore, sin-
gle-vessel software use in bifurcation trials (Online Table 1) or 
first-in-man/registry studies on dedicated bifurcation stents (Online 
Table 2) with planned repeat angiography will lead to less accu-
rate results of the side branch. A recent example was the Tryton 
IDE trial showing different QCA outcomes with dedicated bifur-
cation QCA from those with single-vessel QCA23,24. Furthermore, 
as defined by the Academic Research Consortium25, justification 
of target lesion revascularisation (TLR) (i.e., “ischaemia-driven” 
vs. “non-ischaemia-driven” TLR) is based on %DS assessed by 
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Figure 6. Accuracy and precision of single-vessel QCA software and bifurcation QCA software in all phantom bifurcation segments (n=54). 
Differences between the measured values (MLD, RVD and %DS) and the true phantom values for all 54 segments (18 bifurcations) for the 
single-vessel analysis (CAAS), bifurcation analysis using CAAS, and bifurcation analysis using QAngio XA (T-shape only). The accuracy was 
defined as the mean difference from the true value, and precision was defined as the standard deviation of the mean difference.
QCA. The use of single-vessel software in such trials may there-
fore lead to an increased rate of ischaemia-driven target TLR of the 
side branch.
European Bifurcation Club recommendations in 
reporting QCA
The European Bifurcation Club (EBC) recommends reporting the 
QCA results according to the three segments of the bifurcation (i.e., 
proximal main, distal main, and side branch)9,26. Binary restenosis is 
best reported as QCA-based Medina scores at every time point (i.e., 
pre-procedure, post-procedure and follow-up). One of the advantages 
of such per-segment reporting is that the healing pattern of the bifur-
cation treatment can be better understood (i.e., more complex reste-
nosis patterns including main and side branch vs. relatively simple 
restenosis patterns including main branch only). Another important 
issue is that the MLD can be relocated from one segment to another. 
When using single-vessel software, the post-procedural MLD might, 
for example, be located in the (non-stenotic) distal main branch, 
whilst at follow-up the MLD might be (re-)located in the (stenotic) 
proximal main branches. Especially when there is a large difference 
in reference diameters between the proximal and distal main branch, 
the late lumen loss (LLL) value calculated from these two MLD val-
ues might be artificially low. When the LLL is calculated for the three 
segments separately, the LLL value is probably more accurate in rep-
resenting the restenotic effect in a particular segment.
Conclusions
Conventional single-vessel QCA software is inaccurate in bifur-
cation lesions because it completely ignores the natural anatomy 
of the bifurcation, including the natural “step-down” in diameters 
after each bifurcation. Dedicated bifurcation software algorithms 
have been developed: currently, two different software packages 
are commercially available (CAAS and QAngio XA). The two 
software packages use slightly different approaches, but both have 
proven to be highly accurate when validated against precision-man-
ufactured bifurcation phantoms.
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Online Figure 1. Single-vessel QCA creating a virtual contour crossing the side branch ostium. After indicating the proximal and distal 
boundaries of the region of interest (white dots) in a left anterior descending-first diagonal bifurcation lesion (A), the vessel contour was 
detected automatically by the bifurcation software (B). Note that, in the so-called polygon of confluence (POC), the software detected the 
ostium of a septal side branch as vessel contour. In this case, this was corrected by re-drawing the contour manually, which seems to be 
arbitrary (C). D) The final vessel contour of the QCA.
Online Figure 2. Curvature-based interpolation technique of CAAS bifurcation software.
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Online Figure 3. Introduction steps of QAngio XA bifurcation software. A) A left anterior descending artery-diagonal branch bifurcation 
lesion. First, the analyst defines the segment of analysis by indicating one proximal start point and an endpoint in each of the distal branches, 
after which two wavepath centrelines from proximal to distal are detected (note that the proximal parts overlap) (B). Subsequently, the vessel 
contour is automatically detected using the minimal cost algorithm (C).
Segment - analysis Phantom values A: Single-vessel  B: Bifurcation analysis C: Bifurcation analysis 
  software by CAAS by QAngio XA (T-shape)
Proximal MB-MLD (mm) 1.59 1.41 1.66 1.59
Proximal MB-DS (%) 60.30 55.00 57.54 59.10
Proximal MB-RVD (mm) 4.00 3.62 4.02 3.88
Distal MB-MLD (mm) 0.66 0.74 0.71 0.75
Distal MB-DS (%) 80.00 80.00 78.33 77.00
Distal MB-RVD (mm) 3.30 3.51 3.25 3.24
SB-MLD (mm) 2.60 2.53 2.55 2.54
SB-DS (%) 0.00 23.00 1.16 2.11
SB-RVD (mm) 2.60 3.29 2.58 2.59
A: Single-vessel analysis by CAAS
B: Bifurcation analysis by CAAS
C: Bifurcation analysis by 
     QAngio XA (T-shape)
Online Figure 4. Example of a representative QCA analysis on the bifurcation phantom model. Example of a representative QCA analysis on 
one of the phantom bifurcations using single-vessel software (A) and dedicated bifurcation software (B & C). Note that, in this particular case, 
the single-vessel software underestimates the reference vessel diameter in the proximal main branch, while it overestimates the reference vessel 
diameter in the distal main branch and side branch. Furthermore, the MLD in the proximal main branch is inaccurate.
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Online Table 1. Angiographic endpoints and QCA algorithms used in randomised studies, multicentre studies or ongoing studies.
Year
No. 
patients
Primary endpoint
Planned 
repeat 
angiography, 
Yes or No
Angiographic endpoint QCA software Algorithm Randomisation
Prior to introduction of bifurcation software
Colombo et al 2004 85 Angiographic restenosis 
(either branch) 6 months
Yes Binary in-segment 
restenosis of both the MB 
and SB at 6 months
QCA-CMS 5.1 Single Provisional vs. systematic 
(crush, T, culotte)
Pan et al 2004 91 Composite of cardiac 
death, MI, and the need 
for TVR at 6 months
Yes Angiographic restenosis 
(either branch) 6 months 
CAAS II 4.1.1 Single Provisional vs. systematic (T)
Introduction of bifurcation software
NORDIC 2006 413 Death, MI (non-
procedural), TVR, or stent 
thrombosis at 6 months
Yes Significant restenosis 
(50% diameter stenosis) 
of the MV and/or occlusion 
of the SB
QAngio XA 7.0 Bifurcation Provisional vs. systematic 
(crush, culotte, T)
Ferenc et al 2008 202 Angiographic restenosis 
of the SB at 9 months
Yes In-segment percent 
diameter stenosis of the 
SB at 9 months
QAngio XA 7.0 Bifurcation Provisional vs. systematic (T)
NORDIC 2 2009 424 Death, MI (non-
procedural), TVR, or stent 
thrombosis at 6 months
Yes In-segment and in-stent 
restenosis of MV and/or SB 
after 8 months
QAngio XA 7.0 Bifurcation Systematic (crush vs. culotte)
The DIVERGE 2009 302 Composite of death, MI, 
and TLR at 9 months
Yes Binary angiographic 
restenosis at 9 months 
QAngioXA 7.1 Bifurcation No, a prospective multicentre 
registry (Axxess stent)
DKCRUSH-II 2009 370 Cardiac death, MI, or TVR 
at 12 months
Yes Restenosis in the MV and 
SB at 8 months
CAAS 5.7 Bifurcation Double kissing crush versus 
provisional stenting technique 
for treatment of coronary 
bifurcation lesions
CACTUS 2009 350 Death, MI, TVR at 
6 months
Yes In-segment restenosis rate 
at 6 months
QCA-CMS Single Provisional vs. systematic crush
Thueringer 
Bifurcation 
Study
2009 110 Death, MI, stent 
thrombosis, CABG, or TLR 
at 6 months
Yes Restenosis in the MV and 
SB at 6 months
Quantcor QCA 
V2.0 
Single Stenting of the MB (TAXUS 
stent) and mandatory SB PCI 
kissing balloons with 
provisional SB stenting, or 
stenting of the MB (paclitaxel-
eluting stents) with provisional 
SB-PCI only when the SB had 
a TIMI flow 2
BBC ONE 2010 500 All-cause death, MI, TVF 
at 9 months
No No Not described Single Provisional vs. systematic 
(crush, culotte)
NORDIC 3 2011 477 Cardiac death, 
non-procedure-related 
index lesion MI, stent 
thrombosis, or TLR by 
PCI or CABG within 
6 months
Yes In-segment and in-stent 
restenosis (50% diameter 
stenosis) of the MV and/or 
SB at 8 months
QAngio XA 7.2 Bifurcation Final kissing balloon dilatation 
versus no final kissing balloon 
dilatation
TRYTON trial 2013 704 Cardiac death, MI, or 
TVR at 9 months
Yes In-segment % DS of the 
Tryton SB compared to SB 
balloon angioplasty at 
9 months
QAngio XA 7.2 
CAAS 5.9 or 
5.11*
Single 
Bifurcation*
The Tryton SB vs. SB balloon 
angioplasty
CABG: coronary artery bypass graft; MB main branch; MI, myocardial infarction; MV: main vessel; PCI: percutaneous coronary intervention; SB: side branch; TLR: target vessel 
revascularisation; TVF: target vessel failure; TVR: target vessel revascularisation. * The nine-month follow-up angiograms were re-analysed in both core labs (Cardiovascular Research 
Foundation, New York, NY, USA; Cardialysis B.V., Rotterdam, The Netherlands) using the bifurcation software.
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Online Table 2. Angiographic endpoints and QCA algorithms used in first-in-man studies or registries assessing dedicated bifurcation stents.
Year
No. 
patients
Primary endpoint
Planned 
repeat 
angiography, 
Yes or No
Angiographic endpoint QCA software Algorithm
Prior to introduction of bifurcation software
Frontier™ stent 2005 105 Death, MI, and TLR at 6 months Yes Angiographic restenosis (either branch) 
6 months 
CAAS II Single
Introduction of bifurcation software
Axxess Plus™ 
stent
2007 139 Death, MI, CABG and ischaemia-
driven TLR at 6 months 
Yes Angiographic late loss at 6 months Not described Single
Tryton™ stent 2008 30 In-hospital cardiac death, MI, 
CABG, TLR and TVR 
Yes TLR and TVR at 6 months CAAS 5.4 Bifurcation
Petal™ stent 2010 28 Death, MI and TVR at 1 month Yes Angiographic restenosis (either branch) 
6 months 
Medis (not described 
in detail)
Bifurcation
Stentys™ stent 2011 63 Cardiac death, stroke, MI, CABG, 
TLR and TVR at 6 months 
Yes Vessel patency , late lumen loss and binary 
restenosis rate at 6 months
CAAS 5 Bifurcation
BiOSS™ stent 2011 63 Cardiac death, stroke, MI, CABG, 
TLR and TVR at 12 months
Yes Late lumen loss, percent diameter stenosis 
and binary restenosis rate at 12 months 
QCA-CMS 5.0 Single
Nile Croco™ 
stent
2011 151 Acute device success and 
angiographic success
No No Not described Not 
described
Sideguard™ 
stent
2012 20 Stroke, MI, stent thrombosis and 
TLR/TVR at 6 months
Yes TVR at 6 months QAngio XA Bifurcation
CABG: coronary artery bypass graft; MI: myocardial infarction; TLR: target lesion revascularisation; TVR: target vessel revascularisation
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In Vitro Validation and Comparison of Different
Software Packages or Algorithms for Coronary
Bifurcation Analysis Using Calibrated Phantoms:
Implications for Clinical Practice and Research of Bifurcation
Stenting
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Background: The accuracy and precision of quantitative coronary angiography (QCA)
software dedicated for bifurcation lesions compared with conventional single-vessel
analysis remains unknown. Furthermore, comparison of different bifurcation analysis
algorithms has not been performed. Methods: Six plexiglas phantoms with 18 bifurca-
tions were manufactured with a tolerance<10 mm. The bifurcation angiograms were
analyzed using Cardiovascular Angiography Analysis System (CAAS; Version 5.10, Pie
Medical Imaging, Maastricht, The Netherlands) and QAngio XA (Version 7.3, Medis
Medical Imaging System BV, Leiden, The Netherlands) software packages. Results:
Conventional single-vessel analysis underestimated the reference vessel diameter and
percent diameter stenosis in the proximal main vessel while it overestimated these pa-
rameters in the distal main vessel and side branch. CAAS software showed better
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to the actual phantom diameters; however, the accuracy of these parameters improved
to a similar level as CAAS when the sole T-shape algorithm in the QAnxio XA was
used. Conclusion: The use of the single-vessel QCA method is inaccurate in bifurca-
tion lesions. Both CAAS and QAngio XA (when the T shape is systematically used)
bifurcation software packages are suitable for quantitative assessment of bifurca-
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INTRODUCTION
Two-dimensional quantitative coronary angiography
(QCA) analysis in bifurcation remains technically chal-
lenging. When a conventional single-vessel analysis is
used in a bifurcated lesion, two analyses should be per-
formed: one from the proximal main to the distal main
branch and the other from the proximal main to the
side branch (SB) [1,2]. In the so-called polygon of con-
fluence [3], the edge detection of single-vessel algo-
rithms are not able to define the vessel contours
crossing the bifurcation, which frequently requires
manual corrections of contour and may introduce sub-
jectivity or bias. Due to natural tapering after the bifur-
cation, the interpolated reference diameter calculated
for the proximal main vessel (PMV) and tapered distal
branches underestimates the % diameter stenosis (DS)
of the PMV and overestimate % DS in the distal main
vessel (DMV) or SB [4,5].
To overcome these limitations, the dedicated bifurca-
tion algorithms have been developed. Currently, two
software packages are commercially available: the Car-
diovascular Angiography Analysis System (CAAS; Pie
Medical Imaging, Maastricht, The Netherlands) and
QAngio XA software (Medis Medical Imaging Systems
BV, Leiden, The Netherlands). CAAS has been vali-
dated in a phantom model with quantification of mini-
mum lumen diameter (MLD) measurements showing a
highly accurate and precise performance across a wide
range of diameter values [6,7], whereas bifurcation
algorithm of QAngio XA with segments was shown in
vivo to be robust and reproducible in two clinical stud-
ies [8,9].
However, it remains to be investigated whether the
bifurcation algorithms, compared to a single-vessel
analysis, significantly improve the accuracy of the
analysis. Furthermore, the difference in accuracy
between bifurcation analysis algorithms remains
unknown. We, therefore, aimed to compare single-
vessel analysis and bifurcation QCA analysis using
CAAS and QAngio XA in calibrated phantoms.
MATERIALS AND METHODS
Phantom Models
Six plexiglas phantoms, each of them mimicking a
vessel with three successive bifurcations, were
designed in 3D and manufactured with a
tolerance< 10 mm [10]. Every individual bifurcation
had a lesion, wherein at least one vessel segment had a
DS of >60% with the MLD being located within 3–
6 mm from the point of bifurcation. The range of
diameters, lesion length, angulation, and Medina class
[5] used in the design of these 18 bifurcations reflected
the anatomic variation and the fractal nature of bifurca-
tions in the human coronary tree as derived from rele-
vant literature [6,7,11,12].
Acquisition and Calibration of Phantom Models
The digital angiograms were acquired on a biplane
angiographic system (Axiom ArtisTM; Siemens, For-
chheim, Germany) [9]. All phantoms were filled with
100% Iodixanol 320 (VisipaqueTM; GE Healthcare,
Cork, Ireland) and imaged at 30 frames per second, in
a 20 cm field of view, with the center of the phantom
placed precisely at the isocenter. For validation pur-
poses, images acquired in anteroposterior (AP) direc-
tion by either C-arm were analyzed. Images acquired
at 30

rotation, once in right and once in left anterior
oblique projection, were also analyzed, to investigate
the impact of gantry angulation on the accuracy and
precision of the measurements.
Quantitative Angiographic Analysis
QCA was performed off-line by an experienced ob-
server using a single-vessel analysis and a bifurcation
segmental analysis. As the bifurcation phantom was
made in a flat plane, our analysis was performed in AP
view, to minimize errors resulting from foreshortening
and/or overlap.
Calibration was performed on a 10-mm grid board
and the recording geometry of the x-ray system
obtained from the Digital Imaging and Communica-
tions in Medicine (DICOM) (National Electrical Manu-
facturers’ Association, DICOM, Rosslyn, VA) header
and the phantom thickness were taken into account to
determine the true pixel size in the phantom plane,
separately for each C-arm [9]. Radiographic system
settings, phantom position, table height, and distance
from source to the image intensifier distance were kept
constant throughout each phantom and centimeter grid
acquisition and were identical for all phantoms. Then,
the same pixel size was manually entered in each anal-
ysis.
MLD, reference vessel diameter (RVD), %DS of
PMV, DMV, and SB segments were compared with
the phantom diameters (PDs) for vessel segments.
Single-vessel analysis. Angiographic images of the
18 bifurcations were analyzed using single-vessel anal-
ysis of the CAAS. The middle frame out of the total
frame count of a given acquisition was consistently an-
alyzed to avoid frame selection bias. To obtain the
angiographic parameters separately in PMV, DMV,
and SB, two analyses were performed per bifurcation:
(1) MV analysis; PMV to DMV and (2) SB analysis;
PMV to SB. Subsequently the QCA was manually seg-
mented. To allow a comparison with to the bifurcation
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analyses, the MV was divided into two segments
(PMV and DMV) at the site of the carinal point. For
the SB analysis, the start point of the SB was set at the
carina.
Bifurcation segmental analysis. The angiography
of the bifurcations was analyzed using the CAAS ver-
sion 5.10 and QAngio XA version 7.3 for 2D bifurca-
tion segmental analyses including the edge segments
analysis. Standard procedure for bifurcation analysis
has been previously described [9]. Briefly, it consisted
of the following steps: (1) the middle frame out of the
total frame count of a given acquisition was consis-
tently analyzed to avoid frame selection bias; (2) the
same pixel size with single-vessel analysis was man-
ually entered; (3) the bifurcation segmentation was ini-
tialized by placing one proximal and two distal
delimiter points at the largest possible distance from
the bifurcation to be analyzed, however, not touching
the adjacent bifurcation lesions or the phantom borders;
(4) contours were detected using the lumen detection
algorithm and MLD was determined using previously
described methodology [6,7].
In QAngio XA software, the two bifurcation models
(T shape; a main vessel being a proximal vessel that
continues in the same direction into a distal vessel, and
a SB at an acute angle and Y shape; a proximal vessel
with two distal branches that are approximately equal
in size and split off at similar angles) are available [9].
Initially, software was allowed to automatically select
the analysis algorithm. Subsequently, all bifurcation
analyses with QAngio XA were repeated using both
the Y- and the T-shape algorithms.
Statistics
Statistical analysis was performed using JMPVR 10
for Windows (SAS Institute, Cary, NC). Continuous
variables are presented as mean6 standard deviation
and paired values were compared by Wilcoxon
signed rank test. The individual signed differences
were averaged; the mean of these signed differences
(bias) is a measure of accuracy; the standard devia-
tion is a measure of precision. The agreement for
MLD between the CAAS bifurcation analysis and the
PDs, QAngio XA using default Y- or T-shape bifur-
cation analysis and the PDs or QAngio XA using
solely the T shape and the PDs were also performed
using the Bland–Altman analysis. The accuracy
between the measurements and the PDs and its preci-
sion were calculated; the repeatability coefficient
(equal to 1.96 * standard deviation of the bias) was
determined as the measure of variability. All statisti-
cal tests were two sided and a P-value< 0.05 was
considered statistically significant.TA
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RESULTS
Accuracy and precision of tested software packages
for MLD, RVD, and %DS value are presented in
Tables I and II including measurements obtained exclu-
sively with the T-shape program.
Comparison Between Angiographic
Measurements by Single-Vessel Analyses
and PDs
The conventional single-vessel method measured a
significantly smaller RVD in the PMV and a larger
RVD in the DMV and SB (Fig. 1). Consequently, all
the %DS and RVD were overestimated significantly
compared to the PDs when using the conventional
single-vessel method (P¼ 0.003, P¼ 0.014, respec-
tively). Using single-vessel analyses, MLD values for
each segment had an accuracy and precision of
0.0396 0.130 mm, 0.0086 0.112 mm, and
0.0086 0.045 mm for PMV, DMV, and SB, respec-
tively. The values of MLD for all segments did not
significantly differ between the conventional single-
vessel analysis and the PDs.
CAAS and QAngio XA Bifurcation Algorithms in
Reference to PDs
Agreement between the two bifurcation software
packages in MLD assessment is presented in Fig. 2.
Bland–Altman plots comparing MLD for 54 vessel
segments analyzed by CAAS or QAngio XA compared
Fig. 1. This is an example of a case of the phantom model
results. Quantitative coronary angiography measurement by
CAAS and QAngio XA with automatic selection of Y- or T-shape
algorithm was shown for a bifurcated lesion in the calibrated
phantom. Angiographic parameters including reference diame-
ter, minimal lumen diameter, % diameter stenosis are given in
the PMV, DMV, and side branch (SB). Case1; A cine-angiogram
demonstrated moderate to severe stenosis both in the proximal
main vessel (PMV) and the distal main vessel (DMV) in Medina
class (1,1,0) bifurcation. The conventional single-vessel method
measured a significantly smaller RVD in the PMV and a larger
RVD in the DMV and SB. (A) QCA was shown using the conven-
tional single-vessel algorithm by CAAS. (B) QCA was shown
using the bifurcation algorithm by CAAS. (C) QCA was shown
using the bifurcation algorithm by QAngio XA with automatic
selection of Y or T shape. Case2; A cine-angiogram demon-
strated severe stenosis in the distal main vessel (DMV) in Me-
dina class (0,1,0) bifurcation. QAngio XA software using the
default Y- or T-shape program, accuracy values for RVD and
%DS were quite large (43.07% vs. 0.66%) when Y-shape algo-
rithm was applied as default for Medina class (0,1,0) bifurcation.
(D) QCA was shown using the bifurcation algorithm by CAAS.
(E) QCA was shown using the bifurcation algorithm by QAngio
XA with automatic selection of Y or T shape.
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Fig. 2. The agreement for minimum lumen diameter (MLD) between the CAAS and the phan-
tom diameters (PDs), QAngio XA using default Y- or T-shape bifurcation, and the PDs or QAn-
gio XA using solely the T shape were also performed using the Bland–Altman analysis; (A)
MLD all, (B) MLD proximal main vessel (PMV), (C) MLD distal main vessel (DMV), (D) MLD
side branch (SB). Solid lines represent the mean difference (bias), dotted lines represent the
95% limits of agreement (bias6 1.96 SD).
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to the PDs showed that the limit of agreement between
CAAS and the PDs, QAngio XA using default Y- or
T-shape algorithm and the PDs, or QAngio XA using
solely the T shape and the PDs were 0.179 to 0.214,
0.618 to 0.648 mm, and 0.194 to 0.170, respec-
tively (Fig. 2).
The values of MLD did not significantly differ
between the QAngio XA using the default Y- or T-
shape program and the PDs. Moreover, RVD and %DS
in the QAngio XA using the default Y- or T-shape pro-
gram were overestimated significantly compared to the
PDs (P¼ 0.002, P¼ 0.047, respectively). With the
CAAS software, MLD and %DS were not significantly
different from the PDs.
Accuracy of CAAS and QAngio XA using the default
Y- or T-shape program for MLD, RVD, and %DS were
0.0126 0.103 mm versus 0.0416 0.322 mm (P¼ 0.003),
0.0506 0.043 mm versus 0.1166 0.610 mm
(P¼ 0.026), and 0.946 4.07 % versus 1.746 7.49 %
(P¼ 0.041), respectively (Table I). CAAS software pro-
vided more precise values than QAngio XA software
using the default Y- or T-shape program for MLD, RVD,
and %DS measurements.
QAngio XA software using the default Y- or T-
shape program, accuracy values for RVD and %DS
were quite large in three cases (1.70 mm vs. 0.08 mm
and 43.07% vs. 0.66%, 3.23 mm vs. 0.03 mm and
5.32% vs. 0.32%, 2.62 mm vs. 0.09 mm and
18.51% vs. 2.86%) when Y-shape algorithms were
applied as default for Medina class (0,1,0) bifurcation
(Figs. 1 and 3). As a result, the Y-shape algorithm
over-diagnosed binary restenosis in two cases, yielding
a positive predictive value of 93%.
When the T-shape algorithm was used in all cases,
the accuracy of %DS and RVD improved considerably
up to 0.246 3.80% and 0.0256 0.064 mm,
Fig. 3. The respective comparison between accuracy measures relative to the calibrated
phantom values using the two bifurcation methods and two bifurcation algorithms were
shown for minimum lumen diameter (MLD; panel A), reference vessel diameter (RVD; panel
B), and percent diameter stenosis (%DS; panel C).
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respectively (Fig. 3). The MLD, RVD, and %DS of the
T shape was no longer statistically different from the
CAAS bifurcation method. Conversely, when the Y-
shape algorithm was consistently applied for all bifur-
cations, the accuracy of precision for RVD in reference
to the PDs became worse (Fig. 3).
DISCUSSION
The main findings of this study are: (1) with conven-
tional single-vessel QCA, the RVD, and %DS were
significantly larger than the PDs. (2) CAAS and T
shape in the QAngio XA are highly accurate and pre-
cise for MLD, RVD, and %DS when compared in vitro
with a series of custom-made, precision manufactured
Plexiglas phantoms. (3) When algorithms either T
shape or Y shape were selected by default mode, QAn-
gio XA demonstrated a higher RVD and %DS than
CAAS and the PDs; however, accuracy improved and
became comparable to the CAAS algorithm when the
T shape was systematically used.
Percutaneous treatment of coronary artery bifurca-
tion lesions is a recognized challenge in interventional
cardiology [18–20]. Dedicated software packages for
bifurcation assessment can provide angiographic pa-
rameters; however, it is important to validated preci-
sion and accuracy of available software packages.
The value of MLD in the conventional single-vessel
analysis was similar to the PDs; however, our results
demonstrated that %DS of DMV and SB is overesti-
mated by the conventional single-vessel analysis. Over-
estimation of %DS in the DMV and SB has potentially
clinical implications. First, when the single-vessel anal-
ysis is applied in preprocedural assessment of a bifur-
cation lesion, the lesion severity would be over
exaggerated and may result in the overtreatment of in-
significant stenosis. The major bifurcation trials such
as BBC ONE, CACTUS, and Thueringer bifurcation
study [13–15] have used the single-vessel analysis (Ta-
ble II). The inclusion of lesion based on the single-
vessel analysis may result in biased selection of target
lesion [5]. The use of dedicated bifurcation software
has been recommended by the European Bifurcation
Club Angiographic Sub-Committee to overcome the
numerous limitations of standard QCA when applied
on bifurcation lesions [5]. Second, in the first-in-man/
registry studies testing a dedicated bifurcation stent
with a planned repeat angiography (Table III), overesti-
mation of SB at follow up would result in increased
rates of ischemia driven target lesion revascularization
[13,22,23]. According to the Academic Research Con-
sortium definition [24], at repeat angiography, revascu-
larization for a lesions with >70% stenosis (by corelab
QCA) or >50% stenosis with evidence of ischemia are TA
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considered as ischemic driven. In the trial with planned
repeat angiography, the usage of single-vessel analysis
might influence the event adjudication.
Percentage DS has been less reliable than the MLD
in the evaluation of the functional significance of ostial
SB stenosis and RVD of a given vessel segment gets
interpolated from the diameter outside the obstruction
boundaries [5,7,25]. Compared to single-vessel analy-
sis, accuracy of %DS assessment significantly
improved with the two bifurcation software packages
(Table I, P-values; single-vessel analysis by CAAS vs.
bifurcation segment analysis by CAAS: P< 0.001,
single-vessel analysis by CAAS vs. bifurcation segment
analysis by QAngio XA with a default setting:
P< 0.001). However, the accuracy of %DS was better
in CAAS than QAngio XA with a default setting
(P¼ 0.041). When the analysis was stratified according
to the location of stenosis (Table I), the variance of
%DS was prominent in SB. This is due to an obvious
error of measurement when Y-shape algorithms is by
default applied for Medina class (0,1,0). When the T-
shape algorithm was forced for all analyses, the accu-
racy improved and becomes comparable with CAAS. It
could be, therefore, recommended to systematically use
T-shape algorithm when QAngio XA is used for bifur-
cation studies. Indeed, in the third Nordic bifurcation
study [16,17], the T-shape model was chosen for all
bifurcation analyses. This approach should give the
best measurements of bifurcation lesions with a high
accuracy and precision. Y shape could be considered
when the specific Y-shape device (e.g., Axxess plusTM
stent) [21] is being evaluated (Table III).
LIMITATION
The phantom design naturally has the inherent limi-
tations of an artificial construction trying to mimic real
life. The smooth and static walls of the phantoms nei-
ther resemble the jagged irregular appearance of the
coronary vessel walls, especially after balloon dilation,
nor they reflect movement with each cardiac cycle.
CONCLUSION
The conventional single-vessel QCA method is inac-
curate in bifurcation lesions, underestimating RVD and
%DS in the PMV with overestimation of these parame-
ters in the DMV and SB. CAAS bifurcation software
accurately measured MLD, RVD, and %DS when com-
pared to the PDs. When the default bifurcation algo-
rithms (T shape, Y shape) of the QAngio XA system
was automatically selected, QAngio XA demonstrated
a higher MLD, RVD, and %DS than CAAS and the
PDs. However, if the T-shape algorithm is consistently
used in the QAngio XA bifurcation method, the accu-
racy in measuring RVD and %DS improved and
became comparable to the CAAS bifurcation method.
Therefore, CAAS bifurcation software and QAngio XA
bifurcation software (when the T shape is systemati-
cally used) are both suitable for quantitative assessment
of bifurcation lesion.
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ABSTRACT
OBJECTIVES This study sought to evaluate inter–core lab variability in quantitative coronary angiography (QCA)
analysis of bifurcation lesions.
BACKGROUND QCA of bifurcation lesions is challenging. To date there are no data available on the inter–core lab
variability of bifurcation QCA analysis.
METHODS The randomized Tryton IDE (Tryton Pivotal IDE Coronary Bifurcation Trial) compared the Tryton Side Branch
Stent (Tryton Medical, Durham, North Carolina) with balloon angioplasty as side branch treatment. QCA was performed
in an angiographic subcohort (n ¼ 326) at 9-month follow-up. Inter-core lab variability of QCA analysis between the
Cardiovascular Research Foundation and the Cardialysis core labs was evaluated before and after alignment of the used
QCA methodology using angiographic data derived from this angiographic follow-up cohort.
RESULTS In the original analysis, before alignment of QCA methodology, the mean difference between the core labs
(bias) was large for all QCA parameters with wide 95% limits of agreement (1.96  SD of the bias), indicating marked
variability. The bias of the key angiographic endpoint of the Tryton trial, in-segment percentage diameter stenosis (%DS)
of the side branch, was 5.5% (95% limits of agreement: –26.7% to 37.8%). After reanalysis, the bias of the in-segment
%DS of the side branch reduced to 1.8% (95% limits of agreement: –16.7% to 20.4%). Importantly, after alignment of
the 2 core labs, there was no longer a difference between both treatment groups (%DS of the side branch: treatment
group A vs. group B: 34.4  19.4% vs. 32.4  16.1%, p ¼ 0.340).
CONCLUSIONS Originally, a marked inter–core lab variability of bifurcation QCA analysis was found. After alignment of
methodology, inter–core lab variability decreased considerably and impacted angiographic trial results. This latter ﬁnding
emphasizes the importance of using the same methodology among different core labs worldwide. (Tryton Pivotal
Prospective, Single Blind, Randomized Controlled Study to Evaluate the Safety & Effectiveness of the Tryton Side Branch
Stent Used With DES in Treatment of de Novo Bifurcation Lesions in the Main Branch & Side Branch in Native Coronaries
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E ver since the late 1970s, visual esti-mation of the severity of a stenosison coronary angiography has been
regarded as unreliable due to a marked intra-
and interobserver variability (1,2). Therefore,
quantitative coronary angiography (QCA) was
introduced in the mid-1980s to provide an
objective and reproducible quantiﬁcation of
coronary lesions (3,4). QCA parameters have
been widely used as primary and secondary
endpoints in numerous randomized clinical
trials evaluating the efﬁcacy of new technol-
ogies in percutaneous coronary interventions
and the effect of new pharmaceutical agents
on coronary artery disease progression/regression
(5–7).
Due to the fractal geometry of the coronary tree,
there is a natural tapering of the bifurcation, with
differences in reference vessel diameter (RVD)
among the proximal main branch, distal main branch,
and side branch (8,9). Due to this natural tapering,
the interobserver variability of visual estimation of
lesion severity increases even more in bifurcation
lesions (10). Furthermore, conventional QCA algo-
rithms have the limitation of being inaccurate in
bifurcation lesions because they have been devel-
oped and validated in a single straight coronary
segment (11). To improve the accuracy of QCA in
bifurcation lesions, dedicated bifurcation algorithms
were developed, which subsequently have been
used in recent clinical trials on bifurcation treatment
(12–16).
To eliminate the potential bias stemming from the
investigators, QCA analysis in clinical trials is usually
performed at independent core laboratories (core
labs). These core labs aim to provide unbiased and
reproducible results by using validated QCA software
and by using standard operating procedures during
QCA analysis. Although intraobserver and interob-
server variability of bifurcation QCA algorithms have
been investigated before (14,16,17), to date no data
are available on the differences in bifurcation QCA
measurements between core labs. This study aimed
to examine inter–core lab variability by comparing the
QCA results of 2 core labs using data from the
9-month angiographic follow-up cohort of the ran-
domized trial on the Tryton Side Branch Stent (Tryton
Medical, Durham, North Carolina).
METHODS
SETTING. Tryton IDE (Tryton Pivotal IDE Coronary
Bifurcation Trial), an investigational device exemp-
tion (IDE) randomized trial, compared the Tryton Side
Branch Stent with side branch balloon angioplasty,
both in combination with a regular drug-eluting stent
in the main branch, for the treatment of de novo true
coronary bifurcation lesions. The primary endpoint
(powered for noninferiority), at 9-month follow-up,
was the difference in the occurrence of target vessel
failure, deﬁned as the composite of cardiac death,
Q-wave or non–Q-wave target vessel myocardial
infarction (>3 the upper limit of normal of creatine
kinase isoenzyme), and target vessel revasculariza-
tion. The key secondary endpoint (powered for
superiority) was in-segment percentage diameter
stenosis (%DS) of the side branch in a pre-speciﬁed
subgroup of 374 subjects (with an expected loss to
follow-up of 15%) undergoing planned repeat angi-
ography at 9 months (the angiographic follow-up
cohort).
Two core labs were assigned to perform different
types of analyses in the angiographic follow-up
cohort of the Tryton IDE trial. The Cardiovascular
Research Foundation (CRF, New York, New York)
was assigned to perform 2-dimensional QCA analysis
of the complete angiographic follow-up cohort.
Cardialysis B.V. (Rotterdam, the Netherlands) was
assigned to perform 3-dimensional QCA and intra-
vascular ultrasound analyses and for this purpose
9-month follow-up angiograms of 130 subjects
included in the angiographic follow-up cohort were
available at Cardialysis. Besides 3-dimensional QCA
and intravascular ultrasound analyses, Cardialysis
also performed 2-dimensional QCA analysis in this
subgroup. The inter–core lab variability of the
9-month 2-dimensional QCA analysis between the 2
core labs was investigated in these 130 subjects.
This initial analysis indicated diverging angiographic
results between the 2 core labs (Figure 1A). Thereafter,
both core labs disclosed and shared their QCA anal-
ysis plans to unravel potential explanations for these
differences. Both core labs decided to perform a
reanalysis of the total angiographic follow-up cohort
using an identical QCA analysis plan, which they had
agreed on (Table 1).
INITIAL QCA ANALYSIS PLAN OF CRF. At the start of
the Tryton IDE trial, the dedicated bifurcation QCA
algorithms were not yet validated against precision
phantoms. Therefore, the initial QCA analysis plan of
the trial, approved by the U.S. Food and Drug Admin-
istration and used for the main publication, included
the use of a conventional single-vessel QCA algorithm
(QAngio XA, version 7.2.34, Medis Medical Imaging
Systems, Leiden, the Netherlands). For each bifurca-
tion, 2 analyses were performed: one from the prox-
imal main branch to the distal main branch, and the
ABBR EV I A T I ON S
AND ACRONYMS
%DS = percentage diameter
stenosis
CI = conﬁdence interval
CRF = Cardiovascular Research
Foundation
IDE = investigational device
exemption
MLD = minimal lumen diameter
QCA = quantitative coronary
angiography
RVD = reference vessel
diameter
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other from the proximal main branch to the side
branch. First, calibration was performed using the
guiding catheter and then, the region of interest was
deﬁned by indicating its proximal (i.e., in the prox-
imal main branch) and distal (i.e., in the side branch or
distal main branch) boundaries (Figure 2B). Hereafter,
the QCA software automatically detected the vessel
contour based on the change in brightness of the
pixels (Figure 2C) (4). Then, the analysts were allowed
to manually edit the vessel contour whenever the
contour did not appeared to be smooth or appropri-
ately delineated (Online Figure 1). Because conven-
tional single-vessel QCA software does not recognize
the side branch origin, segmentation of the bifurca-
tion lesion was performed manually, with the carinal
point as the beginning of the side branch segment
(Figure 2E). For the side branch, a single point 5 mm
distal to the balloon/stent edge was taken as the
reference vessel diameter (RVD) (Figure 2F). The
%DS was calculated as follows: (RVD of the side
branch – minimal lumen diameter [MLD] of the
side branch) / RVD of the distal side branch (Figure 2F).
For the main branch, the RVD was deﬁned as
the average of the reference diameter in the
“normal” segments proximal and distal to the stent.
The %DS in the main branch was calculated by using
the MLD and the averaged RVD. QCA measurements
were performed on a single “worst” projection (i.e.,
the projection in which the stenosis looks most
severe).
INITIAL QCA ANALYSIS PLAN OF CARDIALYSIS.
Cardialysis used a dedicated bifurcation software al-
gorithm for their QCA analysis on bifurcation lesions
(Coronary Angiography Analysis System [CAAS],
version 5.9, Pie Medical Imaging, Maastricht, the
Netherlands) (13,18). For each bifurcation, only 1
analysis needed to be performed. The bifurcated re-
gion of interest—including the proximal main branch,
distal main branch, and side branch—was deﬁned by
indicating its proximal (i.e., in the proximal main
branch) and distal (i.e., in both the side branch and
the distal main branch) boundaries (Figure 3A). After
the automatic vessel contour detection (Figure 3B),
analysts were not allowed to manually edit the vessel
contour, except in the cases where the vessel contour
was erroneously detecting a side branch or other
overlapping contours instead of the vessel contour
itself (Online Figure 2). The point of bifurcation is
automatically determined by the software and is
deﬁned as the mid-point of the largest circle that
can be ﬁtted in the bifurcation area, touching all
3 contours (Figure 3C) (19). The centerlines of each of
the 3 segments meet at the point of bifurcation
(Figure 3C). Segmentation of the bifurcation in 3
individual segments was performed automatically
using the point of bifurcation and centerlines as
previously described (19). The %DS was automatically
calculated using the interpolated RVD at the MLD
site of each segment (Figures 3E to 3G). All QCA
measurements were performed on at least 2 pro-
jections (if available), and the average from all
projections were reported.
ALIGNMENT OF QCA ANALYSIS PLANS BETWEEN BOTH
CORE LABS FOR THE REANALYSIS. After establishing
the differences in QCA plans, the 2 core labs agreed to
perform a post-hoc reanalysis. It was decided to use
FIGURE 1 Inﬂuence of Core Lab Alignment on the QCA Trial Results
(A) The divergent results are shown of the initial quantitative coronary analysis (QCA), in a
subgroup of 130 patients, with regard to in-segment diameter stenosis of the side branch
at 9-month follow-up. (B) After reanalysis of the complete angiographic cohort (n ¼ 311),
both core labs show similar results.
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the dedicated CAAS bifurcation software for rean-
alysis, considering the superior accuracy and preci-
sion of this method compared with single-vessel
algorithms (12). After delineating the region of inter-
est and the automatic detection of the vessel con-
tours, the analysts were not allowed to manually edit
the vessel contour, except in cases were the vessel
contour was erroneously not following the vessel
contour, as previously described (Online Figure 2).
Segmentation of the bifurcation was performed
automatically by the software and the %DS was
calculated using the interpolated RVD at the site of
the MLD in each segment. All QCA measurements
were performed on a single worst projection. Both
core labs performed their QCA on exactly the same
frame, which was selected by the CRF core lab.
STATISTICAL ANALYSES. The individual signed dif-
ferences of both core labs were averaged; the mean
of these signed differences (bias) was used as a
measure of accuracy and the standard deviation as
a measure of precision (20). The agreement between
both core labs with regard to the measurement of
%DS of the side branch (in-segment) was evaluated
by nonparametric orthogonal regression analysis us-
ing the Passing-Bablok method (21). The differences
in %DS of the side branch between core labs were also
displayed using Bland-Altman plots: the mean of both
core lab measurements were plotted on the horizontal
axis against the individual signed differences of both
core labs on the vertical axis. The 95% limits of
agreement (mean difference [bias]  1.96 SD of the
bias) were determined as the measure of variability.
For the Passing-Bablok regression analysis, STATA
(version 12, StataCorp LP, College Station, Texas) was
used. All other statistical analyses were performed
using the SPSS software package (version 21.0, IBM,
Chicago, Illinois).
RESULTS
INTER–CORE LAB VARIABILITY. Inter–core lab vari-
ability of the initial QCA analysis of the 130 subjects
is shown in Table 2. Core lab A systematically
measured larger RVD, MLD, and %DS in both main
branch and side branch compared with Core Lab B.
Furthermore, the 95% limits of agreement were wide
for all QCA parameters, indicating a marked vari-
ability between both core labs. The average difference
in the in-segment %DS of the side branch (the key
secondary endpoint of the Tryton IDE trial, powered
for superiority) was 5.54%, with the 95% limits of
agreement between –26.74% and 37.82% (Figure 4).
Passing-Bablok orthogonal linear regression analysis
showed systematic as well as proportional bias be-
tween both core labs with regard to the measurement
of in-segment %DS of the side branch, with an inter-
cept of 7.1% (95% conﬁdence interval [CI]: 4.5% to
10.0%) and a slope of 0.62 (95% CI: 0.50 to 0.74)
(Figure 4).
From the 374 patients included in the pre-speciﬁed
angiographic cohort, 326 patients returned for repeat
angiography (87%). From these 326 patients, 311
matched cases were used to assess the inter–core
lab variability after QCA reanalysis. In 15 cases,
angiography was not available for both core labs due
to missing or corrupt CDs. After reanalysis of the total
angiographic cohort using the same QCA analysis
TABLE 1 Initial QCA Analysis Plans of Both Core Laboratories and After Alignment
Initial QCA Analysis Plan CRF Initial QCA Analysis Plan Cardialysis Aligned QCA Analysis Plan for Reanalysis
QCA software used
Software type QAngio XA (Medis) CAAS (Pie Medical) CAAS
Version Version 7.2.34 Version 5.9 Version 5.9 (Cardialysis) and 5.11 (CRF)
Algorithm used Single-vessel algorithm, separately
applied on the main and side branch
Dedicated bifurcation algorithm Dedicated bifurcation algorithm
QCA analysis
Vessel contour
detection
Manual editing was allowed after
automatic vessel contour detection
Automatic contour detection with
restricted use of manual editing
Automatic contour detection with
restricted use of manual editing
Segmentation User-deﬁned, manual segmentation Automatic segmentation Automatic segmentation
RVD of the MB The average of the distal and proximal
user-deﬁned MB references
Interpolated reference automatically
generated by the software
Interpolated reference automatically
generated by the software
RVD of the SB User-deﬁned distal SB segment Interpolated reference automatically
generated by the software
Interpolated reference automatically
generated by the software
Number of views
used
Single, “worst” view was used Average of $2 views to account
for lumen eccentricity
Single, “worst” view was used
CAAS ¼ Coronary Angiography Analysis System; CRF ¼ Cardiovascular Research Foundation; MB ¼ main branch; QCA ¼ quantitative coronary angiography; RVD ¼ reference
vessel diameter; SB ¼ side branch.
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FIGURE 2 Initial QCA Analysis Plan of CRF Using a Single-Vessel Algorithm
(A) Diagnostic angiogram of a patient with a left anterior descending–diagonal branch bifurcation lesion. QCA was performed using the
conventional single-vessel algorithm of QAngio XA (Medis) software. The region of interest of the diagonal branch was deﬁned by indicating
the proximal and distal boundaries (B; long white arrows). Hereafter, the QCA software automatically detected the vessel contour based on the
change in brightness of the pixels (C). (D) The software detected the contour in the so-called polygon of conﬂuence. Note that the software
detected the outermost vessel wall, opposite to the side branch ostium, as vessel contour (short white arrows). Then, segmentation is
performed manually. (E) Two examples of different segmentations with different side branch origins (green line 1 vs. orange line 2) are shown,
illustrating the potential bias introduced by the manual segmentation. (F) The diameter function as displayed in the QCA report. Note that a
difference in segmentation of the side branch origin (green line 1 vs. orange line 2), results in a difference of in-segment side branch minimal
lumen diameters (0.72 mm [yellow arrow] vs. 1.11 mm [white arrow]), because the true minimal lumen diameter of the complete region of
interest (0.72 mm) was not included in the side branch segment by the second segmentation (orange line 2). (G) The percentage diameter
stenosis was calculated for the initial trial results by using the diameter of the distal normal segment as the reference vessel diameter. Note
how differences in side branch segmentation resulted in differences in percentage diameter stenosis of the side branch. Note that this ﬁgure is
included for illustrative purposes and it does not represent actual analyses performed in the trial. CRF ¼ Cardiovascular Research Foundation;
QCA ¼ quantitative coronary angiography.
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plan with the same frame and QCA bifurcation soft-
ware, less systematic bias was observed (Table 2). The
side branch in-segment QCA measurements were
almost identical between both core labs; only small
average differences were observed with regard to
the MLD (–0.0297 mm; 95% limits of agreement:
–0.4683 to 0.4089 mm) and the RVD (0.0227 mm;
95% limits of agreement: –0.4193 to 0.4647 mm),
FIGURE 3 Initial QCA Analysis Plan of Cardialysis Using a Bifurcation Algorithm
QCA analysis of the same bifurcation lesion as in Figure 2, now performed using the dedicated bifurcation algorithm of the Coronary
Angiography Analysis System (CAAS) software. The bifurcated region of interest was deﬁned by indicating the boundaries in the proximal main
branch, distal main branch, and side branch (A; white arrows). After automatic detection of the vessel contour (B), analysts were not allowed to
further edit the vessel contour manually. (C) The point of bifurcation (POB) and the 3 centerlines. Before the software calculates the QCA
parameters, the analysts deﬁned the proximal and distal ends of the main branch stent and the distal end of the Tryton stent/balloon in the side
branch (D; white lines). (E) The 3 segments of the bifurcation (segments 2, 3, and 5) plus the proximal and distal 5-mm stent/balloon edges
(segments 1, 4, and 6) are shown. (F) The QCA diameter function of the proximal main branch and distal daughter vessels (i.e., distal main
branch and side branch) is shown. Note that each subsegment has its own interpolated reference diameter function, based on the complete
bifurcated region of interest (white vertical lines corresponding with the white lines in D, indicating the stent/balloon edges). (G) The QCA
parameters are shown as they are displayed in the QCA report. Note that the in-segment side branch stenosis calculation is based on the
interpolated reference diameter at the site of the minimal lumen diameter. Note that this ﬁgure is included for illustrative purposes and does
not represent actual analyses performed in the trial. QCA ¼ quantitative coronary angiography.
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resulting in an average difference in %DS of 1.8%
(95% limits of agreement: –16.7% to 20.4%) (Figure 4).
Finally, orthogonal linear regression analysis showed
a marked improvement in reproducibility between
core labs with regard to the measurement of in-
segment %DS of the side branch. The intercept of
the orthogonal regression line was close to 0%, with
0% being enclosed in the 95% CI (intercept: 0.8%,
95% CI: –0.8% to 2.5%), suggesting there was no
systematic bias. The slope of the orthogonal regres-
sion line was closer to the identity line with the
identity line almost being enclosed in the 95% CI,
suggesting only a minimal proportional bias between
both core labs after reanalysis (slope: 0.94, 95%
CI: 0.88 to 0.99) (Figure 4).
Initial QCA analysis in the subgroup of 130 patients
showed diverging results between both core labs
with regard to the Tryton IDE trial key secondary
endpoint of in-segment %DS of the side branch
(Figure 1A). However, after complete reanalysis using
contemporary bifurcation QCA software without the
routine use of manual contour editing and manual
segmentation, both core labs showed similar results
with regard to in-segment %DS of the side branch
(Figure 1B).
DISCUSSION
Our study, for the ﬁrst time, has highlighted a
marked inter–core lab variability in bifurcation QCA
measurements due to the use of different QCA soft-
ware and methodology. After using the same QCA
bifurcation software and aligning the methodology
of the QCA core labs, the inter–core lab variability
improved considerably. Furthermore, after aligning
the QCA methodology, we have demonstrated
that the trial results were affected. These ﬁndings
emphasize the importance of standardization of
QCA methodology among the different core labs.
The steering committee did acknowledge the
methodological differences between core labs that
have been raised retrospectively after the database
have been locked for the IDE submission to the
U.S. Food and Drug Administration. During the
designing phase of the trial, however, the validation
of the CAAS bifurcation QCA algorithm against a
precision bifurcation phantom model was not yet
published (14), and therefore the bifurcation algo-
rithm not yet integrated in the core lab responsible
for the baseline and follow-up QCA analyses. It was
decided to report the data according to the initial
approved methodological plan and analysis in the
main paper, while reporting the post-hoc QCA
results using the bifurcation software in the Online
Appendix (22).
USE OF SINGLE-VESSEL VERSUS DEDICATED
BIFURCATION SOFTWARE. One of the potential
explanations for the differences in the initial anal-
ysis was the use of a single-vessel QCA algorithm,
which is less accurate than a dedicated bifurcation
algorithm is and introduces a systematic bias for
several reasons (8,12). Due to the fractal geometry of
the epicardial coronary tree, there is a natural
tapering of the coronaries with different vessel di-
ameters proximal to and distal from each bifurcation
(9). When using a single-vessel algorithm, the
interpolated reference is determined by the di-
ameters of the proximal and distal branches, which
are by deﬁnition unequal, resulting in a systematic
underestimation of the RVD and %DS in the prox-
imal main branch, and an overestimation of the RVD
and %DS in the distal main branch and side branch
(8). In addition, if the reference diameter is selected
from a normal segment distal to the balloon/stent in
TABLE 2 Table Showing the Inter–Core Lab Variability Before and After Alignment of Core Lab Methodologies
Initial Analysis (n ¼ 130) After Reanalysis of Both Core Labs (n ¼ 311)
Mean Signed
Differences (Bias)
Standard Deviation
(Precision)
95% Limits
of Agreement
Mean Signed
Differences (Bias)
Standard Deviation
(Precision)
95% Limits of
Agreement
Main branch
RVD, mm 0.2710 0.4216 –0.5553 to 1.0973 –0.0108 0.3464 –0.6681 to 0.6897
In-segment MLD, mm 0.1445 0.4420 –0.7218 to 1.0108 –0.0101 0.2652 –0.5299 to 0.5097
In-segment %DS, % 2.81 13.42 –23.47 to 29.11 –0.04 11.44 –22.46 to 22.38
In-stent MLD, mm 0.2030 0.4271 –0.6341 to 1.0401 –0.0084 0.3006 –0.5976 to 0.5808
In-stent %DS, % 0.48 12.10 –23.24 to 24.20 0.69 11.85 –22.54 to 23.92
Side branch
RVD, mm 0.2240 0.3376 –0.4377 to 0.8857 0.0227 0.2255 –0.4193 to 0.4647
In-segment MLD, mm 0.0322 0.4574 –0.8643 to 0.9287 –0.0297 0.2238 –0.4683 to 0.4089
In-segment %DS, % 5.54 16.47 –26.74 to 37.82 1.84 9.45 –16.68 to 20.36
%DS ¼ percentage diameter stenosis; MLD ¼ minimal lumen diameter; RVD ¼ reference vessel diameter.
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the side branch to calculate the %DS, this can
introduce a subjective random error when compared
with the interpolated reference diameter based on
the vessel contour of the complete region of interest
encompassing the side branch (Figure 2). Further-
more, in the so-called polygon of conﬂuence, the
single-vessel software is not able to deﬁne the
vessel contour automatically and often requires
manual editing, potentially introducing another
factor of random error (Figure 2D, Online Figure 1).
Finally, single-vessel algorithms do not recognize
the origin of the distal branches, requiring manual
segmentation, which may introduce another bias
(Figures 2E and 2F).
MANUAL CONTOUR EDITING. Another potential
explanation for the differences in the initial anal-
ysis was the difference in allowance for manual cor-
rections. Lack of smoothness of the automatic
contour delineation, observed when the angiogram is
FIGURE 4 Inter–Core Lab Variability Between CRF and Cardialysis Before and After Alignment of Methodology With Regard to the In-Segment
Percentage Side Branch Stenosis
(A) shows a weak agreement between CRF and Cardialysis with regard to the initial measurements of the in-segment side branch stenosis at 9-
month follow-up. (B) shows a considerable improved agreement between CRF and Cardialysis after reanalysis of the total cohort (solid lines ¼
orthogonal regression lines, dashed lines ¼ 95% conﬁdence intervals of these regression lines). (C and D) show Bland-Altman plots of in-
segment side branch stenosis, with the mean between core labs on the horizontal axis plotted against the signed differences on the vertical
axis. The solid lines represent the mean difference, whereas the dashed lines indicate the 95% limits of agreement (1.96  SD of the mean
difference). Note that after reanalysis (D), the mean difference between core labs was smaller, with less wide limits of agreement indicating
improved accuracy and precision. CRF ¼ Cardiovascular Research Foundation.
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of suboptimal quality (23), should be accepted as
such. Manual editing will introduce subjectivity
(Online Figure 1) and should be allowed only in those
cases where the algorithm erroneously detects other
structures than the vessel contour (side branches, for
example). Analysts should use the “restriction func-
tion” to exclude an area for the automatic contour
detection instead of completely redrawing it them-
selves (Online Figure 2). All corrections and adjust-
ments made after completion of the QCA analysis
should be captured by audit trails and ﬁnal approval
of the QCA should be electronically signed to fulﬁll
the Code of Federal Regulation Title 21, part 11 (CFR
21, part 11) guideline of the U.S. Food and Drug
Administration, which deﬁnes the criteria for reliable
electronic data capturing.
REMAINING INTER–CORE LAB VARIABILITY COMPARED
WITH THE ACCURACY AND PRECISION OF THE
BIFURCATION SOFTWARE. Although the reproduc-
ibility improved remarkably after aligning the core
lab methodology, some systematic bias remained.
This remaining inter–core lab bias for the in-segment
side branch QCA parameters was 0.0227 mm (RVD),
–0.0297 mm (MLD), and 1.84% (%DS) (Table 2). We
believe this is acceptable, considering that the
intrinsic accuracy of the CAAS bifurcation software,
calibrated on a precision phantom model, was com-
parable to this bias: 0.032 mm (side branch RVD),
0.017 mm (side branch MLD), and 0.88% (side
branch %DS) (12).
Inter–core lab variability (standard deviation of
the bias) after reanalysis was 0.2255 mm for the
in-segment side branch RVD, 0.2238 mm for the
in-segment side branch MLD, and 9.45% for the in-
segment %DS. This variability is a little higher as
would have been expected from the phantom vali-
dation, which showed precision of the bifurcation
software of 0.075 mm (side branch RVD), 0.123 mm
(side branch MLD), and 5.35% (side branch %DS) (12).
This somewhat higher variability might be explained
by differences in calibration. Whereas the calibration
in the phantom validation study was performed using
a grid in a static model, the calibration in the current
study was performed using the guiding catheter in
close proximity of the beating heart. Although cali-
bration is preferably performed in the same frame as
the QCA analysis, sometimes this is not possible and
calibration in another frame is needed, which may
introduce extra variability. Given the fact that most
angiograms have a calibration factor of w0.2000 mm/
pixel, a precision with regard to measuring the
MLD and RVD being around this number can be
considered as acceptable.
IMPLICATIONS. Although core lab analysts are
ideally blinded to the treatment groups to minimize
bias, this is not always possible. This is a major limi-
tation, which is not restricted to the current Tryton
IDE trial, but also applies to other trials such as
trials comparing metallic stents with bioresorbable
scaffolds or different types of transcatheter aortic
valves. This is important to realize because device
and pharmaceutical companies cover the costs of the
analysis, which makes core labs not completely in-
dependent. Therefore, it is vital to use a methodology
in which the analysis is performed as automatically
as possible to minimize human subjectivity, with
manual corrections restricted to a minimum.
It seems to remain challenging to aim for stan-
dardization of QCA methodology in various core
labs worldwide (11). Our study has highlighted the
importance of using the same QCA methodology
among different core labs, using software validated
on the same high-resolution calibrated bifurcation
phantom model (10,14,16,24), to ensure reproduc-
ibility and objectivity. Although standard operating
procedures are often not shared because they are
considered intellectual property of the core lab, we
believe it is important to share at least the key
factors of the QCA methodology to ensure re-
producible and generalizable results. Considering
cross-validation, using 2 distinct core labs, of a pre-
speciﬁed proportion of patients enrolled might even
be a valid option to ensure identiﬁcation of any
potential issues precluding data accuracy and
reproducibility.
STUDY LIMITATIONS. Because the agreed QCA rean-
alysis plan included the use of exactly the same
angiographic view and frame, selected by 1 of the
core labs, this study did not investigate the role of
frame selection on the inter–core lab variability.
Although it has been shown that differences in frame
selection from the same angiographic view does not
inﬂuence the accuracy and variability to a large
extent (25), differences in selection of the angio-
graphic view itself is a major determinant of vari-
ability in QCA (26).
CONCLUSIONS
We found a marked inter–core lab variability in QCA
of bifurcation lesions when different QCA methodol-
ogies were used, including difference in software use
(single-vessel vs. dedicated bifurcation software),
differences in allowance for manual vessel contour
correction, and differences in the method for seg-
mentation (automatic vs. manual). However, when
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the same methodology was used, inter–core lab vari-
ability decreased considerably. More importantly,
QCA results of the trial were affected following
alignment of the methodology. This latter ﬁnding
emphasizes the importance of using the same QCA
methodology among different core labs worldwide.
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Comparison Between Two- and Three-dimensional
Quantitative Coronary Angiography Bifurcation
Analyses for the Assessment of Bifurcation Lesions:
A Subanalysis of the TRYTON Pivotal IDE Coronary Bifurcation
Trial
Takashi Muramatsu,1,2 MD, PhD, Maik J. Grundeken,3 MD, Yuki Ishibashi,1 MD, PhD,
Shimpei Nakatani,1 MD, Chrysafios Girasis,1,4 MD, Carlos M. Campos,1,5 MD,
Marie-Ange`le Morel,6 BSC, Hans Jonker,6 BSC, Robbert J. de Winter,3 MD, PhD,
Joanna J. Wykrzykowska,3 MD, PhD, Hector M. Garcıa-Garcıa,1,6 MD, PhD,
Martin B. Leon,7 MD, Patrick W. Serruys,8* MD, PhD, and Yoshinobu Onuma,1 MD, PhD,
On behalf of the TRYTON Pivotal IDE Coronary Bifurcation Trial Investigators
Background: Three-dimensional (3D) quantitative coronary angiography (QCA) provides
more accurate measurements by minimizing inherent limitations of two-dimensional
(2D) QCA. The aim of this study was to compare the measurements between 2D and
3D QCA analyses in bifurcation lesions. Methods and Results: A total of 114 cases
with non-left main bifurcation lesions in the TRYTON pivotal IDE Coronary Bifurcation
Trial (ClinicalTrials.gov: NCT01258972) were analyzed using a validated bifurcation QCA
software (CAAS 5.10, Pie Medical Imaging, Maastricht, the Netherlands). All cases
were analyzed in matched projections between pre- and post-procedure. The 2D analy-
sis was performed using one of two angiographic images used for 3D reconstruction
showing a larger distal bifurcation angle. In the treated segments (stent and balloon),
there were no differences in minimal luminal diameter (MLD) between 2D and 3D, while
diameter stenosis (DS) was significantly higher in 2D compared to 3D both pre-
procedure and post-procedure (53.9% for 2D vs. 52.1% for 3D pre-procedure, P<0.01;
23.2% for 2D vs. 20.9% for 3D post-procedure, P50.01). In the sub-segment level anal-
ysis, lengths of proximal main branch, distal main branch, and side branch were con-
sistently shorter in 2D compared to 3D both pre-procedure and post-procedure. Using
3D QCA, the anatomic location of the smallest MLD or the highest DS was relocated
to a different bifurcation sub-segment in a considerable proportion of the patients
compared to when 2D-QCA was used (kappa values: 0.50 for MLD, 0.55 for DS).
Conclusions: Our data showed differences in addressing anatomical severity and
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location of coronary bifurcation lesions between in vivo 2D and 3D QCA analyses.
More studies are needed to investigate potential clinical benefits in using 3D approach
over 2D QCA for the assessment of bifurcation lesions. VC 2015 Wiley Periodicals, Inc.
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INTRODUCTION
Quantitative coronary angiography (QCA) has been
introduced in the mid-eighties to overcome the short-
comings of visual assessment of stenosis severity, such
as a marked inter- and intra-observer variability [1–4].
Conventional two-dimensional (2D) QCA has been
accepted as an objective and reproducible method to
quantify coronary lesion severity, and QCA parameters
have been accepted as surrogate endpoints in numerous
randomized clinical trials evaluating the efficacy of new
technologies in percutaneous coronary interventions
(PCI) and the effect of new pharmaceutical agents on
coronary artery disease progression/regression [5–7].
Even in the era of drug-eluting stents (DES), bifurca-
tion lesions have still been recognized as one of the
most challenging lesion subsets [8,9]. As a consequence
of the fractal geometry of the coronary tree, there is a
natural step-down of diameters proximal and distal to
the bifurcation [10,11]. The interpolation method of the
single-vessel QCA algorithms to estimate the reference
vessel diameter (RVD) is therefore inaccurate, structur-
ally underestimating the RVD and percentage diameter
stenosis (DS) in the proximal main branch (MB), and
overestimating the RVD and DS of the distal MB and
side branch (SB) [11,12] Dedicated bifurcation 2D QCA
algorithms have therefore been developed to improve
the accuracy of QCA in bifurcation lesions [12–14].
However, 2D bifurcation techniques also include
several inherent limitations, such as vessel overlap and
foreshortening that can lead to inaccurate angiographic
assessment. Three-dimensional (3D) QCA techniques
have been developed to overcome these limitations,
improving the accuracy of QCA, as shown in a phan-
tom bifurcation model [15]. To date, however, compar-
isons between 2D and 3D bifurcation QCA have not
yet been performed in real life. The aim of this study
was therefore to compare the angiographic measure-
ments between 2D and 3D QCA analyses in human
coronary bifurcation lesions using validated bifurcation
QCA analysis software.
METHODS
Study Overview
The TRYTON Pivotal IDE (Investigational Device
Exemption) Coronary Bifurcation Trial is a prospec-
tive, multicenter, single-blind, randomized controlled
study to evaluate the safety and efficacy of the Tryton
side branch stent (Tryton Medical, Durham, NC) in
coronary bifurcation lesions [16]. Patients with single
de novo lesion in a non-left main bifurcation were
randomized in a 1:1 fashion to either the Tryton stent
or SB balloon angioplasty (SBBA), both in conjunction
with a DES in the MB.
The details of the Tryton side branch stent were
described elsewhere [16–18]. The Tryton stent is a
balloon-expandable cobalt chromium (CoCr) bare-
metal stent with strut thickness of 84 lm. It is com-
prised of three zones (a distal side branch, a transition,
and a proximal MB zone), and is implanted in the SB
before an approved conventional DES was implanted
in the MB. The study protocol was approved by the
institutional review boards or medical ethics commit-
tees at each participating center. This study was regis-
tered at ClinicalTrials.gov (identifier: NCT01258972).
Written informed consent was obtained for all enrolled
patients. In the present analysis, angiographic data
were pooled and analyzed regardless of randomization.
Quantitative Coronary Angiography Assessment
Off-line QCA analyses were performed using the
Cardiovascular Angiography Analysis System software
(CAAS 5.10, Pie Medical Imaging, Maastricht, The
Netherlands) in an independent angiographic core labo-
ratory (Cardialysis B.V., Rotterdam, The Netherlands).
The treated segments were defined by three borders.
The proximal MB border was defined by the proximal
MB DES stent edge, the distal MB border was defined
by the distal MB DES stent edge, and the SB border
was defined by either the distal Tryton stent edge or
the distal marker of the most distal balloon used in the
case of SBBA (Fig. 1). The in-segment analyses
included the treated segment plus 5 mm proximally to
the proximal border of MB, and 5-mm distally to the
distal borders of MB and SB.
Only matched pre- and post-procedural projections
were used for QCA analyses. Calibration was per-
formed automatically in both 2D and 3D analysis with
the geometric data of acquisitions provided through the
DICOM headers. Three-dimensional QCA analyses
were performed first, using two angiographic images
separated by a viewing angle of 30 . Subsequently,
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2D analyses were performed by using one of the angio-
graphic images used in 3D QCA with the largest distal
BA (Fig. 2).
Minimal lumen diameter (MLD), DS, and RVD were
quantified pre- and post-procedurally. The MLD in the
3D QCA analysis was derived from the absolute mini-
mal lumen area using the so-called “equivalent diame-
ters” methodology, as previously published [19]
(Supporting Information, Fig. S1). The RVD was calcu-
lated with automatic reference obstruction analysis [13],
and the DS was automatically calculated from the
MLD and the RVD. The QCA analyses were performed
according to the six-segment model (BSM6) [14] plus
the 3-mm ostial SB segment of the 11-segment model
(BSM11) (Fig. 3) [14]. Bifurcation angle (BA) values
were calculated according to the methodology described
previously [13,19]. Binary stenosis was defined as the
presence of stenosis with a DS of 50%.
Statistical Analysis
Continuous variables were expressed as mean SD
and categorical variables as counts and percentages.
Comparisons were performed by paired t test for con-
tinuous variables and chi-squared test for categorical
variables. Agreements between 2D and 3D analyses in
detecting the sub-segment with the smallest MLD or
the highest DS were evaluated using kappa statistics. A
P value <0.05 was considered statistically significant.
Statistical analyses were performed using SPSS Statis-
tics version 21 (IBM, Armonk, NY).
RESULTS
Study Population
A total of 114 patients (114 bifurcation lesions,
matched between pre- and post-procedure) were used
for the paired 2D and 3D analyses (Supporting Infor-
mation, Fig. S2).
Subsegment Level Analysis
Subsegment analyses based on the BSM6 model are
shown in Table I. Preprocedurally, 2D-MLD was
smaller than 3D-MLD in the proximal MB, while the
2D-MLD was larger than 3D-MLD in the SB. Post-
procedurally, 2D-MLD was smaller than 3D-MLD in
Fig. 1. Treatment procedure using the Tryton stent and the
definition of the treated segment. A bifurcation lesion was
observed in the mid segment of left anterior descending ar-
tery and a diagonal branch (left in panel A). After pre-dilata-
tion, a Tryton stent was implanted toward the side branch
(center left), then a drug-eluting stent was implanted through
the Tryton stent in the main vessel (center right). The final
angiogram showed good results (right). The treated seg-
ments were delineated using three white lines (see white
arrows) at the proximal main branch (PMB), distal main
branch (DMB), and side branch (SB) in the matched projec-
tions (white arrows, pre-procedure in panel B and post-pro-
cedure in panel C). Specifically, the proximal and distal
borders of the main vessel were set at the proximal and dis-
tal edge of the DES implanted, respectively. In this case, the
distal border of side branch was defined as the distal edge
of the Tryton stent.
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the distal MB. Specifically at the ostial SB, there were
no differences in MLD between 2D and 3D QCA
(both pre- and post-procedure). Pre-procedural RVD
was consistently larger in 2D QCA than in 3D QCA in
the proximal MB, distal MB, and SB. Post-procedural
RVD was larger with 2D QCA only in the proximal
MB, while in the other segments the RVD was similar
between 2D QCA and 3D QCA. These differences in
MLD and RVD resulted in differences in pre- and
post-procedural DS in the proximal MB and ostial SB
(Fig. 4). Segment lengths were consistently shorter
with 2D QCA than with 3D QCA in all sub-segments,
both pre- and post-procedure.
Treated Segment Level Analysis
There were no differences in either in-segment MLD
or treated segment MLD between 2D and 3D QCA
both pre- and post-procedure (Table II). Conversely,
2D QCA showed a trend toward a higher in-segment
DS compared to 3D QCA, while in the treated segment
DS appeared to be significantly higher in 2D QCA
than in 3D QCA both pre-procedure (53.9% 12.4%
vs. 52.1% 11.3%, P< 0.01) and post-procedure
(23.2% 10.9 vs. 20.9% 11.9%, P¼ 0.01) (Fig. 5).
Bifurcation Angle Analysis
Bifurcation angle analyses are shown in Table III.
Proximal bifurcation angles (BAPMB-SB) were signifi-
cantly larger in 2D QCA than in 3D QCA both pre-
procedure and post-procedure, while there were no dif-
ferences in pre- and post-procedural distal bifurcation
angles (BADMB-SB) between 2D and 3D QCA. Post-
procedurally BAPMB-SB became significantly larger and
BADMB-SB became significantly smaller in both 2D and
3D QCA.
Comparisons of Locations With the Smallest
MLD or the Highest DS Between 2D and 3D QCA
Pre-procedural locations with the smallest MLD
and the highest DS among sub-segments based on the
BSM6 model are shown in Fig. 6. There were appa-
rent inconsistencies in location (i.e., sub-segments)
having in-segment smallest MLD and highest DS
between 2D and 3D analyses. In the BSM6 model,
2D QCA indicated 49 cases and 3D QCA indicated
Fig. 2. Two-dimensional (2D) and three-dimensional (3D)
QCA assessments. Severe stenosis was evident at the ostium
of side branch (yellow arrows) in the LAO cranial view (panel
A), while this part was overlapped and “hidden” by the over-
lapping main vessel in the RAO cranial view (panel B). An
angiogram with the largest bifurcation angle between distal
main branch and side branch was used for 2D quantitative
coronary angiography assessment in the current analysis
(e.g., the panel A in this case).
Fig. 3. Bifurcation segment models in the cardiovascular an-
giography analysis system (CAAS). A composite of segments
2, 3, and 5 in bifurcation six-segment model (BSM6) corre-
sponds to the “treated segment,” where the stents were
implanted or balloons were dilated, including the proximal
main branch (PMB), distal main branch (DMB) and side
branch (SB) respectively. The segments 2, 3, and 5 are di-
vided by the point of bifurcation (POB) defined as the point
where all the centerlines meet and the midpoint of the largest
circle/sphere that can reach all three contours in bifurcation
[13]. Segments 1, 4, and 6 correspond to 5-mm segments
beyond the treated segment (left panel). Segment 8 in BSM11
reflects 3-mm ostial segments of SB (right panel). In this
study, “in-segment” corresponds to a composite of all seg-
ments in BSM6.
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63 cases having the smallest pre-procedural MLD
within the SB (segment 5 in the BSM6 model). Simi-
larly, 2D and 3D QCA indicated the SB as the loca-
tion of the highest pre-procedural DS in 27 and 40
cases, respectively. For the agreement between 2D
and 3D QCA in determining the location of the sub-
segment with the smallest pre-procedural MLD, the
kappa value was 0.50. For the agreement to deter-
mine the location of the highest pre-procedural DS,
the kappa value was 0.55.
TABLE I. Subsegment Level Analysis (Paired Samples N5 114)
Paired samples (N¼ 114)
Variables 2-D QCA 3-D QCA P value
Pre-procedure
Proximal main branch (segment 2 in BSM6)
MLD (mm) 1.75 0.65 1.84 0.61 <0.01
RVD (mm) 3.00 0.57 2.71 0.51 <0.01
DS (%) 41.4 19.5 31.7 19.4 <0.01
Length (mm) 8.34 4.23 9.25 4.72 <0.01
Binary stenosis rate, n (%) 40 (35.1) 25 (21.9) 0.03
Distal Main Branch (segment 3 in BSM6)
MLD (mm) 1.32 0.36 1.33 0.37 0.68
RVD (mm) 2.24 0.40 2.21 0.40 0.08
DS (%) 40.2 15.6 38.9 15.3 0.28
Length (mm) 9.87 5.27 11.63 6.56 <0.01
Binary stenosis rate, n (%) 36 (31.6) 27 (23.7) 0.18
Side Branch (segment 5 in BSM6)
MLD (mm) 1.29 0.38 1.22 0.41 0.02
RVD (mm) 2.08 0.36 1.99 0.33 <0.01
DS (%) 37.8 15.8 38.9 16.7 0.46
Length (mm) 6.23 1.86 6.79 2.23 <0.01
Binary stenosis rate n (%) 30 (26.3) 29 (25.4) 0.88
Ostial Side Branch (segment 8 in BSM11)
MLD (mm) 1.42 0.41 1.44 0.45 0.63
RVD (mm) 2.08 0.35 1.99 0.33 <0.01
DS (%) 31.6 16.3 28.1 16.9 0.02
Length (mm) 2.95 0.39 2.94 0.41 0.57
Binary stenosis rate n (%) 18 (15.8) 9 (7.9) 0.07
Post-procedure
Proximal main branch (segment 2 in BSM6)
MLD (mm) 2.89 0.39 2.89 0.38 0.91
RVD (mm) 3.28 0.44 3.11 0.42 <0.01
DS (%) 11.52 7.25 6.86 6.64 <0.01
Length (mm) 8.01 4.02 8.70 4.35 <0.01
Binary stenosis rate, n (%) 0 (0.0) 0 (0.0) 1.00
Distal Main Branch (segment 3 in BSM6)
MLD (mm) 2.38 0.32 2.42 0.34 0.04
RVD (mm) 2.66 0.32 2.66 0.31 0.84
DS (%) 10.35 8.37 9.28 6.11 0.14
Length (mm) 10.05 5.04 11.40 6.03 <0.01
Binary stenosis rate, n (%) 0 (0.0) 0 (0.0) 1.00
Side branch (segment 5 in BSM6)
MLD (mm) 1.78 0.39 1.75 0.40 0.23
RVD (mm) 2.18 0.31 2.15 0.42 0.37
DS (%) 18.28 14.13 18.61 13.17 0.77
Length (mm) 6.41 2.03 6.66 2.23 0.09
Binary stenosis rate, n (%) 4 (3.5) 2 (1.8) 0.41
Ostial side branch (segment 8 in BSM11)
MLD (mm) 1.81 0.40 1.85 0.39 0.08
RVD (mm) 2.19 0.31 2.16 0.42 0.3
DS (%) 17.58 13.66 14.14 11.62 <0.01
Length (mm) 2.97 0.44 2.96 0.43 0.61
Binary stenosis rate n (%) 4 (3.5) 1 (0.9) 0.18
MLD¼minimal luminal diameter, RVD¼ reference vessel diameter, DS¼ diameter stenosis, BSM¼ bifurcation segment model.
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DISCUSSION
The main findings of this study can be summarized
as follows: (1) DS were estimated to be higher when
2D QCA was used as compared when 3D QCA was
used, specifically within the SB ostium; (2) in most
sub-segments, this difference was based on larger RVD
as measured with 2D QCA, while MLDs were similar
between 2D and 3D, except for the proximal MB (pre-
procedure) and distal MB (post-procedure), in which
the difference in DS was explained by a smaller MLD
measured by 2D QCA; (3) segment lengths appeared
to be shorter in 2D than in 3D QCA; (4) bifurcation
angles were influenced by 2D and 3D analyses; and
(5) the agreement between 2D and 3D QCA to define
the locations with the smallest MLD and the highest
DS was poor.
There have been two studies that compared 2D and
3D QCA in bifurcation lesions [20,21]. However, these
studies used different software with different analysis
Fig. 4. Bland–Altman plots and cumulative frequency distribution (CFD) curves of pre-
procedural MLD and DS in the ostial side branch. In the Bland–Altman plots (upper panels),
solid lines indicate the mean difference between 2D and 3D analyses and dotted lines indi-
cate the upper and lower limit of agreement (LOA). In the CFD curves (lower panels), blue
circles indicate 2D QCA and red squares indicate 3D QCA. MLD5minimal luminal diameter,
DS5diameter stenosis.
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algorithms for the 2D and 3D QCA analyses. We dem-
onstrated that the CardiOp-B system (Paeion Medical,
Rosh Ha’ayin, Israel), used for the 3D QCA analyses
in both studies, was less accurate with respect to the
measurements of luminal diameter and area when com-
pared to the CAAS system [22]. We then applied the
CAAS bifurcation analysis algorithms systematically to
2D and 3D QCA that has been validated in the plexi-
glas bifurcation phantom models with excellent inter-
and intra-observer reproducibility [14,15,23]. In the
present study, sub-segment level analysis based on the
BSM6 model showed a trend toward higher DS in 2D
QCA than in 3D QCA. The differences in DS between
the two QCA approaches could partially be explained
by a larger RVD found with 2D QCA. The RVD at the
MLD site is an interpolated reference diameter based
on the non-stenotic lumens of the analyzed region of
interest. In some sub-segments, a larger RVD deter-
mined with 2D analysis might imply an overestimation
of the non-stenotic regions, resulting in a larger inter-
polated RVD at the MLD site as compared to 3D anal-
ysis. Another possible explanation is that the luminal
shape at the MLD site is often not circular (concentric
plaque), but elliptical (eccentric plaque). 3D QCA
derived MLD is calculated as an “equivalent diameter”
based on the circular assumption of the cross-section
(Supporting Information, Fig. S1). For the current
study, 2D analysis was based on a single projection,
which could result in a smaller MLD if the projection
was perpendicular on the smallest diameter of the ellip-
tical lumen. Furthermore, we found a low agreement
between 2D and 3D QCA to define the location of the
smallest in-segment MLD. As a result, there might also
be a difference in DS because the MLD was located in
a somewhat different site, even in the same sub-
segment, because the two modalities uses different
methodology to calculate the MLD (i.e., smallest area
in 3D vs. smallest diameter in 2D) as mentioned
above. Consequently, the interpolated RVD might be
larger at that site leading to higher DS.
Accuracy in length derivation is one of advantages
of 3D QCA by minimizing possible vessel foreshorten-
ing commonly seen in 2D QCA [15,19,24]. In the pres-
ent study, the length of each sub-segment (proximal
MB, distal MB, and SB) appeared to be significantly
shorter in 2D than in 3D QCA. This finding is in line
with previous studies that showed the superiority of 3D
to 2D QCA in determining the segment length
[22,24–27]. This advantage of 3D QCA may help inter-
ventional cardiologists in their decision making of
appropriate device length when treating bifurcation
lesions.
Recently more attention has been drawn to the BA
assessment since the relative change between systolic
and diastolic BA was related to clinical outcomes after
distal left main PCI [28,29]. Theoretically, 3D QCA
provides more accurate BA compared to 2D QCA by
calculating the vectors of proximal MB, distal MB, and
SB separately in a three-dimensional approach, mini-
mizing the influence of vessel overlap [19]. In the
present study, significant differences were observed
only in BAPMB-SB and not in BADMB-SB.This might be
explained by the fact that the projection with the larg-
est BADMB-SB was selected for 2D QCA analysis,
which might be considered as the most optimal view
for 2D BA assessment if 3D QCA is not available
(Fig. 2).
The present study also highlights the fact that 2D
and 3D QCA detected different locations of the small-
est pre-procedural MLD or the highest pre-procedural
DS in bifurcation lesions. Indeed the kappa values sug-
gested insufficient agreement between the two analysis
approaches (kappa: 0.50 for the smallest MLD sites
and 0.55 for the highest DS sites). From the clinical
perspective, it has been reported that the DS measured
by dedicated 2D bifurcation QCA algorithm showed a
better correlation with invasive fractional flow reserve
(FFR) than that by a conventional single-vessel 2D
QCA technique, and this advantage was more pro-
nounced in SB [30]. It is also noteworthy that Yong
et al. demonstrated that 3D QCA derived measure-
ments showed better predictive ability in detecting
functionally significant stenosis determined by invasive
FFR as compared to 2D QCA derived measurements in
simple lesions [27]. Therefore, the dedicated bifurca-
tion 3D QCA algorithm may provide more accurate in-
formation not only on anatomical severity but also on
TABLE II. Treated Segment Level Analysis
Variables
Paired samples (N¼ 114)
2D QCA 3D QCA P value
In-segment (whole segment
in BSM6)
Smallest MLD (mm)
Pre-procedure 1.07 0.27 1.05 0.29 0.43
Post-procedure 1.56 0.34 1.60 0.34 0.08
Largest DS (%)
Pre-procedure 53.96 12.25 52.09 11.31 0.06
Post-procedure 32.39 10.93 28.66 10.40 0.08
Treated segment (segment
2, 3, 5 in BSM6)
Smallest MLD (mm)
Pre-procedure 1.07 0.28 1.05 0.30 0.47
Post-procedure 1.76 0.37 1.74 0.39 0.36
Largest DS (%)
Pre-procedure 53.87 12.40 52.09 11.31 <0.01
Post-procedure 23.21 10.88 20.89 11.89 0.01
BSM¼ bifurcation segment model, MLD¼minimal luminal diameter,
DS¼ diameter stenosis.
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location of stenosis to be treated in the clinical setting,
although we cannot use the current data to support this
statement.
Study Limitations
First, we presented neither inter- nor intra-observer
reproducibility of QCA analyses in the present study.
Our group has already reported the excellent inter- and
intra-observer reproducibility in both 2D and 3D QCA
analyses in the previous literature [14,15,23]. The
results may be different when using other software
with different algorithms for bifurcation analysis. Sec-
ond, we consistently applied one of the two angio-
graphic images with the largest BADMB-SB to the 2D
analysis since such a view is usually considered as a
more suitable 2D view specifically for the anatomical
evaluation of ostial SB that is the most susceptible part
of the bifurcation to vessel overlap (Fig. 3). Neverthe-
less, image selection may have an impact on the com-
parison between 2D and 3D QCA derived parameters.
Fig. 5. Bland–Altman plots and cumulative frequency distribution (CFD) curves of the small-
est pre-procedural MLD and the highest pre-procedural DS in the treated segment. In the
Bland–Altman plots (upper panels), solid lines indicate the mean difference between 2D and
3D analyses and dotted lines indicate the upper and lower limit of agreement (LOA). In the
CFD curves (lower panels), blue circles indicate 2D QCA and red squares indicate 3D QCA
(lower panels). MLD5minimal luminal diameter, DS5diameter stenosis.
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CONCLUSIONS
There were differences in addressing anatomical se-
verity and location of coronary bifurcation lesions
between in vivo 2D and 3D QCA analyses. Whereas
DS was in general higher with 2D QCA, lesion length
was shorter with 2D QCA than with 3D QCA. No dif-
ferences could be detected in distal bifurcation angles
(BADMB-SB) in the present study, although a difference
in the proximal bifurcation angles (BAPMB-SB) was evi-
dent between the two algorithms. The MLD sites or
the highest DS sites by 2D assessment relocated to dif-
ferent sub-segments in a considerable proportion of the
patients when using 3D assessment. More studies are
needed to investigate the potential clinical benefit in
using 3D approach over 2D QCA for the assessment of
bifurcation lesions.
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Abstract The objective of the study is to validate intravas-
cular quantitative echogenicity as a surrogate for molecular
weight assessment of poly-l-lactide-acid (PLLA) bioresorb-
able scaffold (Absorb BVS, Abbott Vascular, Santa Clara,
California).We analyzed at 9 time points (from1- to 42-month
follow-up) a population of 40 pigs that received 97 Absorb
scaffolds. The treated regions were analyzed by echogenicity
using adventitia as reference, and were categorized as more
(hyperechogenic or upperechogenic) or less bright (hypoe-
chogenic) than the reference. The volumes of echogenicity
categories were correlated with the measurements of molec-
ularweight (Mw)bygel permeationchromatography.Scaffold
struts appeared as high echogenic structures. The quantiﬁca-
tion of grey level intensity in the scaffold-vessel compartment
had strong correlation with the scaffold Mw: hyperechoge-
nicity (correlation coefﬁcient = 0.75; P\0.01), upperech-
ogenicity (correlation coefﬁcient = 0.63; P\ 0.01) and
hyper ? upperechogenicity (correlation coefﬁcient = 0.78;
P\0.01). In the linear regression, the R2 for high echoge-
nicity andMwwas0.57 for the combinationofhyper andupper
echogenicity. IVUS high intensity grey level quantiﬁcation is
correlated to Absorb BVS residual molecular weight and can
be used as a surrogate for the monitoring of the degradation of
semi-crystalline polymers scaffolds.
Keywords Absorb  Bioresorbable vascular scaffold 
Degradation  Echogenicity  IVUS  Porcine
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biomechanical characteristics (with the risk of late recoil)
and may be associated with a second wave of arterial wall
inﬂammation. Therefore, studying the BRS degradation is
crucial to fully understand this technology. The present
work validates echogenicity as a surrogate for polylactide
scaffold degradation.
Introduction
Bioresorbable vascular scaffolds (BRS) are a novel
approach to the interventional treatment of coronary
artery disease (CAD), providing short-term vascular
scaffolding combined with drug-delivery capability. They
may offer potential advantages compared to metallic
drug-eluting stents (e.g. adaptive remodeling, restoration
of vasomotion and late luminal enlargement). The so
called 4th revolution in coronary artery disease revas-
cularization steered extensive scientiﬁc research in BRS
developments [1–3].
It has been shown that the designs and materials of BRS
platforms—either metallic or polymeric—inﬂuence the
resorption process [3–5]. Considering the variety of pos-
sible platforms, it is necessary to establish tools capable of
monitoring the degradation process and its correlated
mechanical characteristics.
Intravascular ultrasound-derived parameters have shown
to be useful to assess the BRS resorption of metallic and
polymeric scaffolds in humans [6–8]. One of the most
studied intravascular ultrasound (IVUS) techniques to
evaluate the resorption process is called differential ech-
ogenicity [8, 9]. This method consists in an automated and
quantitative three-dimensional analysis of coronary tissue
components scored for echogenicity using as reference the
mean level of the adventitia brightness [9] where scaffold
struts appear as bright hyperechogenic structures. In clin-
ical studies, a continuous decrease of echogenicity over
time has been shown in regions treated with BRS, being
putatively correlated to BRS degradation [7, 8]. However,
in serial human assessments, changes in the adventitia and
plaque-media compartment of the treated regions during
the follow-up period could possibly affect these interpre-
tations [10–14].
The objectives of the current study were: (1) to describe
a novel method of echogenicity for tissue analysis; (2) to
evaluate its reproducibility; and (3) to assess its aptitude to
assess the BRS degradation process through a direct cor-
relation with the molecular weight (Mw) in a preclinical
model using a drug-eluting poly-l-lactide-acid (PLLA) bi-
oresorbable scaffold (Absorb BVS, Abbott Vascular, Santa
Clara, California).
Methods
Study devices
The device used in the present preclinical study is the same
used in Cohort B of the ABSORB clinical trial [15, 16].
Absorb is a balloon-expandable BRS that consists of a
polymer backbone of Poly (L-lactide) (PLLA) coated with
a thin layer of a 1:1 mixture of Poly-D, L-lactide (PDLLA)
polymer with the antiproliferative drug everolimus to form
an amorphous drug-eluting coating matrix containing
100 lg of everolimus/cm2 of scaffold [17].
Experimental model
For validation purposes, we analyzed non-atherosclerotic
Yorkshire-Landrace swine which had been implanted with
Absorb BVS via femoral access according to published
procedures [18]. Absorb sizes were matched to the vessel
size at a target balloon-to-artery ratio of 1.0–1.1 (10 %
overstretch). Each animal received a single Absorb
(3.0 9 18 mm for 1-, 3-, and 6-month and 3.0x12 mm for
12- to 42-month) in 2 or 3 main coronary arteries. Forty
pigs (98 arteries) underwent IVUS acquisition and were
then euthanized at 1-month (n = 12 scaffolds), 3-(n = 12),
6-(n = 14), 12-(n = 12), 18-(n = 12), 24-(n = 12),
30-(n = 8), 36-(n = 8) or 42-months (n = 8). Each scaf-
fold had quantiﬁcation of polymer degradation by gel
permeation chromatography (GPC). Experimental studies
received protocol approval from the institutional animal
care and use committee and were conducted in accordance
with American Heart Association guidelines for pre-clini-
cal research and the Guide for the Care and Use of Labo-
ratory Animals (National Institutes of Health 2010).
Gel permeation chromatography (GPC)
A previously reported GPC method, with a slightly modi-
ﬁed sample extraction/puriﬁcation process, was employed
to investigate the degradation of polymer over time by
evaluating the number-average molecular weight (Mn) of
polymer in the Absorb [19]. In the present method, the
extraction and puriﬁcation of the polymer was repeated up
to ﬁve times until the polymer was fully extracted from the
tissue (i.e., the polymer signal in the last extract below the
quantitation limit of 0.3 mg/mL). The samples were ana-
lyzed prior at 1-, 3-, 6-, 12-, 18-, 24-, 30-, 36- and
42-months after implantation.
IVUS acquisition and analysis
All IVUS runs were acquired with 40 MHz mechanical
systems, using Galaxy V2.02 (Boston Scientiﬁc, MA,
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USA) at 1-, 3-, 6- and 12-month follow-ups and iLab at
18-, 24-, 30-, 36- and 42-month (Boston Scientiﬁc, MA,
USA). We used motorized pullback of 0.5 mm/s with a
frame rate of 30 frames/second. The regions of interest
were restrict to the scaffolded areas, identiﬁed by the ﬁrst
and the last cross-sectional IVUS frame in which scaffold
struts could be identiﬁed and/or where the proximal or
distal metallic markers could be identiﬁed. Vessel, scaffold
and lumen contours were delimited every 0.5 mm blind to
molecular weight results. We analysed four compartments
by IVUS: the luminal, scaffold, vessel and the neointimal
volume (vessel volume-lumen volume). The scaffold was
delineated semiautomatically at the luminal leading edge
of the struts and the lumen was delineated at the inner
detectable tissue (Fig. 1).
To evaluate inter-observer reproducibility, 2 readers
(C.C. and Y.I.) independently analyzed 30 segments ran-
domly selected from the total number of the investigated
segments. To determine intra-observer reproducibility, one
reader (C.C.) analyzed these segments twice, with the
second reading occurring 3 months later. The inter- and
intra-observer reproducibility were good according to the
conventional norms [20] (hyperechogenicity inter-observer
interclass correlation coefﬁcient [ICC] = 0.80, intra-
observer ICC = 0.95; hypoechogenicity: inter-observer
ICC = 0.78, intra-observer ICC = 0.97; upperechogenici-
ty: inter-observer ICC = 0.92, intra-observer ICC = 0.97)
(Supplementary material).
Automatic quantitative echogenicity analysis
The principle of echogenicity has been previously descri-
bed elsewhere [9, 21, 22]. Echogenicity aims to classify the
vessel wall components located between the luminal
boundary and the external elastic membrane (EEM) into
categories based on their grey-level intensity in B-mode
IVUS images rather than based on radiofrequency ultra-
sound signal analysis [23–26] (Fig. 1). Here we quantiﬁed
5 tissue types: hypoechogenic, hyperechogenic, calciﬁed,
upperechogenic and unknown.
Comparison with the adventitia allows for normaliza-
tion with respect to transducer variability, gain settings
and across populations [21]. However, in the analysis of
atherosclerotic tissue, the adventitia can be partially
obscured or darkened as a result of the guide-wire
shadowing or the presence of dense tissue (e.g. calcium)
which reduces the average grey-level values of the
adventitia. Therefore, these parts need to be excluded
from the reference adventitial area. To determine the
reference adventitia area in each frame, the full adven-
titial area located just outside the EEM is ﬁrst deter-
mined based on a minimum (0.01 mm) and maximum
(0.21 mm) distance from the EEM contour (Fig. 1). To
remove the low echogenic parts of the adventitia an
adaptive threshold value for the entire adventitia area is
determined based on Otsu’s method [27]. Otsu’s method
is a classic automatic non-parametric threshold selection
method which maximizes the between-class variance.
Next, the adventitial area is divided into 2-degree wide
sectors. If more than half of the pixels inside of a sector
is below the adaptive threshold, the sector is excluded
from the reference adventitia area. Finally, the histo-
grams of the reference adventitial areas of the individual
frames are combined into a global adventitia grey-level
intensity histogram and the median value is computed as
a threshold. Cross-section pixels with an intensity lower
than the median value are classiﬁed as hypoechogenic,
pixels with an intensity higher than the median value
threshold are classiﬁed as hyperechogenic.
Calciﬁed plaque is typically identiﬁed in B-mode
IVUS images as a highly echogenic area creating an
acoustic shadow [21]. To determine the high-intensity
grey-level threshold for highly echogenic components we
use the adaptive threshold selection method described in
[28]. First Otsu’s method is applied to the entire grey-
level histogram of an image resulting in an optimal
threshold value. In the next 2 iterations, Otsu’s method is
applied to the histogram of all intensities above the
threshold found in the previous step. Next, we apply an
in-house developed acoustic shadow detection algorithm.
Highly echogenic areas with a grey-level intensity higher
than the high-intensity threshold but without acoustic
shadow behind them are classiﬁed as upperechogenic,
while highly echogenic areas with acoustic shadow are
classiﬁed as calciﬁed and the shadow itself is classiﬁed
as unknown. The entire method has been implemented
and tested in QCU-CMS-Research v4.69 (research ver-
sion of QIvus, developed by the Leiden University
Medical Center) [29].
Data analysis
Continuous variables are presented as mean ± SD or
medians (interquartile range). The ANOVA test was used
to compare continuous variables. As we had different
scaffold lengths we normalized all measurements by the
mean length for all pigs as described previously [30].
This adjusts for differing segment lengths across animals,
thereby providing equal weighting of each individual in
the calculation of echogenicity volumes. The residual
scaffold molecular weight by GPC was compared to the
echogenicity ﬁndings and the correlation coefﬁcient was
used as a measure of the degree of relationship (Pear-
son’s correlation coefﬁcient). A linear regression was
used to evaluate if hyper and/or upperechogenicity were
able to predict the residual molecular weight. A
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Fig. 1 Differential
echogenicity methodology.
a The ﬁrst step was to determine
the lumen-scaffold and scaffold-
vessel compartments by
deﬁning the vessel, lumen and
luminal scaffold contours in
every 0.5 mm. After guidewire
masking, the software identiﬁes
the adventitia as a ring between
0.01 and 0.21 mm outside
vessel contours. b However, if
the software uses as reference
the whole layer around the
vessel contour, it will include
low intensity structures (e.g.,
pericardium, side branches, low
attenuated tissues, etc.) resulting
in a histogram with a non-
normal distribution (right
panel). c The present software
detects automatically high
signal adventitia as reference,
excluding low intensity
structures (arrow heads). The
right panel shows that the
combination of high signal
adventitia in all frames obtains a
bell shaped normally distributed
histogram. The yellow line
represents the referential
adventitial median value. d The
color legend of each
echogenicity classiﬁcation is
provided. As we used a non-
atherosclerotic porcine model
there was no calciﬁcation and
unknown tissue. Nevertheless,
the present software is able to
detect theses tissues
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hierarchical cluster analysis using Ward’s method
(Squared Euclidean distance) was applied for
hyper ? upperechogenicity and hypoechogenicity vol-
umes. The differences were regarded signiﬁcant when
P\ 0.05 (two-tailed). SPSS version 21.0 (SPSS Inc.,
Chicago, Illinois) was used for all statistical analyses.
Results
The main grey scale IVUS volumetric ﬁndings are shown
in Fig. 2 and the comparisons between each group are
given in the supplementary material (Tables 2-5). The
mean scaffold length was 16.5 mm. Compared with
1-month follow-up, the vessel, scaffold and lumen volumes
had a trend to be larger after 18-month follow-up. These
three aforementioned volumes were signiﬁcantly larger at
36- and 42-month. Additionally, the neointima had the
biggest volume at 1-month follow-up, being similar among
groups thereafter (Fig. 3).
Differential echogenicity and molecular weight
Table 1 summarizes the main ﬁndings on differential
echogenicity and mean Mw at each time point. The highest
total hypoechogenicity volume was found at 1-month fol-
low-up, the time point with also the highest neointimal
hyperplasia as aforementioned. The lumen-scaffold com-
partment had an increase in hyper ? upperechogenic vol-
umes up to 12-month and subsequently a decrease until
42-month. Using the as reference the 1-month group, the
hyper ? upperechogenic decreased signiﬁcantly in the
scaffold vessel compartment after 12 months (supplemen-
tary material).
The GPC results indicated a continuous decrease in
molecular weight over time. The rate of reduction was
slower during the ﬁrst 6-months of scaffold implantation
followed by a more rapid decline thereafter, being fully
resorbed 36-months after implantation (Fig. 2).
To validate the scaffold degradation by echogenicity we
took into consideration the hyper- and upperechogenicity in
Fig. 2 Grey Scale intravascular ultrasound volumetric ﬁndings at different time points. a Vessel volume; b Lumen Volume; c Scaffold Volume
and d Neointimal Volume. Values are median and interquartile range
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the scaffold-vessel compartment (Fig. 1). As shown in
Table 1, the earlier IVUS were more likely to present higher
grey-level intensity (hyper ? upperechogenicity). The scaf-
fold-vessel hyperechogenicity (Pearson correlation coefﬁ-
cient = 0.75; P\ 0.01), upperechogenicity (Pearson
correlation coefﬁcient = 0.63; P\ 0.01) and hyper ? up-
perechogenicity (Pearson correlation coefﬁcient = 0.78;
P\ 0.01) had strong correlation with the scaffold molecular
weight. As shown in Fig. 4, in linear regression, the best
correlation found in linear regression model for molecular
weight was scaffold-vessel hyper ? upperechogenicity (R
squared = 0.57; P\ 0.01); i.e., all grey-level intensity
higher than median adventitia in the scaffold-vessel com-
partment should be considered for monitoring the degrada-
tion process of this semi-crystalline polymers scaffold. Post-
Hoc comparisons between each group are given in the sup-
plementary material (Tables 6-8).
Additionally, a cluster analysis was run for scaffold-
vessel hyper ? upperechogenicity and hypoechogenicity.
It produced ﬁve clusters, among which the variables were
signiﬁcantly different in the main (Fig. 5). The comparison
among clusters of hyper ? upperechogenicity showed a
clear positive association scaffold-vessel hyper ? upper-
echogenicity and molecular weight (Fig. 5).
Fig. 3 IVUS echogenicity
analysis at 1- (a), 18- (b) and
42-month (c). The high
echogenic (including
hyper = light green and
upper = light blue) parameters
decrease over time. d Gel
permeation chromatography
(GPC) for the assessment of
degradation of Absorb showing
the in vivo degradation of
polymer of Absorb over time
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Discussion
In the present study, using IVUS grey scale derived
parameters we attempted to assess the degradation process
of the Absorb poly-L-lactide bioresorbable everolimus-
eluting scaffold at multiple time points in a porcine model.
The major ﬁndings of this study can be summarized as
follows: (1) hyperechogenic and upperechogenic thresh-
olds had strong and positive correlations with the scaffold
molecular weight assessment; (2) the combination of hyper
and upperechogenicity could be used as a surrogate for the
chromatographic assessment of scaffold molecular weight
and (3) echogenicity demonstrated good inter- and intra-
observer reproducibility (Supplementary Material).
The present manuscript describes a new software
designed to assess the differential echogenicity and, for the
ﬁrst time, ascertained the correlation between IVUS grey
scale intensities and quantitative assessment of Mw by
GPC. The ﬁrst novelty is that it was not necessary to use
ECG gating and therefore, it is not needed a dedicated
IVUS console or post-processing correction. The robust-
ness of this method and the aforementioned good repro-
ducibility demonstrate, for the ﬁrst time, good correlation
of echogenicity with the degradation of the scaffold with-
out being mandatory correction for motion artifacts [30].
Image resolution can be deﬁned as the capability of
making distinguishable the individual parts of an object.
Therefore, the use of 40 MHz IVUS catheter in the present
study has potential to be more precise to detect scaffold
degradation than the previous methodology with the
20 MHz ultrasound [7, 31]. Ultrasound at a center fre-
quency of 10 MHz has demonstrated to detect decline in
the acoustic impedance of PLA when molecular weight
varied from 60 to 24 kDa, but further decrease in molecular
weight to 15 kDa did not result in discernible change [32].
In the present study, working with the higher resolution of
the 40 MHz IVUS catheter, we were able to detect acoustic
differences in 150 m thick samples degrading from *100
to\4 kDa.
The use of ultrasound to monitor the degradation
process of polymers has been initially proposed with a
wave pulse-echo method in an in vitro essay [31]. Wu
succeeded to monitor by ultrasound the degradation
process of three biodegradable polymers: poly(glycolic
acid) (PGA), poly(L-lactic acid) (PLLA) and 50:50
poly(D, L-lactide-co-glycolide) (PDLLG) [33]. Another
IVUS based approach to detect the resorption process in
human is virtual histology [6]. The spectral analysis of
the raw backscattered ultrasound misrepresents polymeric
struts as dense calcium (DC) and necrotic core (NC). As
these parameters are shown to decrease over time after
implantation, they have been correlated putatively with
resorption [6, 16, 34, 35].T
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Fig. 4 Linear regressions between molecular weight and echogenicity derived parameters in the scaffold-vessel compartment
Fig. 5 A hierarchical cluster analysis labeled by animal was run for
scaffold-vessel hyper ? upperechogenicity and hypoechogenicity.
Cluster 2 and 3 had similar hyper ? upperechogenicity but statisti-
cally signiﬁcant greater hypoechogenicity volumes in the cluster 2.
Cluster 3 and 5 had similar hypoechogenicity but markedly higher
hyper ? upperechogenicity volumes in cluster 5. There was a clear
positive association between scaffold-vessel hyper ? upperechoge-
nicity and molecular weight. The sample sizes are number of
scaffolds included in each pig cluster. The values are mean ± stan-
dard deviation and the errors bars are 95 % conﬁdence interval
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Previously, echogenicity has been used to assess paired
serial acoustic properties of coronary plaques in BRS-
treated segments in the clinical setting [7, 8, 35]. It has
been shown that these segments had an increase in hy-
perechogenic tissue after implantation which decreased
over time [7, 8, 35]. The aforementioned methodology
succeeds to document the progressive decrease of high
intensity grey level tissues in both metallic and polymeric
BRS [8, 35].
However, until now, the link between echogenicity and
the degradation process has been hypothetically assumed.
The pending question was whether temporal plaque chan-
ges could interfere with the multistage degradation of the
polymer and confound the echogenicity analysis. It has
been shown that coronary atherosclerosis is a dynamic
phenomenon and numerous factors can inﬂuence the ath-
erosclerotic changes as detected by IVUS-derived param-
eters. For instance, statin treatment may reduce the
percentage lipid volume index over time [13] and may
increase the calciﬁed plaque component [11]. Additionally,
there is a signiﬁcant decrease in NC (16 %) and DC (30 %)
content in coronary plaque located behind the struts of the
everolimus-eluting bioresorbable vascular scaffold [36].
All the above-mentioned confounding factors might inﬂu-
ence the acoustic properties in the lumen-vessel compart-
ment and hinder the clinical relevance of echogenicity for
BRS degradation assessment.
As we have used a porcine non-atherosclerotic model,
we did not have the confounding presence of coronary
artery disease, thus enabling the evaluation of Poly-L-
Lactide’s echogenic characteristics over time. Hyperecho-
genic, upperechogenenic and hyper ? upperechogenic
tissues had strong and positive correlations between ech-
ogenicity and the degradation process. Echogenicity is
determined by the difference in acoustic impedance
between two mediums, which is proportional to density and
acoustic velocity. The acoustic velocity is proportional to
the square root of the stiffness (bulk and shear moduli).
Many factors impact the stiffness of PLA, including
molecular weight, polydispersity, crystallinity, orientation
of crystalline microstructure, and other environmental
conditions [37]. As a result, one would expect to change
the impedance of PLA as it degrades and molecular weight
to have a generalized relationship to this decline.
Qualitatively, the correlation was however not perfectly
linear. For instance, at 1-month the combination hyper ?
upper tended (without statistical signiﬁcance; Table 6, sup-
plementary material), in average, to be lower than at
3-months whereas the molecular weight had a continuous
decrease in the same period. From the ultrasonic point of
view, the signiﬁcantly higher neointimal hyperplasia (Fig. 2)
at 1-month might have affected the ultrasound penetration
and therefore the echogenicity interpretation. Additionally,
the scaffold-vessel hyper ? upperechogenicity at
30-months was numerically comparable to that at 18-month.
However, the degradation process may be inﬂuenced by
individual biological factors and it has to be emphasized that
these assessments were not serial. However, we showed a
consistent individual positive correlation between the
molecular weight and echogenicity (Figs. 4 and 5).
Limitations
Arteries used for molecular weight assessment could not be
evaluated histologically. Therefore, changes in the
observed echogenicity (both lumen-scaffold and scaffold-
vessel) could not be related to the histologic changes over
time [19, 38]. As this study has been performed in a non-
atherosclerotic model, it should be acknowledged that the
rate of degradation has not been conﬁrmed in atheroscle-
rotic coronary arteries. However, as the degradation of
PLLA is a hydrolytically driven and not enzymatically
driven process, it is expected that the rates would be largely
equivalent.
We could not test the reproducibility of the echogenicity
IVUS ﬁndings in the two different consoles. However as we
worked at the same ultrasound frequency (40 MHz) and the
tissue classiﬁcations were normalized by the individual
adventitia grey scale intensity we could show a robust cor-
relation between scaffold degradation and high echogenic
parameters. It has been shown that the comparison with the
adventitia allows for normalization with respect to trans-
ducer variability, gain settings and across populations [21].
The changes in vessel, lumen, scaffold and neointima
volumes over time are in line with the serial IVUS ﬁndings
in the pre-clinical model and clinical setting showing
progressive increase in vessel, lumen area and scaffold area
[16, 18, 39, 40]. However, in the porcine model the somatic
growth can inﬂuence our ﬁndings [39]. As we do not have
the IVUS at baseline we could not normalize these geo-
metrical changes for the increase in the reference vessel
size. Nevertheless, this information has been described in
the literature and are beyond the main scope of the current
manuscript.
Conclusion
IVUS high intensity grey level quantiﬁcation is correlated
to Absorb scaffold residual molecular weight assessment.
Echogenicity is a reproducible technique which could be
considered as a surrogate assessment of polylactide
molecular weight decrease as assessed by chromatography
and allows for monitoring of the degradation of semi-
crystalline polymeric scaffolds.
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TRANSLATIONAL
Bioresorption and Vessel Wall Integration
of a Fully Bioresorbable Polymeric
Everolimus-Eluting Scaffold
Optical Coherence Tomography, Intravascular Ultrasound, and
Histological Study in a Porcine Model With 4-Year Follow-Up
Shimpei Nakatani, MD,a Yuki Ishibashi, MD, PHD,a Yohei Sotomi, MD,b Laura Perkins, DVM, PHD,c
Jeroen Eggermont, PHD,d Maik J. Grundeken, MD,b Jouke Dijkstra, PHD,d Richard Rapoza, PHD,c Renu Virmani, MD,e
Patrick W. Serruys, MD, PHD,f Yoshinobu Onuma, MD, PHDa
ABSTRACT
OBJECTIVES The aim of the present study was to investigate the relationship between the integration process and
luminal enlargement with the support of light intensity (LI) analysis on optical coherence tomography (OCT), echoge-
nicity analysis on intravascular ultrasound, and histology up to 4 years in a porcine model.
BACKGROUND In pre-clinical and clinical studies, late luminal enlargement has been demonstrated at long-term
follow-up after everolimus-eluting poly-L-lactic acid coronary scaffold implantation. However, the time relationship and
the mechanistic association with the integration process are still unclear.
METHODS Seventy-three nonatherosclerotic swine that received 112 Absorb scaffolds were evaluated in vivo by OCT,
intravascular ultrasound, and post-mortem histomorphometry at 3, 6, 12, 18, 24, 30, 36, 42, and 48 months.
RESULTS The normalized LI, which is the signal densitometry on OCT of a polymeric strut core normalized by the vicinal
neointima, was able to differentiate the degree of connective tissue inﬁltration inside the strut cores. Luminal enlarge-
ment was a biphasic process at 6 to 18 months and at 30 to 42 months. The latter phase occurred with vessel wall
thinning and coincided with the advance integration process demonstrated by the steep change in normalized LI (0.26
[interquartile range (IQR): 0.20 to 0.32] at 30 months versus 0.68 [IQR: 0.58 to 0.83] at 42 months, p < 0.001).
CONCLUSIONS In this pre-clinical model, late luminal enlargement relates to strut integration into the arterial wall.
Quantitative LI analysis on OCT could be used as a surrogate method for monitoring the integration process of poly-L-
lactic acid scaffolds, which could provide insight and understanding on the imaging-related characteristics of the
bioresorption process of polylactide scaffolds in human. (J Am Coll Cardiol Intv 2016;9:838–51)
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A s an alternative approach to metal drug-eluting stents, fully bioresorbable polymericdrug-eluting scaffolds provide transient
vessel support with drug-delivery capability. As the
scaffold begins to resorb, the vessel is no longer
caged, and therefore luminal area as well as vessel
area could increase simultaneously without creating
evagination (1–5). The everolimus-eluting scaffold
(Absorb; Abbott Vascular, Santa Clara, California)
consists of a semicrystalline poly-L-lactic acid (PLLA)
backbone coated by a thin amorphous layer of poly-
D,L-lactic acid containing the antiproliferative agent
everolimus. After implantation, the polylactide strut
progressively degrades by hydrolysis, and its molecu-
lar weight starts to decrease from its initial molecular
weight of around 100 kDa (molecular weight loss) (6).
The PLLA molecules remain at the implanted site un-
til the polymeric chains become small enough to
diffuse from the site into the surrounding tissue
(mass loss). As small oligomers or monomers gradu-
ally leave the site, there is progressive replacement
by a provisional matrix initially composed of a milieu
of extracellular matrix components. This initially
acellular provisional matrix is gradually cellularized
with connective tissues, and the struts and footprints
eventually become fully integrated into the sur-
rounding neointimal tissue of the vessel wall (6,7).
It is well-established that the scaffolding efﬁcacy
of the device is related to the timing of molecular
weight reduction and the loss of mechanical
integrity (8). However, at a late phase, it is
still unclear whether the integration of strut
footprints is associated with the late luminal
enlargement. In the pre-clinical assessment
of fully bioresorbable scaffolds, it is there-
fore important to assess the processes of
molecular weight loss and integration in vivo.
In humans, intravascular imaging has been
used in vivo as a surrogate marker to under-
stand the bioresorption and integration process,
but the correlation between the surrogate assessment
and the true bioresorption process needs to be
established.
On intravascular ultrasound (IVUS), quantitative
echogenicity has been demonstrated to correlate with
the molecular weight of PLLA (9). On optical coher-
ence tomography (OCT), the visual categorizations of
strut appearance have previously been demonstrated
to correlate with the integration process (10). How-
ever, this visual categorization was limited by its
moderate reproducibility (k ¼ 0.58). Recently, log-
transformed optical coherence tomographic signal
measurement (light intensity analysis) of strut cores
was introduced as a feasible and reproducible method
to assess the degree of strut integration after scaffold
implantation (11). In humans, the median intensity
value of strut cores increased signiﬁcantly at 24
months and kept increasing up to 36 months, and
most of pre-existing struts were indiscernible at 60
months on OCT (Figure 1). It was hypothesized
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FIGURE 1 Strut Appearance on Optical Coherence Tomography of Revision 1.0 (Used in the ABSORB Cohort A Study) and Revision 1.1
(Used in the ABSORB Cohort B Study) of the Absorb Device
The time to complete degradation of the Absorb A device was approximately 2 years, whereas that for the Absorb B device was approximately
3 years, resulting in the different appearance of strut cores on optical coherence tomography over time in Absorb B devices compared
with that of Absorb A devices in humans (5,26).
SEE PAGE 852
AB BR E V I A T I ON S
AND ACRONYM S
IQR = interquartile range
IVUS = intravascular
ultrasound
OCT = optical coherence
tomography
PLLA = poly-L-lactic-acid
TD = time-domain
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that light reﬂectivity is correlated with connective
tissue inﬁltration of the strut cores. However, this
hypothetical correlation between light intensity and
histological changes has so far not been demonstrated
with strut histology-matched light intensity.
The aim of this study was to demonstrate the
relationship between light intensity and histological
changes with regard to strut integration at 3, 6, 12, 18,
24, 30, 36, 42, and 48 months in a porcine coronary
artery model. In addition, IVUS echogenicity analysis
was also assessed to monitor early changes in
molecular weight.
METHODS
The present study was conducted from 2009 to 2013.
Eight nonatherosclerotic juvenile domestic crossbred
farm swine and 65 Yucatan mini-swine underwent
Absorb scaffold implantation with a targeted balloon-
to-artery ratio of 1.0:1.1. Each animal received a single
everolimus-eluting scaffold (Absorb; 3.0  18 mm for
1, 3, and 6 months and 3.0  12 mm for 12 to 48
months) in 1 or 2 main coronary arteries. The Absorb
scaffold used in the present study is the same as the
device used in cohort B of the ABSORB clinical
trials. Seventy-three pigs with 112 Absorb scaffolds
implanted were examined by OCT at baseline and
anesthetized at the designated endpoints with the
optical coherence tomographic and IVUS examina-
tions at 3 months (n ¼ 10 Absorb scaffolds in 8 farm
swine), as well as 6 (n ¼ 10 Absorb scaffolds in 8
Yucatan mini-swine), 12 (n ¼ 11 in 7), 18 (n ¼ 12 in 7),
24 (n ¼ 12 in 7), 30 (n ¼ 12 in 8), 36 (n ¼ 12 in 8), 42
(n ¼ 13 in 8), and 48 (n ¼ 20 in 12) months (Figure 2).
Optical coherence tomographic acquisition was
executed by the frequency-domain optical coherence
tomographic imaging system (C7 Dragonﬂy or Drag-
onﬂy Duo, St. Jude Medical, St. Paul, Minnesota),
with the exception of a few early investigations
performed with the time-domain (TD) OCT imaging
system in 2 animals. IVUS runs were acquired with
40-MHz mechanical systems, using Galaxy version
2.02 or iLab (Boston Scientiﬁc, Natick, Massachu-
setts). After performing intravascular imaging studies
(OCT and IVUS), animals were humanely euthanized.
Hearts were excised and pressure perfused with 0.9%
saline solution, followed by pressure perfusion ﬁxa-
tion with 10% neutral buffered formalin overnight in
preparation for histology. Embedded arteries were
divided into a minimum of 3 blocks representing the
proximal, medial, and distal regions of the scaffold.
Duplicate 4- to 6-mm sections from each of the
FIGURE 2 Study Flowchart of the Pigs Receiving Absorb Scaffolds Evaluated by Optical Coherence Tomography, Intravascular
Ultrasound, and Histology
IVUS ¼ intravascular ultrasound; M ¼ month; OCT ¼ optical coherence tomography.
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3 blocks were collected, and each was stained with
Movat’s pentachrome and hematoxylin and eosin for
evaluation by light microscopy.
Experimental studies received protocol approval
from the Institutional Animal Care and Use Commit-
tee and were conducted in accordance with American
Heart Association guidelines for pre-clinical research
and the Guide for the Care and Use of Laboratory
Animals (National Institutes of Health, 1996).
HISTOLOGICAL CATEGORIZATION OF STRUT AND
STRUT FOOTPRINT. On histology, the integration
grade of each strut was semiquantitatively classiﬁed
into 6 groups according to the connective tissue
composition within a strut core in Movat’s pentach-
rome–stained sections: 0) acellular, no connective
tissue composition; 1) hypointegration, 1% to 10%
connective tissue composition; 2) low integration,
11% to 25% connective tissue composition; 3) moder-
ate integration, 26% to 50% connective tissue
composition; 4) moderate to high integration, 51% to
75% connective tissue composition; and 5) high
integration, >75% connective tissue composition.
Figure 3 shows examples of strut appearance on the
basis of histological classiﬁcation of integration (10).
OPTICAL COHERENCE TOMOGRAPHIC QUANTITATIVE
MEASUREMENTS. Cross sections with unacceptable
image quality for measurements due to suboptimal
ﬂushing (4 scaffolds at 48 months) were excluded
from the quantitative analysis and light intensity
analysis. Quantitative measurements (scaffold area,
incomplete scaffold apposition area, and neointimal
area) were performed in the scaffolded segment and
periscaffolded segments (within 5 mm proximal and
distal to the stent edge) at 1-mm intervals according
to previously published methods (12). As the porcine
coronary artery grows, the luminal area in the peri-
scaffolded segment (reference luminal area) is
enlarged (2,13). To compare the time-dependent
changes, the normalized scaffold and luminal area
was calculated as the ratio of the scaffold and lumen
to the reference luminal area (2).
OPTICAL COHERENCE TOMOGRAPHIC LIGHT
INTENSITY ANALYSIS OF STRUT CORES. Because
the light intensity values vary between TD and
frequency-domain OCT, images obtained by TD OCT
(1 scaffold at 3 months and 2 at 12 months) were
excluded from the light intensity analysis. Pull-backs
with high intraluminal signal intensity with shadows
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FIGURE 3 Light Intensity Analysis on Optical Coherence Tomography and Categorization on Histology
Representative strut appearance according to the normalized light intensity on optical coherence tomography (A) and histological
categorization (B) of the strut core and footprint.
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due to suboptimal ﬂushing were excluded from the
light intensity analysis (1 scaffold at 6 months, 3 at 36
months, and 4 at 48 months).
Light intensity analysis of the strut cores was per-
formed using dedicated software (QCU-CMS version
4.69 [research version]; Leiden, the Netherlands).
Raw images with 16 bits in original polar format
were used to ensure that interpolation, dynamic
range compression, or other image processing did not
alter the signal and bias the analysis. The contours of
strut cores were delineated manually with “box-
shape” by visual inspection in Cartesian images
(Online Figure 1) (11). According to the strut contours,
the median light intensity values were computed
with the subtraction of 2 pixels inside of the manual
strut core contour by the software automatically, as
described previously (11).
To minimize bias in light intensity measurement
caused by the variation in optical signal due to
eccentric location of the optical coherence tomo-
graphic catheter or the uneven distribution of neo-
intima on top of the strut, the light intensity values of
strut cores were normalized by the median light
intensity value of the interstrut neointima in the
vicinity (bilaterally 22.5 wide originating from the
strut center) of each strut (referred to as the normal-
ized light intensity of strut cores) (Online Figure 1).
The light intensity analysis was performed in cross
sections at intervals of 1 mm and additionally in the
OCT-imaged struts matched with histology. Figure 3
shows examples of strut appearance on the basis of
normalized light intensity of strut cores on OCT.
MATCHING OF STRUTS ON HISTOLOGY AND OCT.
To correlate strut cores and histology at a strut level,
1 observer (Y.O.) aware of the histological image
selected the matched OCT-histology cross sections
at each time point using landmarks such as
side branches, metallic radiopaque markers, or the
appearance of neointima and media (Online
Appendix). In the selected cross sections of OCT and
histology, individual struts were further matched by
identifying struts with similar angular orientation and
peculiar appearance of struts (strut-level matching)
(Online Figure 2). To ensure accurate identiﬁcation of
the strut areas by OCT and histology, especially at
later time points (36, 42, and 48 months), when struts
are more integrated and thus more difﬁcult to iden-
tify, strut contours drawn on optical coherence
tomographic analysis were superimposed on histol-
ogy to match the strut core regions and to calculate
the percentage of inﬁltration by connective tissue
normalized for the strut footprint area.
These matched strut images were sent to the in-
dependent optical coherence tomographic analyst
(S.N.) and the pathologist (L.P.). The normalized light
intensity of the OCT-imaged strut and the histological
categorization of integration of this strut into the
surrounding neointimal tissue was blinded to the
observer who had performed the matching.
ECHOGENICITY ANALYSIS IN IVUS GRAYSCALE.
IVUS quantitative analysis (vessel, scaffold, and
luminal area)was performed in 0.5-mm intervals in the
scaffolded segment and periscaffolded segments
(deﬁned by a length 5 mm proximal and distal to the
stent edge). The normalized vessel area was calculated
as the ratio of the vessel to the reference vessel area,
and the normalized scaffold and luminal area was
calculated as the ratio to the reference luminal area.
According to the contours of lumen and vessel, the
dedicated software (QCU-CMS version 4.69 [research
TABLE 1 Light Intensity Analysis in Matched Struts Over Time
Time
Point
(months)
Matched
Struts
Accellular Struts Integrated Struts
p Value
0. Acellular:
No connective
Tissue
Composition
1. Hypointegration:
1%–10% Connective
Tissue
Composition
2. Low Integration:
11%–25% Connective
Tissue
Composition
3. Moderate Integration:
26%–50% Connective
Tissue
Composition
4. Moderate to High
Integration: 51%–75%
Connective
Tissue Composition
5. High Integration:
>75% Connective
Tissue
Composition
3 228 220 (96.5%) 8 (3.5%) — — — —
6 255 231 (90.6%) 24 (9.4%) — — — —
12 219 194 (88.6%) 20 (9.1%) 4 (1.8%) 1 (0.5%) — —
18 310 256 (82.6%) 37 (11.9%) 16 (5.2%) 1 (0.3%) — —
24 251 199 (79.3%) 38 (15.1%) 14 (5.5%) — — —
30 294 222 (75.5%) 46 (15.6%) 24 (8.2%) 2 (0.7%) — —
36 214 29 (13.6%) 38 (17.8%) 85 (4.0%) 34 (15.9%) 13 (6.1%) 15 (7.0%)
42 334 — 1 (3.0%) 14 (4.2%) 158 (47.3%) 92 (27.5%) 69 (20.7%)
48 350 — 1 (2.9%) 29 (8.3%) 106 (30.3%) 124 (35.4%) 90 (25.7%)
Normalized light
intensity
0.16 [0.11–0.23] 0.25 [0.17–0.38]* 0.43 [0.32–0.61]† 0.65 [0.54–0.77]‡ 0.72 [0.58–0.88] 0.80 [0.67–0.96] <0.001
*p < 0.05 versus category 0, †p < 0.05 versus category 1, and ‡p < 0.05 versus category 2, performed by performed by post hoc multiple comparison.
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version]) calculates the areas of 5 tissue types
categorized by using the median brightness of the
adventitia as a reference in the lumen-vessel
compartments automatically: 1) hypoechogenic, 2)
hyperechogenic, 3) calciﬁed, 4) upper echogenic, and
5) unknown (9).
STATISTICAL ANALYSIS. All statistical analyses were
performed using the SPSS version 23.0 (SPSS, Chi-
cago, Illinois). Normality of distributions was tested
with the Kolmogorov-Smirnov statistic. Continuous
variables are presented as mean  SD or median
(interquartile range [IQR]), as indicated in the tables.
Generalized estimating equations modeling was per-
formed to take into an account the clustered nature of
>1 scaffold analyzed from the same pig, which might
result in unknown correlations among measurements
within these scaffold clusters. Categorical variables
are presented as absolute values and percentages.
Relations between histological categories and
normalized light intensity of strut cores were
analyzed by Spearman’s rank-order correlation.
Bayesian analysis of normalized light intensity
included estimation of area under the receiver-
operating characteristic, curve with the optimal cut-
off value for the detection of the onset of “strut
integration” into the neointimal surrounding and the
shift to “moderate to high ﬁltration into the strut
core,” with associated sensitivity and speciﬁcity. A
modiﬁcation of the classiﬁcation of Swets (13) was
used to classify diagnostic efﬁciency of normalized
light intensity according to the values of the area
under the curve as low (<0.70), moderate (0.70 to
0.90), or high (>0.90).
RESULTS
In total, 336 histological cross sections and 112 optical
coherence tomographic pull-backs were available
(Figure 2). After excluding 4 optical coherence
tomographic pull-backs because of impaired image
quality, 108 pull-backs were analyzed for quantita-
tive measurements. Of 108 pull-backs, 7 were
excluded from the light intensity analysis for
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FIGURE 4 Normalized Light Intensity and Histological Findings in Matched Strut Cores
(A) Whisker plots combined with scatterplots of matched strut cores in normalized light intensity (dimensionless) over time. Normalized light intensity increased
gradually between 18 and 30 months, then surged between 30 and 42 months and approached 1.0 at 48 months. (B) Changes in histological categories of struts over
time. The rate of acellular struts decreased gradually during the ﬁrst 30 months, then abruptly decreased from 75.5% at 30 months to 13.6% at 36 months. Spon-
taneously, the frequency of moderately to highly integrated struts (histological grade $3) increased from 0.7% to 94% between 30 and 42 months. After 42 months,
there was no strut without integration. (C) Correlation between normalized light intensity on optical coherence tomography and histological categorization on whisker
plots in combination with scatterplots. Normalized light intensity was signiﬁcantly different between categories 0 and 1 (p < 0.05), between categories 1 and 2
(p < 0.05), and between categories 2 and 3 (p < 0.05). There were no signiﬁcant differences in normalized light intensity among categories 3, 4, and 5. M ¼ month.
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technical reasons (3 because of TD OCT and 4 because
of inappropriate image quality for light intensity
analysis), resulting in 101 OCT pull-backs available
for light intensity analysis. After excluding 33 histo-
logical cross sections because of lack of analyzable
OCT pull-backs, 2,979 struts were identiﬁed in 303
histological cross sections. Using sectorial approxi-
mate locations and landmarks such as metallic radi-
opaque markers, side branches, and neointimal
formation, a total of 2,455 struts were matched
between OCT and histology.
LIGHT INTENSITY ANALYSIS OVER TIME. The light
intensity analysis in 2,455 matched struts over time is
summarized in Table 1 and Figure 4A. There was no
signiﬁcant difference in the normalized light in-
tensity of strut cores until 18 months after scaffold
implantation: 0.14 (IQR: 0.11 to 0.22) at 3 months, 0.12
(IQR: 0.08 to 0.17) at 6 months, 0.15 (IQR: 0.10 to 0.21)
at 12 months, and 0.15 (IQR: 0.11 to 0.19) at 18 months.
The normalized light intensity increased gradually
between 18 and 30 months (0.19 [IQR: 0.14 to 0.26] at
24 months; p ¼ 0.001 vs. 18 months; 0.26 [IQR: 0.20 to
0.32] at 30 months; p < 0.001 vs. 24 months). After 30
months, the normalized light intensity surged until
42 months: 0.48 (IQR: 0.37 to 0.62) at 36 months
(p < 0.001 vs. 30 months) and 0.68 (IQR: 0.58 to 0.83)
at 42 months (p < 0.001 vs. 36 months) and was close
to 1.0 at 48 months (0.76 [IQR: 0.61 to 0.90]; p ¼ 1.00
vs. 42 months), suggesting that the strut cores were
completely integrated into the surrounding tissue.
HISTOLOGICAL FINDINGS. The categorization of
histological integration of 2,455 matched struts over
time is summarized in Table 1 and Figure 4B. From 3 to
12 months, the struts were completely separated from
the lumen by a thin, ﬁbromuscular neointima and had
well-deﬁned, squared appearances. Most of the struts
were classiﬁed as acellular (96.5% at 3 months, 90.6%
at 6 months, and 88.6% at 12 months). From 18 to 30
months, the strut footprints maintained their discrete
borders but began to appear blue with Movat’s pen-
tachrome. The percentage of acellular struts decreased
gradually (82.6% at 18 months, 79.3% at 24 months,
and 75.5% at 30 months). Six months later (at 36
months), the percentage of acellular struts has
abruptly decreased to 13.6%, and the strut footprints
were generally colonized by connective tissue. These
strut footprints further progressed up to the point at
which the strut footprint was only poorly discernible.
Twenty-nine percent of matched struts were classiﬁed
as grade $3 (>25% of cellularization and connective
tissue composition). After 42 months, there was no
strut without integration, and the rate of highly inte-
grated struts increased gradually up to 48 months. At
48 months, 61.1% of matched struts showed >50% of
connective tissue composition.
COMPARISON BETWEEN OPTICAL COHERENCE
TOMOGRAPHIC LIGHT INTENSITY ANALYSIS AND
HISTOLOGICAL CLASSIFICATION. The correlation
between the normalized light intensity on OCT and
histological categorization of 2,455 matched struts is
summarized in Table 1 and Figure 4C. There were
signiﬁcant differences among the histological cate-
gories with respect to normalized light intensity: 0.16
(IQR: 0.11 to 0.23) in category 0 (acellular), 0.25 (IQR:
0.17 to 0.38) in category 1 (1% to 10%), 0.43 (IQR: 0.32
to 0.61) in category 2 (11% to 25%), 0.65 (IQR: 0.54 to
0.77) in category 3 (26% to 50%), 0.72 (IQR: 0.58 to
TABLE 2 Optical Coherence Tomographic Quantitative Measurements
Quantitative Measurement
3 months
(n ¼ 10)
6 months
(n ¼ 10)
12 months
(n ¼ 11)
18 months
(n ¼ 12)
24 months
(n ¼ 12)
30 months
(n ¼ 12)
36 months
(n ¼ 12)
Mean scaffold area (mm2) 7.05  0.64 7.33  0.51 7.82  1.98 9.47  2.39 9.90  2.33 11.72  2.97 10.49  1.58
Minimum scaffold area (mm2) 5.96  1.24 6.42  0.46 6.71  1.61 8.33  2.45 8.95  2.21 10.81  2.77 9.32  1.45
Normalized scaffold area 0.95  0.17 1.08  0.23 1.08  0.24 1.07  0.24 1.10  0.19 1.07  0.07 1.35  0.22
Mean luminal area (mm2) 4.04  0.62 4.37  0.64 5.28  1.12 6.49  2.33 6.96  2.25 8.45  2.63 7.27  1.48
Minimum luminal area (mm2) 3.30  0.96 3.33  0.71 4.37  0.85 5.56  2.43 5.99  1.95 7.47  2.53 6.31  1.54
Normalized luminal area 0.54  0.13 0.65  0.16 0.73  0.13 0.72  0.19 0.76  0.16 0.77  0.20 0.93  0.17
Mean neointimal area (mm2) 2.76  0.60 2.69  0.39 2.38  0.98 2.71  0.34 2.71  0.31 3.00  0.55 2.90  0.54
Neointimal thickness on top of struts (mm) 218  73 208  15 151  72 165  47 162  42 159  38 179  47
Area stenosis (%) 29.9  8.8 27.8  7.1 19.4  6.5 20.7  8.0 19.6  6.7 17.9  6.0 20.2  5.4
Mean reference luminal area (mm2) 7.69  1.69 7.03  1.49 7.29  1.03 8.97  1.92 9.11  2.08 11.21  2.39 7.97  1.77
n ¼ 1,369
struts in
9 pigs
n ¼ 1,646
struts in
9 pigs
n ¼ 904
struts in
9 pigs
n ¼ 1,364
struts in
12 pigs
n ¼ 1,030
struts in
12 pigs
n ¼ 1,134
struts in
12 pigs
n ¼ 1,365
struts in
9 pigs
Normalized light intensity 0.17 (0.15–0.19) 0.15 (0.14–0.18) 0.14 (0.12–0.15) 0.19 (0.18–0.22) 0.25 (0.21–0.29) 0.3 (0.28–0.32) 0.55 (0.55–0.64)
Continued on the next page
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0.88) in category 4 (51% to 75%), and 0.80 (IQR: 0.67
to 0.96) in category 5 (>75%) (p < 0.01). In paired
comparison, normalized light intensity was signiﬁ-
cantly different between categories 0 and 3, whereas
there were no signiﬁcant differences between cate-
gories 3 and 5 (Table 1, Figure 4C). In Spearman rank-
order correlation analysis, there was a signiﬁcant
positive correlation between histological category of
integration and normalized light intensity of strut
cores (r ¼ 0.791; p < 0.01).
Receiver-operating characteristic curves demon-
strated that the diagnostic efﬁciency of the normal-
ized light intensity of strut cores for the detection of
the onset of the “strut integration” into the sur-
rounding neointima (histological category $1, area
under the curve 0.924, cutoff value 0.326) and for the
detection of the shift to “moderate to high ﬁltration
into the strut core” (histological category $3, area
under the curve 0.965, cutoff value 0.413) were
excellent (Online Figure 3).
QUANTITATIVE MEASUREMENTS ON OCT. The opti-
cal coherence tomographic quantitative measure-
ments and light intensity analysis of strut cores
performed in 1-mm interval cross sections are sum-
marized in Table 2 and Online Figure 4. At baseline,
there were no signiﬁcant difference in scaffold and
ﬂow area among all time-point groups (scaffold area,
p ¼ 0.113; ﬂow area, p ¼ 0.124). Compared with 3
months (0.54  0.13), the normalized luminal area
was signiﬁcantly larger after 12 months (p < 0.05).
The neointimal thickness on top of struts decreased
signiﬁcantly at 48 compared with 3 months (218 
73 mm at 3 months vs. 140  19 mm at 48 months,
p < 0.001).
The light intensity analysis of strut core in 1-mm
intervals was in line with the matched struts,
showing a surge between 30 and 42 months.
QUANTITATIVE MEASUREMENTS AND ECHOGENICITY
CHANGES ON IVUS. The IVUS quantitative measure-
ments and echogenicity analysis on the basis of
0.5-mm-interval cross sections are summarized in
Table 3. The area of vessel wall (including media and
neointima) did not change over time, whereas the
thickness of vessel wall signiﬁcantly decreased at 48
months (0.33  0.06 mm) compared with 3 months
(0.41  0.05 mm) (p < 0.001).
The hyperechogenicity plus upper echogenicity
area, a surrogate parameter for the molecular weight
of PLLA (9), signiﬁcantly decreased during the ﬁrst 24
months (0.42 [IQR: 0.29 to 0.56] at 24 months vs. 1.10
[IQR: 1.07 to 1.48] at 3 months, p < 0.001).
DISCUSSION
The main ﬁndings of the present analysis are as fol-
lows (Figures 5 and 6A). First, following polymeric
scaffold implantation, the normalized light intensity
of strut cores did not change between 3 and 18
months; thereafter it gradually increased from 18 to
30 months, but the change in light intensity signiﬁ-
cantly surged between 30 and 42 months. Second, the
histological evaluation showed that the frequency of
acellular strut cores (absence of tissue inﬁltration)
remained the same up to 12 months and then gradu-
ally decreased up to 30 months and began to
dramatically change between 30 and 42 months,
virtually disappearing at 48 months. Third, in
matched struts for OCT and histology, the normalized
TABLE 2 Continued
42 months
(n ¼ 13)
48 months
(n ¼ 16)
p Value
Overall
6 vs.
3 months
12 vs.
3 months
18 vs.
3 months
24 vs.
3 months
30 vs.
3 months
36 vs.
3 months
42 vs.
3 months
48 vs.
3 months
12.14  2.00 12.64  1.72 <0.001 0.182 0.238 0.002 <0.001 <0.001 <0.001 <0.001 <0.001
11.02  2.31 11.60  1.76 <0.001 0.138 0.209 0.004 <0.001 <0.001 <0.001 <0.001 <0.001
1.22  0.18 1.20  0.15 0.001 0.137 0.244 0.246 0.044 0.189 <0.001 0.001 <0.001
9.27  2.02 9.69  1.61 <0.001 0.116 <0.001 0.001 <0.001 <0.001 <0.001 <0.001 <0.001
8.41  2.30 8.81  1.80 <0.001 0.924 <0.001 0.005 <0.001 <0.001 <0.001 <0.001 <0.001
0.93  0.16 0.92  0.13 <0.001 0.098 0.002 0.022 <0.001 0.002 <0.001 <0.001 <0.001
2.57  0.22 2.63  0.24 0.241 0.714 0.352 0.802 0.766 0.345 0.562 0.284 0.48
138  34 140  19 <0.001 0.689 0.056 0.04 0.021 0.016 0.128 <0.001 <0.001
15.0  5.0 14.6  2.2 <0.001 0.476 0.002 0.007 0.001 <0.001 0.001 <0.001 <0.001
10.09  2.01 10.68  1.80 <0.001 0.346 0.485 0.128 0.051 <0.001 0.703 0.004 <0.001
n ¼ 1,335
struts in
13 pigs
n ¼ 1,894
struts in
16 pigs
0.8 (0.77–0.87) 0.82 (0.79–0.83) <0.001 0.296 0.426 0.565 0.001 <0.001 <0.001 <0.001 <0.001
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light intensity was able to differentiate the degree
and intensity of connective tissue inﬁltration inside
the strut cores. Using a cutoff value of 0.413, the
normalized light intensity could detect the advanced
process of integration of the strut cores (histological
grade $3) with an accuracy of 0.922. Fourth, the op-
tical coherence tomographic quantitative measure-
ments demonstrated that the scaffold and luminal
area normalized to the reference luminal area
increased between 30 and 36 months. The neointimal
thickness on top of the struts and the black core strut
thickness (if visible) decreased concurrently between
36 and 42 months. Fifth, the IVUS quantitative mea-
surements were in line with the results of optical
coherence tomographic measurements but were not
as discrete as those of OCT. The area of neointima
plus media in absolute value did not show a signiﬁ-
cant change over time, whereas there was a thinning
of the vessel wall (thickness between lumen and
vessel) due to the late luminal enlargement. Finally,
the upper echogenicity plus hyperechogenicity area
steadily decreased during the ﬁrst 24 months,
reﬂecting the early loss of molecular weight.
LUMINAL ENLARGEMENT IN THE FIRST 2 YEARS:
LOSS OF MECHANICAL INTEGRITY AND ADAPTIVE
EXPANSION TO THE INHERENT ARTERIAL GROWTH
OF THE MODEL. One of the most important ﬁndings
of the present study is that there are 2 phases of
vessel and luminal growth in 4 years after implanta-
tion of the Absorb bioresorbable scaffold. On IVUS
and OCT, the ﬁrst signiﬁcant luminal and scaffold
enlargement occurs between 6 to 18 months, whereas
the second occurs between 30 and 42 months
(Figure 6A). Of note, these luminal gains were
not observed following permanent metallic stent
implantation, because of the permanent mechanical
caging (2,14).
The ﬁrst growth of the scaffold and luminal area
seems to be related to the loss of mechanical integrity
and the natural growth of coronary artery. The Absorb
device loses its mechanical strength 6 months after
implantation (15,16). On OCT, at 3 months, luminal
and scaffold area is normalized by the reference
lumen smaller than the reference area (0.54), but af-
ter 6 months, and coinciding with the loss of me-
chanical integrity, the scaffold and lumen started to
follow the enlargement of reference area (normalized
lumen area at 12 to 30 months: 0.72 to 0.77). The
current animal study was performed in the Yucatan
pig model, which is known to have inherent coronary
arterial growth over time (2,17).
SECOND-PHASE LUMINAL ENLARGEMENT: INTEGRATION
OF STRUT CORE. The second phase of vessel remod-
eling, which occurred between 30 and 42 months, is
presumably due to the integration process. During
this period, the normalized luminal area further
increased from 0.77 to 0.93. On histology, rapid
integration of the struts in the surrounding neointima
was observed. The frequency of moderately to highly
integrated struts (histological grade $3) increased
from 0.7% to 94%, which was clearly illustrated by
the surge of light intensity inside the strut core void
on OCT.
During the inﬁltration of connective tissue into
the provisional matrix, the thickness of the neo-
intima on top of struts decreased. It is still unclear
whether maturation from a provisional matrix to
collagen-rich connective tissue may further inﬂuence
TABLE 3 Intravascular Ultrasound Quantitative Measurements
Quantitative Measurement
3 months
(n ¼ 10)
6 months
(n ¼ 7)
12 months
(n ¼ 11)
18 months
(n ¼ 12)
24 months
(n ¼ 12)
30 months
(n ¼ 12)
Mean vessel area, mm2 8.30  1.12 8.66  1.34 8.86  1.93 10.79  2.46 11.86  2.53 11.81  3.31
Normalized vessel area by reference vessel area 0.94  0.19 1.06  0.18 0.99  0.12 1.04  0.12 1.05  0.13 0.99  0.17
Mean scaffold area, mm2 5.81  1.17 6.12  1.20 6.39  1.82 8.16  2.30 8.74  2.06 9.13  3.00
Normalized scaffold area by reference luminal area 0.76  0.15 0.92  0.16 0.82  0.14 0.93  0.15 0.86  0.13 0.84  0.17
Mean luminal area, mm2 4.59  0.88 4.96  1.02 5.01  1.18 6.73  2.23 7.11  2.01 7.89  2.79
Normalized luminal area by reference luminal area 0.60  0.10 0.74  0.13 0.65  0.12 0.76  0.16 0.70  0.12 0.72  0.16
Mean neointimal area þ media 3.73  0.73 3.70  0.45 4.01  1.20 4.03  .0.60 4.75  0.67 3.95  0.61
Vessel wall thickness (thickness between lumen and vessel) 0.41  0.05 0.40  0.03 0.35  0.11 0.39  .0.08 0.44  0.04 0.36  0.02
Mean reference vessel area, mm2 8.96  1.54 8.30  1.63 8.93  1.53 10.46  .2.60 11.39  2.65 12.06  3.18
Mean reference luminal area, mm2 6.08  1.29 5.60  1.27 6.56  1.07 8.06  .2.24 8.74  2.08 9.61  2.68
Echogenicity analysis
Mean upper, mm2 0.4 (0.30–0.46) 0.3 (0.17–0.34) 0.22 (0.16–0.29) 0.26 (0.17–0.29) 0.26 (0.16–0.28) 0.25 (0.16–0.27)
Mean hyper, mm2 0.73 (0.64–1.04) 0.78 (0.74–0.84) 0.46 (0.38–0.65) 0.65 (0.23–0.83) 0.24 (0.10–0.35) 0.24 (0.16–0.32)
Mean upper þ hyper, mm2 1.10 (1.07–1.48) 0.98 (0.90–1.16) 0.8 (0.68–0.87) 0.91 (0.47–1.10) 0.42 (0.35–0.60) 0.46 (0.43–0.54)
Continued on the next page
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mechanotransduction by improving the transmission
of mechanical signal (18). The stimulation of initial
smooth muscle cells can induce matrix metal-
loproteinase release, which plays a key role in matrix
deposition and reorganization by collagen type I
deposition that leads to negative arterial remodeling
and potential neointimal shrinkage (18–21).
CLINICAL IMPLICATIONS. The present analysis con-
ﬁrms that 1) OCT light intensity correlated with the
integration process and that 2) IVUS echogenicity can
detect early changes in molecular weight. By using
IVUS echogenicity, molecular weight loss could be
monitored, and the timing of loss of mechanical
integrity could be predicted. Without any reference to
gel permeate chromatography in vivo, it would be
clinically useful to judge by echogenicity the
degree of biodegradation related to the loss of
mechanical strength and subsequent restoration of
mechanotransduction.
Optical coherence tomographic light intensity is
more sensitive for the integration process, which is
associated with the thinning of the vessel wall as well
as very late luminal enlargement. By using the clas-
siﬁcation of strut (using a proposed cutoff of 0.413 for
inﬁltration greater than 25%), clinicians can assess
the stage of integration that heralds late luminal
enlargement.
When the quantitative light intensity analysis is
applied to the human data obtained from ABSORB
cohort B (Figure 6B), the light intensity surge had not
yet been detected at 36 months (the average of
normalized light intensity was 0.22 in 161 sequen-
tially matched struts). This suggests that the inte-
gration process in humans is somewhat slower than
that in animals and that either late luminal enlarge-
ment could commence later than 3 years or that the
underlying plaque fails to allow positive remodeling
because it is rich in type I collagen.
The inﬂuence of the underlying plaque on the
integration process remains unclear. In previous
clinical studies, the Absorb scaffold was associated
with a decrease of the plaque area on IVUS in the long
term when compared with post-implantation (22). It
was questioned whether this is due to the disap-
pearance of struts or the real reduction of athero-
sclerotic plaque. In the present animal study, the area
of neointima plus media remained unchanged
throughout the 4-year follow-up period, whereas
vessel wall thickness was reduced as a result of the
very late luminal expansion or conversion of type III
collagen to type I with cross-linking of collagen
(Figure 6A). This suggests that the integration of the
struts does not signiﬁcantly affect the area of neo-
intima plus media but induces the expansion of the
lumen and the vessel, which could be mediated by
the mechanotransduction and the restoration of shear
stress (1).
FROM VISUAL CATEGORIZATION TO QUANTITATIVE
MEASUREMENT OF LIGHT INTENSITY. In the present
analysis, we used quantitative assessment of light
intensity, which is more reproducible than visual
assessment. The method has been applied to optical
coherence tomographic analysis of struts in humans.
The intraclass correlation coefﬁcient for interob-
server variability was as high as 0.91 (11).
The present OCT analysis using the second
iteration of the Absorb device showed that using a
cutoff of 0.413, the measured light intensity can
TABLE 3 Continued
36 months
(n ¼ 12)
42 months
(n ¼ 13)
48 months
(n ¼ 20)
p Value
Overall
6 vs.
3 months
12 vs.
3 months
18 vs.
3 months
24 vs.
3 months
30 vs.
3 months
36 vs.
3 months
42 vs.
3 months
48 vs.
3 months
11.21  1.65 13.37  1.83 13.43  1.64 <0.001 0.596 0.478 0.002 <0.001 0.004 <0.001 <0.001 <0.001
1.08  0.10 1.07  0.08 0.97  0.06 0.005 0.203 0.521 0.135 0.124 0.552 0.042 0.048 0.734
8.50  1.26 10.47  1.44 10.14  1.28 <0.001 0.57 0.396 0.001 <0.001 0.002 <0.001 <0.001 <0.001
0.94  0.11 0.96  0.07 0.86  0.07 0.001 0.07 0.429 0.012 0.109 0.282 0.003 <0.001 0.041
7.04  1.22 9.21  1.26 9.45  1.18 <0.001 0.428 0.391 0.002 <0.001 0.001 <0.001 <0.001 <0.001
0.78  0.10 0.85  0.07 0.81  0.08 <0.001 0.033 0.341 0.007 0.06 0.055 <0.001 <0.001 <0.001
4.19  0.61 4.13  0.72 3.99  0.16 0.005 0.925 0.48 0.274 0.001 0.469 0.085 0.2 0.365
0.39  0.05 0.35  0.05 0.33  0.06 <0.001 0.824 0.056 0.666 0.176 0.019 0.385 0.006 <0.001
10.50  1.97 12.57  2.18 13.96  1.79 <0.001 0.347 0.959 0.061 0.004 0.003 0.027 <0.001 <0.001
7.98  1.62 9.79  1.63 10.57  1.45 <0.001 0.436 0.369 0.007 <0.001 <0.001 0.003 <0.001 <0.001
0.18 (0.12–0.20) 0.18 (0.11–0.20) 0.11 (0.07–0.14) <0.001 0.056 0.001 <0.001 <0.001 <0.001 <0.001 <0.001 <0.001
0.25 (0.14–0.34) 0.19 (0.17–0.31) 0.10 (0.07–0.16) <0.001 0.688 0.003 0.022 <0.001 <0.001 <0.001 <0.001 <0.001
0.42 (0.29–0.56) 0.38 (0.32–0.50) 0.22 (0.15–0.29) <0.001 0.197 <0.001 0.001 <0.001 <0.001 <0.001 <0.001 <0.001
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differentiate moderately to highly integrated struts
from low-integrated struts with an accuracy of 0.922.
This integration progressively occurs between 30 and
42 months after implantation, which seems to be the
critical timing for maximal vessel remodeling.
The other possible optical coherence tomographic
methods to evaluate the bioresorption process
include the refractive index or dispersion to dif-
ferentiate the provisional matrix and polymer, or
birefringence analysis using polarization-sensitive
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FIGURE 5 Change of Strut Core on Histology, Optical Coherence Tomography, and Intravascular Ultrasound From 3 to 48 Months
The ﬁgure summarizes the changes in strut cores from 3 to 48 months in the matched struts between histology (A–I), optical coherence tomography (OCT) (a–i),
intravascular ultrasound (IVUS) grayscale (a0–i0), and IVUS echogenicity (a00–i00). During the ﬁrst 18 months, the struts were completely sequestered from the lumen by a
thin and ﬁbromuscular neointima with well-deﬁned and squared edge on histology. (A–D) Although the normalized light intensity (NLI) on OCT showed low values (a–d),
the echogenicity of struts on IVUS decreased gradually (light blue area plus green area in a00–d00). At 24 and 30 months, the strut footprints had discrete borders but
started to be replaced by provisional matrix (E), followed by inﬁltration by connective tissue on histology (F–I). The NLI slightly increased (e,f), whereas the echogenicity
of struts reached to plateau (e00,f00). On histology, the ﬁltration inside of strut void rapidly advanced between 30 and 42 months (G,H). Correspondingly, the normalized
intensity on OCT surged (g,h). At 48 months, the integration of strut cores was almost complete (I), and the NLI reached a plateau (i0). Light blue indicates upper
echogenicity, and light green indicates hyperechogenicity.
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OCT (23). In terms of quantitative measurement, OCT
is presumably more close to the in vivo dimension
than histomorphometric measurement, because of
the absence of vessel shrinkage from histological
preparation (24).
On histology, we used a semiquantitative scale to
classify the degree of integration. Theoretically, the
inﬁltration rate of connective tissues into the strut
footprint could also be quantiﬁable on histology;
however, because of tissue shrinkage due to formalin
ﬁxation and dehydration with tissue processing, it is
unclear which segment of the vessel may be most
affected. It is likely to be proteoglycans, which are
water rich, and dehydration affects water-rich areas
more than other regions. It was also possible that the
strut footprint could deform during the histological
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FIGURE 6 Relationships Among Quantitative Light Intensity Analysis, Luminal Area, and Echogenicity in Animal and Human Models
(A) The relationships among quantitative light intensity, normalized luminal area, and echogenicity with superimposed wall thickness and
neointimal thickness on top of struts in swine. There are 2 periods of facilitated enlargement of normalized luminal area (red bar). The ﬁrst
enlargement of lumen occurs during the ﬁrst 30 months, which could be related to the loss of mechanical integrity and the natural growth of
the coronary artery. During this period, the upper echogenicity plus hyperechogenicity area on intravascular ultrasound (IVUS) echogenicity
decreased and reached a plateau (gray line). The second luminal enlargement occurred between 30 and 42 months. During this period, the
normalized light intensity on optical coherence tomography (OCT) surged (orange line). In addition, the vessel wall thickness (gray bar) was
reduced with the thinning of the neointima on top of struts (green bar). (B) The relationships among quantitative light intensity, luminal area,
and echogenicity in humans. In the ABSORB cohort B trial, at 36 months IVUS echogenicity had decreased (gray line), whereas the normalized
light intensity on OCT had not yet surged (the average of normalized light intensity was 0.22 at 36 months; orange line). Luminal area did not
change signiﬁcantly from 12 to 36 months.
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processing; after 4 years, the original area occupied
by the polymeric strut is poorly discernible by light
microscopy, which made quantitative measurement
on histology difﬁcult. The use of time-of-ﬂight sec-
ondary iron mass spectroscopic analysis might facili-
tate future pre-clinical studies to quantify the degrees
of degradation and integration (25).
STUDY LIMITATIONS. The present study was per-
formed in a healthy porcine model without athero-
sclerosis, so the generalizability of the concepts to
human is therefore limited. The methodology for
normalization is not necessarily applicable to humans,
because homogeneity of neointima is different be-
tween human and porcine models. The expected
complex relationships among plaque burden, mecha-
notransduction, luminal enlargement and vascular
remodeling, and natural coronary artery growth are
not yet elucidated in the current models, although the
initial molecular weight loss due to depolymerization
is not different between human and pigs, because the
process is purely chemical via hydrolysis.
From a regulatory perspective, it is mandatory to
investigate the process of bioresorption of each fully
bioresorbable scaffold, because the rate can vary ac-
cording to the manufacturing process. The current
assessment for monitoring bioresorption and inte-
gration process by echogenicity on IVUS and light
intensity on OCT could be applied only to scaffolds
made of PLLA, with similar molecular weights and
similar manufacturing processes, but it could not be
applied to other scaffolds made of different materials
(e.g., magnesium), with different molecular weights
(e.g., Igaki-Tamai) or different manufacturing pro-
cesses (e.g., Mirage).
CONCLUSIONS
In this pre-clinical model, luminal enlargement is a
biphasic process in which the latter phase likely
relates, at least in part, to strut integration of
the Absorb scaffold into the arterial wall. The
quantitative light intensity analysis of strut cores on
OCT could be used as a surrogate method for moni-
toring matrix inﬁltration and integration of collagen-
rich connective tissue within the polymeric struts
that coincide with the time of late luminal enlarge-
ment. These intravascular methods may provide
insight and understanding of the imaging-related
characteristics of the bioresorption process of
various polylactide scaffolds in human.
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PERSPECTIVES
WHAT IS KNOWN? Visual categorizations of strut
appearance of bioresorbable scaffolds on OCT have
previously been demonstrated to correlate with the
integration process with limited reproducibility. Light
intensity analysis of strut cores has been introduced
as a feasible and reproducible method for a quanti-
tative assessment of strut integration after scaffold
implantation.
WHAT IS NEW? In a porcine pre-clinical model, IVUS
echogenicity analysis and light intensity analysis on
OCT were well correlated with the depolymerization
process of the strut and the integration process after
the complete bioresorption, respectively. The late
luminal enlargement observed between 3 and 4 years
seems to be related to strut integration.
WHAT IS NEXT? Further studies are needed to
evaluate the generalizability of the concepts to hu-
man and to elucidate the expected complex relation-
ships among plaque burden, mechanotransduction,
luminal enlargement and vascular remodeling, and
natural coronary artery growth.
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4.4  Receding of aneurysm after implantation of 
bioresorbable scaffolds 
 
Development and receding of a coronary artery aneurysm after 
implantation of a fully bioresorbable scaffold. 
 
Circulation. 2015 Feb 24;131(8):764-7.  
[Case report, IF 14.95] 
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A 83-year-old man included in the ABSORB cohort B trial underwent successful percutaneous coronary inter-
vention of the middle left anterior descending artery with a 
3.0×18-mm bioresorbable scaffold (Absorb, Abbott Vascular, 
CA) that was postdilated with a 3.0-mm noncompliant bal-
loon at 24 atm (Figure 1A and 1B). The 2-dimensional and 
3-dimensional (3D) optical coherence tomography (OCT) 
conﬁrmed the absence of structural discontinuity after the pro-
cedure (Figure 2B and Figure 3A’). At 6 months, the planned 
angiography showed the absence of restenosis but an ectasia 
in the scaffolded segment (Figure 1C). Intravascular ultra-
sound revealed a focal vessel and lumen enlargement (17.93 
mm2 [Δ+20.5%] and 6.99 mm2 [Δ+9.6%], respectively, in 
the matched cross-section analysis; Figure 2C), whereas 3D 
OCT suggested a deformation of the scaffold in the 2-mm seg-
ment of the ectasia (Figure 3B’). At 18 months, the planned 
multislice computed tomography showed lumen dilatation in 
the scaffolded segment (Figure 1D). At 2 years, on angiog-
raphy, the ectatic lesion in the scaffold became aneurysmal 
(50% increase compared with the adjacent reference vessel; 
Figure 1E). Intravascular imaging revealed the increase in 
the vessel area and lumen area (20.90 mm2 [Δ+40.5%] on 
intravascular ultrasound and 10.91 mm2 [Δ+35.7%] on OCT, 
respectively, from baseline; Figure 1E and 1F), whereas 3D 
OCT showed a focal cleavage of the scaffold rings and a 
bulge of the vessel in the segment free from the scaffold struts 
(Figure 3C and C’). Five years after implantation, angiography 
revealed that the aneurysm was still present but had become 
smaller compared with the previous time points (Figure 1F). 
Intravascular ultrasound and OCT demonstrated the dimin-
ished vessel and lumen area (17.11 mm2 [Δ−18.1%] and 8.78 
mm2 [Δ−19.5%], respectively, from 2 years; Figure 2G and 
2H), making the scaffold indiscernible on OCT.
In general, aneurysm after drug-eluting device implan-
tation is attributed to residual dissection and deep arterial 
wall injury and to inﬂammatory and allergic reactions to 
the drug, polymer, or device such as metal. In rare cases, a 
fully bioresorbable poly(L-lactide) acid prosthesis can cause 
inﬂammation.1 Further insight can be obtained from the 3D 
reconstructions of the OCT signal (Figure 3A’, 3B’, and 3C’), 
in which the pattern of the struts can qualitatively outline the 
time history of the aneurysmal expansion. From implantation 
to 6 months, the wall distended and displaced the strut pattern 
without an apparent change in intracrown angulations, indi-
cating a wall distention that occurred while the strut material 
was still continuous and minimally degraded. Further expan-
sion from 6 to 24 months occurred in part after substantial 
polymer degradation had already occurred, as evidenced by 
the widening of intracrown angulations or complete separa-
tion of strut segments, indicating that strut migration follows 
wall migration entirely and continuity of struts has dimin-
ished to subpattern levels. Cross-sectional and longitudi-
nal reconstructions of these segments appear to show that, 
although diameter is substantially distended, the arterial wall 
thickness over and under the struts is uniform in nature, an 
appearance inconsistent with severe inﬂammatory reactions 
to polymer.
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Figure 1. Coronary angiography of the left anterior descending artery before (A) and after (B) intervention at baseline. At 6 months, the 
planned angiography showed an ectasia in the scaffolded segment (C). The planned multislice computed tomography showed lumen 
dilatation in the scaffolded segment at 18 months (D). Repeat angiography demonstrated that the ectatic lesion in the scaffold became 
aneurysmal at 2 years (E) and diminished at 5 years (F).
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Figure 2. Intravascular ultrasound (IVUS) and optical coherence tomography (OCT) images from matched sites (aneurysm site and near 
proximal site) after the procedure (A and B), at 6 months (C and D), at 2 years (E and F), and at 5 years (G and H) after scaffold implan-
tation. The white lines in the longitudinal view indicate the sites corresponding to the cross sections of A’ to H”. Postprocedural OCT 
showed some malapposed struts but conﬁrmed the absence of structural discontinuity. At 6 months, IVUS revealed a focal vessel and 
lumen enlargement (C”). IVUS and OCT revealed the increase in the vessel and the lumen area at 2 years (E” and F”) and the subsequent 
decrease in the aneurysm, with the scaffold becoming indiscernible on OCT at 5 years (G” and H”). FA indicates ﬂow area; LA, lumen 
area; SA, scaffold area; and VA, vessel area.
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Figure 3. Three-dimensional (3D) reconstruction of cross-sectional images corresponding to the scaffold segment. A’ through D’ are 
reconstructed for emphasizing the scaffold structure. 3D optical coherence tomography (OCT) conﬁrmed the absence of structural dis-
continuity after the procedure. At 6 months, 3D OCT suggested a deformation of the scaffold in the 2-mm segment corresponding to the 
ectasia (B and B’). At 2 years, 3D OCT showed a focal cleavage of the scaffold rings and a bulge of the vessel in the segment free from 
the scaffold struts (C and C’). At 5 years, the aneurysm started to reduce, with the scaffold becoming indiscernible on OCT (D and D’). In 
A’ to D’, the yellow and green dots indicate the proximal and distal radiopaque makers. The blue struts indicate malapposed struts.
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4.5  Multislice Computed Tomography Coronary 
Angiography assessment 
 
A medium term follow-up by Multislice Computed Tomography 
Coronary Angiography assessing the persistent  presence of  
Bioresorbable Vascular Scaffold metallic radiopaque markers at the 
site of implantation. 
 
JACC Cardiovasc Interv. 2015 Jul;8(8):1130-2.  
[Letter, IF 7.44] 
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revascularization are needed. We also agree with
Conti’s opinion that, unless ischemia is present, col-
laterals do not appear angiographically; if the collat-
eral provides excellent blood ﬂow to ischemic
myocardium, the collaterals will remain (2). Werner et
al. (3) reported that even collaterals that appear well
developed on angiography are not able to fully
replace anterograde blood ﬂow; therefore, restoring
ﬂow reserve does little to prevent myocardial
ischemia. Our hypothesis was that well-developed
collateral ﬂow in patients with stable CTO lesions
may partially protect the myocardium and the
revascularization may allow complete maintenance
of viable myocardium (4), and we identiﬁed long-
term survival beneﬁts of aggressive revasculariza-
tion compared with medical therapy in our study.
Unfortunately, because we did not routinely per-
form contralateral injections after successful re-
vascularization of CTO in our practice, we could not
identify the existence or disappearance of collaterals
after CTO revascularization, as mentioned in Conti’s
letter. However, we agree with his hypothesis that
the change of collateral ﬂow after CTO revasculari-
zation in coronary angiography might correlate
with whether ischemia of viable myocardium occurs
or not. This hypothesis requires further detailed
study.
As stated by Barbato and Wijns (1), our study
might have reported a higher rate of successful
percutaneous coronary intervention (PCI) or coronary
bypass grafting (CABG) compared to previous studies
of CTO revascularization. However, remarkable
developments in the survival beneﬁts posed by CTO
revascularization are rapidly becoming a reality
because CTO PCI techniques have improved and the
experience of CABG has also increased. We anticipate
that the survival beneﬁts of aggressive reduction of
remnant ischemia by revascularization or intensive
medication in patients with CTO lesions will be veri-
ﬁed by future large-scale randomized trials.
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Fate of Bioresorbable
Vascular Scaffold Metallic
Radio-Opaque Markers at
the Site of Implantation
After Bioresorption
The use of bioresorbable vascular scaffolds (BRS) is
increasing in patients with coronary artery disease
undergoing percutaneous coronary interventions.
Because the devices are radiolucent on ﬂuoroscopy,
2 adjacent cylindrical platinum markers are incor-
porated in the proximal and distal edges of the
polymeric devices for precise scaffold deployment
and post-dilation during the procedure. In addition,
the metallic radio-opaque markers (MRMs) also
provide anatomic landmarks for long-term follow-up
when all the polymeric struts have been bioresorbed.
There has been concern about the potential risk of
MRM beads becoming dislodged from the device and
embolized into the coronary bed after complete
bioresorption of the polymeric struts. Beyond the
biological hazard of MRMs embolization, the addi-
tional inconvenience is that the embolization may
result in the incapacity to locate the coronary
segment where the fully bioresorbed scaffold was
implanted. Invasive assessment of BRS such as
quantitative coronary angiography (QCA), intravas-
cular ultrasound (IVUS), or optical coherence to-
mography (OCT) may be unable to detect the precise
location of the MRMs either because of the
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resolution of the imaging technique (QCA) or as a
result of wire artifact (IVUS, OCT) or mimicry by
heavy calcium (IVUS). Multislice computed tomog-
raphy coronary angiography (MSCT) has provided
reliable assessment of the angiographic results up to
3 to 5 years (1,2) after scaffold implantation with
accurate detection of the position of MRMs and their
blooming effect without being dependent on the rate
of image acquisition and wire artifact. In order to
dispel the question of embolization of MRMs, we
evaluated the persistent presence and location at
18 months of the MRMs following implantation of
these fully bioresorbable scaffolds.
We retrospectively pooled data from the ABSORB
trials (ABSORB Cohort A, ABSORB Cohort B, and
ABSORB EXTEND) in which 943 patients with de novo
native coronary artery lesions were treated with the
fully resorbable everolimus-eluting Absorb scaffold
(Abbott Vascular, Santa Clara, California); the details
and primary outcome of each trial have been pub-
lished (2–4). Of these 943 patients, 165 patients with
168 lesions underwent MSCT at 18 months. A list of
the MSCT scanners, the acquisition protocol, and the
MSCT analysis are described in the Online Appendix.
To establish the persistent presence of the MRMs
in MSCT, both qualitative and quantitative evidence
were required. The qualitative evidence was the abil-
ity to identify both proximal and distal MRMs posi-
tion. Because calciﬁed nodules (CN) could mimic
MRMs, 4 criteria were used to identify the position of
the radio-opaque markers: 1) typical location and
orientation of the MRMs; 2) marker-to-marker length;
3) topographical relationship of the radio-opaque
markers with anatomic landmarks visualized on
MSCT and conventional coronary angiography; and
4) blooming artifact and its peak attenuation. The
description of criteria and examples of MSCT images
by using these 4 criteria are provided in Online
Figure 1. The quantitative evidence is the MSCT scaf-
fold length compared with its nominal length.
The statistical analysis is detailed in the Online
Appendix.
A total of 168 lesions (12 lesions in ABSORB Cohort
A, 61 lesions in ABSORB Cohort B, and 95 lesions in the
ABSORB EXTEND study) were analyzed, and the study
proﬁle is shown in Online Figure 2. A total of 348
MRMs were evaluated by both quantitative and qual-
itative analyses; all MRMs were detected at the im-
plantation site; and there was no evidence of marker
embolization to distal vascular beds. The median
MSCT scaffold length was 18.0 mm (ranging from
12 mm to 36 mm; interquartile range [IQR]: 17 to
19 mm) as well as the median nominal scaffold length
was 18.0 mm (ranging from 12mm to 28 mm) (Figure 1).
The median difference in length between MSCT scaf-
fold length and nominal scaffold length was 0.0 mm
(IQR: 1.0 to 1.0 mm). There was a moderate correla-
tion between MSCT mean lumen area (Mean LA) and
QCAMean LA (r¼ 0.54, p< 0.0001). A good correlation
was observed between MSCT Mean LA and IVUS Mean
LA, and between MSCT Mean LA and OCT Mean LA
(r¼ 0.74 and r¼ 0.73, respectively; p< 0.0001) (Online
Figure 3). The Mean LA measured by MSCT was com-
parable to QCA, but statistically lower than IVUS
and OCT (Online Table 1). The reproducibility of the 4
criteria to identify MRMs from CN was good, r ¼ 0.97;
p < 0.0001 (Online Figure 4).
The attenuation of MRMs was approximately 30%
higher than dense CN attenuation, but there was
nevertheless a modest overlap of the attenuation
values; MRM attenuation was sometimes lower than
1,000 HU as a result of the partial volume effect. The
median peak density of MRMs was 1,368 HU (IQR:
1,158 to 1,715 HU) in contrast to the median peak
density of CN that was 946 HU (IQR: 844 to 1,133 HU).
The main ﬁndings of this study are the following:
1) according to the criteria, all MRMs were identiﬁed
and located at the site of the initial implantation;
2) the MSCT Mean LA was comparable to the Mean LA
measured by QCA but lower than OCT and IVUS; and
3) the reproducibility in detecting of MRMs by using
4 criteria was high.
FIGURE 1 MSCT Scaffold Length Compared With Nominal Scaffold Length
The median and the 1st and 3rd quartiles of each multislice computed tomography (MSCT)
scaffold length corresponding to its nominal length are shown in boxes, and the minimum
and maximum values as whiskers. The asterisks and the dots above/below indicate the
outlier cases.
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However, the distinction between calciﬁed spots
and metallic markers with computed tomography
is also not easy to determine compared with OCT.
The possible advantages of OCT are the ability to:
1) distinguish the MRMs from underlying calcium
more clearly than MSCT; 2) measure the embedment
of the struts; and 3) evaluate the thickness of neo-
intima because of a higher axial resolution of around
10 to 15 mm as compared with MSCT.
The limitation in this study is that the study result
was able to conﬁrm the persistent presence of MRMs
only at medium-term follow-up, and the long-term
results still require investigation.
In conclusion, MRM recognition by MSCT is critical
for precise noninvasive assessment of the coronary
location of all MRMs. On the basis of our study criteria,
there was no evidence of MRMs dislodgement and
embolization 18 months after scaffold implantation.
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3-Year Follow-Up of the
Balloon Elution and Late
Loss Optimization Study
(BELLO)
The optimal treatment of de novo small-vessel coro-
nary artery disease remains unclear. The use of drug-
eluting stents in this patient group are limited by
high rates of restenosis (1) and the requirement of
prolonged treatment with dual antiplatelet therapy.
The use of drug-coated balloons (DCB) might be an
alternative treatment option. There are currently
limited data with regard to the long-term efﬁcacy of
this strategy (2), and currently no randomized data
to support this approach. The BELLO (Balloon
Elution and Late Loss Optimization) study (3) was
an investigator-initiated, prospective, multicenter,
single-blinded, active-treatment controlled cli-
nical trial. In BELLO, 182 patients undergoing percu-
taneous revascularization of small coronary vessels
(reference vessel diameter <2.8 mm by visual esti-
mation) were randomly assigned in a 1:1 ratio to
treatments with: 1) In.Pact Falcon paclitaxel DCB
(Medtronic, Inc., Santa Rosa, California) dilation and
provisional bare-metal stenting; or 2) paclitaxel-
eluting stent (PES) (Taxus Liberté, Boston Scientiﬁc,
Marlborough, Massachusetts) implantation as per
standard clinical practice. We have shown that
treatment of small-vessel disease with a paclitaxel
DCB is associated with less angiographic late loss and
similar rates of restenosis and revascularization as
PES is at 1 year. Here we report the ﬁnal pre-deﬁned,
protocol-mandated 3-year clinical follow-up results
of this study population.
A total of 182 patients were enrolled at 15 Italian
centers and randomized to treatment with DCB
(n ¼ 90) in 94 lesions or PES (n ¼ 92) in 98 lesions.
Patients were eligible if $18 years of age, with a
diagnosis of stable or unstable angina or documented
ischemia and a maximum of 2 angiographically sig-
niﬁcant de novo lesions <25 mm in length in native
coronary arteries with a visually estimated reference
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4.6  Edge vascular response following implantation of 
bioresorbable scaffolds 
 
Scaffold and edge vascular response following implantation of 
everolimus-eluting bioresorbable vascular scaffold: a 3-year serial 
optical coherence tomography study. 
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Scaffold and Edge Vascular Response
Following Implantation of Everolimus-
Eluting Bioresorbable Vascular Scaffold
A 3-Year Serial Optical Coherence Tomography Study
Yao-Jun Zhang, MD, PHD,*y Javaid Iqbal, PHD,*z Shimpei Nakatani, MD,* Christos V. Bourantas, MD, PHD,*
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ABSTRACT
OBJECTIVES This study sought to investigate the in-scaffold vascular response (SVR) and edge vascular response
(EVR) after implantation of an everolimus-eluting bioresorbable scaffold (BRS) using serial optical coherence tomography
(OCT) imaging.
BACKGROUND Although studies using intravascular ultrasound have evaluated the EVR in metal stents and BRSs,
there is a lack of OCT-based SVR and EVR assessment after BRS implantation.
METHODS In the ABSORB Cohort B (ABSORB Clinical Investigation, Cohort B) study, 23 patients (23 lesions) in Cohort
B1 and 17 patients (18 lesions) in Cohort B2 underwent truly serial OCT examinations at 3 different time points (Cohort B1:
post-procedure, 6 months, and 2 years; B2: post-procedure, 1 year, and 3 years) after implantation of an 18-mm scaffold.
A frame-by-frame OCT analysis was performed at the 5-mm proximal, 5-mm distal edge, and 2-mm in-scaffold margins,
whereas the middle 14-mm in-scaffold segment was analyzed at 1-mm intervals.
RESULTS The in-scaffold mean luminal area signiﬁcantly decreased from baseline to 6 months or 1 year (7.22  1.24
mm2 vs. 6.05  1.38 mm2 and 7.64  1.19 mm2 vs. 5.72  0.89 mm2, respectively; both p < 0.01), but remained
unchanged from then onward. In Cohort B1, a signiﬁcant increase in mean luminal area of the distal edge was observed
(5.42  1.81 mm2 vs. 5.58  1.53 mm2; p < 0.01), whereas the mean luminal area of the proximal edge remained un-
changed at 6 months. In Cohort B2, the mean luminal areas of the proximal and distal edges were signiﬁcantly smaller
than post-procedure measurements at 3 years. The mean luminal area loss at both edges was signiﬁcantly less than the
mean luminal area loss of the in-scaffold segment at both 6-month and 2-year follow-up in Cohort B1 or at 1 year and
3 years in Cohort B2.
CONCLUSIONS This OCT-based serial EVR and SVR evaluation of the Absorb Bioresorbable Vascular Scaffold (Abbott
Vascular, Santa Clara, California) showed less luminal loss at the edges than luminal loss within the scaffold. The luminal
reduction of both edges is not a nosologic entity, but an EVR in continuity with the SVR, extending from the in-scaffold
margin to both edges. (ABSORB Clinical Investigation, Cohort B [ABSORB B]; NCT00856856) (J Am Coll Cardiol Intv
2014;7:1361–9) © 2014 by the American College of Cardiology Foundation.
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R estenosis in the segments adjacent tothe proximal and distal edges of apermanent or transient coronary
implant has been a concern for many years
(1–5). In the metal drug-eluting stent (DES)
era, studies demonstrated effective inhibi-
tion of neointimal hyperplasia reducing the
risk of edge restenosis and the need for
repeat intervention on the edges (6,7). Our
group, using intravascular ultrasound (IVUS)
imaging, previously investigated the edge
vascular response (EVR) after implantation
of fully bioresorbable scaffold (BRS) and re-
ported a luminal area reduction at the prox-
imal edge at 2-year follow-up (8).
Optical coherence tomography (OCT) offers sub-
stantially superior resolution that allows a precise
evaluation of luminal dimensions, edge dissections,
and relevant vessel wall pathology (9–12). To date, no
study has used serial OCT imaging to examine the
EVR and its relationship with in-scaffold vascular
response (SVR) at 3-year follow-up after BRS im-
plantation. We hypothesized that the local changes in
luminal dimensions at the edge of the Absorb Bio-
resorbable Vascular Scaffold (Absorb BVS) (Abbott
Vascular, Santa Clara, California) are simply the
extension of the changes in luminal dimension ob-
served at the in-scaffold margins and not a separate
pathological entity. This study aimed to evaluate the
OCT-based SVR and EVR after Absorb BVS (Abbott
Vascular) implantation in the ABSORB Cohort B
(ABSORB Clinical Investigation, Cohort B) trial.
METHODS
STUDY DESIGN AND POPULATION. The ABSORB
Cohort B trial was described in detail previously (12).
Brieﬂy, thiswas a nonrandomized,multicenter, single-
arm trial that enrolled 101 patients (102 lesions) treated
with the second-generation Absorb BVS (Abbott Vas-
cular) (A complete list of the members of the ABSORB
Cohort B Study appears in the Online Appendix). The
participants were divided into 2 groups according
to the pre-deﬁned invasive follow-up: Cohort B1 at
post-procedure, 6 months, and 2 years and Cohort B2
at post-procedure, 1 year, and 3 years. OCT was an
optional examination conducted at selected centers
with OCT capability and previous experience. The
registry was approved by the ethics committee at
each participating institution, and each patient gave
written informed consent before inclusion.
STUDY DEVICE AND TREATMENT PROCEDURE.
The Absorb BVS (Abbott Vascular) is a balloon-
expandable scaffold consisting of a polymer back-
bone of poly-L-lactide coated with a thin layer of a 1:1
SEE PAGE 1370
FIGURE 1 Flowchart of the Patients Included in the Current Analysis
*Edge restenoses in Cohort B that mandated repeat revascularization. †This case had in-segment restenosis at the distal margin of the scaf-
folded segment and distal edge. 1Y ¼ 1 year; 2Y ¼ 2 years; 3Y ¼ 3 years; BL ¼ baseline; FUP ¼ follow-up; NL ¼ number of lesions; NP ¼ number
of patients; OCT ¼ optical coherent tomography.
ABBR EV I A T I ON S
AND ACRONYMS
BMS = bare-metal stent(s)
BRS = bioresorbable
scaffold(s)
BVS = bioresorbable vascular
scaffold(s)
CI = conﬁdence interval
DES = drug-eluting stent(s)
EVR = edge vascular response
IVUS = intravascular
ultrasound
OCT = optical coherence
tomography
SVR = in-scaffold vascular
response
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mixture of amorphous poly-D,L-lactide polymer and
the antiproliferative drug everolimus to form a drug-
eluting coating matrix that contains 100 mg of ever-
olimus per square centimeter of scaffold (13–15).
Target lesions were treated with routine interven-
tional techniques, and pre-dilation was mandatory.
The Absorb BVS (Abbott Vascular) inﬂation pressure
did not exceed 16 atm, the burst pressure according to
the product chart. Post-dilation with a balloon shorter
than the implanted scaffold was at the discretion of
the operator. OCT imaging was performed after
optimal Absorb BVS (Abbott Vascular) implantation
and at follow-up.
OCT ACQUISITIONS AND DATA ANALYSIS. OCT
acquisitions were performed using 3 different com-
mercially available systems: the M2 and M3 Time-
Domain Systems and the C7XR Fourier-Domain
System (LightLab Imaging, Westford, Massachusetts).
OCT images were acquired at frame rates of 15.6, 20,
and 100 frames/s with pullback speeds of 2, 3, and 20
mm/s in theM2Time-Domain System (n¼ 11),M3Time-
Domain System (n ¼ 11), and C7XR Fourier-Domain
System (n ¼ 101) (LightLab Imaging), respectively. All
recordings were performed according to the recom-
mended procedure for each OCT system (16). The OCT
images acquired post-procedure and at follow-upwere
analyzed off-line, using proprietary LightLab Imaging
software (St. Jude Medical Inc., St. Paul, Minnesota).
Truly serial OCT data were deﬁned as the patient un-
dergoing OCT examinations at all 3 time points.
The SVR analysis included all 18-mm scaffold seg-
ments, analyzed at 1-mm intervals by an indepen-
dent core laboratory (Cardialysis, Rotterdam, the
Netherlands). The EVR analysis included the 5-mm
proximal and distal edges, analyzed in a frame-by-
frame fashion (128-mm interval for the M2, 150-mm
interval for the M3, 200-mm interval for the C7). In
addition, we performed a frame-by-frame analysis of
changes in the lumen area at the 2-mm margins of the
scaffold to explore the relationship between in-
scaffold margins and the edges. The scaffold edge
was deﬁned as the ﬁrst cross section exhibiting
visible struts in a circumference <270 (10). If the
5-mm edge had a side branch with a vessel
diameter $1.5 mm, the analysis included only frames
between the scaffold’s margin and the ostium of the
side branch. If the vessel diameter of the side branch
was <1.5 mm, only the frames at the ostium of the
side branch were excluded. In addition, we excluded
the cases that needed a bailout stent as well as the
frames with insufﬁcient assessment of the entire
luminal circumference due to inadequate blood
clearance or incomplete scanning perimeter. Edge
dissection was deﬁned as disruption of the endolumi-
nal vessel surface at the proximal and distal edges (17).
STATISTICAL ANALYSIS. Continuous variables are
presented as mean  SD or median (interquartile
range). Binary variables are presented as count and
percent. Absolute difference and 95% conﬁdence
interval (CI) of baseline characteristics was generated
by normal approximation for continuous variables and
Newcombe score method for binary variables. A paired
t test orWilcoxon signed rank test was used to compare
SVR and EVR within groups at different time points.
The normality of the data was determined with the
D’Agostino Pearson test and veriﬁed by histogram
plots. To evaluate the relationship of the lumen area
TABLE 1 Baseline and Lesion Characteristics of Fully Serial OCT Available Patients
Cohort B1
(n ¼ 23)
Cohort B2
(n ¼ 17) Difference (95% CI)
Age, yrs 63.4  9.8 61.6  8.0 1.8 (3.9 to 7.5)
Male 82.6 64.7 17.9 (8.8 to 43.5)
Diabetes mellitus 4.3 5.9 1.5% (22.9 to 15.8)
Hypertension 52.2 70.6 18.4 (43.5 to 11.7)
Hypercholesterolemia 95.7 76.5 19.2 (2.6 to 43.2)
Current smoker 21.7 29.4 7.7% (34.3 to 18.2)
Family history of CAD 52.2 66.7 14.5% (40.9 to 16.6)
Previous MI 43.5 12.5 31.0 (1.5–52.7)
History of PCI 26.1 11.8 14.3 (12.0 to 36.4)
Unstable angina 17.4 5.9 11.5 (12.0 to 31.8)
Target-lesion vessel, %
LAD 26.1 11.1 15.0 (10.6 to 36.9)
LCX 26.1 33.3 7.3 (33.9 to 19.3)
RCA 47.8 55.6 7.7 (35.0 to 21.4)
RVD before intervention 2.59  0.40 2.57  0.26 0.02 (0.19 to 0.23)
Maximal balloon artery ratio 1.01  0.15 1.05  0.11 0.04 (0.12 to 0.05)
Maximal inﬂation pressure 18.4  3.0 16.6  5.3 1.8 (1.1 to 4.7)
Values are mean  SD or %.
CAD ¼ coronary artery disease; CI ¼ conﬁdence interval; LAD ¼ left anterior descending artery; LCX ¼ left
circumﬂex artery; MI ¼ myocardial infarction; OCT ¼ optical coherent tomography; PCI ¼ percutaneous coronary
intervention; RCA ¼ right coronary artery; RVD ¼ reference vessel diameter.
TABLE 2 In-Scaffold Vascular Response Analysis
Luminal Area Changes
In-Scaffold Vascular Response (18 mm)
p Value
Distal
Subsegment
(6 mm)
Middle
Subsegment
(6 mm)
Proximal
Subsegment
(6 mm)
Cohort B1
6 months vs. baseline 1.21  0.79 0.98  0.68 1.34  0.79 0.27
2 yrs vs. 6 months 0.44  0.91 0.05  1.46 0.12  1.29 0.25
2 yrs vs. baseline 1.65  0.99 0.94  1.62 1.22  1.24 0.18
Cohort B2
1 yr vs. baseline 1.91  1.24 1.77  1.10 2.06  0.87 0.73
3 yrs vs. 1 yr 0.18  0.93 0.26  0.84 0.05  0.72 0.29
3 yrs vs. baseline 2.10  1.59 1.51  1.23 2.00  1.03 0.36
Values are mean  SD.
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within different segments of the scaffold (3 sub-
segments: proximal, middle, and distal), multilevel
generalized estimating equation model ﬁtting, with
the mean lumen area as the response and the sub-
segments and the follow-up visits as categorical vari-
ables, were nested within each patient. Multiple
comparisons were conducted without adjustment.
Statistical signiﬁcance was assumed at p < 0.05. All
statistical analyses were performed with SAS version
9.1.3 (SAS Institute Inc., Cary, North Carolina).
RESULTS
STUDY POPULATION AND OCT ACQUISITION.
A ﬂowchart of the subjects included in the current
TABLE 3 Edge Vascular Response Analysis
Luminal Area Cohort B1 Cohort B2
Distal edge, 5 mm 6M 2Y 1Y 3Y
Baseline 5.42  1.81 5.78  2.04
FUP (6M/2Y, 1Y/3Y) 5.58  1.53 5.26  1.40 5.63  1.45 5.29  1.77
Difference 0.19  1.05 0.16  1.24 0.14  1.25 0.49  1.17
p value (BL vs. FUP) <0.01 0.03 0.11 <0.01
Proximal edge, 5 mm 6M 2Y 1Y 3Y
Baseline 6.84  2.86 7.27  2.01
FUP (6M/2Y, 1Y/3Y) 6.76  2.63 6.75  2.60 6.66  1.74 6.51  1.63
Difference 0.07  1.14 0.08  1.13 0.61  1.33 0.76  1.57
p value (BL vs. FUP) 0.31 0.25 <0.01 <0.01
Values are mean  SD.
6M ¼ 6 months; 1Y ¼ 1 year; 2Y ¼ 2 years; 3Y ¼ 3 years; BL ¼ baseline; FUP ¼ follow-up.
FIGURE 2 Scaffold and Its EVR
The images present the global mean luminal area changes including in-scaffold, 5-mm proximal and distal edges at follow-up. (A) Cohort B1. (B) Cohort B2. Mean luminal
area of the 18-mm in-scaffold segment signiﬁcantly decreased from baseline to 6-month or 1-year follow-up, but no change from 6 months to 2 years or 1 year to
3 years. The EVR analysis showed an increase in mean luminal area at the distal edge at 6 months and a reduction at both the proximal and distal edges at long-term
follow-up. The transitional regions with a 200-mm interval analysis are presented in the embedded panels, indicating a continuous pattern of luminal reduction extending
from the in-scaffold margins to the ﬁrst 1 mm of proximal and distal edges. *Indicates a signiﬁcant change in mean luminal area in each 1-mm interval at the proximal or
distal edge (p < 0.05). EVR ¼ edge vascular response; other abbreviations as in Figure 1.
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analysis is shown in Figure 1. A total of 183 OCT
pullbacks at baseline and follow-up were performed
in 80 patients (81 lesions). Twenty-three patients
(23 lesions) in Cohort B1 and 17 patients (18 lesions) in
Cohort B2 had truly serial OCT examinations at 3
different time points. Three patients who had a target
lesion revascularization did not undergo OCT exami-
nation before the reintervention.
Baseline characteristics of the patients with truly
serial OCT pullbacks are shown in Table 1. There was a
greater prevalence of patients with previous
myocardial infarction (43.5% vs. 12.5%; difference:
31.0%; 95% CI: 1.5% to 52.7%) and lesions in the left
anterior descending artery in Cohort B1 (26.1% vs.
11.1%; difference: 15.0%; 95% CI: 10.6% to 36.9%)
than in Cohort B2.
SVR ANALYSIS. In Cohort B1, there was a signiﬁcant
reduction in mean in-scaffold luminal area at
6 months (7.22  1.24 mm2 vs. 6.05  1.38 mm2,
p < 0.01). However, the mean luminal area remained
unchanged from 6 months to 2 years (5.97  1.61 mm2,
p ¼ 0.75). Similarly, in Cohort B2, there was a signif-
icant reduction in mean in-scaffold luminal area from
baseline to 1 year (7.64  1.19 mm2 vs. 5.72  0.89
mm2, p < 0.01), but no change from 1 year to 3 years
(5.81  1.29 mm2, p ¼ 0.60).
At 3-year follow-up, there was no signiﬁcant dif-
ference in behavior of the 3 in-scaffold subsegments
(proximal, middle, and distal) (Table 2). The mean
luminal area of proximal and middle subsegments
numerically increased from 6 months to 2 years or 1
year to 3 years (B1: 0.12  1.29 mm2, 0.05  1.46 mm2;
B2: 0.05  0.72 mm2, 0.26  0.84 mm2; respectively),
whereas the mean luminal area of the distal segment
numerically decreased (B1: 0.44  0.91 mm2, 0.18
 0.93 mm2).
EVR ANALYSIS. The changes in mean luminal area of
the proximal and distal edges at different time points
are shown in Table 3. In Cohort B1, a signiﬁcant in-
crease in mean luminal area at the distal edge (5-mm
FIGURE 2 Continued
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segment) was observed at 6 months (5.42  1.81 mm2
vs. 5.58  1.53 mm2, p < 0.01) (Figure 2A), whereas at
the proximal edge (5-mm segment), the mean luminal
area remained unchanged (6.84  2.86 mm2 vs. 6.76 
2.63 mm2, p ¼ 0.31). In Cohort B2, the mean luminal
area at the distal edge was unchanged at 1-year follow-
up (5.78  1.45 mm2 vs. 5.63  1.45 mm2, p ¼ 0.11)
(Figure 2B). At 3-year follow-up, a signiﬁcant reduc-
tion in the mean luminal area was observed at both
edges (distal: 5.78  2.04 mm2 vs. 5.29  1.77 mm2;
proximal: 7.27  2.01 mm2 vs. 6.51  1.63 mm2; both
p < 0.01).
PATTERN OF CHANGES IN LUMINAL DIMENSIONS
FROM IN-SCAFFOLD MARGINS TO EDGES. At all time
points, reduction in the luminal area was observed in
the ﬁrst 1 mm of the edges, both proximally and
distally, indicating a continuous pattern of luminal
reduction extending from the scaffold margin to the
proximal or distal edge (Figure 2). The overall reduc-
tion in mean luminal area at both edges was signiﬁ-
cantly less than the in-scaffold segments (all p < 0.05)
(Table 4).
EDGE RESTENOSIS, EDGE DISSECTION, AND STENT
THROMBOSIS. Of 101 patients in the entire ABSORB
Cohort B trial, 2 patients (2.0%) had proximal edge
restenosis and 1 patient (1%) had distal edge reste-
nosis. Patients with the proximal edge restenosis had
a repeat revascularization at day 168 and day 383,
respectively. The patient with the distal edge reste-
nosis had a repeat revascularization at day 833. These
3 patients were treated without previous OCT to
examine edge restenosis. In 2 of these patients, a
geographic miss (injured or diseased segment not
covered by the device, balloon-artery ratio <0.9 or
>1.3) was previously reported (15).
In total, 12 proximal (24%) and 21 distal (42%) edge
dissection ﬂaps were observed post-procedure. In the
truly serial OCT analysis, 9 proximal (21%) and 16
distal (38%) edge dissection ﬂaps were identiﬁed
post-procedure, which decreased to 1 proximal (2%)
and 2 distal (5%) at 6 months, only proximal 1 (2%) at
1-year follow-up, and none at 2- and 3-year follow-up
(Figure 3). No scaffold thrombosis was reported in this
trial.
DISCUSSION
This study, for the ﬁrst time, reported OCT-derived
EVR and SVR evaluation after Absorb BVS (Abbott
Vascular) implantation at mid- and long-term follow-
up. The primary ﬁndings are the following: 1) an
increase in mean luminal area at the distal edge at
6 months; 2) a reduction in the mean luminal area at
both edges at long-term (2- or 3-year) follow-up;
3) reduction in luminal area at the in-scaffold
segment from baseline to 6 or 12 months, but no
change from then onward. A uniform pattern of lu-
minal reduction extending from the in-scaffold mar-
gins to the ﬁrst 1-mm of the proximal and distal edges
of the scaffold is also demonstrated, suggesting that
the edge changes in luminal dimension is not a noso-
logic entity, but a progressive transition in luminal
dimension from the in-scaffold margin to the edges.
EVOLUTION OF DEVICES AND EVR. The introduction
of coronary metal stents has markedly reduced the
risk of restenosis (14). The EVR in the era of bare
metal stents (BMS) was mainly due to an increase in
plaque and medial area and reduction in luminal area
within the ﬁrst 1 to 2 mm of the device (15,18).
Radioactive stents, developed to reduce restenosis,
were proved to be safe in initial studies (19,20), but
led to a profound edge effect deﬁned angiographic-
ally as a diameter stenosis of >50% at the proximal
and distal stent edges (2,3). In the DES era, the EVR
can also be inﬂuenced by the drug and polymer
incorporated into the stent (21). A high degree of
variability in EVR was identiﬁed among the different
DES types (5). In the TAXUS II trial, paired-edge an-
alyses with IVUS showed a signiﬁcant increase in
luminal area at the distal edge of paclitaxel-eluting
stent compared with the BMS at 6 months, whereas
a signiﬁcant decrease in the luminal area was
observed at the proximal edge (22). The beneﬁcial
effect of the paclitaxel-eluting stent was most notable
in the area closest to its distal edge (23). Trials with
the Endeavor stent (Medtronic, Minneapolis, Minne-
sota) demonstrated a reduction in the luminal area at
both the proximal and distal edges, mainly due to
negative remodeling, plaque growth, and rapid
elution of zotarolimus (24,25). However, serial IVUS
TABLE 4 Overall Vascular Response Analysis
Luminal Area Changes
Distal
Edge, 5 mm
In-Scaffold,
18 mm
Proximal
Edge, 5 mm
p Value
(Distal vs.
In-Scaffold)
p Value
(Proximal vs.
In-Scaffold)
Cohort B1
6 months vs. baseline,
mm2
0.16  1.05 1.18  1.06 0.07  1.14 <0.01 <0.01
2 years vs. baseline,
mm2
0.16  1.24 1.23  1.64 0.08  1.13 <0.01 <0.01
Cohort B2
1 year vs. baseline,
mm2
0.14  1.25 1.88  1.29 0.61  1.33 <0.01 <0.01
3 years vs. baseline,
mm2
0.49  1.17 1.85  1.50 0.76  1.56 <0.01 <0.01
Values are mean  SD.
339
examination in sirolimus- and everolimus-eluting
stents revealed an enlargement of the luminal area
at the distal edge (26–28). Our results are in agree-
ment with those of previous reports on metal
everolimus-eluting stents (28), with a signiﬁcant in-
crease in the distal-edge luminal area and a nonsig-
niﬁcant decrease in the proximal edge at 6-month
follow-up. The difference in behavior of the 2 edges
can partially be explained by downstream diffusion of
antiproliferative drug to the distal edge (21).
IN-DEPTH ANALYSIS OF EVR AND SVR. IVUS imag-
ing has contributed to our understanding of EVR
after BRS implantation. However, this approach has
inherent limitations (e.g., poor resolution, cardiac
motion artifacts) and makes it difﬁcult to assess EVR
precisely (29–31). The present study, performed with
OCT, for the ﬁrst time evaluated EVR in frame-by-
frame (#200 mm) fashion after Absorb BVS (Abbott
Vascular) implantation and provided additional in-
sights into the changes in luminal dimensions at the
proximal and distal edges.
Our previous IVUS-based study demonstrated a
nonsigniﬁcant reduction in luminal area at the distal
edge at 6 months (32); however, accurate assessment
with OCT has documented it to be a signiﬁcant
change. By the virtue of the high resolution of OCT,
we also demonstrated that the pattern of in-scaffold
luminal reduction extended progressively from the
in-scaffold margins to the contiguous ﬁrst 1 mm of
the edges outside the scaffold, both proximally
and distally, presumably related to neointimal
FIGURE 3 Dissections at the Distal Edge
(A) Longitudinal view of patients with distal dissection. (B) Three-dimensional reconstruction of optical coherence tomography pullbacks show that dissection is visible
at distal edge (double white arrow). (C, D) Three-dimensional reconstruction at 6-month and 2-year follow-up showed that dissection has healed. (E) No distal edge
dissection (arrow) is visible from the post-procedure angiograms. The curved line indicates the scaffolded segment. (F) Dissection extends into at least the media from
multiple cross-sectional views. (G) Increased luminal area without visible dissection at 6-month follow-up. (H) The luminal area decreased with detected calciﬁc tissue at
2-year follow-up. LA ¼ lumen area. *Indicates a side branch.
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hyperplasia or neoatherosclerosis (33). In addition,
the discrepancy with previous IVUS observations can
also be attributed to the nonserial nature of the data
in previous IVUS studies. Thus, we believe that OCT-
based EVR evaluation with truly serial data can pro-
vide more reliable and precise information.
Finally, the SVR analysis presented here is consis-
tent with the previous ﬁnal 3-year report of the
ABSORB Cohort B study (32). The analysis of changes
in mean luminal area of different in-scaffold sub-
segments using a generalized estimating equation
model did not show any signiﬁcant difference in
vascular response; however, there was a numerical
increase in luminal area in the middle subsegment
from 1 year to 3 years. Preclinical studies of the BRS
have demonstrated that late luminal positive remod-
eling was observed at late follow-up (34). It will be
interesting to re-evaluate this subsegment behavior at
5-year follow-up of the ABSORB Cohort B study.
CLINICAL IMPLICATIONS. The Absorb BVS (Abbott
Vascular) does not produce a pathological edge effect
that was seen with BMS or notoriously with radio-
active stents. The stable luminal area after 6 to
12 months without late catch-up is a potential supe-
riority of BRS over metal DES. In the ABSORB Cohort B
trial, there were only 3 cases of edge restenosis,
and 2 of them could be attributed to longitudinal
geographic miss (13). Edge dissections, considered
to be a trigger for early stent thrombosis, were often
detected by post-procedure OCT in the present
study; however, most of these dissections healed
within 6 months, without any clinical adverse events.
STUDY LIMITATIONS. First, the number of patients
in the current study is small; however, it is the
largest and longest series available to date, and due
to the truly serial OCT data, potential patient-
to-patient variability was minimized. Second, OCT
examination was not available for patients under-
going repeat revascularization, and, therefore, we
decided to exclude these patients from this analysis.
Finally, OCT cannot visualize external elastic lamina
due to its low penetration, and, hence, changes
in plaque media or vessel area cannot be assessed
adequately.
CONCLUSIONS
In this study, truly serial OCT imaging was used to
assess the EVR and SVR after Absorb BVS (Abbott
Vascular) implantation up to 3-year follow-up. We
found a signiﬁcant increase in the luminal area at the
distal edge at 6-month follow-up. However, at longer
term (1, 2, and 3 years), the luminal area decreased at
both edges, resulting in a repeat revascularization
rate of 3%. In-scaffold luminal area signiﬁcantly
decreased from post-procedure to 6 months or 1 year,
but remained unchanged from then onward. A
continuous pattern of luminal loss extending from
the in-scaffold margins to the ﬁrst 1-mm of scaffold
edges has suggested that the changes in luminal area
at the edge of a BRS is not a nosologic entity in itself,
but an extension of the in-scaffold response to the
edges.
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SUMMARY AND CONCLUSIONS 
 
Vessel Sizing, Acute Performance and Patient Outcome after Implantation of Bioresorbable 
Scaffolds 
The use of bioresorbable scaffolds has several challenges that justify careful assessment 
of this technology. The performance of the second-generation Absorb bioresorbable 
everolimus-eluting scaffold was investigated in the ABSORB II as well as in the Cohort B1, 
Cohort B2, and ABSORB EXTEND studies, and demonstrated excellent clinical results. As the 
Absorb scaffold has a strict upper limit of expansion, assessment of pre-procedural Dmax 
of proximal and distal sites has been used for Absorb scaffold size selection in the ABSORB 
studies. The MACE and MI rates at 1 year were significantly higher in the scaffold oversize 
group (both proximal and distal Dmax values were smaller than the nominal size of the 
implanted scaffold) than in the scaffold nonoversize group (MACE: 6.6% vs. 3.3%, log-rank p 
< 0.01, all MI: 4.6% vs. 2.4%; log-rank p= 0.04), mainly driven by a higher rate of MI within 1 
month after the procedure (3.5% vs. 1.9%; p= 0.08). Selection of an appropriate scaffold size 
according to the vessel Dmax showed a trend toward less frequent ID-TLR, whereas 
implantation of an oversized Absorb scaffold in a relatively small vessel may be associated 
with a higher risk of MACE at 1 year (chapter 1.1). The conformability of the stent has been 
described as the flexibility of a stent in its expanded state with adaptation to the natural 
shape of the vessel. A higher conformability of the stent is associated with less potential for 
vessel distortion and trauma. In the deployment of long coronary scaffolds/ stents (28mm 
in length), bioresorbable vascular scaffolds provides better conformability compared with 
metallic stents (chapter 1.2). Chapter 1.3 is the first randomized clinical trial (ABSORB II) to 
analyze the difference in frequencies of periprocedural myocardial infarction (PMI) and 
cardiac biomarker (CB) rise after implantation of Absorb scaffold or Everolimus eluting 
stent (EES). Incidence of any anatomic complications including side branch occlusion (SBO) 
assessed by angiography was similar between the 2 treatment arms (Absorb: 16.4% vs. EES: 
19.9%, p = 0.39). There were no statistically significant differences in the incidence of CB rise 
and PMI between Absorb and EES. Treatment with overlapping devices was an 
independent determinant of per-protocol PMI (OR: 5.07, 95% CI: 1.78 to 14.41, p = 0.002). In 
addition, binary definition of PMI is not only dependent on the selection of CB but also on 
the thresholds of the CB rise which are arbitrarily chosen (chapter 1.3). In the ABSORB II 
randomized controlled trial, lower acute gain occurred more frequently in the Absorb arm 
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than in the Xience arm (3.46 mm2 vs. 4.27 mm2, p<0.001; risk ratio, 3.04; 95%CI, 1.94-4.76). 
The plaque morphology at the minimum lumen area (MLA) cross-section was not 
independently associated with acute gain. On angiography, device acute recoil was 
comparable but expansion of the device was different. The influence of post-dilatation on 
MLD was somewhat limited (chapter 1.4). The relationship between the IVUS geometrical 
morphologies and clinical events has never been investigated in the context of a 
randomized trial. The principal independent determinants of eccentric and asymmetric 
morphology of scaffold/stent post implantation were high pre-implantation EI [OR 
0.03(0.00-0.31), p=0.003] and treatment with Absorb [OR 7.29(3.24-16.37), p<0.001]. 
Lesions with pre-implantation negative remodeling and high post-implantation AI were 
independently associated with 1-year DoCE (chapter 1.5). Despite rapid dissemination of an 
everolimus-eluting bioresorbable scaff old for treatment for coronary artery disease, no 
data from comparisons with its metallic stent counterpart are available. In ABSORB II trial, 
the everolimus-eluting bioresorbable scaff old showed similar 1-year composite secondary 
clinical outcomes to the everolimus-eluting metallic stent (chapter 1.6). In the BVS STEMI 
study, the Absorb scaffolds implantation in patients presenting with acute MI appeared 
feasible, with high rate of final TIMI-flow III and good scaffold apposition (chapter 1.7). 
Furthermore, the implantation of the everolimus eluting bioresorbable vascular scaffold in 
an expanded range of coronary lesion types and clinical presentations was observed to be 
safe and feasible with promising angiographic results and mid-term clinical outcomes 
(chapter 1.8). 
 
Failure Mode of Bioresorbable Scaffolds 
In the early Absorb studies, several technical failure and adverse events were documented. 
We thus summarised the cases who experienced subacute/late scaffold thrombosis or 
scaffold dislodgement. In the first 450 patients enrolled in the ABSORB EXTEND trial, all 
dislodgements occurred in the LCX, and in two cases dislodgement was observed after 
reinsertion of the same device. Two subacute scaffold thromboses and two late scaffold 
thromboses were observed. Two scaffold thromboses seemed to be related to either 
premature discontinuation of DAPT or resistance to clopidogrel (chapter 2.1). Potential 
mechanism causes of scaffold thrombosis could be: 1) suboptimal implantation resulting in 
underexpansion/acute incomplete strut apposition or acute disruption of struts; 2) platelet 
activation due to low shear stress created by the relatively thick strut; 3) delayed tissue 
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coverage in an overlapped segment; 4) discontinuation of DAPT or resistance to DAPT 
(chapter 2.2). We summarizes the rate of scaffold thrombosis in each individual report. 
Excluding the GHOST-EU registry, the rate of definite/probable scaffold thrombosis was 
0.89% in all-comers, 0.68% in SAP, 1.71% in ACS and 0.67% in STEMI (chapter 2.2). In the 
ABSORB Cohort B trial, there were six cases of in-segment binary restenosis at the 3-year 
imaging and clinical follow-up,: two early ISR (<6 months), one late ISR (6-12 months) and 
three very late ISR (>12 months). Three of these ISR cases seemed to be induced by 
anatomical or procedural factors. In the other three cases, intravascular imaging 
(IVUS/OCT) demonstrated that the main mechanism of restenosis was significant 
intra-scaffold tissue growth, while the structural circularity and diameter of the scaffold 
were not affected (chapter 2.3). 
 
Validation and application of bifurcation algorithm 
  The challenge in QCA of bifurcations is to assess an accurate reference diameter (RVD) to 
calculate the percent diameter stenosis (%DS). Conventional single-vessel QCA software is 
inaccurate in bifurcation lesions because it completely ignores the natural anatomy of the 
bifurcation, including the natural “step-down” in diameters after each bifurcation (chapter 
3.1). Overestimation of the %DS of the distal main and side branch by single-vessel analysis 
may potentially have clinical implications. We are already aware that ostial side branch 
stenosis severity is overestimated with visual estimation. However, the side branch stenosis 
will also be overestimated when single-vessel QCA analysis is used pre-procedure, which 
may lead to the overtreatment of insignificant stenosis (chapter 3.1). Dedicated bifurcation 
software algorithms have been developed: currently, two different software packages are 
commercially available (CAAS and QAngio XA). The two software packages use slightly 
different approaches, but both have proven to be highly accurate when validated against 
precision-manufactured bifurcation phantoms (chapter 3.2). Single-vessel software use in 
bifurcation trials or first-in-man/registry studies on dedicated bifurcation stents with 
planned repeat angiography will lead to less accurate results of the side branch (chapter 
3.2). A recent example was the Tryton IDE trial showing different QCA outcomes with 
dedicated bifurcation QCA from those with single-vessel QCA (chapter 3.3). The use of 
single-vessel software in such trials may therefore lead to an increased rate of 
ischaemia-driven target TLR of the side branch (chapter 3.3). Three-dimensional (3D) 
quantitative coronary angiography (QCA) provides more accurate measurements by 
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minimizing inherent limitations of two-dimensional (2D) QCA (chapter 3.4). There were 
differences in addressing anatomical severity and location of coronary bifurcation lesions 
between in vivo 2D and 3D QCA analyses. Whereas DS was in general higher with 2D QCA, 
lesion length was shorter with 2D QCA than with 3D QCA (chapter 3.4). The implantation of 
a bioresorbable scaffold is a new approach that provides transient vessel support with drug 
delivery capability, potentially without the limitations of permanent metallic implants. 
 
Long Term Assessment of Bioresorbable Scaffolds 
 Using IVUS grey scale derived parameters, we attempted to assess the degradation 
process of the Absorb poly-L-lactide bioresorbable everolimuseluting scaffold at multiple 
time points in a porcine model. Hyperechogenic and upperechogenic thresholds had strong 
and positive correlations with the scaffold molecular weight assessment. The combination 
of hyper and upperechogenicity could be used as a surrogate for the chromatographic 
assessment of scaffold molecular weight (chapter 4.1). Quantitative light intensity analysis 
by OCT was capable of detecting subtle changes in the bioresorbable strut appearance over 
time, and could be used to monitor the bioresorption and integration process of polylactide 
struts (chapter 4.2). The quantitative OCT-light intensity analysis could be used as a 
surrogate method for monitoring the integration process of PLLA scaffolds throughout 5 
years, which could help the clinicians to better interpret the human OCT images with 
regarding to the phases of integration process (chapter 4.3). Development and receding of 
a coronary artery aneurysm after implantation of a fully bioresorbable scaffold was 
documended in the Cohort B trial for 5 years (Chapter 4.4). Multislice computed 
tomography coronary angiography (MSCT) has provided reliable assessment of the 
angiographic results up to 3 to 5 years. The metallic radio-opaque markers (MRM) 
recognition by MSCT is critical for precise noninvasive assessment of the coronary 
location of all MRMs (chapter 4.5). We found a significant increase in the luminal area at the 
distal edge at 6-month follow-up. However, at longer term (1, 2, and 3 years), the luminal 
area decreased at both edges, resulting in a repeat revascularization rate of 3% (chapter 
4.6). 
 
CONCLUSIONS 
 In the randomised comparison, the Absorb everolimuseluting bioresorbable scaffolds 
showed similar one-year clinical outcomes to the everolimus-eluting Xience metallic stent, 
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and side branch occlusion and other angiographic complications are not different in the 
acute performance. Implantation of an oversized Absorb scaffold in a relatively small vessel 
appears to be associated with a higher 1-year MACE rate driven by more frequent early MI. 
In the early Absorb studies, several failure modes of bioresorbable scaffolds were 
documented. To avoid scaffold dislodgement, appropriate lesion preparation is mandatory. 
In case of unsuccessful initial delivery, a second insertion of the same scaffold should be 
avoided. Adherence to antiplatelet therapy is of paramount importance to avoid acute or 
subacute scaffold thrombosis. QCA bifurcation was validated and clinical applicable. IVUS, 
OCT and MSCT could be used to assess long term bioresorption and serial changes in lumen 
dimension.  
Further investigation using intravascular imaging is needed to establish the relationship 
between acute potential mechanism and late adverse events.  
 
May 2016, 
Yuki Ishibashi 
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Samenvatting en conclusies 
 
Bepaling bloedvat diameter, acute prestaties en patiënten uitkomsten na implantatie van 
biologisch oplosbare stents (scaffolds). 
Het gebruik van biologisch oplosbare stents heeft verschillende uitdagingen die een 
zorgvuldige evaluatie van deze technologie justificeert. De prestaties van de tweede 
generatie biologisch oplosbare everolimus-afgevende stents onderzocht in ABSORBII 
studie en ook in cohort B1/B2 en ABSORB-Extend studies laten goede klinische resultaten 
zien. Omdat de Absorb scaffold een strikte maximale bovengrens van expansie heeft, 
worden in de ABSORB studies de beoordeling van de pre-procedure Dmax 
(maximale-Diameter) van proximale en distale kanten van de scaffold gebruikt voor het 
selecteren van de juiste Absorb scaffold maat (diameter). De negatieve uitkomsten zoals 
dood, myocard infarct (MI), reinterventie (MACE) waren op 1 jaar aanzienlijk hoger in de 
patiënten groep met een te grote scaffold maat in relatie tot het bloedvat (zowel de 
proximale als distale Dmax waren kleiner dan de nominale maat van de geïmplanteerde 
scaffold) dan in de scaffold groep met een juiste scaffold maat zonder oversizing (MACE: 
6,6% versus 3,3%, log-rank p <0,01, alle MI: 4,6% versus 2,4%; log-rank p= 0,04), voornamelijk 
gedreven door een hoger percentage van MI binnen 1 maand na de procedure (3,5% versus 
1,9%; p= 0,08). Selectie van een geschikte grootte van de scaffold in relatie tot de Dmax van 
het bloedvat toonde een trend naar minder frequente reinterventies, terwijl het 
implanteren van een oversized Absorb scaffold in een relatief klein bloedvat kan worden 
geassocieerd met een hoger risico van MACE op 1 jaar (hoofdstuk 1.1). De verhoogde 
pasbaarheid (conformability) van de stent is omschreven als de flexibiliteit van een stent in 
de uitgerekte vorm met aanpassing aan de natuurlijke vorm van het bloedvat. Een betere 
conformabiliteit van de scaffold wordt geassocieerd met minder bloedvat vervorming en 
andere trauma. Bij de implantatie van lange coronaire scaffolds/ stents (28 mm lang) bieden 
biologisch oplosbare stents een betere/verhoogde pasbaarheid in vergelijking met metalen 
stents (hoofdstuk 1.2). In hoofdstuk 1.3 wordt de eerste gerandomiseerde klinische 
trial (ABSORB II) behandeld en wordt het verschil in frequentie van peri-procedure myocard 
infarct (PMI) en cardiale biomarker (CB) verhoging na implantatie van de biologisch 
oplosbare everolimus-afgevende stents (EWS) beschreven. Incidentie van anatomische 
complicaties waaronder zijtak occlusie (SBO) beoordeeld door angiografie was 
vergelijkbaar tussen de twee behandelings armen (de biologisch oplosbare 
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everolimus-afgevende stent (ABSORB): 16,4% versus de metalen everolimus-afgevende 
stent (XIENCE): 19,9%, p = 0,39). Er waren geen statistisch significante verschillen in de 
incidentie van CB verhoging en PMI tussen ABSORB en XIENCE. Behandeling met een 
overlappende stent/scaffold was een onafhankelijke factor van de per-protocol PMI (OR: 
5,07, 95% CI: 1.78 tot 14.41, p = 0.002). Bovendien, is de binaire definitie van PMI niet alleen 
afhankelijk van de keuze van CB, maar ook van de keuze van de drempel (threshold) van de 
CB verhoging die willekeurig gekozen wordt (hoofdstuk 1.3). In de ABSORB II 
gerandomiseerde gecontroleerde trial, zien we in de scaffold arm vaker een lagere acute 
gain (winst in diameter) dan in de XIENCE arm (3,46 mm2 vs. 4.27 mm2, P<0,001; risico ratio, 
3.04; 95%CI, 1.94-4.76). De morfologie van de plaque op het punt van de minimale lumen 
dwarsdoorsnede (MLA) was niet onafhankelijk geassocieerd met acute gain. Op angiografie, 
was de acute recoil (afname in diameter/terugveren) vergelijkbaar tussen de ABSORB en de 
XIENCE maar de expansie tussen de twee producten was verschillend. De invloed van 
post-dilatatie op de minimale lumen diameter (MLD) was enigszins beperkt (hoofdstuk 1.4). 
De relatie tussen de IVUS geometrische morfologie en klinische gebeurtenissen is nooit 
onderzocht in het kader van een gerandomiseerde trial. De belangrijkste onafhankelijke 
determinanten van excentrische en asymmetrische morfologie van scaffold/stent na 
implantatie zijn hoge pre-implantatie EI [OR 0.03 (0.00-0.31), p=0.003] en behandeling met 
Absorb [OR 7.29(3.24-16.37), p<0,001]. Vernauwingen met pre-implantatie negatieve 
remodeling en hoge post-implantatie AI zijn onafhankelijk geassocieerd met 1 jaar 
gebeurtenissen (Device oriented Cardiac Endpoints; dood, infarct, reinterventie) 
(hoofdstuk 1.5). Ondanks een snelle verspreiding van de biologisch oplosbare 
everolimus-afgevende stents voor behandeling van coronaire hartziekte, zijn er nog geen 
gegevens beschikbaar van vergelijkingen met zijn metalen counterpart. In de ABSORB II 
studie, laat de biologisch oplosbare everolimus-afgevende stent soortgelijke 1 jaar 
samengestelde secundaire klinische resultaten zien dan de everolimus-afgevende metalen 
stent (hoofdstuk 1.6). De BVS STEMI-studie laat zien dat de implantatie van de biologisch 
oplosbare everolimus-afgevende stents mogelijk is bij patiënten met een acuut myocard 
infarct met een goede TIMI flow III en een goede scaffold appositie in de bloedvatwand 
(hoofdstuk 1.7). Bovendien blijkt de implantatie van de biologisch oplosbare 
everolimus-afgevende stents in een uitgebreid scala van coronaire laesies types en klinische 
presentaties veilig en haalbaar met goede angiografische en tussentijdse klinische 
resultaten (hoofdstuk 1.8). 
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 Failure Mode van biologisch oplosbare stents  
In het begin van de ABSORB studies werden er diverse technische problemen en 
ongewenste klinische gebeurtenissen gedocumenteerd. Wij hebben gevallen van 
subacute/late scaffold trombose en van scaffold dislodgement gerapporteerd. In de eerste 
450 patiënten gerekruteerd in de ABSORB EXTEND studie gebeurde alle dislodgements in 
de LCX, en in twee gevallen werd dislodgement waargenomen na het opnieuw inbrengen 
van dezelfde scaffold. Twee subacute scaffold thromboses en twee late scaffold 
thromboses werden waargenomen. Twee scaffolds thromboses lijken te zijn gelieerd aan 
een voortijdige beëindiging van DAPT of resistentie voor clopidogrel (hoofdstuk 2.1). 
Potentiële oorzaken van scaffold trombose kunnen zijn: 1) suboptimale implantatie met 
onder expansie/acute onvolledige strut aanhechting (appositie) of acute ontwrichting van 
struts; 2) bloedplaatjes activatie door lage shear stress veroorzaakt door de relatief dikke 
struts; 3) vertraagde weefsel dekking in een segment met overlappende struts; 4) 
onderbreking/ stoppen van DAPT of resistentie tegen DAPT (hoofdstuk 2.2). We hebben het 
percentage scaffold trombose samengevat in elk individueel verslag. Met uitzondering van 
de ghost-eu registrie, het percentage van de definitieve/waarschijnlijke scaffold trombose 
0,89% in all-comer patiënten, 0,68% in stabiele patiënten, 1,71% in acute patiënten en 0,67% in 
ST-elevation myocardial infarction (hoofdstuk 2.2). In de ABSORB cohort-B trial, waren er 
zes gevallen van in-segment restenosis (ISR) tijdens de 3-jarige klinische follow-up met 
beeldvorming: twee vroege ISR (<6 maanden), één late ISR (6-12 maanden) en drie zeer late 
gevallen van ISR (>12 maanden). Drie van deze ISR gevallen blijken te worden geïnduceerd 
door anatomische of procedurele factoren. In de drie andere gevallen, heeft intravasculaire 
imaging (IVUS/OCT) aangetoond dat het belangrijkste mechanisme van restenosis 
significante intra-scaffold weefselgroei is, terwijl de structurele circulariteit en de diameter 
van de scaffolds niet werden beïnvloed (hoofdstuk 2.3). 
 
Validatie en toepassing van bifurcatie algoritme 
De uitdaging van QCA in bifurcaties is het beoordelen van een nauwkeurige referentie 
diameter (RVD) voor het berekenen van percentage diameter stenose [%DS]. Conventionele 
single-bloedvat QCA software is onnauwkeurig in bifurcatie laesies omdat deze software 
volledig voorbij gaat aan de natuurlijke anatomie van de bifurcatie, waaronder de 
natuurlijke "step-down" in diameters na iedere zijtak/ bifurcatie (hoofdstuk 3.1). 
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Overschatting van de %DS van de distale hoofdtak en zijtak door single-bloedvat analyse 
hebben mogelijkerwijs klinische implicaties. We weten al dat een ostiale zijtak vernauwing 
wordt overschat met visuele analyse. Echter, deze ostiale zijtak vernauwing wordt ook 
overschat wanneer single-bloedvat QCA analyse wordt gebruikt pre-procedure, wat kan 
leiden tot de overbehandeling van onbeduidende vernauwingen (hoofdstuk 3.1). Speciale 
bifurcatie software-algoritmen zijn ontwikkeld; momenteel zijn twee verschillende 
softwarepakketten commercieel verkrijgbaar (CAAS en QAngio XA). Deze twee 
softwarepakketten gebruiken enigszins verschillende methoden, maar beide hebben zijn 
uiterst nauwkeurig wanneer gevalideerd tegen precisie vervaardigde bifurcatie fantomen 
(hoofdstuk 3.2). Single-bloedvat analyse software gebruikt in bifurcatie en 
first-in-man/register studies met toegewijde bifurcatie stents met geplande follow-up 
angiografie zal leiden tot minder nauwkeurige resultaten (hoofdstuk 3.2). Een recent 
voorbeeld hiervan is de Tryton IDE studie die verschillende QCA resultaten laat zien 
wanneer speciale bifurcatie QCA wordt gebruikt vergeleken met singel-bloedvat QCA 
(hoofdstuk 3.3). Het gebruik van single-bloedvat QCA software in dergelijke processen kan 
dan ook leiden tot een foutieve mate van reinterventie van de zijtak (hoofdstuk 3.3). 
Driedimensionale (3D) kwantitatieve coronaire angiografie (QCA) verschaft nauwkeurigere 
metingen door het minimaliseren van inherente beperkingen van tweedimensionale (2D) 
QCA (hoofdstuk 3.4). Er zijn verschillen tussen in-vivo 2D en 3D QCA-analyses in aanpak van 
de anatomische vernauwing en van de locatie van coronaire bifurcaties. DS% was in het 
algemeen hoger met 2D-QCA, laesie lengte was korter met 2D-QCA dan met 3D-QCA 
(hoofdstuk 3.4). De implantatie van een biologisch oplosbare stent met medicijn afgevende 
capaciteit en met kortstondige support van het bloedvat is een nieuwe benadering, 
mogelijk zonder de beperkingen van permanente metalen implantaten. 
 
Lange termijn beoordeling van biologisch oplosbare stents 
Met IVUS afgeleide parameters, hebben we geprobeerd om in het varkensmodel op 
meerdere tijdstippen het afbraak proces te analyseren van de poly-L-lactide bioresorbable 
everolimus-eluting Absorb. Hyperechogenic en upperechogenic drempels hadden een 
sterke en positieve correlaties met de beoordeling van het molecuulgewicht van de scaffold. 
De combinatie van hyper en upperechogenicity konden worden gebruikt als surrogaat voor 
de chromatografische analyse van het molecuulgewicht van de scaffold (hoofdstuk 
4.1). Kwantitatieve lichtintensiteit analyse door OCT kunnen subtiele veranderingen 
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detecteren in het uiterlijk van de bioresorbable strut in de loop van de tijd, en kan worden 
gebruikt voor bewaking van de bioresorption- en integratieproces van de polylactide 
struts (hoofdstuk 4.2). De kwantitatieve OCT-lichtintensiteit analyse gedurende 5 jaar kan 
worden gebruikt als surrogaat voor het integratieproces van PLLA scaffolds die de artsen 
kunnen helpen om de menselijke OCT beelden beter te kunnen interpreteren met 
betrekking tot het integratie proces (hoofdstuk 4.3). Ontwikkeling en afname van een 
coronaire bloedvat aneurysma voor 5 jaar na implantatie van een volledig bioresorbable 
scaffold is gedocumenteerd in Absorb cohort B trial (hoofdstuk 4.4). Multislice 
computertomografie coronaire angiografie (MSCT) heeft gezorgd voor een betrouwbare 
beoordeling van de angiografische resultaten van 3 tot 5 jaar. De herkenning van de 
metalen radio-opaque marker (MRM) van de scaffold door MSCT is essentieel voor 
nauwkeurige niet-invasieve evaluatie van alle MRMs in het bloedvat (hoofdstuk 4.5). We 
vonden een significante toename in de luminal area aan de distale rand bij 6 maanden 
follow-up. Echter, op langere termijn (1, 2 en 3 jaar) is de luminal area afgenomen aan beide 
kanten wat resulteerde in 3% re-interventies (hoofdstuk 4.6). 
 
Conclusies 
In de gerandomiseerde vergelijking, de biologisch oplosbare everolimus-afgevende stent 
(ABSORB) vertoonden soortgelijke eenjarige klinische resultaten dan de metalen 
everolimus-afgevende stent (XIENCE), en zijtak occlusie en andere angiografische 
complicaties verschillen niet in de acute prestaties. Implantatie van een oversized Absorb 
scaffold in een relatief klein bloedvat lijkt geassocieerd te worden met een hogere 1-jaar 
MACE percentage gedreven door vroege myocard infarcten. In het begin van de Absorb 
studies zijn diverse tekortkomingen van bioresorbable scaffolds gedocumenteerd. Om het 
vroegtijdig breken van scaffolds te voorkomen is een nauwkeurige laesie voorbereiding 
verplicht. In geval van een niet-succesvolle eerste poging, moet een tweede poging met 
eenzelfde scaffold worden vermeden. Naleving van antiplatelet therapie is van het 
allergrootste belang om acute of subacute scaffold trombose te voorkomen. Bifurcatie 
QCA werd gevalideerd en is klinische toepasbaar. IVUS, CTO en MSCT kunnen worden 
gebruikt voor het beoordelen van langdurige bioresorption en seriële veranderingen in 
lumen dimensie.  
Nader onderzoek met behulp van intravasculaire beeldvorming is vereist om de relatie 
tussen acute potentiële mechanisme en late ongewenste gebeurtenissen te bevestigen.  
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*UXQGHNHQ0-,VKLEDVKL<5DPFKDULWDU67XLQHQEXUJ-&5HLEHU-+7X
6$EHQ-3*LUDVLV&:\NU]\NRZVND--2QXPD<6HUUX\V3:
(XUR,QWHUYHQWLRQ0D\6XSSO99

5LVN VWUDWLILFDWLRQ LQ YHVVHO FRURQDU\ DUWHU\ GLVHDVH $SSO\LQJ WKH
6<17$; 6FRUH ,, LQ WKH +HDUW 7HDP'LVFXVVLRQ RI WKH 6<17$; ,,
WULDO
&DPSRV &0 6WDQHWLF %0 )DURRT 9:DOVK 6 ,VKLEDVKL < 2QXPD <
*DUFLD*DUFLD+0(VFDQHG-%DQQLQJ$6HUUX\V3:6<17$;,,6WXG\
*URXS
&DWKHWHU&DUGLRYDVF,QWHUY0D\

9DOLGLW\ RI 6<17$; VFRUH ,, IRU ULVN VWUDWLILFDWLRQ RI SHUFXWDQHRXV
FRURQDU\LQWHUYHQWLRQV$SDWLHQWOHYHOSRROHGDQDO\VLVRISDWLHQWV
HQUROOHGLQFRQWHPSRUDU\FRURQDU\VWHQWWULDOV
&DPSRV&0*DUFLD*DUFLD+0YDQ.ODYHUHQ',VKLEDVKL<&KR<.
9DOJLPLJOL05lEHU/-RQNHU+2QXPD<)DURRT9*DUJ6:LQGHFNHU
60RUHO0$6WH\HUEHUJ(:6HUUX\V3:
,QW-&DUGLRO0D\

(FKRJHQLFLW\ DV D VXUURJDWH IRU ELRUHVRUEDEOH HYHUROLPXVHOXWLQJ
VFDIIROG GHJUDGDWLRQ DQDO\VLV DW         DQG
PRQWKIROORZXSLQDSRUFLQHPRGHO
&DPSRV&0,VKLEDVKL<(JJHUPRQW-1DNDWDQL6&KR<.'LMNVWUD-
5HLEHU -+ 6KHHK\ $ /DQH - .DPEHUL 0 5DSR]D 5 3HUNLQV /
*DUFLD*DUFLD+02QXPD<6HUUX\V3:
,QW-&DUGLRYDVF,PDJLQJ0DU

,Q YLWUR YDOLGDWLRQ DQG FRPSDULVRQ RI GLIIHUHQW VRIWZDUH SDFNDJHV RU
DOJRULWKPVIRUFRURQDU\ELIXUFDWLRQDQDO\VLVXVLQJFDOLEUDWHGSKDQWRPV
LPSOLFDWLRQVIRUFOLQLFDOSUDFWLFHDQGUHVHDUFKRIELIXUFDWLRQVWHQWLQJ
,VKLEDVKL<*UXQGHNHQ0-1DNDWDQL6,TEDO-0RUHO0$*pQpUHX[3
*LUDVLV&:HQW]HO--*DUFLD*DUFLD+02QXPD<6HUUX\V3:
&DWKHWHU&DUGLRYDVF,QWHUY0DU

(DUO\ EHIRUH  PRQWKV ODWH  PRQWKV DQG YHU\ ODWH DIWHU 
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PRQWKV DQJLRJUDSKLF VFDIIROG UHVWHQRVLV LQ WKH $%625% &RKRUW %
WULDO
1DNDWDQL62QXPD<,VKLEDVKL<0XUDPDWVX7,TEDO-=KDQJ<-YDQ
*HXQV5-2UPLVWRQ-$6HUUX\V3:
(XUR,QWHUYHQWLRQ0DU

'HYHORSPHQW DQG UHFHGLQJ RI D FRURQDU\ DUWHU\ DQHXU\VP DIWHU
LPSODQWDWLRQRIDIXOO\ELRUHVRUEDEOHVFDIIROG
1DNDWDQL6,VKLEDVKL<6XZDQQDVRP3*UXQGHNHQ0-+¡M&KULVWLDQVHQ
(2QXPD<6HUUX\V3:$%625%&RKRUW%,QYHVWLJDWRUV
&LUFXODWLRQ)HE

,QWHUFRUHODEYDULDELOLW\LQDQDO\]LQJTXDQWLWDWLYHFRURQDU\DQJLRJUDSK\
IRUELIXUFDWLRQOHVLRQVDSRVWKRFDQDO\VLVRIDUDQGRPL]HGWULDO
*UXQGHNHQ 0- ,VKLEDVKL < *pQpUHX[ 3 /D6DOOH / ,TEDO -
:\NU]\NRZVND -- 0RUHO 0$ 7LMVVHQ -* GH :LQWHU 5- *LUDVLV &
*DUFLD*DUFLD+02QXPD</HRQ0%6HUUX\V3:
-$&&&DUGLRYDVF,QWHUY)HE

$ ELRUHVRUEDEOH HYHUROLPXVHOXWLQJ VFDIIROG YHUVXV D PHWDOOLF
HYHUROLPXVHOXWLQJVWHQWIRULVFKDHPLFKHDUWGLVHDVHFDXVHGE\GHQRYR
QDWLYHFRURQDU\DUWHU\OHVLRQV$%625%,,DQLQWHULP\HDUDQDO\VLV
RI FOLQLFDO DQG SURFHGXUDO VHFRQGDU\ RXWFRPHV IURP D UDQGRPLVHG
FRQWUROOHGWULDO
6HUUX\V 3: &KHYDOLHU % 'XGHN ' &HTXLHU $ &DUULp ' ,QLJXH] $
'RPLQLFL0YDQGHU6FKDDI5-+DXGH0:DVXQJX/9HOGKRI63HQJ/
6WDHKU3*UXQGHNHQ0-,VKLEDVKL<*DUFLD*DUFLD+02QXPD<
/DQFHW-DQ

6KRUWterm effects of Nano+™ polymerIUHHVLUROLPXVHOXWLQJVWHQWVRQ
QDWLYHFRURQDU\YHVVHOVDQRSWLFDOFRKHUHQFHWRPRJUDSK\LPDJLQJVWXG\
6XZDQQDVRP3%HQLW(*DFK2YRQ%LUJHOHQ&+RIPD6%R;=KDQJ
<-1DNDWDQL6,VKLEDVKL<2QXPD<*DUFtD*DUFtD+0*DR5 
6HUUX\V3:
$VLD,QWHUYHQWLRQ

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6FDIIROG DQG HGJH YDVFXODU UHVSRQVH IROORZLQJ LPSODQWDWLRQ RI
HYHUROLPXVHOXWLQJ ELRUHVRUEDEOH YDVFXODU VFDIIROG D \HDU VHULDO
RSWLFDOFRKHUHQFHWRPRJUDSK\VWXG\
=KDQJ<-,TEDO-1DNDWDQL6%RXUDQWDV&9&DPSRV&0,VKLEDVKL<
&KR<.9HOGKRI6:DQJ-2QXPD<*DUFLD*DUFLD+0'XGHN'YDQ
*HXQV5-6HUUX\V3:$%625%&RKRUW%6WXG\,QYHVWLJDWRUV
-$&&&DUGLRYDVF,QWHUY'HF

3HULSURFHGXUDOP\RFDUGLDOLQMXU\DQGULJKWEXQGOHEUDQFKEORFNGXULQJ
FRURQDU\RSWLFDOFRKHUHQFHWRPRJUDSK\LQDQDFXWHFRURQDU\V\QGURPH
SDWLHQWZLWKVHYHUHFRURQDU\HFWDVLD
.R\DPD . <RQH\DPD . 0LWDUDL 7 .RED\DVKL < 6DLWR 0 2RQR 7
.XZDWD6,VKLEDVKL<.RQJRML.$NDVKL<-+DUDGD7
,QW-&DUGLRO'HF

)DVW YLUWXDO IXQFWLRQDO DVVHVVPHQW RI LQWHUPHGLDWH FRURQDU\ OHVLRQV
XVLQJ URXWLQHDQJLRJUDSKLFGDWDDQGEORRG IORZVLPXODWLRQ LQKXPDQV
FRPSDULVRQZLWKSUHVVXUHZLUHIUDFWLRQDOIORZUHVHUYH
3DSDIDNOLV 0, 0XUDPDWVX 7 ,VKLEDVKL < /DNNDV /6 1DNDWDQL 6
%RXUDQWDV&9/LJWKDUW-2QXPD<(FKDYDUULD3LQWR07VLUND*.RWVLD
$1LNDV'10RJDEJDE2YDQ*HXQV5-1DND..)RWLDGLV',%ULODNLV
(6*DUFLD*DUFLD+0(VFDQHG-=LMOVWUD)0LFKDOLV/.6HUUX\V3:
(XUR,QWHUYHQWLRQ6HS

6LPXOWDQHRXVRFFOXVLRQRI OHIW DQWHULRUGHVFHQGLQJDQG OHIW FLUFXPIOH[
DUWHULHVE\YHU\ODWHVWHQWWKURPERVLVYDVFXODUUHVSRQVHWRGUXJHOXWLQJ
VWHQWVDVVHVVHGE\LQWUDYDVFXODUXOWUDVRXQG
<DPDZDNL02QXPD<1DNDQR00XUDPDWVX71DNDWDQL6 
,VKLEDVKL<,VKLPRUL++LUDQR.,WR<7VXNDKDUD50XUDPDWVX7
+HDUW9HVVHOV-XO

/HVVRQV OHDUQHG IURPDFXWH DQG ODWH VFDIIROG IDLOXUHV LQ WKH$%625%
(;7(1'WULDO
,VKLEDVKL<2QXPD<0XUDPDWVX71DNDWDQL6 ,TEDO-*DUFLD*DUFLD
+0 %DUWRUHOOL $/ :KLWERXUQ 5 $EL]DLG $ 6HUUX\V 3: $%625%
(;7(1',QYHVWLJDWRUV
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(XUR,QWHUYHQWLRQ$XJ

7HPSRUDO HYROXWLRQ RI VWUXW OLJKW LQWHQVLW\ DIWHU LPSODQWDWLRQ RI
ELRUHVRUEDEOHSRO\PHULFLQWUDFRURQDU\VFDIIROGVLQWKH$%625%FRKRUW
% WULDODQ DSSOLFDWLRQ RI D QHZ TXDQWLWDWLYH PHWKRG EDVHG RQ RSWLFDO
FRKHUHQFHWRPRJUDSK\
1DNDWDQL62QXPD<,VKLEDVKL<(JJHUPRQW-=KDQJ<-&DPSRV&0
&KR<./LX 6'LMNVWUD -5HLEHU -+ 3HUNLQV / 6KHHK\$9HOGKRI 6
5DSR]D 5 YDQ (V *$ *DUFLD*DUFLD +0 YDQ *HXQV 5- 6HUUX\V 3:
$%625%&RKRUW%LQYHVWLJDWRUV
&LUF-

,PSOLFDWLRQVRIDELRUHVRUEDEOHYDVFXODUVFDIIROGLPSODQWDWLRQRQYHVVHO
ZDOOVWUDLQRIWKHWUHDWHGDQGWKHDGMDFHQWVHJPHQWV
%RXUDQWDV&9*DUFLD*DUFLD+0&DPSRV&$=KDQJ<-0XUDPDWVX7
0RUHO0$1DNDWDQL6*DR;&KR<.,VKLEDVKL<*LMVHQ)-2QXPD<
6HUUX\V3:
,QW-&DUGLRYDVF,PDJLQJ0DU

,QVWHQW SURWUXVLRQ DIWHU LPSODQWDWLRQ RI D GUXJHOXWLQJ VWHQW LQ D
KRQH\FRPEOLNH FRURQDU\ DUWHU\ VWUXFWXUH FRPSOHWH UHVROXWLRQ RYHU 
PRQWKV DQG WKH UROH RI RSWLFDO FRKHUHQFH WRPRJUDSK\ LPDJLQJ LQ WKH
GLDJQRVLVDQGIROORZXS
.R\DPD.<RQH\DPD.0LWDUDL7.XZDWD6 ,VKLEDVKL<.RQJRML.
$NDVKL<-
-$&&&DUGLRYDVF,QWHUY0D\H

(YHUROLPXVHOXWLQJ ELRUHVRUEDEOH YDVFXODU VFDIIROGV IRU WUHDWPHQW RI
SDWLHQWV SUHVHQWLQJ ZLWK 67VHJPHQW HOHYDWLRQ P\RFDUGLDO LQIDUFWLRQ
%9667(0,ILUVWVWXG\
'LOHWWL 5 .DUDQDVRV $ 0XUDPDWVX 7 1DNDWDQL 6 9DQ 0LHJKHP 10
2QXPD<1DXWD67,VKLEDVKL</HQ]HQ0-/LJWKDUW-6FKXOW]&5HJDU
(GH-DHJHUH336HUUX\V3:=LMOVWUD)YDQ*HXQV5-
(XU+HDUW-0DU

$ UDUH DGXOW FDVH RI FRUUHFWHG WUDQVSRVLWLRQ RI WKH JUHDW YHVVHOV ZLWK
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VLWXVLQYHUVXVZLWKDVLQJOHFRURQDU\DUWHU\DQGDQDWULDOVHSWDOGHIHFW
.XZDWD6<RQH\DPD.,]XPR0,VKLEDVKL<+D\DVKL$<DPDXFKL0
0XVKD+$NDVKL<-
,QW-&DUGLRO2FWH

$FDVH UHSRUWV(IIHFWLYH XVH RI7DGDODILO LQ D SDWLHQWZLWK SXOPRQDU\
K\SHUWHQVLRQDQGVLOHQWWK\URLGLWLVLQGXFHGE\SUHJQDQF\ 
0LWDUDL7,VKLEDVKL<<DPDXFKL00XVKD+0L\DNH)
7KHUDSXWLF5HVHDUFK

5HOHYDQFHRI ,%0,33GHOD\HGVFLQWLJUDSKLF LPDJLQJIRUSDWLHQWVZLWK
DQJLQDSHFWRULVDSLORWVWXG\
.R\DPD.$NDVKL<-.LGD.6X]XNL.,VKLEDVKL<0XVKD+ 
%DQDFK0
$UFK0HG6FL-XQ

6LJQLILFDQFH RI P7FVHVWDPLEL P\RFDUGLDO VFLQWLJUDSK\ DIWHU
SHUFXWDQHRXV FRURQDU\ LQWHUYHQWLRQ LQ SDWLHQWV ZLWK DFXWH P\RFDUGLDO
LQIDUFWLRQ
$NDVKL <- $VKLNDJD . 7DNDQR 0 ,]XPR 0 ,VKLEDVKL < .LGD .
<RQH\DPD.6X]XNL.0L\DNH)%DQDFK0
0HG6FL0RQLW)HE&5

,PSDFW RI FRQWUDVWLQGXFHG QHSKURSDWK\ DQG FDUGLRYDVFXODU HYHQWV E\
VHUXP F\VWDWLQ & LQ UHQDO LQVXIILFLHQF\ SDWLHQWV XQGHUJRLQJ FDUGLDF
FDWKHWHUL]DWLRQ
,VKLEDVKL<<DPDXFKL00XVKD+0LNDPL7.DZDVDNL.0L\DNH)
$QJLRORJ\1RY

3HDNWLPHRIDFXWHFRURQDU\V\QGURPHLQSDWLHQWVZLWKVOHHSGLVRUGHUHG
EUHDWKLQJ
,VKLEDVKL<2VDGD1 6HNLGXND+ ,]XPR0 6KLPR]DWR7+D\DVKL$
.LGD.<RQH\DPD.7DNDKDVKL(6X]XNL.7DPXUD0$NDVKL<-,QRXH
.2PL\D.0L\DNH),]DZD.:DWDQDEH6
-&DUGLRO$SU

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5HODWLRQVKLSEHWZHHQ VOHHSGLVRUGHUHG EUHDWKLQJ OHYHO DQG DFXWH RQVHW
WLPHRIFRQJHVWLYHKHDUWIDLOXUH
<RQH\DPD.2VDGD16KLPR]DWR7,VKLEDVKL<+D\DVKL$7DNDKDVKL(
.LGD.6X]XNL.7DPXUD0,QRXH.$NDVKL<-2PL\D.0L\DNH)
,]DZD.3:DWDQDEH6
,QW+HDUW--XO

$&RPSDUDWLYH6WXG\ LQ WKH 6DPH3DWLHQWV7UHDWHGZLWK WKH  )UHQFK
$FLVW3RZHU,QMHFWLRQ6\VWHPDQGWKH)UHQFK0DQXDO&DWKHWHUL]DWLRQ
7HFKQLTXH 
,VKLEDVKL<<DPDXFKL00XVKD+0LNDPL7.DZDVDNL.0L\DNH)
7KH6W0DULDQQD0HGLFDO-RXUQDO

6PDOO GHQVH ORZGHQVLW\ OLSRSURWHLQ FKROHVWHURO LV D XVHIXO PDUNHU RI
PHWDEROLFV\QGURPHLQSDWLHQWVZLWKFRURQDU\DUWHU\GLVHDVH
1R]XH70LFKLVKLWD,,VKLEDVKL<,WR6,ZDNL70L]XJXFKL,0LXUD0
,WR<+LUDQR7
-$WKHURVFOHU7KURPE$XJ

)XQFWLRQDO FDSDFLW\ VNHOHWDO PXVFOH VWUHQJWK DQG VNHOHWDO PXVFOH
YROXPHLQSDWLHQWVZLWKP\RFDUGLDOLQIDUFWLRQ
.LGD . 2VDGD 1 $NDVKL <- 6HNL]XND + ,]XPR 0 ,VKLEDVKL <
6KLPR]DWR7+D\DVKL$<RQH\DPD.7DNDKDVKL(6X]XNL.7DPXUD0
,QRXH.2PL\D.0L\DNH)
,QW+HDUW-6HS

%DFWHULDOPHQLQJLWLVDQGFHUHEUDOKHPRUUKDJLFLQIDUFWLRQFDXVHGE\
LQIHFWLYHHQGRFDUGLWLV
,VKLEDVKL<+RQPD+<DPDGD.7DNDKDVKL<6DPHMLPD+
1HXURORJLFDO0HGLFLQH)HE 

$FDVHRIGLDJQRVLVRI%DUWWHU6\QGURPHDIWHUSUHJQDQF\
,VKLEDVKL<6KLPD<+DJLPRWR.6DWR7.LPXUD.  
3URFHHGLQJVRIWKH&RQJUHVVRQ(OHFWURO\WH0HWDEROLVP


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38%/,&$7,2167H[W%RRN

 $%625%%LRUHVRUEDEOH9DVFXODU6FDIIROG$VFLHQWLILF&RPSHQGLXP
,9IURPWR
,VKLEDVKL<%LOO*RJDV2QXPD<6HUUX\V3:


35(6(17$7,216,QWHUQDWLRQDOILUVWDXWKRURQO\

 ,VKLEDVKL<
4&$'PD[DVJXLGDQFHIRUDSSURSULDWHVL]HVHOHFWLRQDQGGHSOR\PHQWRI
WKH$EVRUEVFDIIROGVLQSDWLHQWVIURPWKUHHVWXG\FRKRUWV$%625%
&RKRUW%$%625%(;7(1'DQG$%625%,,,PSDFWRQWKHFOLQLFDO
RXWFRPHVDW\HDU(6&$XJXVW/RQGRQ


 ,VKLEDVKL<
,QFLGHQFHDQG3RWHQWLDO0HFKDQLVPVRI3RVW3URFHGXUDO5LVHRI&DUGLDF
%LRPDUNHULQ3DWLHQWV:LWK&RURQDU\$UWHU\1DUURZLQJ$IWHU,PSODQWDWLRQ
RIDQ(YHUROLPXV(OXWLQJ%LRUHVRUEDEOH9DVFXODU6FDIIROGRU(YHUROLPXV
(OXWLQJ0HWDOOLF6WHQW
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